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COLORECTAL CANCER AS A PUBLIC HEALTH PROBLEM
The impact of colorectal cancer on population health
In most developed countries, colorectal cancer (CRC) is an important public health 
problem. In the Netherlands alone, 13,370 individuals were diagnosed with CRC in 2013.[1] 
In the same year, 4,940 individuals died of the disease. This makes CRC the second most 
common cancer and the second most common cause of cancer-related death in the 
Netherlands today (Figure 1). The lifetime risk of developing CRC in the Netherlands is 
4.4%. The lifetime risk of dying of the disease is 1.8%. In the US, CRC is the fourth most 
common cancer and the second most common cause of cancer-related death.[2] The 
lifetime risks of developing CRC and dying of the disease are similar to those observed in 
the Netherlands: 4.5% and 1.9%, respectively.
Figure 1   The number of individuals who were diagnosed with cancer (A) and who died 
of cancer (B) by type of cancer in the Netherlands in 2013.[1]
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declined during the past three decades.[2] This is likely to be explained, at least partially, 
by the gradual introduction of CRC screening in the US from the early 1980s onwards. 
In the Netherlands, screening for CRC was not implemented until 2014.
The impact of colorectal cancer on health care budgets
CRC does not only pose a burden on population health. It also poses a burden on health 
care budgets. In the Netherlands alone, the costs of CRC care were estimated to be €488 
million in 2011.[3] This corresponds to 10.2% of the total costs of cancer care in that year. 
In the near future, the costs of CRC care are expected to rise due to the detection of 
prevalent cancers within the Dutch national CRC screening program. In the more distant 
future, the costs are expected to decline because screening also prevents cancers (see 
Chapter 2 of this thesis). In the US, the costs of CRC care were estimated to be $14.1 billion 
in 2010, corresponding to 11.3% of the total costs of cancer care in that year.[4] 
THE NATURAL HISTORY OF COLORECTAL CANCER
The colorectum
The colorectum is the final section of the gastrointestinal tract that performs the vital 
task of absorbing water and vitamins while converting digested food into feces. 
The colorectum is approximately 1.5m in length and 6-7cm in diameter. It is generally 
subdivided into 6 regions: the cecum, ascending colon, and transverse colon (that 
together comprise the proximal colon) and the descending colon, sigmoid colon, and 
rectum (that together comprise the distal colon) (Figure 4).
CRC incidence and mortality increase markedly with age and are higher in men than in 
women (Figure 2).[1] However, because women tend to live longer than men, the total 
burden of CRC in women is comparable to that in men. In 2013, 44% of CRC diagnoses and 
47% of CRC deaths in the Netherlands occurred in women. 
In the Netherlands, the incidence of CRC increased substantially during the past 25 years 
(Figure 3).[1] This increase is likely to be explained by unfavorable trends in risk factors 
for CRC such as unhealthy dietary habits and overweight/ obesity. In the same period, 
CRC mortality remained relatively stable: a result of the improved treatment options that 
became available. In contrast with the Netherlands, in the US, CRC incidence and mortality 
Figure 2   CRC incidence (A) and mortality (B) by gender in the Netherlands in 2013.[1]
Figure 3   Time-trends in CRC incidence and mortality in the Netherlands and the US.[1 2]
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In most developed countries, such as the Netherlands and the US, 40%-50% of all 
individuals will develop at least one adenoma during life.[6] However, most of these 
adenomas will never develop into CRC. Adenomas that do develop into CRC take a long 
time to do so. Using a model-based approach, we estimated that CRC is already present in 
the form of a preclinical cancer for an average of 4.7 years and in the form of an adenoma 
for an average of 12.5 years before it gets diagnosed.
In the period 2010-2012, 18%, 30%, 28%, and 24% of CRCs in the Netherlands were 
diagnosed in stage I, II, III, and IV, respectively (Figure 6).[1] This distribution is very 
comparable to that observed in the US between 1975 and 1979, just before screening was 
introduced.[2] After the introduction of screening, the stage distribution of CRC in the US 
improved: in the period 2000-2003 25% of CRCs were diagnosed in stage I and only 19% 
of CRCs were diagnosed in stage IV.
The probability that a patient dies of CRC depends largely on the stage of the cancer at 
diagnosis and the localization of the cancer in the colorectum. Of all patients diagnosed 
with stage I colon cancer in the Netherlands between 2003 and 2009, only 6.0% died of 
the disease during the first 5 years after diagnosis (Figure 7).[1] The corresponding 
percentage for patients diagnosed with stage I rectal cancer was 10.0%. Of all patients 
with stage IV disease approximately 90% died within 5 years after diagnosis.
The adenoma-carcinoma sequence
Most CRCs are believed to develop from adenomas in a process called the adenoma- 
carcinoma sequence (Figure 5).[5] Adenomas are visible lesions (i.e., polyps) of the colonic 
epithelium that result from a series of epithelial mutations. They can develop anywhere in 
the colorectum and can grow in size and develop high-grade dysplasia. Some adenomas 
eventually invade the mucosa and become malignant (i.e., CRC). CRC does not cause 
symptoms immediately: somewhere in the process of progressing from a localized stage 
I cancer to a metastasized stage IV cancer, symptoms will present and as a result CRC will 
be diagnosed. 
Figure 4   The colorectum.
Figure 6   The stage distribution of CRC in the Netherlands and the US.[1 2]
Figure 5   The adenoma-carcinoma sequence.
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is, the detection and treatment of cancers that would not have been diagnosed without 
screening). 
There are multiple tests available for CRC screening. These tests can be subdivided into 
three categories: stool tests, endoscopic tests, and imaging tests. There are three types of 
stool tests: the guaiac fecal occult blood test (gFOBT), the fecal immunochemical test 
(FIT), and the stool DNA test (Figure 8). While the gFOBT is aimed at detecting any blood 
in stool, the FIT is aimed at detecting human blood only, and the stool DNA test is aimed 
at detecting human blood as well as mutated DNA from neoplastic cells. Whereas the FIT 
requires only one stool sample to be taken, the gFOBT requires two samples from 3 
consecutive bowel movements, and the stool DNA test requires a full bowel movement 
for analysis. Moreover, whereas the gFOBT is a qualitative test (the result is either positive 
or negative), the FIT and stool DNA test are quantitative tests (the result is a concentration 
of blood in stool/ a score on a logistic regression algorithm, respectively), allowing one to 
vary the cut-off value for a positive test. For all tests, individuals with a positive result are 
referred for full endoscopic examination (i.e., a colonoscopy).
INTERVENTIONS TO REDUCE COLORECTAL CANCER MORTALITY
Primary prevention
Primary prevention of CRC can be achieved by improving a population’s lifestyle. The most 
important modifiable risk factors for CRC are smoking, being overweight/ obese, being 
physically inactive, and consuming insufficient amounts of vegetables.[8] Although lifestyle 
modification is challenging, we recently showed that 35% of the reduction in CRC mortality 
observed in the US during the past three decades could be attributed to favorable risk 
factor trends.[9] 
Another strategy that might be used for primary prevention of CRC is chemoprevention 
using either aspirin or cyclooxygenase (COX) inhibitors. Both drugs have shown to reduce 
CRC risk.[10 11] However, since the use of aspirin and COX inhibitors is associated with 
gastrointestinal and cardiovascular events (COX inhibitors only),[10 11] chemoprevention is 
currently not recommended for average-risk individuals.[12] 
   
Screening
Screening is defined as ‘a strategy used in a population to identify an unrecognized 
disease in individuals without signs or symptoms’. The aim of screening is to detect disease 
in an earlier stage with a more favorable prognosis. CRC is particularly well suited for 
screening because it tends to have a long pre-clinical screen-detectable phase. During 
this phase, screening might prevent cancer by detecting and removing adenomas or it 
might detect cancer early, resulting in an improved prognosis. However, screening can 
also result in serious complications and overdiagnosis and overtreatment of cancers (that 
Figure 7   CRC survival by stage at diagnosis and localization in the colorectum in the 
Netherlands between 2003 and 2009.[1]
Figure 8   An example of a gFOBT (the Hemoccult II SENSA, Beckman Coulter, US)  
(A), a FIT (the OC-SENSOR, Eiken Chemical, Japan) (B), and a stool DNA test  
(the Cologuard, Exact Sciences Corporation, US) (C).
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31%.[23-26] For colonoscopy screening two RCTs are currently being conducted, but no 
mortality data are available yet.[27 28] Since the principle of colonoscopy screening is 
identical to that of sigmoidoscopy screening, and since a colonoscopy covers a larger part 
of the colorectum than a sigmoidoscopy, colonoscopy screening is generally expected 
to be more effective than sigmoidoscopy screening given equal screening intensity.
A relatively new imaging technique that can be used for CRC screening is computed 
tomography (CT) colonography. During this procedure two CT scans are made of the 
colorectum. From these scans, two-dimensional and three-dimensional images are 
constructed which are used to investigate the presence of lesions in the colorectum. No 
RCTs have yet demonstrated the effectiveness of CT colonography screening. An ongoing 
Dutch RCT comparing colonoscopy and CT colonography screening did demonstrate 
that participation in CT colonography screening is higher than participation in colonoscopy 
screening.[29] However, in those participating in screening, colonoscopy screening 
detected significantly more advanced neoplasia than CT colonography screening. Other 
disadvantages of CT colonography screening are that it requires a burdensome bowel 
preparation and that individuals with a positive test still have to undergo a colonoscopy.
Surveillance in adenoma patients
Individuals in whom adenomas are detected and removed (either as a result of screening 
or during a colonoscopy indicated because of symptoms) are recommended to undergo 
intensive testing using colonoscopy, so-called ‘colonoscopy surveillance’.[30 31] The 
effectiveness of colonoscopy surveillance has never been demonstrated by means of an 
RCT. However, since adenoma patients are at increased risk for CRC compared with the 
general population and since screening in the general population is effective,[32] 
The gFOBT Hemoccult II (Beckman Coulter, US) is the only stool test for which the 
effectiveness has been demonstrated in randomized controlled trials (RCTs) (Table 1). 
The observed reduction in CRC mortality ranged from 11% to 32%.[13-16] The effectiveness 
of FIT screening has never been demonstrated by means of a conventional RCT. However, 
several ongoing RCTs comparing gFOBT and FIT screening have demonstrated that 
participation in FIT screening is higher than participation in gFOBT screening and that FIT 
screening detects more advanced neoplasia at similar positivity rates.[17-21] FIT screening is 
therefore generally expected to be more effective than gFOBT screening given equal 
screening intensity. The effectiveness of stool DNA testing has also not been demonstrated 
by means of an RCT. However, a recent, large, back-to-back study in asymptomatic 
individuals demonstrated that stool DNA testing has a higher sensitivity for the detection 
of adenomas and CRC than FIT screening, but at a substantially lower specificity.[22]
Endoscopic screening involves inspecting the colorectum by inserting a flexible tube 
with a fiber optic camera into the anus (Figure 9). During the procedure adenomas and 
cancers can be biopsied or even completely removed. The two endoscopic procedures 
that can be used for CRC screening are sigmoidoscopy and colonoscopy. Both procedures are 
highly sensitive for detecting adenomas and cancers within the reach of the endoscope. 
With sigmoidoscopy only the rectum and distal part of the colon are inspected. Individuals 
with a positive sigmoidoscopy are referred for a colonoscopy. With colonoscopy the entire 
colorectum is visualized. Both procedures require a bowel preparation and can result in 
serious complications. However, the preparation for a colonoscopy is more burdensome 
than that for a sigmoidoscopy and the risks for complications are higher. 
The effectiveness of one-time sigmoidoscopy screening has been demonstrated in 
multiple RCTs (Table 2). The observed reduction in CRC mortality ranged from 22% to 
Table 1  RCTs evaluating screening using a gFOBT (Hemoccult II, Backman Coulter, US).
Trial Age 
group 
(y)
Screening 
interval (y)
Screening 
rounds (n)
Participation 
first round 
(%)
Average 
length of 
follow up (y)
CRC mortality 
reduction (% 
(95%CI))
Denmark[13] 45-75 2 9 671 17 11 (-1-22) 
Sweden[14] 60-64 1-2 2-3 63 16 16 (1-29) 
UK[15] 45-74 2 3-5 57 20 13 (3-22)
US[16] 50-80 1 11 75 182 32 (18-44)
US[16] 50-80 2 6 78 182 22 (3-38)
RCT = randomized controlled trial, gFOBT = guaiac fecal occult blood test, y = year, n = number,  
CI = confidence interval, UK = United Kingdom, US = United States
1 Only those participating in all previous screening rounds were re-invited for screening.
2 Maximum length of follow-up.
Figure 9   Endoscopic inspection of the colorectum.
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THE STATUS OF COLORECTAL CANCER SCREENING
The Netherlands
In 2009, the Dutch Health Council advised the Dutch Minister of Health to implement a 
national CRC screening program.[36] Based on the outcomes of Dutch trials comparing 
gFOBT and FIT screening and subsequent modeling work,[37-39] the Council recommended 
biennial FIT screening between ages 55 and 75 years using a cut-off for referral to 
colonoscopy of 15µg hemoglobin/g feces. In response, the Minister of Health commissioned 
the Dutch National Institute for Public Health and the Environment to investigate the 
feasibility of such a CRC screening program in the Netherlands.[40] The outcomes of this 
study led a new Minister of Health to decide to implement a national CRC screening 
program in accordance with the Health Council advice in 2011.[41 42] After two years of 
preparation of program infrastructure, quality assurance protocols, and communication 
materials, the national program was first piloted in the Rotterdam-Rijnmond area in the 
fall of 2013 and then rolled out nationally starting in January 2014. In that year, only 
individuals aged 63, 65, 67, 75, and 76 years (a one-time exception) were invited. In 
upcoming years, the number of age groups invited for screening will be gradually 
expanded.
The Dutch national CRC screening program was an immediate success. Participation was 
higher than expected (68% instead of 60%), as was the detection rate of advanced 
adenomas/CRC (4.0% instead of 2.7%).[43] However, the proportion of individuals with a 
positive test was also considerably higher than expected (13.4% instead of 6.4%). As a 
result, waiting times for diagnostic colonoscopy increased. To solve this problem, the 
National Institute for Public Health and the Environment decided to elevate the cut-off for 
colonoscopy surveillance is also believed to be effective. Based on a large cohort study, 
colonoscopy surveillance is estimated to reduce the risk for CRC mortality in adenoma 
patients by 66% up to 75%.[33] The most recent Dutch guidelines for surveillance in 
adenoma patients are based on the study described in Chapter 3 of this thesis.
CRC treatment
Depending on the stage at diagnosis and the localization of the cancer, CRC is treated by 
resection and chemotherapy and/ or radiation therapy. In recent years, treatment of CRC 
has undergone some important changes. The acceptance of total mesorectal excision as 
the preferred treatment option for rectal cancer has resulted in lower local recurrence 
rates, while the application of pre-surgical radiotherapy has increased the proportion of 
rectal cancers suitable for this treatment option.[34] Moreover, advances in the treatment 
of metastatic disease, such as portal vein embolization, have made liver resection a 
possibility for more patients.[35] In terms of systemic management, traditional treatment 
comprised 5-fluorouracil and leucovorin. This was augmented by treatment with 
irinotecan and oxaliplatin in the late 1990s, while more recently the monoclonal antibodies 
bevacizumab and cetuximab were added to regular treatment protocols.
As a result of these changes in treatment, the prognosis of CRC patients has improved 
over time (Figure 10). For Dutch CRC patients diagnosed between 1999 and 2002, 5-year 
survival was 92%, 74%, 56%, and 5% for stage I, II, III, and IV disease, respectively.[1] For 
patients diagnosed between 2003 and 2009, these percentages were 93% (+1%), 80% 
(+6%), 65% (+9%), and 9% (+4%). According to a recent analysis we performed, 12% of the 
total reduction in CRC mortality in the US in the past three decades could be explained by 
improvements in CRC treatment.[9]
Table 2  RCTs evaluating screening using sigmoidoscopy.
Trial Age 
group 
(y)
Screening 
interval (y)
Screening 
rounds (n)
Participation 
first round (%)
Average 
length of 
follow up (y)
CRC mortality 
reduction (% 
(95%CI))
UK[23] 55-64 NA 1 71 11 31 (18-41)
Norway[24] 50-64 NA 1 63 11 27 (6-44)
US[25] 55-74 3-5 2 84 12 26 (13-37)
Italy[26] 55-64 NA 1 58 11 22 (-8-44)
RCT = randomized controlled trial, y = year, n = number, CI = confidence interval, UK = United Kingdom
Figure 10   Time-trends in stage-specific CRC survival in the Netherlands.[1]
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almost invariably healthier than those who do not, they are likely to have better outcomes, 
even in the absence of screening. Studies comparing survival rates between screen- 
detected and clinically detected cases of cancer are hardly informative, since (in addition 
to selection bias) they are prone to two other forms of bias: ‘lead-time bias’ and ‘length 
bias’. Lead-time bias is caused by the fact that screening detects disease earlier in time. 
As a result, screen-detected cases seem to have a more favorable survival than clinically 
detected cases, even if screening does not postpone death. Length bias is caused by the 
fact that screening is more likely to detect slowly progressing disease than rapidly 
progressing disease. As a result, screening seems to prolong survival even if it does not.
Because cancer is relatively rare and because of the inherent time lag between a screening 
intervention and its effect on mortality, RCTs evaluating screening have to be large and 
follow-up has to be long. As a result, screening trials are relatively expensive. Still, it is 
important to realize that they are indispensable.
Step 2: Benefits versus harms
The second step in evaluating screening is to determine whether the benefits of screening 
outweigh the harms. To do this, all potential effects of screening on health (see Table 3) 
should be measured, valued, and integrated into one measure. A frequently used method 
to value the health effects of screening is by using utility weights. These weights correct 
the time spent in a certain disease state for the quality of life experienced in that state. 
The valued effects can be summed up to arrive at one measure for the net health effect of 
screening: the number of quality-adjusted life-years (QALYs) gained. A positive number of 
QALYs gained indicates a net health benefit; a negative number of QALYs gained indicates 
a net harm. An alternative to explicitly valuing and weighing effects is to present all effects 
to a group of decision makers and let them judge whether screening is associated with 
a net health benefit or harm.
Step 3: Economic evaluation
The third step in evaluating screening is to determine whether the effects of screening 
justify the costs (for an answer to the question of why costs should be considered see Box 1). 
In general, three types of economic evaluation are distinguished: cost-effectiveness 
analyses, cost-utility analyses, and cost-benefit analyses. For all types of evaluation, the 
costs of screening have to be determined (see Table 4 for the cost categories that should 
be considered). The difference between the types of economic evaluation lies in the 
effects that are considered and the method that is used to value these effects. In cost- 
effectiveness analyses, a single effect of interest is measured. This effect (e.g. screen- 
detected cases, deaths prevented, life-years gained) is not valued. In cost-utility analyses 
multiple effects are measured. These effects are valued using utility weights and integrated 
in terms of QALYs gained. Screening is regarded cost-effective if the costs per QALY gained 
are lower than a predefined cost-effectiveness threshold (in the Netherlands a threshold of 
referral to colonoscopy to 47µg/g in July 2014, which was the best measure to be taken 
according to the study described in Chapter 2 of this thesis.[44]
The United States
In the US, screening for CRC was introduced more than three decades ago. Participation 
rates in individuals aged 50 years and older rose from 18% in 1987 to 58% in 2010.[45] 
In contrast with the Netherlands, there is no nationally organized CRC screening program 
in the US. Instead, most screening is carried out opportunistically. That is, the system 
relies on the patient and the health care provider to remember that screening should 
take place. Moreover, in the US, individuals are free to choose between screening tests. 
Medicare (i.e., a national social insurance program for individuals aged 65 years and older) 
started covering CRC screening using gFOBT, sigmoidoscopy, and barium enema in 1998. 
In 2001, colonoscopy screening was added to the menu of options. Subsequently, in 2003, 
Medicare began covering FIT screening. Since October 2014, Medicare also covers stool 
DNA testing. 
All US guidelines for CRC screening recommend starting screening at age 50 years for all 
individuals, except the American College of Gastroenterology, which recommends 
starting screening at age 45 years for African Americans.[46-49] Recommendations on the 
appropriate age to stop screening differ between guidelines. The US Preventive Services 
Task Force (USPSTF) and the American College of Physicians recommend against routine 
screening in individuals aged older than 75 years and against screening in individuals 
aged older than 85 years.[46 48] The other guidelines do not specify an age to stop 
screening.[47 49] The screening strategies that are recommended also differ between 
guidelines. The USPSTF recommends annual screening with a high sensitivity gFOBT or FIT, 
5-yearly sigmoidoscopy screening combined with 3-yearly screening with a high sensitivity 
gFOBT or FIT, or 10-yearly colonoscopy screening.[46] The American Cancer Society, the 
US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology 
jointly recommend the same strategies, but also 5-yearly double-contrast barium enema, 
5-yearly CT colonography, and fecal DNA testing at an unspecified interval.[47] 
EVALUATING SCREENING
A three-step approach
Step 1: Effectiveness
The first step in evaluating screening is to determine whether it is effective. That is, 
whether screening reduces mortality due to the target disease. This can only be done by 
means of an RCT with disease-specific mortality as the primary endpoint. Observational 
studies (i.e., case-control studies and cohort studies) should be interpreted with caution, 
since they are prone to ‘selection bias’: because individuals participating in screening are 
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range of effects that can be valued in money terms is fairly limited. Thus whilst in theory it 
is a broad form of evaluation, in practice many of the cost-benefit analyses published to 
date are more restricted than cost-utility or cost-effectiveness analyses.
The World Health Organization criteria for screening
Already in the late 1960s, medical officer James Maxwell Glover Wilson and clinical chemist 
Gunner Jungner were commissioned by the World Health Organization to write a book 
that sets out the principles and practice of screening for disease in a clear and simple way.
[50] At that time, there were many technological advances in medicine, which made 
screening a topic of growing importance and controversy. Although the authors merely 
hoped to stimulate discussion, many still view their 10 ‘principles of early disease detection’ 
(see Box 2) as the gold standard for the evaluation of screening. 
In 2008, the criteria by Wilson and Jungner were revisited (see Box 2).[51] More emphasis 
was put on the need for evidence on the effectiveness of screening (Step 1 from the 
3-step approach) and on the importance of balancing the benefits of screening against 
the harms (Step 2 from the 3-step approach). However, the criterion that the costs of case 
finding should be economically balanced in relation to expenditure on medical care as a 
whole (Step 3 from the 3-step approach) was abandoned.
MODELING
The need for modeling
As said before, RCTs are indispensable for evaluating screening. However, they also have 
their limitations. First, RCTs are relatively expensive and time consuming. As a result, the 
number of RCTs that have evaluated CRC screening is limited. Second, RCTs usually have a 
limited follow-up time. As a result, they cannot be used to determine lifetime health 
effects and costs, which is necessary to determine the (cost-)effectiveness of screening. 
€20,000 per QALY gained is often used; in the US thresholds of $50,000 and $100,000 per 
QALY gained are often used). In cost-benefit analyses the effects of screening are valued 
in money terms, so as to make them commensurate with costs. Therefore potentially this 
is the broadest form of analysis. However, measurement problems often mean that the 
Table 3  Potential effects of screening on health.
Positive effects on health
Screening might prevent mortality
Screening might prevent morbidity caused by (late-stage) disease
Screening might prevent morbidity caused by treatment of (late-stage) disease
True negative test results might result in justified reassurance
Screening might positively affect risk behavior
Negative effects on health
The screening test might be burdensome and possibly harmful
A possible diagnostic test might be burdensome and possibly harmful
Awaiting test results might cause psychological distress
False negative test results might result in false reassurance and diagnostic delay
False positive test results might result in unnecessary diagnostic tests
Screening might result in overdiagnosis and overtreatment of disease
Screening will result in disease diagnoses earlier in life
Screening might negatively affect risk behavior
Table 4  Potential effects of screening on costs.
Costs
Costs of screening tests
Costs of diagnostic tests
Costs of complications of screening tests or diagnostic tests
Costs of overdiagnosis and overtreatment of cancers/ precursor stages of cancer
Savings
Savings due to the prevention of (late stage) cancer
Box 1  Why costs should also be considered.
The basic economic problem is that wants are infinite, while the resources required to obtain these 
wants are limited. This problem, called ‘scarcity’, implies that choices on how to deploy resources 
have to – and will be – made. It is important to realize that all choices involve a trade-off. The  so-
called ‘opportunity costs’ of a choice are the benefits of the next best alternative that is forgone 
because of a choice being made. If these opportunity costs exceed the benefits of the choice that 
was made, the net result of a choice will be a loss of the outcome that one wants to achieve, and 
hence, should not have been made. An example: If a government only has sufficient resources 
to implement either CRC screening or HPV vaccination, and if the potential health effects of 
CRC screening exceed the potential health effects of HPV vaccination, the government should 
choose not to implement HPV vaccination, even though it might be very effective, as the choice 
to implement HPV vaccination would mean that CRC could not be implemented and, hence, 
affect population health.
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MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for CRC developed at the 
Department of Public Health of the Erasmus University Medical Center (Rotterdam, the 
Netherlands). The general model structure is shown in Figure 11. In brief, MISCAN-Colon 
simulates the life histories of a large population of persons from birth to death. As each 
simulated person ages, one or more adenomas may develop. These adenomas can 
progress from small (≤5mm in diameter) to medium (6-9mm) to large size (≥10mm). Some 
adenomas can develop into preclinical cancer, which may progress through stages I to IV. 
During each stage, CRC may be diagnosed because of symptoms. Survival after clinical 
diagnosis is determined by the stage at diagnosis, the localization of the cancer, and the 
person’s age.
Screening will alter some of the simulated life histories: some cancers will be prevented by 
the detection and removal of adenomas; other cancers will be detected in an earlier stage 
with a more favorable chance of survival. However, screening can also result in serious 
complications and overdiagnosis and overtreatment of CRC. By comparing all life histories 
with screening with the corresponding life histories without screening, MISCAN-Colon 
quantifies the effectiveness, as well as the costs of screening.
All studies in this thesis are conducted using MISCAN-Colon. For more detailed information 
on MISCAN-Colon we refer to the Model Appendix included at the end of this thesis.
Third, the effectiveness of screening might differ from setting to setting. For example, a 
sigmoidoscopy screening trial in Norway showed a 63% participation rate,[24] while in the 
Netherlands a participation rate of only 32% was observed.[19] Finally, country-level 
resource demands for a certain screening program cannot easily be inferred from an RCT. 
To summarize: RCTs alone do not answer the question of which screening strategy is 
optimal given a certain context.
Decision models provide a useful tool to extrapolate evidence from RCTs and address the 
question of which screening strategy is optimal given local conditions with respect to CRC 
risk, life expectancy, costs, resource availability, and population preferences.
Box 2  World health organization criteria for screening.
The criteria by Wilson and Jungner (1968):
 1) The condition sought should be an important health problem;
 2) There should be an accepted treatment for patients with recognized disease;
 3) Facilities for diagnosis and treatment should be available;
 4) There should be a recognizable latent or early symptomatic stage;
 5) There should be a suitable test or examination;
 6) The test should be acceptable to the population;
 7) The natural history of the condition, including development from latent to declared disease, 
should be adequately understood;
 8) There should be an agreed policy on whom to treat as patients;
 9) The costs of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to expenditure on medical care as a whole; and
 10) Case finding should be a continuing process and not a “once and for all” project.
The revisited criteria (2008):
 1) The screening program should respond to a recognized need.
 2) The objectives of screening should be defined at the outset.
 3) There should be a defined target population.
 4) There should be scientific evidence of screening program effectiveness. 
 5) The program should integrate education, testing, clinical services and program 
management.
 6) There should be quality assurance, with mechanisms to minimize potential risks of screening.
 7) The program should ensure informed choice, confidentiality and respect for autonomy.
 8) The program should promote equity and access to screening for the entire target population.
 9) Program evaluation should be planned from the outset.
 10) The overall benefits of screening should outweigh the harm.
Figure 11   The general model structure of MISCAN-Colon.
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- Is more intensive colonoscopy screening than recommended favorable for Medicare 
beneficiaries and, if so, is it efficient from a societal perspective? (Chapter 4)
- Should CRC screening be considered in elderly individuals without previous screening? 
If so, up to what age and which screening test should be used at what age? (Chapter 5) 
- Why should decisions on cancer screening be personalized and how can personalized 
screening recommendations be derived? (Chapter 6) 
- What is the appropriate age to stop colonoscopy screening given an individual’s sex, 
race, screening history, background risk for CRC, and comorbidity status? (Chapter 7)
- What could be the effect of personalizing colonoscopy screening in the Medicare 
population on population health and Medicare spending? (Chapter 8)  
Chapter 9 contains a general discussion of the studies described in this thesis.
AN IMPORTANT TREND IN SCREENING: PERSONALIZATION
The effectiveness of screening depends on the characteristics of the screening strategy 
that is applied, that is, the screening test that is used, the screening interval that is applied, 
and the ages at which screening is started and stopped. However, the effectiveness of 
screening also depends on characteristics on the individual being screened, such as sex, 
race, screening history, exposure to risk factors for the target disease, and comorbidity 
status, which together determine an individual’s risk for the target disease and life- 
expectancy. While much effort has been put in extrapolating evidence from RCTs to 
determine optimal screening strategies for “average individuals” (i.e., individuals at average 
risk for the target disease with an average life expectancy), so far, relatively little effort has 
been put in specifying optimal screening strategies for individuals that differ from the 
“average individual” in important respects. Hence, until now, both high-risk individuals 
with a favorable life expectancy and low-risk individuals with an unfavorable life 
expectancy were recommended “average individual”-screening. This has resulted in 
underuse of screening (i.e., the denial of cost-effective screening) for some and overuse 
of screening (i.e., screening that is not cost-effective or even harmful) for others. In order 
to target screening at those individuals most likely to benefit, screening recommenda-
tions should be tailored according to individual patient characteristics. This process is 
called personalization. Chapters 5-8 of this thesis deal with personalization of CRC 
screening recommendations for US elderly individuals. Chapter 3 of this thesis deals with 
personalization of recommendations for colonoscopy surveillance in Dutch adenoma 
patients. 
RESEARCH QUESTIONS AND OUTLINE OF THIS THESIS
The aim of the first study described in this thesis (Chapter 2) was to demonstrate how 
models can be used to help policy makers make better decisions about CRC screening 
programs. The aim of the subsequent study (Chapter 3) was to help Dutch clinicians 
make better decisions about surveillance in adenoma patients. The aim of the last 5 
studies described in this thesis (Chapters 4-8) was to help US clinicians make better 
decisions about CRC screening in the wide variety of patients they encounter. 
More specifically, we addressed the following questions:
- How can models be used to inform policy decisions regarding screening programs? 
(Chapter 2)
- What is the appropriate interval for a first surveillance colonoscopy in adenoma patients 
given the characteristics of adenomas removed and the sex and age of the patient? 
(Chapter 3) 
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BACKGROUND
More than 1 million people worldwide are diagnosed with colorectal cancer (CRC) each 
year.(2) Half of these patients die from the disease, making CRC the fourth leading cause 
of cancer death in the world.(2) Randomised controlled trials (RCTs) have shown that 
screening can prevent many of these deaths by detecting CRC in an earlier stage or by 
detecting and removing its precursor lesion: the adenoma.(3, 4) 
Although RCTs are the gold standard for determining the effectiveness of screening, they 
also have their limitations. First, RCTs are expensive and time consuming. As a result, the 
number of RCTs that have evaluated CRC screening is limited. Until now, only guaiac faecal 
occult blood test (gFOBT) and sigmoidoscopy screening have been evaluated by means 
of an RCT. Screening modalities such as the faecal immunochemical test (FIT) and 
colonoscopy, although expected to be more effective, have not. For the same reasons, so 
far, direct comparisons between different CRC screening modalities, as well as comparisons 
between different screening strategies using the same screening modality (except annual 
vs biennial gFOBT screening), have never been made. Second, RCTs usually have a limited 
follow-up time. As a result, they cannot be used to determine lifetime health effects and 
costs, which is necessary to determine the (cost-)effectiveness of screening. Third, the 
effectiveness of screening might differ from setting to setting. For example, a sigmoidoscopy 
screening trial in Norway showed a 63% attendance rate,(5) while in the Netherlands an 
attendance rate of only 32% was observed.(6) This will impact the comparative (cost-)
effectiveness of sigmoidoscopy screening compared with FIT screening, for example. 
Finally, country-level resource demands for a certain screening programme cannot easily 
be inferred from an RCT. To summarise: RCTs alone do not answer the question of which 
screening strategy is optimal for a certain country. This might explain the large differences 
between the screening programmes that are currently implemented in the European 
Union (Table 1).
Decision models provide a useful tool to extrapolate evidence from RCTs and address the 
question of which screening strategy is optimal given local conditions with respect to CRC 
risk, life expectancy, resource availability and population preferences, which is the central 
question in the decision phase of a CRC screening programme. This is the phase in which 
models have been most frequently used. However, modelling is also valuable in the 
phases afterwards: during the planning, implementation and evaluation of a screening 
programme. In this paper, we will illustrate the value of models during the whole cycle of 
a screening programme using the role of the MISCAN-Colon model in the Dutch CRC 
screening programme as an example.
MISCAN-Colon decision model
The Dutch CRC screening programme has been co-informed by MISCAN-Colon. 
MISCAN-Colon is a microsimulation model for CRC developed at the Department of 
ABSTRACT
In May 2011, the Dutch government decided to implement a national programme for 
colorectal cancer (CRC) screening using biennial faecal immunochemical test screening 
between ages 55 and 75.(1) Decision modelling played an important role in informing this 
decision, as well as in the planning and implementation of the programme afterwards. In 
this overview, we illustrate the value of models in informing resource allocation in CRC 
screening using the role that decision modelling has played in the Dutch CRC screening 
programme as an example.
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Public Health of the Erasmus University Medical Center (Rotterdam, the Netherlands). The 
model’s structure, underlying assumptions and calibration are described extensively in a 
standardized model profile (available at http://cisnet.cancer.gov/colorectal/profiles.html) 
and previous publications.(7, 8) In brief, MISCAN-Colon simulates the life histories of a large 
population of individuals from birth to death. CRC arises in this population according to 
the adenoma–carcinoma sequence.(9, 10) More than one adenoma can occur in an 
individual, and each adenoma can independently develop into CRC. Adenomas may 
progress in size from small (≤5 mm) to medium (6–9 mm) to large (≥10 mm), and some 
adenomas will eventually become malignant. Cancer can progress from a localised stage 
I cancer to a metastasised stage IV cancer. However, during each stage, there is a probability 
of the cancer being diagnosed due to symptoms. At any time during the development of 
the disease, the process may be interrupted because the individual dies of another cause. 
Screening will alter some of the simulated life histories: some cancers will be prevented by 
the detection and removal of adenomas; other cancers will be detected in an earlier stage 
with a more favourable survival. However, screening can also result in serious complications 
and overdiagnosis and overtreatment of CRC (ie, the detection and treatment of cancers 
that would not have been diagnosed without screening). By comparing all life histories 
with screening with the corresponding life histories without screening, MISCAN-Colon 
quantifies the benefits of screening, as well as the associated harms and costs. 
MISCAN-Colon was calibrated to data on the age-specific, stage-specific and localisation- 
specific incidence of CRC in the Netherlands(11) and the age-specific prevalence and 
multiplicity distribution of adenomas as observed in autopsy and colonoscopy studies.
(12–22) Furthermore, MISCAN-Colon was calibrated to the reductions in CRC incidence 
and mortality observed in RCTs evaluating the effectiveness of screening with either 
gFOBTs or flexible sigmoidoscopy and showed good concordance with these trials results.
(8, 23, 24)
The value of MISCAN-Colon in informing the Dutch CRC screening 
programme
The run-up to the Dutch CRC screening programme is characterized by a long history of 
decision-making and planning by various stakeholders. Figure 1 gives an overview of the 
most important milestones in this process. The process and milestones as well as the role 
MISCAN-Colon has played in this process are described in more detail below.
Decision phase
The discussion on population screening for CRC was initiated in the Netherlands by a 
report of the Dutch Health Council in 2001.(25) This report not only recommended that 
feasibility studies and screening trials should be conducted, but also that a simulation 
model should be developed in order to make well-founded judgements about screening 
strategies. In 2003 and 2004, more landmark reports were published stressing the need to 
Table 1  Colorectal cancer screening programmes in the European Union.
Country Programme 
number
Test Screening 
interval (yrs)
Start age 
(yrs)
Stop age 
(yrs)
Belgium 1 gFOBT nd 50 74
Croatia 1 gFOBT 2 50 74
Czech Republic1 1 gFOBT 1 50 54
gFOBT 2 55 nd
2 gFOBT 1 50 54
COL 10 55 nd
Denmark 1 gFOBT 2 50 74
Estonia 1 FOBT 2 50 74
Finland 1 gFOBT 2 60 69
France 1 gFOBT 2 50 74
Germany1 1 gFOBT 1 50 54
gFOBT 2 55 nd
2 gFOBT 1 50 54
COL 10 55 nd
Hungary 1 FIT 2 50 70
Ireland 1 FIT 2 55 74
Italy1 1 FIT 2 50 70
2 SIG once only 58-60 58-60
Latvia 1 gFOBT 1 50 nd
Malta 1 FIT 2 60 64
Netherlands 1 FIT 2 55 75
Poland 1 COL 10 50 66
Portugal 1 FOBT 2 50 70
Slovenia 1 FIT 2 50 69
Spain 1 FIT 2 50 69
Sweden 1 gFOBT 2 60 69
UK 1 gFOBT 2 50 74
FOBT = fecal occult blood test; gFOBT = guaiac fecal occult blood test; FIT = fecal immunochemical test;  
SIG = sigmoidoscopy; COL = colonoscopy; nd = no data
1  In the Czech Republic and Germany 2 screening programmes are offered from age 55 onwards: 2-yearly gFOBT 
and 10-yearly colonoscopy screening. In Italy 2 screening programmes are offered: 2-yearly FIT screening and 
a once only screening sigmoidoscopy. This table is based on data obtained from a paper by Altobelli and 
colleagues.[60] 
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(Hemoccult II, Beckman Coulter, USA) or a FIT (OC-Sensor, Eiken, Japan). For the FIT, a cut-off 
for referral to colonoscopy of 50 ng/mL buffer (10 mg/g faeces) was applied, which 
allowed us to also calculate positivity and detection rates for higher cut-offs. All three 
regions showed higher attendance and detection rates for FIT compared with gFOBT 
screening.(30, 31) FIT detection rates were higher at lower cut-offs, but applying a low 
cut-off also required substantially more colonoscopies. What could not be estimated from 
the trials was whether the health benefit of detecting more advanced neoplasia justified 
the additional upfront costs of colonoscopies. To answer that question, MISCAN-Colon 
was developed and adjusted to reproduce the positivity and detection rates of gFOBT 
and FIT screening as observed in the Dutch screening trials. The model was subsequently 
used to predict the costs and effects of different screening strategies, varying the test and 
cut-off for referral to colonoscopy, as well as the age range and screening interval to 
determine the optimal FOBT screening strategy for the Dutch setting.
Figure 2 presents the outcomes of this analysis.(32) Each symbol in the graph represents 
a screening strategy. The higher the symbol in the graph, the more effective the strategy, 
the more to the right, the more expensive. The strategies lying on the top-left, which are 
connected by the solid line, form the efficient frontier, that is, the economically rational 
subset of choices.(33) Symbols lying beneath the efficient frontier represent strategies that 
are not as effective for the given amount of money as a point lying on the efficient frontier. 
implement a national CRC screening programme.(26–28) In response to these signals, the 
Netherlands Organisation for Health Research and Development and the Dutch Cancer 
Society joined forces and organised a consensus development meeting in February 2005 
in which both public health researchers (in favour of faecal occult blood test (FOBT) 
screening) and clinicians (in favour of endoscopy screening) participated. During this 
meeting, consensus was reached to perform population screening with FOBT biennially 
with the specific test (FIT or gFOBT), the cut-off for referral to colonoscopy in case of a FIT 
and the age range for screening to be decided within 2–3 years based upon further 
research.(29)
In 2006 and 2007, screening trials were conducted in the Amsterdam, Rotterdam and 
Nijmegen areas to compare attendance rates and detection rates of advanced neoplasia 
for different FOBTs. More than 30 000 individuals aged between 50 and 74 were randomly 
selected from the municipal registries and randomised to receive either a gFOBT 
Figure 1   Overview of the most important milestones in the run-up to the Dutch 
 national colorectal cancer screening programme.
The Dutch Minister of Health decides to implement a national CRC screening programme.
The screening programme is piloted in the Rotterdam-Rijnmond area.
The screening programme is rolled out nationally.
Based on a MISCAN-Colon analysis, the cut-off for referral is elevated to 275ng/mL (47µg/g).
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Figure 2   The costs and life-years gained associated with FOBT-based screening 
 programmes in the Dutch setting (MISCAN-Colon predictions).1
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These strategies are ‘dominated’ by (combinations of) other strategies. All gFOBT strategies 
clearly lie beneath the efficient frontier, and hence, are dominated by FIT strategies. 
In other words, FIT screening is more effective than gFOBT screening at lower cost. 
The strategies that form the efficient frontier all consist of FIT screening with a cut-off for 
referral to colonoscopy of 50 ng/mL (10 mg/g), indicating that screening using this low 
cut-off does not only result in more life-years (LYs) gained, but that the higher upfront 
costs of colonoscopies are also more than compensated for by higher future savings on 
CRC treatment.
Table 2 gives an overview of the FIT strategies on the efficient frontier. The strategy with 
the lowest costs per LY gained was 3-yearly screening between ages 60 and 69; next came 
lowering the start age to 55. The age range recommended by the Council of Europe 
(50–75) was not among the cost-effective options. As said, each of these strategies is an 
economically rational choice. Which strategy to choose depends on the willingness-to-pay 
for a LY gained. Generally in the Netherlands, a threshold between €20 000 and €40 000 
per quality-adjusted life-year gained is used for preventive interventions. All efficient 
strategies resulted in costs per LY gained well beneath that threshold, making the most 
intensive strategy (ie, annual screening between ages 45 and 80) still an appropriate 
choice in the Dutch setting.
This MISCAN-Colon analysis was an important component of the 2009 Health Council 
advice on CRC screening.(34) The Health Council advised the Minister of Health to 
implement biennial FIT screening between ages 55 and 75 using a cut-off for referral to 
colonoscopy of 75 ng/mL (15 mg/g). Based on the outcomes of the cost-effectiveness 
analysis, a different age range was chosen than recommended by the European Council 
(ie, 55–75 instead of 50–75) and a different cut-off was chosen than recommended by the 
FIT manufacturer (ie, 75 ng/mL (15 mg/g) instead of 100 ng/mL (20 mg/g)). The Health 
Council recognised that applying a lower cut-off for referral to colonoscopy was more 
cost-effective and that the willingness-to-pay threshold allowed for more intensive FIT 
screening. However, their choice also reflects the anticipated lack of colonoscopy capacity 
in the Netherlands to implement such a colonoscopy-intensive programme.(34)
Planning phase
In January 2010, the Minister of Health responded to the Health Council advice. He 
acknowledged the value of a nationwide CRC screening programme, but felt forced to 
postpone a final decision on its implementation.(35) The financial climate at that time put 
the government in a situation of radical cost reductions, so there was no budget for a 
national CRC screening programme. In addition, the minister considered the anticipated 
shortage of colonoscopy capacity(36) an important bottleneck that needed to be resolved 
before a national CRC screening programme could be implemented and emphasised the 
need for a system for quality assurance. He therefore commissioned the National Institute 
for Public Health and the Environment to investigate the feasibility of a national CRC T
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Assuming attendance, positivity and detection rates for FIT screening with a cut-off of 75 
ng/mL (15 mg/g), the model predicted the annual numbers of FIT analyses, colonoscopies, 
histopathological examinations, surgical procedures, as well as the numbers of CRC deaths 
prevented, and the costs of screening from the anticipated start of the programme in 2013 
until 2042 when resource requirements and screening benefits were expected to stabilise 
(Figure 4).(37, 38) A comparison of required and available endoscopy capacity showed 
that in 2016, 2017 and 2018 there would be a shortage of endoscopy capacity (Figure 5). 
The professional groups proposed that increasing colonoscopy efficiency and increasing 
the intake to training programmes could overcome the expected shortage in these years.
Implementation phase
Based on the outcomes of the feasibility study, a new Minister of Health decided in May 
2011 to implement a national CRC screening programme in accordance with the Health 
Council advice.(1) After 2 years of preparation of programme infrastructure, quality 
assurance protocols and communication materials, the national programme was first 
piloted in the Rotterdam-Rijnmond area in the fall of 2013 and then gradually rolled out 
nationally starting in January 2014. Based on the outcome of a public tender, the FOB-Gold 
(Sentinel, Italy) was chosen as the preferred test. The cut-off for referral to colonoscopy 
was set at 88 ng/mL (15 mg/g), which corresponds with the 75 ng/mL (15 mg/g) of the 
OC-Sensor as recommended by the Dutch Health Council. Because of the slight delay in 
the start of the programme (January 2014 instead of September 2013), not only individuals 
aged 63, 65, 67 and 75 but also individuals aged 76 were invited in 2014, thereby assuring 
that these individuals, originally scheduled for screening in 2013, still got a chance to 
participate in screening at least once.
Because the information technology (IT)-system especially developed for the CRC 
screening programme allowed for continuous monitoring of the programme, attendance, 
positivity and detection rates could be tracked real time. The programme was an 
immediate success. Attendance to the programme was higher than expected (68% vs 
60%),(39) as was the detection rate of advanced adenomas/CRC (4.0% vs 2.7%).(34, 40) 
However, the positivity rate was also considerably higher than expected (13.4% vs 6.4%) 
and the observed positive predictive value for detecting an advanced adenoma/CRC was 
substantially lower than expected (30.0% vs 42.5%).(37, 40) Consequently, colonoscopy 
capacity became an important bottle neck and waiting times for diagnostic colonoscopy 
increased.
Several steps were taken to address this problem. In a first step, positivity and detection 
rates at several cut-offs as observed in the national programme were compared with 
those observed in the Rotterdam screening trial. This comparison showed that applying 
the same cut-off level resulted in a higher positivity and a higher detection rate in the 
national programme than in the trial (Figure 6A, B).  The correlation between the positivity 
rate and the detection rate, however, was strikingly similar (Figure 6C). Based on a 
screening programme in the Netherlands. The purpose of this feasibility study was to 
ascertain the prerequisites for a CRC screening programme and to determine how such a 
programme could be introduced successfully. The study should identify potential problems 
with implementation and suggest how to deal with them, including issues of capacity, 
communication, quality assurance, flexibility in the light of new technological developments, 
link with further diagnostics and care, as well as monitoring and evaluation.(37)
To investigate the issue of capacity, the National Institute for Public Health and the 
Environment requested Erasmus MC to predict the resource requirements for a national 
CRC screening programme using MISCAN-Colon.(38) The model was used to simulate the 
Dutch population from 2013 up to 2042 under the implementation of a national CRC 
screening programme as proposed by the Health Council, including a phased roll-out 
from 2013 to 2018 (Figure 3).
Figure 3   The phased roll-out of the Dutch national colorectal cancer screening 
 programme as recommended by the Dutch Health Council.
Birth year 2013 2014 2015 2016 2017 2018
1963 50 51 52 53 54 55
1962 51 52 53 54 55 56
1961 52 53 54 55 56 57
1960 53 54 55 56 57 58
1959 54 55 56 57 58 59
1958 55 56 57 58 59 60
1957 56 57 58 59 60 61
1956 57 58 59 60 61 62
1955 58 59 60 61 62 63
1954 59 60 61 62 63 64
1953 60 61 62 63 64 65
1952 61 62 63 64 65 66
1951 62 63 64 65 66 67
1950 63 64 65 66 67 68
1949 64 65 66 67 68 69
1948 65 66 67 68 69 70
1947 66 67 68 69 70 71
1946 67 68 69 70 71 72
1945 68 69 70 71 72 73
1944 69 70 71 72 73 74
1943 70 71 72 73 74 75
1942 71 72 73 74 75 76
1941 72 73 74 75 76 77
1940 73 74 75 76 77 78
1939 74 75 76 77 78 79
1938 75 76 77 78 79 80
AGE (years)
Calendar year
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Figure 4   The resource demands (A–D), health effects (E) and costs (F) of the Dutch 
national colorectal cancer screening programme between 2013 and 2042 
(MISCAN-Colon predictions).1
Figure 4   Continued.
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MISCAN-Colon analysis in which we corrected for the difference in the age distribution 
between the individuals screened within the Rotterdam screening trial and the national 
programme, who were substantially older, it was concluded that the test characteristics 
corresponding to a cut-off level of 75 ng/mL (15 mg/g) as observed in the trial could 
be reproduced by elevating the cut-off level in the national programme to 275 ng/mL 
(47 mg/g).
In a second step, MISCAN-Colon was used to quantify the impact of the modified roll-out, 
the higher-than-expected attendance and the higher-than-expected positivity rate on 
the anticipated colonoscopy demand for 2014 and to determine which measure could 
best be taken to reduce this demand. Also screening 76 year olds in 2014 was found to 
increase the anticipated colonoscopy demand for 2014 from 28 000 to 33 000 (Figure 7). 
The higher attendance rate further increased this demand to 38 000 colonoscopies. 
However, the higher positivity rate resulted in the largest increase in colonoscopy demand 
Figure 4   Continued.
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1  We simulated the Dutch population on 1 January 2013. In this population, we simulated screening as 
recommended by the Dutch Health Council (ie, biennial FIT screening (OC-Sensor, Eiken, Tokyo, Japan) between 
ages 55 and 75 with a cut-off for referral to colonoscopy of 75 ng/mL (ie, 15 μg/g)) and applied the roll-out 
scheme shown in Figure 3. We assumed that no opportunistic screening took place before 2013 and that no 
such screening would take place after 2013, neither in a scenario with, nor in a scenario without a screening 
programme. We assumed that the age-specific risks for CRC, the age-specific risks for other cause mortality and 
the age-specific, stage-specific and localisation-specific CRC survival probabilities remained constant over time. 
2  We assumed that 10% of the target population will never participate in screening. In the remainder of the 
population, we assumed a 67% attendance rate at first invitation to arrive at a 60% overall attendance rate 
as observed in the Rotterdam pilot study. In those attending, we assumed an 80% attendance rate in the 
subsequent screening round; in those not attending, we assumed a 40% attendance rate, again arriving at 
an average attendance rate of 60% in the total target population. We assumed that all returned FITs could be 
analysed and that no one had to return multiple FITs.
3  We considered three categories of colonoscopies: (1) diagnostic colonoscopies after a positive FIT; (2) 
surveillance colonoscopies after the detection and removal of adenomas and (3) colonoscopies during 
which CRC is clinically detected. We assumed that 85% of those with a positive FIT underwent a diagnostic 
colonoscopy, as was observed in the Rotterdam pilot study. Moreover, we assumed that 80% of those referred 
for a surveillance colonoscopy—according to a slightly de-intensified version of the 2002 Dutch surveillance 
guidelines—underwent this colonoscopy. Finally, we took into account that screening reduces the number of 
clinically detected cancers and corresponding colonoscopies.
4  We considered three categories of histopathological examinations: (1) examinations of adenomas, cancers and 
hyperplastic polyps detected during a diagnostic or surveillance colonoscopy; (2) examinations of surgically 
removed adenomas and cancers; and (3) examinations of clinically detected cancers. We assumed that each 
hyperplastic polyp, adenoma and cancer detected during a diagnostic or surveillance colonoscopy resulted in 
one histopathological examination. Moreover, we assumed that each surgically removed adenoma and cancer 
resulted in one additional examination. We assumed that all cancers, except 58% of all stage I cancers, and 
3.9% of all large adenomas (≥10 mm) required surgery. Finally, we took into account that screening reduces the 
number of clinically detected cancers and corresponding histopathological examinations.
5  We assumed that all adenomas and cancers that had to be surgically removed required one surgical procedure. 
Since screening eventually prevents cancers, the screening programme results in a reduction in surgical 
procedures from year 2023 onward.
6  We calculated costs from a third-party payer perspective and took into account the costs of (1) FITs (ie, the costs 
of the test kit, analysis, organisation of the programme and telephonic consultations by primary care physicians 
in case of a positive FIT), (2) all colonoscopies (see footnote 3), (3) all histopathological examinations (see 
footnote 4), (4) complications of colonoscopy, (5) surgical removal of adenomas and (6) short-term and long-
term CRC care. Since screening eventually prevents cancers, the costs of the screening programme decrease 
over time. For all calculations, see van Veldhuizen et al.(37) for more details.
CRC, colorectal cancer; FIT, faecal immunochemical test.
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Figure 5   The endoscopy demand and supply (A) and resulting endoscopy shortage  
(B) in the Netherlands between 2013 and 2020.1
Figure 6   The differences in the associations between the cut-off for referral to 
 colonoscopy and the positivity rate (A); the cut-off for referral to colonoscopy 
and the detection rate of advanced neoplasia1 (B); and the positivity rate and 
the detection rate of advanced neoplasia (C) between the Rotterdam pilot 
study and the first half year of the Dutch national colorectal cancer screening 
programme.2
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1  We simulated the Dutch national CRC screening programme applying the phased roll-out scheme shown 
in Figure 3 to estimate the endoscopy demand for the Dutch national CRC screening programme (see also 
Figure 4B). The endoscopy demand outside the programme and the endoscopy supply were determined by 
independent management consulting firm Berenschot (http://www.berenschot.com/). 
CRC, colorectal cancer.
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demand by 54, 60 and 53 colonoscopies per CRC death not prevented, respectively. 
However, temporarily elevating the cut-off for referral in all age groups to 275 ng/mL 
(47 mg/g) reduced colonoscopy demand by 68 colonoscopies per CRC death not 
prevented and was most efficient. The National Institute for Public Health and the 
Environment therefore decided to increase the cut-off for referral to colonoscopy to 
275 ng/mL (47 mg/g), starting on 23 July 2014.(40) MISCAN-Colon predicted that applying 
this higher cut-off will result in a similar number of CRC deaths prevented as anticipated 
based on the 2010–2011 feasibility study (Figure 8).
for 2014: up to 64 000 colonoscopies. By 2030, the higher attendance and positivity rate 
would result in a doubling of colonoscopy demand compared with what was anticipated 
based on the feasibility study.
To reduce colonoscopy demand for 2014, two measures could be taken: screening could 
be postponed until 2016 in one or more of the age groups scheduled for screening in 
2014 or the cut-off for referral to colonoscopy could be elevated in all age groups. To 
determine which of these measures was best suited to reduce colonoscopy demand for 
2014, MISCAN-Colon was used to estimate the associated loss in benefit from screening 
and the reductions in colonoscopy demand for 2014. The best measure to reduce 
colonoscopy demand for 2014 was defined as the measure that resulted in the largest 
reduction in colonoscopy demand per CRC death not prevented.
Postponing screening in 75-year-old and 76-year-old individuals, which implies not 
screening them at all, reduced colonoscopy demand by 21 and 22 colonoscopies per 
CRC death not prevented, respectively (Table 3). Postponing screening in 63-year-old, 
65-year-old and 67-year-old individuals was somewhat more efficient, reducing colonoscopy 
Figure 6   Continued. Figure 7   The cumulative effects of modifying the roll-out of the Dutch national 
 colorectal cancer screening programme, the higher-than-expected attendance 
and the higher-than-expected positivity and detection rates on colonoscopy 
demand (MISCAN-Colon predictions).
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FIT88 test characteristics - higher than expected positivity and detection rates4 
1  The detection rate of advanced neoplasia was defined as the proportion of individuals with an analysable FIT 
that were diagnosed with CRC or an advanced adenoma (ie, an adenoma with a diameter ≥10 mm, and/or with 
a ≥25% villous component and/or high-grade dysplasia).
2  In the Rotterdam pilot study, individuals aged between 50 and 74 were included, whereas the Dutch national 
CRC screening programme data are largely based on individuals aged 75 and 76. This is likely to explain part of 
the observed differences.
1  The original estimates were based on adherence, positivity and detection rates as observed in the Dutch 
screening trials and the original phased roll-out scheme (see Figure 3). See also Figure 4B.
2  Because the Dutch national colorectal cancer screening programme started in 2014 instead of 2013, the roll-out 
of the programme was modified. In 2014, not only individuals aged 63, 65, 67 and 75 but also individuals aged 
76 were invited for screening. 
3  In the first half of 2014, the attendance rate to screening was higher than expected based on the screening trials: 
68% instead of 60%.
4  In the first half of 2014, when a cut-off of 88 ng/mL (15 mg/g) was used, the positivity rate and detection rate 
of advanced adenomas/CRC were higher than expected based on the screening trials: 13.4% instead of 6.4% 
and 4.0% instead of 2.7%, respectively. The positive predictive value for detecting an advanced adenoma/CRC 
was substantially lower than expected: 30.0% instead of 42.5%. FIT88, FIT screening with a cut-off for referral to 
colonoscopy of 88 ng/mL (15 mg/g).
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Figure 8   The effects of applying a cut-off for referral to colonoscopy of 275 ng/mL  
(47 mg/g) rather than 88 ng/mL (15 mg/g) from the second half of 2014 
onward on the colonoscopy demand (A) and health effects (B) of the Dutch 
national colorectal cancer screening programme (MISCAN-Colon predictions).
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1  The original estimates were based on adherence, positivity and detection rates as observed in the Dutch 
screening trials and the original phased roll-out scheme (see Figure 3). See also Figure 4.
2  In the first half of 2014, the roll-out of the screening programme was modified and attendance, positivity and 
detection rates for advanced adenomas/CRC were higher than expected. For details on model assumptions, 
see Figure 7 legend.
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Finally, medicine in general, and CRC screening in particular, is a continuously developing 
field and therefore a moving target. New technologies for screening may become viable 
such as computed tomographic colonography, stool DNA testing and serum testing.
(42–44) In addition, the call for precision medicine, and in that light risk-stratified screening, 
is increasing.(45–47) It is important to continuously follow these developments and 
determine their potential benefits and harms for an existing CRC screening programme. 
For example, for CRC screening, it is well known that test characteristics of FIT differ by 
gender and age (48, 49) and using differential cut-offs for men versus women and older 
versus younger people has therefore been proposed. Modelling can help determine 
whether these calls are justified and what the potential benefit of gender-specific and 
age-specific FIT screening is.
DISCUSSION
This overview shows that decision modelling played an important role in the decision, 
planning and implementation phase of the Dutch CRC screening programme, and we 
believe it will continue to do so in the coming years as it has done for other programmes. 
On several occasions, model results have influenced the programme: in the decision 
phase, FIT screening was chosen over gFOBT screening, a higher age to start screening 
was chosen than that recommended by the Council of Europe and a lower cut-off for 
referral to colonoscopy was chosen than that recommended by the test’s manufacturer. 
To remediate the higher-than-anticipated colonoscopy demand during the implementation 
phase, the cut-off for referral to colonoscopy was temporarily elevated. If modelling would 
not have been available or used, these choices might not have been made and the 
benefits and harms of the screening programme could have turned out less favourable 
than they will now.
Validation of model results
This overview describes how modelling has influenced and changed the Dutch CRC 
screening programme. However, the use of a model does not necessarily imply that the 
right decisions are made. Policymakers considering using a model to inform their (CRC) 
screening programmes should be aware of the considerable variation in quality of 
available models. An important strength of the MISCAN-Colon model is that it has been 
extensively validated against available evidence from RCTs and other sources, and, where 
necessary, adapted to accurately predict the impact of screening on CRC incidence and 
mortality. The good fit with trial results builds confidence in model extrapolations to the 
Dutch population and other settings. However, it remains very important to closely 
monitor the outcomes of the screening programme and compare them with model 
predictions. Important outcomes to consider include detection rates during repeat 
The increased cut-off will be sustained in 2015, but in that same year the MISCAN-Colon 
model will again be used to compare the increased cut-off with other measures to reduce 
colonoscopy requirements for the longer term: lengthening the screening interval and 
narrowing the age range. In addition, when data from repeat screenings become available, 
the model will be updated to reflect observed positivity and detection rates for repeat 
screenings and will again be used to predict long-term resource requirements and 
benefits of the Dutch CRC screening programme. In case of substantial changes in 
anticipated resource requirements and benefits, the impact of changes to the programme 
may need to be evaluated anew. 
Established programme
In an established programme that has been running for several years and in which a 
steady state has been reached, the value of modelling may be less apparent than in the 
decision, planning and implementation phase of a screening programme. However, 
modelling also has its value in a well-established programme. In the first place, modelling 
can be used for evaluation of the screening programme. Is the programme working as 
expected? What are the expected changes in the long-term impact of the programme 
based on differences in anticipated and observed programme indicators? Model 
predictions can be used as a benchmark for observed CRC incidence and mortality to 
determine whether the programme is having the anticipated benefit. An important 
example of such work has been done using the MISCAN-breast model. Because screening 
resulted in a substantial increase in the incidence of breast cancer in women in the 
screen-eligible age range, there was considerable debate about the amount of 
overdiagnosis from mammography screening. Using the model, we demonstrated that 
this increase in incidence could be anticipated and that it is almost completely 
compensated for by a sharp decrease in breast cancer incidence at older age.(41)
Second, in every programme, even the well-conducted programmes, there is room for 
improvement. There might be regional variation in performance indicators (eg, attendance, 
delay in diagnostic follow-up) and modelling can be used to estimate the impact of this 
regional variation on long-term outcomes of the screening programme. This way the 
impact of reducing regional variation can be determined for each indicator and 
interventions can be prioritised. 
3  In this scenario, we maintained the modified roll-out and higher attendance rate; however, we simulated 
screening using a cut-off for referral to colonoscopy of 275 ng/mL (47 mg/g), rather than 88 ng/mL (15 μg/g) 
from July 1st 2014 onward. At this cut-off level, the positivity rate during the first half of 2014 would have been 
7.9%, the detection rate of advanced adenomas/CRC would have been 3.0% and the positive predictive value 
for the detection of advanced adenomas/CRC would have been 38.3%. 
CRC, colorectal cancer; FIT88, FIT screening with a cut-off for referral to colonoscopy of 88 ng/mL (15 mg/g); 
FIT275, FIT screening with a cut-off for referral to colonoscopy of 275 ng/mL (47 mg/g).
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screening rounds, interval cancer rates and CRC mortality. For example, to validate the 
decision to increase the cut-off for a positive FIT in the programme, it is important to 
monitor the interval cancer rate after a negative screening in the programme. This rate 
should not exceed the rate predicted by the model.
An important example of how model-induced changes to a screening programme were 
validated by subsequent monitoring of the programme comes from the Dutch cervical 
cancer screening programme. This programme originally offered women 3-yearly Pap 
smear testing between ages 35 and 53: a total of seven smears. Evaluation using the 
MISCAN-Cervix model indicated that spreading those seven smears over a wider age 
range increased the benefits of screening without increasing its costs.(50) Based on this 
analysis, the cervical cancer screening programme was changed to offer 5-yearly screening 
between ages 30 and 60. Evaluation of this change several years later showed that the 
9-year incidence of cervical cancer after a negative primary smear did not increase.(51) 
This example clearly illustrates how modelling resulted in the right decision to change an 
existing screening programme.
Conditions for decision modelling
Decision modelling in the Dutch CRC screening programme could only be applied 
because several critical conditions were met. First of all, the availability of local data on 
adherence and yield of FIT screening from the Dutch screening trials was essential to 
reliably estimate the required capacity and long-term impact of FIT screening in the 
Netherlands. Second, involvement of monitoring and evaluation experts of the 
Department of Public Health in the development of quality indicators ensured that all 
indicators relevant for decision modelling were consistently collected in the screening 
programme. Third, the IT-system developed for the CRC screening programme allowed 
real-life tracking, and thus, continuous monitoring of all relevant data from the screening 
programme. These data timely revealed the higher-than-anticipated adherence to and 
referral rate of FIT screening and allowed for further diagnosis of the problem followed by 
the model analysis described above. However, perhaps the most important factor was the 
good collaboration between the Department of Public Health, the National Institute for 
Public Health and the Environment, and the Dutch Ministry of Health and the willingness 
of the decision-makers involved to consider model results.
Other examples of applications of decision modeling in screening
The Dutch CRC screening programme is not the only screening programme that has 
applied modelling to inform the design, planning and implementation of screening. 
Modelling has also been used to inform the Irish, Canadian and Australian CRC cancer 
screening programmes.(52–54) For Ireland, modeling showed that FIT-based screening 
would be very effective, but that colonoscopy demand could not be met instantly. A 
staggered age-based roll-out was therefore suggested to gain time to increase 
colonoscopy capacity to meet the programme demand.(54) In Canada, modelling was 
used to inform the National Committee on Colorectal Cancer Screening on the mortality 
reduction, cost-effectiveness and resource requirements of biennial gFOBT screening.(53) 
The expansion of screening ages in the Australian CRC screening programme has been 
accelerated to occur in the coming 5 years instead of the previously proposed 17 years 
after a model analysis showed that this would increase the number of CRC deaths 
prevented in the upcoming 40 years by almost 30%.(52) Models were also used to inform 
the US Preventive Services Task Force (USPSTF) recommendations for lung, breast and CRC 
screening(55–57) and the Centers for Medicare and Medicaid Services coverage decisions 
for FIT, stool DNA and CT colonography screening.(58, 59) Co-informed by modelling 
outcomes, the USPSTF no longer recommends routine screening for breast cancer before 
age 50 and after age 74, nor CRC screening after age 75 in those with an adequate 
screening history. Interestingly, most examples relate to the use of modelling in the 
decision phase of screening programmes. The potential of modelling in the planning, 
implementation and established programme phase is currently underused.
Conclusion
In this overview, we have shown that modelling has been very useful in the decision, 
planning and implementation phase of the Dutch CRC screening programme. In the 
absence of a decision model, decisions concerning the programme would have to be 
made based on expert opinion and implicit assumptions. Decision models synthesise all 
relevant available data and can be used to extrapolate trial findings and generate 
information to support optimal resource allocation in CRC screening. When using models 
to inform health policy, it is important to select a well-validated model for the analysis and 
closely monitor outcomes of the screening programme in comparison with model 
predictions. We believe that the MISCAN-Colon microsimulation model has contributed 
and will continue to contribute to the success of the Dutch CRC screening programme.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes 
of cancer-related death in the Western world today.[1] Screening for CRC is effective and 
cost-effective in reducing the morbidity and mortality caused by this disease and is 
therefore widely recommended.[2-6] Individuals in whom precursor lesions for CRC, 
so-called adenomas, are detected and removed are at increased risk for CRC compared 
with the general population. They are therefore recommended to undergo more intensive 
testing by means of colonoscopy surveillance.[7 8] 
Recent studies have identified several important predictors of advanced adenoma 
recurrence in newly diagnosed adenoma patients.[9 10] These predictors include charac-
teristics of the adenomas removed during colonoscopy: the presence of multiple, large 
(≥10mm), villous and proximal adenomas, as well as patient characteristics: male sex and 
older age. The identification of these predictors allows for extensive risk stratification of 
adenoma patients followed by careful tailoring of surveillance recommendations. 
However, most surveillance guidelines do not consider all relevant predictors and are thus 
restricted in providing tailored recommendations. The 2002 Dutch guidelines, for example, 
risk stratified adenoma patients based on adenoma multiplicity only.[11] Other guidelines, 
that do consider multiple predictors, only consider these predictors in simple combinations. 
The recently published European guidelines, for example, classify patients as high-risk if 
either 3 or more adenomas or at least one high-risk adenoma is removed (i.e., a large 
adenoma or an adenoma with villous histology or high grade dysplasia).[7] However, since 
the number of adenomas removed, large size and villous histology are independent 
predictors of advanced adenoma recurrence, a patient with 3 large, villous adenomas is at 
substantially higher risk for CRC than a patient with 3 small, non-villous adenomas, likely 
justifying a shorter surveillance interval in the former than in the latter patient. 
In prior work, we analysed data from the Dutch Surveillance After Polypectomy (SAP) 
study to develop a score chart to risk-stratify newly diagnosed adenoma patients. This 
score chart uses information on all relevant characteristics of adenomas removed during 
colonoscopy and integrates this information into one measure: the adenoma risk score 
(range: 0-5).[12] The objective of our current study was to determine the appropriate 
interval for a first surveillance colonoscopy in adenoma patients given their adenoma risk 
score, sex and age. We performed analyses for the Netherlands (base-case analysis) and 
various other European countries (scenario analyses). Through this work we hope to 
facilitate a more personalised approach to surveillance in adenoma patients, ultimately 
resulting in more efficient surveillance. Since several European countries recently adopted 
a population based CRC screening programme,[13] and many of those participating in 
screening will eventually enter surveillance, a more personalised approach will become 
increasingly important.
ABSTRACT
Objective: Existing guidelines for colonoscopy surveillance in adenoma patients do not 
consider all important predictors of advanced adenoma recurrence and might therefore 
be suboptimal. We aimed to determine the appropriate interval for surveillance given a 
patient’s adenoma risk score (i.e., risk according to a previously developed and validated 
score chart), sex and age.  
Design: Microsimulation modelling study.
Setting: The Netherlands (base-case analysis) and various other European countries 
(scenario analyses).
Populations: Adenoma patients characterised by their adenoma risk score (0-5), sex and 
age (40-80 years).
Interventions: Colonoscopy surveillance after 1-10 years and referral to biennial faecal 
immunochemical test (FIT) screening. 
Main Outcome Measure: The appropriate interval for colonoscopy surveillance given a 
threshold for the willingness-to-pay per quality-adjusted life-year gained equal to the 
incremental cost-effectiveness ratio of biennial FIT screening.  
Results: The appropriate interval for colonoscopy surveillance depended heavily on 
adenoma risk score and to a lesser extent on sex and age. While some patients with risk 
score 0 should receive a surveillance colonoscopy after 10 years, some patients with risk 
scores 4 and 5 should receive a surveillance colonoscopy after only 2 years. Surveillance 
should no longer be recommended in patients with risk score 0 aged 70 years or older, 
patients with risk score 1 and males with risk score 2 aged 75 years or older and higher risk 
patients aged 80 years or older. Results were robust to variations in the overall level of 
health care costs in a country. However, applying higher willingness-to-pay thresholds 
resulted in substantially more intensive surveillance recommendations, particularly in 
those with a low adenoma risk score. 
Conclusions: The appropriate interval for colonoscopy surveillance depends heavily on a 
patient’s adenoma risk score. Personalising surveillance using this score targets 
colonoscopies at those patients most likely to benefit and has great potential to increase 
its efficiency.
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simulated person ages, one or more adenomas may develop. These adenomas can 
progress from small (≤5mm in diameter), to medium (6-9mm), to large size (≥10mm). 
Some adenomas can develop into preclinical cancer, which may progress through stages 
I to IV. However, during each stage, CRC may also be diagnosed because of symptoms. 
Survival after clinical diagnosis is determined by the stage of the cancer at diagnosis, the 
localization of the cancer and the person’s age and is based on CRC survival data observed 
in the South of the Netherlands, as national data were not available.[14]
Surveillance in adenoma patients will alter some of the simulated life histories. Some 
cancers will be prevented by the detection and removal of adenomas; other cancers will 
be detected in an earlier stage with a more favourable survival. However, surveillance can 
also result in serious complications and overdiagnosis and overtreatment of CRC (i.e., the 
detection and treatment of cancers that would never have been diagnosed without 
surveillance). By comparing all life histories with surveillance with the corresponding life 
histories without surveillance, MISCAN-Colon quantifies the effectiveness of surveillance 
as well as the associated costs.
MISCAN-Colon was calibrated to the age-, stage- and localization-specific incidence of 
CRC as observed in the Netherlands before the introduction of screening (i.e., between 
1999 and 2003) and the age-specific prevalence and multiplicity distribution of adenomas 
as observed in autopsy and colonoscopy studies.[15-26] The preclinical duration of CRC 
and the adenoma dwell-time were calibrated to the rates of screen-detected and interval 
cancers observed in randomised controlled trials evaluating screening using guaiac faecal 
occult blood tests and a once-only sigmoidoscopy.[27-31] We validated MISCAN-Colon 
against the long-term outcomes of the National Polyp Study (i.e., a study on the 
effectiveness of colonoscopic polypectomy).[32] The model showed good concordance 
with the mortality outcomes observed (Model Appendix). 
Populations simulated
We used MISCAN-Colon to simulate the SAP population after index colonoscopy by age 
(40, 45, (…), 80 years) and assumed that the model correctly predicted the average risk for 
CRC over time for all ages (Appendix 2). We used these populations and the relative risks 
associated with adenoma risk score (score 0: 0.58, score 1: 0.95, score 2: 1.53, score 3: 2.42, 
score 4: 3.69 and score 5: 5.35) and sex (males: 1.14, females: 0.85) obtained from the 
SAP-study to simulate cohorts of 10 million adenoma patients for each combination of 
adenoma risk score, sex and age. Life-expectancy was based on sex-specific life-tables 
from 2011 obtained from Statistics Netherlands.[33]
Surveillance strategies
Within each cohort, we simulated colonoscopy surveillance with intervals ranging from 
every 1 up to 10 years. To increase model flexibility in simulating surveillance strategies, 
we allowed three stopping ages: 75, 80 and 85 years. As alternative ‘surveillance’ strategies, 
METHODS
SAP Score Chart
In the SAP study, we gathered data on adenoma findings during index colonoscopy (i.e., 
the first colonoscopy during which adenomas were detected and removed) and at least 
one surveillance colonoscopy for almost 3,000 Dutch adenoma patients.[10] Based on 
these data, we developed a score chart that can be used to stratify newly diagnosed 
adenoma patients by their risk for advanced adenoma recurrence based on all relevant 
characteristics of adenomas removed during colonoscopy (Figure 1).[12] The score 
resulting from this chart, the ‘adenoma risk score’, ranges between 0 and 5. Compared 
with the average age- and sex-specific risks for advanced adenoma recurrence in 
adenoma patients, the relative risks associated with scores 0 up to 5 were 0.58, 0.95, 1.53, 
2.42, 3.69 and 5.35, respectively (Appendix 1). 
Cost-Effectiveness Analyses
MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for CRC developed at the 
Department of Public Health of the Erasmus University Medical Center (Rotterdam, the 
Netherlands). The model’s structure, underlying assumptions and calibration are described 
in the Model Appendix included at the end of this thesis. In brief, MISCAN-Colon 
simulates the life histories of a large population of persons from birth to death. As each 
Figure 1   The SAP Score Chart: Calculating the Adenoma Risk Score.
Adenoma Characteristic Values Points
Number of adenomas 1 0
2 - 4 1
 5 2
Presence of at least one large adenoma ( 10mm) no 0
yes 1
Presence of at least one villous adenoma* no 0
yes 1
Presence of at least one proximal adenoma no 0
yes 1
Adenoma risk score†
*An adenoma with at least 75% villous histology.
† The adenoma risk score ranges between 0 and 5. 
SAP SCORE CHART
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we simulated referral to the Dutch national CRC screening programme from the first 
subsequent screen eligible age onwards as well as after a minimum of 10 years. Within this 
recently started programme, individuals are invited for biennial faecal immunochemical 
test (FIT) screening from age 55 up to age 75 years.[34] In all cohorts, we also simulated a 
comparator scenario without further testing: the ‘no surveillance’ scenario.  
Test characteristics
The sensitivity of colonoscopy for the detection of adenomas and CRC was obtained from 
a systematic review on miss-rates observed in tandem colonoscopy studies and was 75% 
for small adenomas (≤5mm), 85% for medium-sized adenomas (6-9mm) and 95% for large 
adenomas (≥10mm) and CRC.[35] We assumed that 95% of all colonoscopies reached the 
cecum; for the remaining 5%, the reach of the procedure was assumed to be distributed 
uniformly over colon and rectum. We assumed that in 10% of all negative colonoscopies 
a hyperplastic polyp was detected and removed. 
The sensitivity of FIT for the detection of adenomas and CRC was calibrated to positivity 
and detection rates observed in the Dutch trials on FIT screening and was 0% for small 
adenomas (≤5mm), 6.5% for medium-sized adenomas (6-9mm), 29.2% for large adenomas 
(≥10mm), 46.7% for cancers that would not have been clinically detected in their current 
stage and 80.3% for cancers that would have been clinically detected in their current 
stage.[30] The specificity of FIT was calibrated to the same data and was 97.0%.  
Complications of colonoscopy
Age-specific risks for gastrointestinal and cardiovascular complications of colonoscopy 
requiring a hospital admission or emergency department visit were derived from a study 
by Warren and colleagues.[36 37] The overall risk associated with colonoscopies with poly- 
pectomy increased exponentially with age: from 2 complications per 1,000 colonoscopies at 
age 40 to 38 complications per 1,000 colonoscopies at age 85. Colonoscopies without 
polypectomy were not associated with an increased risk for complications.[36 37] We 
assumed that one out of every 30,000 colonoscopies involving polypectomy resulted in 
death.[37 38]
Utility losses
We assumed a utility loss (i.e., a loss of quality of life) equivalent to two full days of life per 
colonoscopy (0.0055 quality-adjusted life-years [QALYs]) and two weeks of life per 
complication (0.0384 QALYs). We also assigned a utility loss to each life-year (LY) with CRC 
care (Table 1).[39] 
Costs
The cost-effectiveness analyses were conducted from a societal perspective. The costs of 
FIT include the costs of the test kit, analysis and organization of the screening programme 
Table 1  The Utility Losses and Costs Associated with Surveillance in Adenoma Patients.
UTILITY LOSS, QALYs*
Per FIT 0
Per colonoscopy
Without polypectomy/ biopsy 0.005
With polypectomy/ biopsy 0.005
Per complication of colonoscopy 0.038
Per LY with CRC care†‡ Initial care Continuing  
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
COSTS, 2012 €§
Per FIT 38
Per colonoscopy
Without polypectomy/ biopsy 319
With polypectomy/ biopsy 456
Per complication of colonoscopy 1,627
Per LY with CRC care† Initial care Continuing  
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 17,219 686 23,787 9,353
Stage II CRC 22,177 686 23,787 8,912
Stage III CRC 26,584 686 24,889 10,235
Stage IV CRC 30,992 686 32,051 19,931
QALY = quality-adjusted life-year; FIT = fecal immunochemical test; LY = life-year; CRC = colorectal cancer
*The loss of quality of life associated with a particular event.
†Care for CRC was divided in three clinically relevant phases: the initial, continuing, and terminal care phase. 
The initial care phase was defined as the first 12 months after diagnosis; the terminal care phase was defined as 
the final 12 months of life; the continuing care phase was defined as all months in between. In the terminal care 
phase, we distinguished between CRC patients dying from CRC and CRC patients dying from another cause. 
For patients surviving less than 24 months, the final 12 months were allocated to the terminal care phase and 
the remaining months were allocated to the initial care phase. 
‡Utility losses for LYs with initial care were derived from a study by Ness and colleagues.[39]  For LYs with 
continuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing care for 
stage III and IV CRC, we assumed the corresponding utility losses for LYs with initial care. For LYs with terminal 
care for CRC, we assumed the utility loss for LYs with initial care for stage IV CRC. For LYs with terminal care for 
another cause, we assumed the corresponding utility losses for LYs with continuing care. 
§Costs include patient time costs (i.e. the opportunity costs of spending time on surveillance or being treated for 
a complication of colonoscopy or CRC), but do not include travel costs, costs of lost productivity, and unrelated 
health care and non-health care costs in added years of life. We assumed that the value of patient time was equal 
to the mean wage rate in 2012: €15.93 per hour. We assumed that FITs, colonoscopies, and complications used 
up 1, 8, and 16 hours of patient time, respectively. Patient times associated with CRC care were derived from a 
study by Yabroff and colleagues.[43]
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recurrence in adenoma patients obtained from the SAP study, respectively) (Appendix 1); 
3) a less favourable average life-expectancy for adenoma patients compared with the 
general population (78.3 instead of 83.3 years for females and 74.7 instead of 79.7 years for 
males); 4) twice the base-case colonoscopy miss rates for adenomas and CRC; 5) half and 
twice the base-case utility losses for colonoscopies and complications; 6) half and twice 
the base-case costs for colonoscopies; 7) half and twice the base-case costs for CRC care; 
and 8) differential discounting of costs and effects as recommended by the Dutch National 
Health Care Institute (using a 4% and 1.5% annual discount rate, respectively). Since the 
cost-effectiveness of the Dutch national CRC screening programme depends on the 
assumptions made in the various sensitivity analyses, we adjusted the willingness-to-pay 
threshold that was applied accordingly (Appendix 3).
Scenario Analyses 
To explore the generalizability of our results to other European countries, we performed 
scenario analyses in which we assumed a lower and a higher overall level of health care 
costs (using half and twice the base case costs for colonoscopies and CRC care, 
respectively). For all levels of health care costs (i.e., Dutch, low and high) we determined 
the appropriate surveillance intervals applying cost-effectiveness thresholds of €2,600, 
€5,000, €10,000, €20,000 and €40,000 per QALY gained.  
RESULTS
The Impact of Adenoma Risk Score on the Effects and Costs of Surveillance
Surveillance was substantially more effective in patients with a high rather than a low 
adenoma risk score. For example, 3-yearly colonoscopy surveillance up to age 80 
prevented more CRC cases (140 vs. 20 per 1,000 patients) and CRC deaths (93 vs. 13 per 
1,000 patients) in 60-year-old females with risk score 5 than in 60-year-old females with 
risk score 0 (Table 2). It also resulted in more LYs gained (764 vs. 98 per 1,000 patients) and 
QALYs gained (858 vs. 92 per 1,000 patients). As a result of the larger savings made on CRC 
care, the net costs of surveillance were substantially lower in patients with a higher 
adenoma risk score. Among 1,000 60-year-old females, 3-yearly colonoscopy surveillance 
up to age 80 was associated with a net cost of €823,250 in those with risk score 0 and a net 
saving of €2,625,092 in those with risk score 5. Hence, each particular surveillance strategy 
was substantially more cost-effective in patients with a high, rather than a low adenoma 
risk score. 
Appropriate Surveillance Intervals for 60-Year-Old Females
Figure 2 shows the costs and effects of all surveillance strategies in 60-year-old females 
with risk scores 0 up to 5. Among the efficient surveillance strategies, more intensive 
(Table 1).[40] Colonoscopy costs were obtained from a Dutch trial comparing colonoscopy 
with CT colonography screening.[24] The costs of complications and initial and continuing 
care for CRC were based on reimbursement rates obtained from the Dutch Health Care 
Authority.[41] The costs of terminal care for CRC were based on the average costs of 
CRC death obtained from a Dutch study on the disease-specific costs of the last year of life 
and the relationship between these costs and stage as observed in the US.[42 43] As the 
costs of terminal care for CRC death in the Netherlands were approximately 40% of the 
corresponding US costs, we assumed that the costs of terminal care for non-CRC death in 
CRC patients were also 40% of the corresponding US costs.[43] We adjusted all costs to 
reflect the 2012 level using the Dutch consumer price index and added patient time costs 
to all cost estimates.
Outcomes 
For each cohort, we quantified the lifetime effectiveness of each surveillance strategy (i.e., 
CRC cases prevented, CRC deaths prevented, LYs gained and QALYs gained) as well as the 
lifetime costs, applying the internationally conventional 3% annual discount rate to both. 
We expressed the cost-effectiveness of surveillance in terms of the costs per QALY gained.
Analysis
For each cohort, we ruled out all surveillance strategies that were more costly and less 
effective than other strategies (i.e., simple dominance) or combinations of other strategies 
(i.e., extended dominance). For each remaining (i.e., efficient) strategy, we calculated the 
incremental cost-effectiveness ratio by comparing its costs and QALYs gained with those 
of the next less costly and less effective efficient strategy. We selected the appropriate 
surveillance strategies by applying a threshold for the willingness-to-pay per QALY gained 
equal to the incremental cost-effectiveness ratio of the Dutch national CRC screening 
programme (i.e., €2,600 per QALY gained given our base case assumptions) (Appendix 3). 
The surveillance intervals applied in the selected surveillance strategies are the appropriate 
intervals for a first surveillance colonoscopy in adenoma patients. In the results section, we 
present detailed results for 60-year-old females followed by an overview of the appropriate 
surveillance intervals for all other patients.
Sensitivity Analyses
To explore the uncertainty in the results of our base-case analysis, we repeated our analysis 
assuming: 1) a weaker and a stronger association between adenoma risk score and the risk 
for advanced adenoma recurrence (using the lower and upper boundary of the 95% 
confidence interval of the relative risk associated with a one point increase in adenoma 
risk score obtained from the SAP study, respectively (Appendix 1)); 2) a lower and higher 
average risk for advanced adenoma recurrence in adenoma patients (using the lower and 
upper boundary of the 95% confidence interval of the average risk for advanced adenoma 
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surveillance resulted in only small increases in the effectiveness of surveillance compared 
with the increases in costs. In 60-year-old females with risk score 0, for example, the least 
effective, efficient surveillance strategy (i.e., 10-yearly colonoscopy surveillance up to age 
75) resulted in 49 QALYs gained per 1,000 females (Table 3). The most effective, efficient 
surveillance strategy (i.e., 4-yearly colonoscopy surveillance up to age 80), on the other 
hand, resulted in 92 QALYs gained per 1,000 females: a 2-fold increase. Simultaneously, the 
costs of surveillance increased from €538 to €46,488 per 1,000 females: a 22-fold increase.
 Based on a willingness-to-pay threshold equal to the incremental cost-effectiveness 
ratio of the Dutch national CRC screening programme, the appropriate surveillance 
strategy in 60-year-old females with adenoma risk score 0 was 10-yearly colonoscopy 
surveillance up to age 75 (Table 3). In 60-year-old females with a higher adenoma risk 
score more intensive surveillance strategies remained cost-effective. As a result, the 
appropriate interval for colonoscopy surveillance decreased from 10 years in females with 
risk score 0 to 7 years, 5 years, 4 years, 3 years and 2 years in those with risk scores 1 up to 5. 
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Figure 2   The Effectiveness and Costs of All Surveillance Strategies in 60-year-old 
 Females with Adenoma Risk Scores 0 up to 5.*
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* Results are based on a comparison with the ‘no surveillance’ scenario (i.e., no further testing), reported per 
1,000 females and discounted by 3% per year.
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Appropriate Surveillance Intervals for Other Adenoma Patients
In general, surveillance was more cost-effective in patients with a high, rather than a low 
adenoma risk score; in males compared with females; and in older compared with younger 
patients. As a result, the appropriate surveillance intervals in these groups were shorter 
(Table 4). The appropriate interval ranged from 10 years in some patients with adenoma 
risk score 0 to 2 years in some patients with adenoma risk scores 4 and 5. Referral to FIT 
screening was dominated by colonoscopy surveillance in all cohorts. 
Surveillance was no longer cost-effective in patients with risk score 0 aged 70 years or 
older, patients with risk score 1 and males with risk score 2 aged 75 years or older and 
females with risk score 2 and patients with risk scores 3-5 aged 80 years or older (Table 4). 
Sensitivity Analyses
The appropriate surveillance intervals were most sensitive to varying the costs of 
colonoscopies and the costs of CRC care (Table 5). Higher colonoscopy costs resulted in 
longer surveillance intervals (patients with risk score 0 should even be referred to FIT 
screening). Conversely, higher CRC care costs resulted in shorter surveillance intervals, 
particularly in those with a low adenoma risk score. The ages at which surveillance was no 
longer cost-effective were also sensitive to the average risk for advanced adenoma 
recurrence in adenoma patients, the average life expectancy of adenoma patients and 
the sensitivity of colonoscopy for the detection of adenomas and CRC (Table 5). 
Table 3   The Incremental Cost-Effectiveness of All Efficient Surveillance Strategies in 
60-year-old Females with Adenoma Risk Scores 0 up to 5.*
Adenoma 
Risk Score
Surveillance Strategy 
(interval, yrs  
(stopping age, yrs))
QALYs Gained, n Costs, €† Incremental Costs  
per QALY Gained, €
0 10 (75) 49 26,513 538‡
9 (75) 50 28,231 4,357
7 (75) 71 131,732 4,739
6 (80) 82 251,780 11,337
5 (80) 88 395,541 23,866
4 (80) 92 573,362 46,488
1 9 (75) 85 -113,302 cost saving
7 (75) 123 -83,687 776‡
6 (80) 143 -5,379 3,996
5 (80) 155 102,341 8,738
4 (80) 164 242,769 16,099
3 (80) 167 464,661 77,368
3 (85) 169 671,107 84,041
2 (80) 170 1,193,016 492,047
2 6(75) 201 -401,168 cost saving
5(75) 237 -384,384 472‡
5(80) 256 -328,588 2,870
4(80) 272 -240,439 5,451
3(80) 280 -66,217 22,122
3(85) 286 122,246 29,822
2(80) 294 581,276 57,199
3 5(75) 364 -927,511 cost saving
5(80) 395 -922,363 168
4(80) 422 -910,897 417‡
3(80) 437 -799,237 7,378
3(85) 449 -638,431 13,644
2(80) 468 -271,927 19,955
2(85) 468 -75,378 694,588
4 4(80) 612 -1,727,635 cost saving
3(80) 638 -1,693,368 1,341‡
3(85) 657 -1,570,667 6,502
2(80) 689 -1,324,835 7,576
Table 3   Continued.
Adenoma 
Risk Score
Surveillance Strategy 
(interval, yrs  
(stopping age, yrs))
QALYs Gained, n Costs, €† Incremental Costs  
per QALY Gained, €
2(85) 691 -1,143,723 84,042
1(80) 697 487,378 281,496
5 3(80) 858 -2,625,092 cost saving
2(80) 936 -2,443,321 2,356‡
2(85) 940 -2,280,636 36,843
1(80) 963 -826,352 62,305
QALY = quality-adjusted life-year
* Results are based on a comparison with the ‘no surveillance scenario (ie, no further testing), reported per 
1,000 females, and discounted by 3% per year.
† The costs of colonoscopies, complications, and LYs with CRC care with surveillance minus the costs of LYs 
with CRC care without surveillance.
‡ The appropriate strategies are selected using a cost effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (ie, €2,600 per QALY gained) (Appendix 3). 
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Scenario Analyses
While results were sensitive to varying the costs of either colonoscopies or CRC care, they 
were relatively robust to varying both costs simultaneously (i.e. the overall level of health 
care costs in a country) (Table 6). Applying higher cost-effectiveness thresholds resulted 
in substantially more intensive surveillance recommendations, again particularly in those 
with a low adenoma risk score.
Table 4   The Appropriate Intervals For Colonoscopy Surveillance by Adenoma  
Risk Score, Sex, and Age.*
FEMALE
Age, yrs
Adenoma 
Risk Score
40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 8 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 6 5 6 5 5 5 5 4 NS
3 4 5 4 4 4 4 4 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
MALE
Age, yrs
Adenoma 
Risk Score
40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 7 NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening program (ie, €2,600 per QALY gained) (Appendix 3).
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DISCUSSION
Principal findings
Our study demonstrates that the appropriate interval for a first surveillance colonoscopy 
in adenoma patients depends heavily on adenoma risk score and to a lesser extent on sex 
and age. While some patients with risk score 0 (i.e., with 1 small (<10mm), non-villous, 
distal adenoma) should be recommended a surveillance colonoscopy after 10 years, some 
patients with risk scores 4 and 5 should be recommended a surveillance colonoscopy 
after only 2 years. Surveillance should no longer be recommended in patients with risk 
score 0 aged 70 years or older, patients with risk score 1 and males with risk score 2 aged 
75 years or older and patients at higher risk aged 80 years or older. Results were relatively 
robust to the overall level of health care costs in a country. However, applying less stringent 
cost-effectiveness thresholds resulted in substantially more intensive surveillance recom-
mendations, particularly in those with a low adenoma risk score. 
Strengths and weaknesses 
The most important strength of our study is that it provides surveillance recommenda-
tions that are carefully tailored to the individual adenoma patient. This ensures that 
surveillance colonoscopies are targeted at those patients most likely to benefit. The two 
factors that determine the benefit of surveillance are the patient’s risk for CRC and life 
expectancy. By stratifying patients using the adenoma risk score, we assure that all 
adenoma findings that predict CRC risk are considered in an appropriate way. Meanwhile, 
MISCAN-Colon incorporates the impact of sex and age on both CRC risk and life 
expectancy. Another strength of our study is that we based our recommendations on a 
formal cost-utility analysis. Within this type of analysis all short and long term costs and 
health effects (both on quantity and quality of life) of an intervention are explicitly 
identified, measured, valued and weighed. 
A limitation of our study is that it focuses on the appropriate interval for a first surveillance 
colonoscopy only. Although this is often considered as the most important clinical 
decision to be made in adenoma patients, most patients will have to undergo multiple 
surveillance colonoscopies over the course of their lives. To determine the appropriate 
intervals for subsequent surveillance colonoscopies, studies are required that quantify the 
risk for advanced adenoma recurrence based on finding during index colonoscopy and at 
least one surveillance colonoscopy. So far, only few, small studies have been conducted in 
this area. 
Generalizability
The SAP score chart is based on data collected in Dutch adenoma patients. However, 
since the risk factors for advanced adenoma recurrence observed in the SAP study (as well as 
the magnitude of risk associated with each risk factor) were very comparable to those T
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6-fold higher risk for CRC. Therefore, according to our study, the former patient can be 
recommended a substantially longer surveillance interval (i.e. 7 instead of 3 years), whereas 
the latter patient should be recommended a shorter surveillance interval (i.e. 2 instead of 
3 years). 
Implications for clinicians
Our study demonstrates that existing guidelines for colonoscopy surveillance in adenoma 
patients are suboptimal and that more extensive risk stratification of adenoma patients is 
indicated. However, we realise that it might not be feasible to stratify adenoma patients to 
the level we have done in our current study. Since the appropriate surveillance intervals 
and stop ages are primarily affected by adenoma risk score and to a lesser extent by sex 
and age, one way to simplify would be to base surveillance recommendations on 
adenoma risk score only. This approach was chosen by the Dutch Association of Gastro-
enterologists when they revisited their guidelines for colonoscopy surveillance based on 
results of this study in May 2013.[45] Moreover, we believe that our study is the first to 
demonstrate that colonoscopy surveillance should no longer be recommended in very 
old patients.
Future research 
The benefits of surveillance in elderly adenoma patients depend heavily on a patient’s life 
expectancy. While surveillance may no longer be cost-effective in patients with an 
average life expectancy, it may still be relevant in patients with a better-than-average life 
expectancy. Conversely, surveillance that is cost-effective in patients with an average life 
expectancy may not be cost-effective or even harmful, in patients with a worse-than- 
average life expectancy. Hence, studies are required that investigate the appropriate age 
to stop surveillance based on a patient’s life expectancy. Moreover, modelling studies 
estimating the population impact of more targeted surveillance on the costs and health 
effects of surveillance would be useful. These studies should also assess the potential 
effects of more targeted surveillance guidelines on adherence to surveillance recommen-
dations, which might either increase or decrease.
Conclusions
Our study demonstrates that existing guidelines for colonoscopy surveillance in adenoma 
patients do not consistently target colonoscopies at those patients most likely to benefit. 
A more personalised approach to surveillance in adenoma patients, using the adenoma 
risk score, targets colonoscopies at those patients most likely to benefit and has great 
potential to increase the efficiency of surveillance. Since several European countries 
recently adopted a population based CRC screening program and many of those 
participating in screening will eventually enter colonoscopy surveillance, a more 
personalised to surveillance approach will become increasingly important.
found in an earlier meta-analysis of 8 North American studies,[9] we believe that the SAP 
score chart is a reliable instrument to risk-stratify adenoma patients in many different 
settings. The fact that we used a microsimulation model quantified to the Dutch clinical 
setting is also unlikely to severely hamper the generalizability of our results. Sensitivity 
analyses show that the appropriate surveillance intervals, as well as the ages to stop 
surveillance are relatively robust to varying the average risk for advanced adenoma 
recurrence in adenoma patients, while life-expectancy and CRC survival rates do not differ 
substantially between Western European countries. Perhaps a more serious threat to the 
generalizability of our results is the fact that our analysis is based on the Dutch economic 
setting. In our base case analysis we used Dutch cost estimates and we applied a 
willingness- to-pay threshold equal to the incremental cost-effectiveness ratio of the 
Dutch national screening programme to determine appropriate surveillance intervals. 
We addressed this issue by performing extensive sensitivity analyses on the costs of 
colonoscopies and CRC care (Table 5). Moreover, we performed simple scenario analyses 
in which we varied the overall level of health care costs (i.e. of both colonoscopies and 
CRC care) and determined the appropriate surveillance intervals using several higher 
cost-effectiveness thresholds (Table 6). Whereas results were sensitive to varying the 
costs of either colonoscopies or CRC care, they were relatively robust to varying the overall 
level of health care costs. Applying higher cost-effectiveness thresholds resulted in more 
intensive surveillance recommendations.   
Comparison with existing surveillance guidelines 
Our study demonstrates that existing surveillance guidelines do not consistently target 
colonoscopies at those patients most likely to benefit. The 2002 Dutch guidelines, for 
example, risk stratified adenoma patients based on adenoma multiplicity only. This implied 
that a 60-year-old female with 3 small, non-villous, distal adenomas was recommended 
colonoscopy surveillance after 3 years, while a 60-year-old female with 2 large, villous, 
proximal adenomas was recommended colonoscopy surveillance after 6 years.[11] 
However, according to the SAP score chart, the former patient has an adenoma risk score 
of 1, whereas the latter patient has an adenoma risk score of 4, corresponding to an almost 
4-fold higher risk for CRC. Therefore, according to our study, the former patient should be 
recommended colonoscopy surveillance after 7 years, while the latter patient should be 
recommended colonoscopy surveillance after 3 years: almost the exact opposite of 
surveillance as recommended by the Dutch guidelines. Moreover, our study demonstrates 
that it is important to treat relevant adenoma characteristics as separate predictors of risk. 
According to the current European guidelines, for example, both a 60-year-old female 
with 3 small, non-villous, distal adenomas and a 60-year-old female with 5 large, villous, 
proximal adenomas are recommended colonoscopy surveillance after 3 years.[44] 
However, according to the SAP score chart, the former patient has an adenoma risk score 
of 1, whereas the latter patient has an adenoma risk score of 5, corresponding to an almost 
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Appendix 1 – Relative Risks Associated with Adenoma Risk Scores 0 up to 5
In the SAP study, a one-point increase in adenoma risk score corresponded with an 
increase in the odds for advanced adenoma recurrence of 1.688 (95% CI: 1.475 - 1.932).[12] 
Within the SAP study, there were 886 patients with risk score 0, 1,153 patients with risk 
score 1, 607 patients with risk score 2, 206 patients with risk score 3, 57 patients with risk 
score 4, and 5 patients with risk score 5. Hence, the average adenoma risk score in the SAP 
study was 1.111. This score corresponds with an odds ratio (OR) for advanced adenoma 
recurrence of 1. Hence, in the base case analysis, the OR corresponding with risk score x 
was 1.688 ^ (x - 1.111), which corresponds to 0.559, 0.943, 1.593, 2.688, 4.538, and 7.660 for 
risk scores 0 up to 5, respectively. To use these ORs in MISCAN-Colon, we translated them 
to relative risks (RRs) using the formula: RR = OR / (1 – r + (OR*r)).[46] In this formula r is the 
average risk for advanced adenoma recurrence observed in the SAP study, which was 
0.065 (95% CI: 0.056 – 0.074). The resulting, rounded RRs for risk scores 0 up to 5 were 0.58, 
0.95, 1.53, 2.42, 3.69, and 5.35, respectively. For sensitivity analyses 1a (‘Weaker association 
adenoma risk score and risk’) and 1b (‘Stronger association adenoma risk score and risk’), 
we repeated the exercise described above using odds ratios for a one-point increase in 
adenoma risk score of 1.475 and 1.932, respectively. This resulted in RRs for risk scores 0 up 
to 5 of 0.66, 0.96, 1.38, 1.95, 2.71, and 3.69 and 0.50, 0.93, 1.71, 2.99, 4.89, and 7.30, respectively. 
For sensitivity analyses 2a (‘Lower average risk for advanced adenoma recurrence’ and 2b 
(‘Higher average risk for advanced adenoma recurrence’) we multiplied the base case RRs 
with 0.056 / 0.065 = 0.86 and 0.074 / 0.065 = 1.14. This resulted in RRs for risk scores 0 up to 
5 of 0.50, 0.82, 1.32, 2.09, 3.18, and 4.61 and 0.66, 1.08, 1.74, 2.75, 4.20, and 6.09, respectively.
Appendix 2 – Simulation of the SAP Population at Baseline
To estimate the average age-specific risks for CRC in adenoma patients, we simulated the 
SAP population after index colonoscopy by age (40, 45, (…), 80 years). We were able to 
closely mimic the observed characteristics of the SAP population (Appendix 2, Table 1). 
The 10-year cumulative risk for CRC ranged from 0.37% in patients aged 40 years to 1.41% 
in patients aged 70 years (Appendix 2, Figure 1).
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Appendix 2, Table 1  The Observed and Simulated Characteristics of the SAP  
Population at Baseline by Age.
Age 
(yrs)
Characteristics  Observed 
(%)
Simulated 
(%)
Simulated (%)/
Observed (%)
40 Number of adenomas 1 76.6 76.6 1.00
    2 16.2 16.2 1.00
    3 4.5 4.5 1.00
    4 0.6 0.6 1.00
    5+ 1.9 1.9 1.00
  Presence of at least one   Yes 35.1 35.7 1.02
  large adenoma (≥10mm) No 64.9 64.3 0.99
Presence of at least one Yes 21.4 21.8 1.02
proximal adenoma No 78.6 78.2 1.00
45 Number of adenomas 1 76.6 76.6 1.00
    2 16.5 16.5 1.00
    3 4.6 4.6 1.00
    4 0.9 0.9 1.00
    5+ 1.4 1.4 1.00
  Presence of at least one Yes 31.6 33.1 1.05
  large adenoma (≥10mm) No 68.4 66.9 0.98
Presence of at least one Yes 22.7 28.8 1.27
proximal adenoma No 77.3 71.2 0.92
50 Number of adenomas 1 73.1 73.1 1.00
    2 17.6 17.6 1.00
    3 6.7 6.7 1.00
    4 1.8 1.8 1.00
    5+ 0.9 0.9 1.00
  Presence of at least one Yes 32.4 34.9 1.08
  large adenoma (≥10mm) No 67.6 65.1 0.96
Presence of at least one Yes 25.3 37.5 1.48
proximal adenoma No 74.7 62.5 0.84
55 Number of adenomas 1 69.3 69.3 1.00
    2 19.8 19.8 1.00
    3 6.9 6.9 1.00
    4 1.9 1.9 1.00
    5+ 2.1 2.1 1.00
Appendix 2, Table 1  Continued.
Age 
(yrs)
Characteristics  Observed 
(%)
Simulated 
(%)
Simulated (%)/
Observed (%)
  Presence of at least one Yes 36.3 39.8 1.10
  large adenoma (≥10mm) No 63.7 60.2 0.94
Presence of at least one Yes 29.3 41.9 1.43
proximal adenoma No 70.7 58.1 0.82
60 Number of adenomas 1 66.5 66.5 1.00
    2 19.9 19.9 1.00
    3 8.2 8.2 1.00
    4 2.0 2.0 1.00
    5+ 3.3 3.3 1.00
  Presence of at least one Yes 39.8 43.2 1.08
  large adenoma (≥10mm) No 60.2 56.8 0.94
Presence of at least one Yes 33.0 47.7 1.44
proximal adenoma No 67.0 52.3 0.78
65 Number of adenomas 1 66.3 66.3 1.00
    2 17.9 17.9 1.00
    3 10.1 10.1 1.00
    4 2.4 2.4 1.00
    5+ 3.2 3.2 1.00
  Presence of at least one Yes 40.4 45.0 1.12
large adenoma (≥10mm) No 59.6 55.0 0.92
Presence of at least one Yes 34.2 49.5 1.45
  proximal adenoma No 65.8 50.5 0.77
70 Number of adenomas 1 65.9 65.9 1.00
    2 18.3 18.3 1.00
    3 9.3 9.3 1.00
    4 3.1 3.1 1.00
    5+ 3.4 3.4 1.00
  Presence of at least one Yes 41.9 46.9 1.12
  large adenoma (≥10mm) No 58.1 53.1 0.91
Presence of at least one Yes 34.8 51.5 1.48
proximal adenoma No 65.2 48.5 0.74
75 Number of adenomas 1 64.3 64.3 1.00
    2 19.6 19.6 1.00
    3 9.5 9.5 1.00
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Appendix 3 – Cost-Effectiveness of the Dutch National Colorectal Cancer 
Screening Programme
Within the Dutch national CRC screening programme, individuals are invited for biennial 
faecal immunochemical test (FIT) screening from age 55 up to age 75 years. The test that 
is used is the FOB-Gold (Sentinel, Italy) with a cut-off for referral to colonoscopy of 275ng 
Hb/mL buffer (47μg/g faeces). At this cut-off the test characteristics of the FOB-Gold are 
broadly equivalent to those observed in the Dutch pilot studies executed prior to the 
implementation of the national screening programme.[47]
To determine the incremental cost-effectiveness ratio of the national screening 
programme, we determined the costs and the QALYs gained associated with all possible 
screening strategies with starting ages 40, 45, 50, 55, 60 and 65 years, stopping ages 70, 75, 
80 and 85 years and screening intervals 1, 1.5, 2 and 3 years (96 combinations). Test charac-
teristics for the FOB-Gold had to be estimated based on data from the Dutch pilot studies, 
since data from the national screening programme were still very sparse. 
Appendix 3, Figure 1 shows the costs and QALYs gained for all screening strategies given 
the assumptions used in the base-case analysis of the paper. As can be seen in the figure, 
the national screening programme is on the efficient frontier. Its incremental cost-effec-
Appendix 2, Table 1  Continued.
Age 
(yrs)
Characteristics  Observed 
(%)
Simulated 
(%)
Simulated (%)/
Observed (%)
    4 3.5 3.5 1.00
    5+ 3.2 3.2 1.00
  Presence of at least one Yes 45.9 51.3 1.12
  large adenoma (≥10mm) No 54.1 48.7 0.90
Presence of at least one Yes 36.8 55.0 1.49
proximal adenoma No 63.2 45.0 0.71
80 Number of adenomas 1 64.1 64.1 1.00
    2 20.0 20.0 1.00
    3 9.8 9.8 1.00
    4 3.1 3.1 1.00
    5+ 3.1 3.1 1.00
  Presence of at least one Yes 47.8 55.3 1.16
large adenoma (≥10mm) No 52.2 44.7 0.86
Presence of at least one Yes 40.3 56.8 1.41
  proximal adenoma No 59.7 43.2 0.72
Appendix 2, Figure 1  The Average Cumulative Risk for CRC in Adenoma Patients by 
Age After Polypectomy According to MISCAN-Colon.*
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tiveness ratio is €2,600 (Appendix 3, Table 1). Appendix 3, Table 2 shows the incremental 
cost-effectiveness ratios of the Dutch national screening programme given the 
assumptions used in the various sensitivity analyses performed (Table 5 of the paper).
Appendix 3, Figure 1  The Costs and QALYs Gained for All Screening Strategies Given 
the Assumptions Used in the Base-Case Analysis of the Paper.*
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*  Results are based on a comparison with no screening, reported per 1,000 individuals aged between 55 and 75 
years in 2015 and discounted by 3% per year.
†  The costs of FITs, colonoscopies, complications, and LYs with CRC care with screening minus the costs of LYs 
with CRC care without screening.
Appendix 3, Table 1  The Incremental Cost-Effectiveness of All Efficient Screening 
Strategies Given the Assumptions Used in the Base-Case Analysis of the Paper  
(see also Appendix 3, Figure 1).*   
Number Screening Strategy
(starting age-stopping age  
(screening interval))
QALYs 
Gained, n
Costs, €† Incremental Costs  
per QALY Gained, €
1 65-70 (3) 69 53,915 Reference
2 60-70 (3) 112 79,644 603
3 60-70 (2) 134 107,200 1,250
4 60-70 (1.5) 140 118,959 2,125
5 55-70 (2) 154 153,505 2,339
6‡ 55-75 (2) 188 239,606 2,593
7 55-75 (1.5) 199 294,367 4,649
8 50-75 (1.5) 215 378,642 5,431
9 50-80 (1.5) 235 498,777 6,075
10 50-80 (1) 255 677,983 8,816
11 45-80 (1) 264 820,917 15,853
12 45-85 (1) 270 930,802 18,841
13 40-85 (1) 271 1,048,845 138,845
QALY = quality-adjusted life-year
* QALYs gained and costs are based on a comparison with no screening, reported per 1,000 individuals aged 
between 55 and 75 years in 2015 and discounted by 3% per year.            
† The costs of FITs, colonoscopies, complications, and LYs with CRC care with screening minus the costs of LYs 
with CRC care without screening.             
‡ The Dutch national CRC screening programme.
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Appendix 4 – Sensitivity Analyses – Detailed Results
Appendix 3, Table 2  The Incremental Cost-Effectiveness of the Dutch National  
CRC Screening Programme given the assumptions made in the various sensitivity 
analyses performed.   
Analysis Incremental Costs  
per QALY Gained, €
Base case 2,600
1a. Weaker association adenoma risk score and risk* 2,600
1b. Stronger association adenoma risk score and risk* 2,600
2a. Lower average risk for advanced adenoma recurrence* 2,600
2b. Average risk for advanced adenoma recurrence* 2,600
3. Less favorable life-expectancy for adenoma patients (-5 yrs)† 5,100
4. Colonoscopy miss rates x 2 3,400
5a. Utility losses colonoscopies and complications x 0.5 2,600
5b. Utility losses colonoscopies and complications x 2 2,700
6a. Colonoscopy costs x 0.5 1,800
6b. Colonoscopy costs x 2 4,600
7a. CRC care costs x 0.5 4,100
7b. CRC care costs x 2† 0
8.Differential discounting of costs and effects† 2,800
* We assumed that the assumptions made in these analyses did not change the incremental cost-effectiveness 
of the Dutch National CRC screening programme.
† The Dutch national CRC screening programme was dominated by other strategies in these analyses. We 
used the incremental cost-effectiveness ratio of the most similar strategy (in terms of the life-time number of 
screens) that was on the efficient frontier instead.
Appendix 4, Table 1  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 1a. Weaker Association 
Adenoma Risk Score and Risk.*   
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 10 10 8 9 7 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 6 6 6 6 5 6 5 3 NS
3 5 5 5 5 4 4 4 3 NS
4 4 4 4 4 4 4 3 3 NS
5 4 4 3 3 3 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 9 9 8 8 6 NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 6 5 5 5 5 5 4 NS NS
3 5 4 4 4 4 4 4 3 NS
4 4 4 4 3 3 3 3 3 NS
5 3 3 3 3 3 3 3 2 NS
NS = no surveillance
* The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
94 | Chapter 3 Personalizing colonoscopy surveillance in adenoma patients | 95
3
Appendix 4, Table 2  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 1b. Stronger 
Association Adenoma Risk Score and Risk.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 10 10 FIT10 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 5 5 5 5 5 4 4 4 NS
3 4 4 4 4 4 3 3 2 NS
4 3 3 3 3 3 3 2 2 NS
5 3 3 2 2 2 2 2 2 3
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 9 NS NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 4 4 4 4 3 NS
3 4 4 3 3 3 3 3 3 NS
4 3 3 3 3 2 3 2 2 NS
5 2 2 2 2 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 3  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 2a. Lower Average Risk 
for Advanced Adenoma Recurrence.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 10 10 NS NS NS NS
1 9 10 8 8 7 7 NS NS NS
2 6 6 6 6 6 5 5 4 NS
3 5 5 5 4 4 4 4 3 NS
4 4 4 4 4 4 3 3 2 NS
5 3 3 3 3 3 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 9 NS NS NS NS
1 8 7 7 6 6 6 NS NS NS
2 6 6 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 3 3 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 4, Table 4  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 2b. Higher Average Risk 
for Advanced Adenoma Recurrence.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 10 10 9 9 7 NS NS NS
1 8 8 7 7 7 6 5 NS NS
2 5 5 5 5 5 4 4 4 NS
3 4 4 4 4 4 3 3 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 6 NS NS NS
1 7 6 6 6 6 5 5 NS NS
2 5 5 4 4 4 4 4 3 NS
3 4 4 4 3 3 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 2 2 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 5  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 3. Less Favourable Life-
Expectancy for Adenoma Patients (-5yrs)*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 9 NS NS NS NS
1 7 7 7 6 6 6 NS NS NS
2 5 5 5 5 5 5 5 NS NS
3 4 4 4 4 4 4 4 3 NS
4 3 3 3 3 3 3 3 3 NS
5 3 3 3 3 3 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 8 9 7 8 NS NS NS NS
1 6 7 7 7 6 6 NS NS NS
2 5 5 5 5 4 4 4 NS NS
3 4 4 4 4 3 3 3 NS NS
4 3 3 3 3 3 3 3 3 NS
5 3 3 3 2 2 2 3 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 4, Table 6  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 4. Colonoscopy Miss 
Rates x 2.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 10 10 NS NS NS NS
1 7 8 7 7 7 7 NS NS NS
2 5 5 5 5 5 4 5 NS NS
3 4 4 4 4 4 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 2 2 2 2 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 9 NS NS NS NS
1 6 6 6 6 6 7 NS NS NS
2 5 4 4 4 4 4 5 NS NS
3 4 3 3 3 3 3 3 3 NS
4 3 3 3 3 2 3 3 2 NS
5 2 2 2 2 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 7  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 5a. Utility Losses 
Colonoscopies and Complications x 0.5.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 8 NS NS NS
1 9 8 7 7 7 7 6 NS NS
2 6 5 5 5 5 5 5 4 NS
3 4 5 4 4 4 4 4 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 6 NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 5 5 4 4 3 NS
3 4 4 4 4 4 4 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 2 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 4, Table 8  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 5b. Utility Losses 
Colonoscopies and Complications x 2.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 8 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 6 6 6 6 5 5 5 4 NS
3 5 5 4 4 4 4 4 3 NS
4 4 4 3 3 3 3 3 2 NS
5 3 3 3 3 3 3 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 7 NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 2 2 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 9  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 6a. Colonoscopy 
Costs x 0.5.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 7 7 7 7 7 5 NS NS
1 5 5 5 5 5 4 4 3 NS
2 4 4 4 4 4 3 3 3 NS
3 3 3 3 3 3 3 3 2 NS
4 3 3 2 2 2 2 2 2 3
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 6 6 6 6 6 6 4 NS NS
1 5 4 4 4 4 4 4 3 NS
2 4 3 3 3 3 3 3 3 NS
3 3 3 3 3 2 3 2 2 NS
4 2 2 2 2 2 2 2 2 NS
5 2 2 2 2 2 2 2 1 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 4, Table 10  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 6b. Colonoscopy 
Costs x 2.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 FIT10 FIT10 FIT10 FIT10 FIT10 NS NS NS NS
1 10 10 10 9 10 8 NS NS NS
2 9 8 8 7 7 7 6 NS NS
3 6 7 6 6 6 6 5 4 NS
4 5 5 5 4 4 4 4 4 NS
5 4 4 4 4 4 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 FIT10 FIT10 FIT10 FIT10 NS NS NS NS NS
1 10 9 10 8 8 7 NS NS NS
2 7 7 7 6 6 6 5 NS NS
3 6 6 5 5 5 5 5 NS NS
4 5 5 4 4 4 4 4 3 NS
5 4 4 4 3 3 3 3 3 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 11  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 7a. CRC Care  
Costs x 0.5.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 10 10 FIT10 NS NS NS
1 9 10 8 9 7 8 NS NS NS
2 7 7 7 6 6 6 6 NS NS
3 5 5 5 5 5 5 4 4 NS
4 4 4 4 4 4 3 3 4 NS
5 4 4 3 3 3 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 9 NS NS NS NS
1 9 8 8 8 7 7 NS NS NS
2 6 6 6 5 5 5 5 NS NS
3 5 5 5 4 4 4 4 3 NS
4 4 4 4 4 4 3 3 3 NS
5 3 3 3 3 3 3 3 2 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 4, Table 12  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 7b. CRC Care Costs x 2.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 9 8 8 7 7 NS NS NS
1 6 6 6 5 5 5 5 NS NS
2 4 5 4 4 4 4 4 3 NS
3 4 3 3 3 3 3 3 2 NS
4 3 3 3 3 2 2 2 2 NS
5 2 2 2 2 2 2 2 1 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 7 7 6 6 6 NS NS NS
1 5 5 5 5 5 4 4 NS NS
2 4 4 4 4 3 4 3 3 NS
3 3 3 3 3 3 3 3 2 NS
4 2 2 2 2 2 2 2 2 NS
5 2 2 2 2 2 2 2 1 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
Appendix 4, Table 13  The Appropriate Intervals For Colonoscopy Surveillance 
by Adenoma Risk Score, Sex and Age: Results of Sensitivity Analysis 8. Differential 
Discounting of Costs and Effects.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 8 8 9 7 8 8 NS NS NS
1 6 6 6 6 6 6 6 NS NS
2 5 5 5 5 4 5 5 4 NS
3 4 4 3 4 4 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 2 2 2 3 2 2 3
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 8 8 8 7 7 7 NS NS NS
1 5 5 6 5 5 5 5 NS NS
2 4 4 4 4 4 4 4 3 NS
3 3 3 3 3 3 3 3 3 NS
4 3 3 3 3 2 3 3 2 NS
5 2 2 2 2 2 2 2 1 NS
NS = no surveillance
*The appropriate intervals are selected using a cost-effectiveness threshold equal to the incremental cost-
effectiveness ratio of the Dutch national CRC screening programme (Appendix 3). 
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Appendix 5 – Scenario Analyses – Detailed Results
Appendix 5, Table 1  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 1a. Low Health Care 
Costs, Cost-Effectiveness Threshold: €2,600/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 10 8 9 7 8 NS NS NS
1 7 7 7 6 6 6 6 NS NS
2 5 5 5 5 5 4 4 4 NS
3 4 4 4 4 4 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 2 2 3 2 2 3
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 8 9 8 8 7 6 NS NS NS
1 6 6 6 5 5 5 5 NS NS
2 5 4 4 4 4 4 4 3 NS
3 4 3 3 3 3 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 2 2 2 2 2 2 2 NS
NS = no surveillance
Appendix 5, Table 2  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 1b. Low Health Care 
Costs, Cost-Effectiveness Threshold: €5,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 7 7 7 7 7 6 NS NS
1 5 5 5 5 5 5 5 4 NS
2 4 5 3 4 4 4 4 4 NS
3 4 3 3 3 3 3 3 2 NS
4 3 3 3 3 2 3 2 2 3
5 2 2 2 2 2 2 2 2 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 6 6 6 6 6 6 NS NS
1 5 5 5 5 5 4 5 4 NS
2 4 4 4 4 4 4 4 3 NS
3 3 3 3 3 3 3 3 2 NS
4 3 3 2 2 2 2 2 2 3
5 2 2 2 2 2 2 2 2 3
NS = no surveillance
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Appendix 5, Table 3  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 1c. Low Health Care 
Costs, Cost-Effectiveness Threshold: €10,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 6 6 6 6 6 6 6 4 NS
1 5 5 5 4 4 5 3 4 NS
2 4 4 3 3 4 3 3 2 3
3 3 3 3 3 3 3 2 2 3
4 2 2 2 2 2 2 2 2 2
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 5 5 5 5 5 5 5 4 NS
1 4 4 4 4 4 4 4 4 NS
2 3 3 3 3 3 3 3 2 NS
3 3 3 3 3 2 3 2 2 3
4 2 2 2 2 2 2 2 2 3
5 2 2 2 2 2 2 2 1 2
NS = no surveillance
Appendix 5, Table 4  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 1d. Low Health Care 
Costs, Cost-Effectiveness Threshold: €20,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 5 5 5 5 5 5 5 4 NS
1 4 4 4 4 4 3 3 4 3
2 3 3 3 3 3 3 3 2 3
3 2 2 2 2 2 2 2 2 2
4 2 2 2 2 2 2 2 1 2
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 4 5 4 4 4 4 4 4 NS
1 4 3 3 3 3 3 3 4 NS
2 3 3 3 3 3 3 3 2 3
3 2 2 2 2 2 2 2 2 3
4 2 2 2 2 2 2 2 1 2
5 2 2 2 2 2 1 1 1 2
NS = no surveillance
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Appendix 5, Table 5  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 1e. Low Health Care 
Costs, Cost-Effectiveness Threshold: €40,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 4 4 4 4 4 5 5 4 NS
1 3 3 3 3 3 3 3 2 3
2 3 3 3 3 2 3 2 2 3
3 2 2 2 2 2 2 2 1 2
4 2 2 2 2 2 2 2 1 2
5 2 2 2 1 1 1 1 1 1
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 4 4 4 4 4 4 4 4 NS
1 3 3 3 3 3 3 3 2 3
2 2 2 2 2 2 2 2 2 3
3 2 2 2 2 2 2 2 1 2
4 2 2 2 2 2 2 2 1 2
5 1 1 1 1 1 1 1 1 1
NS = no surveillance
Appendix 5, Table 6  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 2a. Dutch Health Care 
Costs, Cost-Effectiveness Threshold: €2,600/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 8 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 6 5 6 5 5 5 5 4 NS
3 4 5 4 4 4 4 4 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 7 NS NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 2 2 2 NS
NS = no surveillance
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Appendix 5, Table 7  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 2b. Dutch Health Care 
Costs, Cost-Effectiveness Threshold: €5,000/QALY gained.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 10 8 9 7 8 NS NS NS
1 7 7 7 6 6 6 6 NS NS
2 5 5 5 5 5 4 4 4 NS
3 4 4 4 4 4 3 3 2 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 2 2 3 2 2 3
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 9 8 8 7 6 NS NS NS
1 6 6 6 5 5 5 5 NS NS
2 5 5 4 4 4 4 4 3 NS
3 4 3 3 3 3 3 3 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 2 2 2 2 2 2 2 NS
NS = no surveillance
Appendix 5, Table 8  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 2c. Dutch Health Care 
Costs, Cost-Effectiveness Threshold: €10,000/QALY gained.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 7 7 7 7 6 6 NS NS
1 5 5 5 5 5 5 5 4 NS
2 4 5 4 4 4 4 4 4 NS
3 3 3 3 3 3 3 3 2 3
4 3 3 3 3 2 3 2 2 3
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 6 6 6 6 6 6 NS NS
1 5 5 5 5 5 4 4 4 NS
2 4 4 4 4 4 4 4 3 NS
3 3 3 3 3 3 3 3 2 NS
4 3 3 2 2 2 2 2 2 3
5 2 2 2 2 2 2 2 1 3
NS = no surveillance
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Appendix 5, Table 9  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 2d. Dutch Health Care 
Costs, Cost-Effectiveness Threshold: €20,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 6 6 6 6 6 6 6 4 NS
1 4 5 5 4 4 5 5 4 NS
2 4 3 3 3 4 3 3 2 3
3 3 3 3 3 2 3 2 2 3
4 2 2 2 2 2 2 2 2 2
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 5 5 5 5 5 5 5 4 NS
1 4 4 4 4 4 4 4 4 NS
2 3 3 3 3 3 3 3 2 NS
3 3 3 3 2 2 3 2 2 3
4 2 2 2 2 2 2 2 2 2
5 2 2 2 2 2 2 2 1 2
NS = no surveillance
Appendix 5, Table 10  The Appropriate Intervals For Colonoscopy Surveillance by 
Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 2e. Dutch Health Care 
Costs, Cost-Effectiveness Threshold: €40,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 5 5 5 5 5 5 5 4 NS
1 4 4 4 4 4 3 3 2 3
2 3 3 3 3 3 3 3 2 3
3 2 2 2 2 2 2 2 2 2
4 2 2 2 2 2 2 2 1 2
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 4 5 4 4 4 4 4 4 NS
1 4 3 3 3 3 3 3 2 NS
2 3 3 3 3 3 3 2 2 3
3 2 2 2 2 2 2 2 2 3
4 2 2 2 2 2 2 2 1 2
5 2 2 2 2 2 1 1 1 2
NS = no surveillance
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Appendix 5, Table 11  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 3a. High Health Care 
Costs, Cost-Effectiveness Threshold: €2,600/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 FIT10 NS NS NS
1 9 9 8 8 7 7 6 NS NS
2 6 6 6 6 5 5 5 NS NS
3 5 5 5 4 4 4 4 3 NS
4 4 4 4 3 4 3 3 2 NS
5 3 3 3 3 3 3 3 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 FIT10 NS NS NS
1 8 7 7 6 6 6 6 NS NS
2 6 6 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 4 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
NS = no surveillance
Appendix 5, Table 12  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 3b. High Health Care 
Costs, Cost-Effectiveness Threshold: €5,000/QALY gained.*
FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 10 10 9 10 8 NS NS NS
1 9 8 8 7 7 7 6 NS NS
2 6 5 6 5 5 5 5 4 NS
3 4 5 4 4 4 4 4 3 NS
4 4 4 3 3 3 3 3 2 NS
5 3 3 3 3 2 3 2 2 NS
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 10 9 10 8 8 7 6 NS NS
1 7 7 6 6 6 6 5 NS NS
2 5 5 5 5 5 5 4 NS NS
3 4 4 4 4 4 4 4 3 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 3 2 2 2 2 NS
NS = no surveillance
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Appendix 5, Table 13  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 3c. High Health Care 
Costs, Cost-Effectiveness Threshold: €10,000/QALY gained.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 10 8 9 7 8 NS NS NS
1 7 7 7 6 6 6 6 NS NS
2 5 5 5 5 5 4 4 4 NS
3 4 4 4 4 4 3 3 2 NS
4 3 3 3 3 3 3 3 2 NS
5 3 3 3 2 2 2 2 2 3
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 9 9 9 8 7 6 6 NS NS
1 6 6 6 5 5 5 5 NS NS
2 5 5 4 4 4 4 4 3 NS
3 4 3 3 3 3 3 3 3 NS
4 3 3 3 3 3 3 2 2 NS
5 3 2 2 2 2 2 2 2 NS
NS = no surveillance
Appendix 5, Table 14  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 3d. High Health Care 
Costs, Cost-Effectiveness Threshold: €20,000/QALY gained.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 8 7 7 7 7 6 6 NS NS
1 5 5 5 5 5 5 5 4 NS
2 4 5 4 4 4 4 4 4 NS
3 3 3 3 3 3 3 3 2 3
4 3 3 3 3 2 3 2 2 3
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 7 6 6 6 6 6 6 NS NS
1 5 5 5 5 5 4 4 4 NS
2 4 4 4 4 4 3 4 3 NS
3 3 3 3 3 3 3 3 2 NS
4 3 3 2 2 2 2 2 2 3
5 2 2 2 2 2 2 2 1 2
NS = no surveillance
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Appendix 5, Table 15  The Appropriate Intervals For Colonoscopy Surveillance  
by Adenoma Risk Score, Sex and Age: Results of Scenario Analysis 3e. High Health Care 
Costs, Cost-Effectiveness Threshold: €40,000/QALY gained.*
  FEMALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 6 6 6 6 6 6 6 4 NS
1 4 5 5 4 4 5 5 4 NS
2 4 3 3 3 4 3 3 2 3
3 3 3 3 3 2 3 2 2 3
4 2 2 2 2 2 2 2 1 2
5 2 2 2 2 2 2 2 1 2
  MALE
 Age, yrs
Adenoma Risk Score 40 45 50 55 60 65 70 75 80
0 5 5 5 5 5 5 5 4 NS
1 4 4 4 4 4 4 4 4 NS
2 3 3 3 3 3 3 3 2 NS
3 3 3 3 2 2 3 2 2 3
4 2 2 2 2 2 2 2 2 2
5 2 2 2 2 2 2 2 1 2
NS = no surveillance
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INTRODUCTION
All guidelines for colorectal cancer (CRC) screening recommend a screening interval of 10 
years for colonoscopy screening in average-risk individuals.(1-4) Moreover, the US 
Preventive Services Task Force and the American College of Physicians recommend 
against routine screening in adults older than 75 years with an adequate screening history.
(1,3) Whereas CRC screening is well known to be underused by many Medicare 
beneficiaries,(5,6) recent studies have also demonstrated that many beneficiaries undergo 
more intensive colonoscopy screening than recommended:(7,8) 1 in 5 beneficiaries with a 
negative screening colonoscopy result undergoes a repeated screening colonoscopy 
within 5 years’ time instead of after 10 years. Furthermore, 1 in 4 beneficiaries with a 
negative screening colonoscopy result at 75 years or older receives yet another screening 
colonoscopy at an even more advanced age. Although the reasons for these practices 
vary, on some occasions they are likely to result from the beneficiary’s or clinician’s 
perception that screening should occur more frequently than recommended. However, 
whether such practices are actually favorable for Medicare beneficiaries (ie, whether they 
result in a net health benefit) is uncertain: The low risk for CRC after a negative screening 
colonoscopy result limits the life-years (LYs) that can be gained by applying a shorter 
screening interval than recommended,(9-13) whereas the high risk for other-cause 
mortality at advanced age limits the LYs that can be gained by continuing screening 
beyond 75 years.(13-15) On the other hand, both practices will substantially increase the 
number of colonoscopies performed and, hence, the number of colonoscopy-related 
complications experienced.(16) Moreover, continuing screening beyond 75 years might 
substantially increase overdiagnosis and overtreatment of CRC (ie, the detection and 
treatment of cancers that would not have been diagnosed without screening). As a result, 
more intensive screening than recommended might be associated with a balance among 
benefits, burden, and harms that is unfavorable for Medicare beneficiaries: it might 
negatively affect health. 
If more intensive screening than recommended is favorable for Medicare beneficiaries, 
the subsequent question is whether it is efficient from a societal perspective (ie, whether 
the net health benefit justifies the additional colonoscopies and financial resources 
required). This is important because both colonoscopy capacity and financial resources 
are constrained. 
The objective of this study was to determine whether more intensive colonoscopy 
screening than recommended is favorable for Medicare beneficiaries and, if so, whether it 
is efficient from a societal perspective. In a prior analysis,(13) we already demonstrated that 
applying a screening interval of 5 instead of 10 years and continuing screening beyond 75 
years result in a small increase in LYs gained relative to the increase in colonoscopies 
performed in those starting screening at 50 years. In this study, we extend this work by 
determining the net health benefit and cost-effectiveness of screening. Moreover, in our 
ABSTRACT
Importance Many Medicare beneficiaries undergo more intensive colonoscopy screening 
than recommended. Whether this is favorable for beneficiaries and efficient from a societal 
perspective is uncertain.
Objective To determine whether more intensive colonoscopy screening than recommended 
is favorable for Medicare beneficiaries (ie, whether it results in a net health benefit) and 
whether it is efficient from a societal perspective (ie, whether the net health benefit 
justifies the additional resources required).
Design, setting, and participants Microsimulation modeling study of 65-year-old Medicare 
beneficiaries at average risk for colorectal cancer (CRC) and with an average life expectancy 
who underwent a screening colonoscopy at 55 years with negative results.
Interventions Colonoscopy screening as recommended by guidelines (ie, at 65 and 
75 years) vs scenarios with a shorter screening interval (5 or 3 instead of 10 years) or in 
which screening was continued to 85 or 95 years.
Main outcomes and measures Quality-adjusted life-years (QALYs) gained (measure of 
net health benefit); additional colonoscopies required per additional QALY gained and 
additional costs per additional QALY gained (measures of efficiency).
Results Screening previously screened Medicare beneficiaries more intensively than 
recommended resulted in only small increases in CRC deaths prevented and life-years 
gained. In comparison, the increases in colonoscopies performed and colonoscopy-related 
complications experienced were large. As a result, all scenarios of more intensive screening 
than recommended resulted in a loss of QALYs, rather than a gain (ie, a net harm). The only 
exception was shortening the screening interval from 10 to 5 years, which resulted in 
0.7 QALYs gained per 1000 beneficiaries. However, this scenario was inefficient because 
it required no less than 909 additional colonoscopies and an additional $711 000 per 
additional QALY gained. Results in previously unscreened beneficiaries were slightly less 
unfavorable, but conclusions were identical.
Conclusions and relevance Screening Medicare beneficiaries more intensively than 
recommended is not only inefficient from a societal perspective; often it is also unfavorable 
for those being screened. This study provides evidence and a clear rationale for clinicians 
and policy makers to actively discourage this practice.
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Screening Scenarios
In both cohorts we simulated “recommended screening” (ie, colonoscopy screening at 65 
and 75 years), as well as 2 scenarios in which a shorter screening interval was applied:  (1) 
screening at a 5-year interval (screening at 65, 70, and 75 years) and (2) screening at a 
3-year interval (screening at 65, 68, 71, and 74 years). Furthermore, we simulated 2 scenarios 
of continued screening beyond 75 years: (1) screening up to 85 years (screening at 65, 75, 
and 85 years) and (2) screening up to 95 years (screening at 65, 75, 85, and 95 years). 
Beneficiaries in whom adenomas were removed were assumed to undergo colonoscopy 
surveillance according to current guidelines.(35) We assumed that surveillance continued 
until the diagnosis of CRC or death and that adherence to surveillance was 100%.
Test Characteristics
The sensitivity of colonoscopy for the detection of adenomas and CRC was obtained from 
a systematic review on miss rates observed in tandem colonoscopy studies and was 75% 
for small adenomas (≤5 mm in diameter), 85% for medium-sized adenomas (6-9 mm), and 
95% for large adenomas (≥10 mm) and CRC.(36) We assumed that 95% of all colonoscopies 
reached the cecum; for the remaining 5%, the reach of the procedure was assumed to be 
distributed uniformly over colon and rectum.
Complications of Colonoscopy
Age-specific risks for gastrointestinal and cardiovascular complications associated with 
colonoscopy were derived by performing additional statistical analyses on Medicare data 
used in a study by Warren and colleagues(16) (Appendix 1). According to these analyses, 
colonoscopies with polypectomy were associated with an excess risk for complications, 
whereas colonoscopies without polypectomy were not. The risks associated with colono - 
scopies with polypectomy increased exponentially with age (Figure 1). Only complications 
necessitating hospitalization or an emergency department visit were considered. We 
assumed that 1 of every 30,000 colonoscopies involving a polypectomy resulted in death.
(16,37)
Utility Losses Associated With Colonoscopy Screening
We assumed a utility loss (ie, a loss of quality of life) equivalent to 2 days of life per 
colonoscopy (0.0055 quality-adjusted life-years [QALYs]) and 2 weeks of life per 
complication (0.0384 QALYs) (Table 1). We also assigned a utility loss to each LY with CRC 
care.(38) Assigning utility losses to LYs with CRC care works 2 ways: On the one hand, 
screening prevents cancers by the detection and removal of adenomas. This reduces LYs 
with CRC care and, hence, results in a gain of quality of life. On the other hand, screening 
results in earlier detection and overdiagnosis and overtreatment of cancers. This adds LYs 
with CRC care and, hence, results in a loss of quality of life. The resulting net impact on 
quality of life can be either positive or negative.
current analysis, we focus on the Medicare population. Analyses were performed using 
the microsimulation model MISCAN-Colon (Microsimulation Screening Analysis–Colon).
METHODS
MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for CRC developed at the 
Department of Public Health of the Erasmus University Medical Center (Rotterdam, the 
Netherlands). The model’s structure, underlying assumptions, and calibration are 
described in the Model Appendix included at the end of this thesis. In brief, MISCAN-Colon 
simulates the life histories of a large population of persons from birth to death. As each 
simulated person ages, 1 or more adenomas may develop. These adenomas can progress 
from small (≤5mmin diameter) to medium (6-9 mm) to large size (≥10 mm). Some 
adenomas can develop into preclinical cancer, which may progress through stages I to IV. 
During each stage, CRC may be diagnosed because of symptoms. Survival after clinical 
diagnosis is determined by the stage at diagnosis, the localization of the cancer, and the 
person’s age.(17)
Screening will alter some of the simulated life histories: Some cancers will be prevented by 
the detection and removal of adenomas; other cancers will be detected in an earlier stage 
with a more favorable chance of survival. However, screening can also result in serious 
complications and overdiagnosis and overtreatment of CRC. By comparing all life histories 
with screening with the corresponding life histories without screening, MISCAN-Colon 
quantifies the effectiveness and efficiency of screening.
MISCAN-Colon was calibrated to the age-specific, stage-specific, and localization-specific 
incidence of CRC as observed before the introduction of screening and the age-specific 
prevalence and multiplicity distribution of adenomas as observed in autopsy studies.
(18-28) The preclinical duration of CRC and the adenoma dwell-time were calibrated to the 
rates of interval cancers and surveillance-detected cancers observed in randomized 
clinical trials evaluating screening using guaiac fecal occult blood tests and a once-only 
sigmoidoscopy.(29-33) 
Model Inputs 
Populations Simulated 
We simulated 2 cohorts of 10 million 65-year-old Medicare beneficiaries. In the first cohort, 
all beneficiaries had received a negative screening colonoscopy result at 55 years (ie, were 
up-to-date with screening recommendations). In the second cohort, all beneficiaries were 
previously unscreened. For both cohorts, we assumed the average population risk for CRC 
and an average life expectancy.(34) 
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Costs Associated With Colonoscopy Screening
The cost-effectiveness analyses were conducted from a societal perspective. The costs of 
colonoscopies were based on 2007 Medicare payment rates and copayments (Table 1).(41) 
The costs of complications were obtained from a cost-analysis of cases of unexpected 
hospital use after endoscopy in 2007.(42) We added patient time costs to both.(39) The 
costs of LYs with CRC care were obtained from an analysis of Surveillance, Epidemiology, 
and End Results–Medicare linked data and included patient deductibles, copayments, 
and patient time costs.(40) We adjusted all costs to reflect the 2013 level using the US 
Consumer Price Index.(43)
Assigning costs to LYs with CRC care also works 2 ways: On the one hand, screening 
prevents LYs with CRC care, reducing costs. On the other hand, screening adds LYs with 
CRC care, increasing costs. The net effect can be either a reduction or an increase in costs.
Figure 1   Model Inputs: Age-Specific Risks for Complications Associated With 
 Colonoscopies With Polypectomy.
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Derived by performing additional statistical analyses on Medicare data used in a study by Warren et al(16) 
(Appendix 1). Only complications necessitating hospitalization or an emergency department visit were 
considered.
a  Perforations, gastrointestinal bleeding, or complications necessitating transfusions; risk per colonoscopy = 1/
[exp(9.27953 − 0.06105 × Age) + 1] − 1/[exp(10.78719 − 0.06105 × Age) + 1].
b  Paralytic ileus, nausea and vomiting, dehydration, abdominal pain; risk per colonoscopy = 1/[exp(8.81404 − 
0.05903 × Age) + 1] − 1/[exp(9.61197 − 0.05903 × Age) + 1].
c  Myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac or respiratory arrest, syncope, 
hypotension, or shock; risk per colonoscopy = 1/[exp(9.09053 − 0.07056 × Age) + 1] − 1/[exp(9.38297 − 0.07056 
× Age)+1].
Table 1   Model Inputs: Utility Losses and Costs Associated with Colonoscopy Screening.
UTILITY LOSS (QALYs)a
Per colonoscopy
without polypectomy/ biopsy 0.005
with polypectomy/ biopsy 0.005
Per complication of colonoscopy 0.038
Per LY with CRC careb, c Initial  
care
Continuing  
care
Terminal care  
Death CRC
Terminal care  
Death other cause
Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
COSTS (2013 US$)
Per colonoscopy
without polypectomy/ biopsy 887
with polypectomy/ biopsy 1,096
Per complication of colonoscopy 6,045
Per LY with CRC care Initial  
care
Continuing 
care
Terminal care  
Death CRC
Terminal care  
Death other cause
Stage I CRC 36,683 3,050 63,809 19,176
Stage II CRC 49,234 2,870 63,555 17,279
Stage III CRC 59,759 4,021 67,041 21,457
Stage IV CRC 77,790 12,178 88,368 49,866
QALY = quality-adjusted life-year; LY = life-year; CRC = colorectal cancer
a The loss of quality of life associated with a particular event.
b Care for CRC was divided in three clinically relevant phases: the initial, continuing, and terminal care phase. 
The initial care phase was defined as the first 12 months after diagnosis; the terminal care phase was defined 
as the final 12 months of life; the continuing care phase was defined as all months in between. In the terminal 
care phase, we distinguished between CRC patients dying from CRC and CRC patients dying from another 
cause. For patients surviving less than 24 months, the final 12 months were allocated to the terminal care pha-
se and the remaining months were allocated to the initial care phase. A patient diagnosed with CRC at age 65, 
who dies from CRC at age 70, will be in the initial care phase from age 65 up to age 66, in the continuing care 
phase from age 66 up to age 69, and in the terminal care phase associated with death from CRC from age 69 
up to age 70. CRC patients who do not die from CRC will be in the continuing care phase from one year after 
diagnosis until one year before death from another cause.
c Utility losses for LYs with initial care were derived from a study by Ness and colleagues.(38) For LYs with 
continuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing care for 
stage III and IV CRC, we assumed the corresponding utility losses for LYs with initial care. For LYs with terminal 
care for CRC, we assumed the utility loss for LYs with initial care for stage IV CRC. For LYs with terminal care for 
another cause, we assumed the corresponding utility losses for LYs with continuing care. 
d Costs include copayments and patient time costs (i.e. the opportunity costs of spending time on screening 
or being treated for a complication or CRC), but do not include travel costs, costs of lost productivity, and 
unrelated health care and non-health care costs in added years of life. We assumed that the value of patient 
time was equal to the median wage rate in 2012: $16.71 per hour.(39) We assumed that colonoscopies and 
complications used up 8 and 16 hours of patient time, respectively. Patient time costs were already included 
in the estimates for the costs of LYs with CRC care obtained from a study by Yabroff and colleagues.(40)
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Outcomes and Analysis
For each scenario of more intensive screening than recommended, we determined 
the associated increase in CRC cases prevented, CRC deaths prevented, LYs gained, LYs 
with CRC care prevented, colonoscopies performed, and complications experienced. 
Subsequently, we determined the resulting increases in QALYs gained: the net health 
benefit of screening. If more intensive screening resulted in a gain of QALYs, it was 
considered favorable for Medicare beneficiaries; if it resulted in a loss of QALYs, it was 
considered unfavorable. In a second step, we determined the increase in costs associated 
with all scenarios simulated. For those scenarios that were favorable for Medicare 
beneficiaries, we related the increases in colonoscopies performed and costs to the 
increase in QALYs gained to determine the efficiency of screening.
We present both undiscounted and discounted results (applying the conventional 3% 
annual discount rate for both effects and resources required). We based our conclusions 
on the discounted results. Screening strategies associated with an incremental cost per 
QALY gained exceeding $100 000 (discounted) were considered inefficient.
Sensitivity Analyses
We repeated our analysis assuming (1) half and twice the base case utility losses for 
colonoscopies and colonoscopy-related complications; (2) no utility loss for LYs with 
continuing care for CRC and a utility loss of 0.12, 0.18, 0.24, and 0.70 QALYs lost for each LY 
with continuing care for stage I, II, III, and IV CRC, respectively; (3) twice the base-case costs 
for LYs with CRC care; (4) twice the base-case miss rates for proximal adenomas and CRC 
(44-47); and (5) twice the base-case miss rates for all adenomas and CRCs. Furthermore, to 
determine the extent to which our results were driven by more intensive screening rather 
than more beneficiaries entering surveillance, we repeated our analysis assuming 0% 
adherence to surveillance. Finally, we repeated our analysis for beneficiaries at 25% higher 
and 25% lower risk for CRC and for beneficiaries without comorbidity and with severe 
comorbidity, using comorbidity status–specific life tables.(48)
RESULTS
Previously Screened Beneficiaries
Benefits, Burden, and Harms
Screening Medicare beneficiaries with a negative screening colonoscopy result at 55 years 
according to current guideline recommendations (ie, colonoscopy screening at 65 and 75 
years) resulted in 14.1 CRC cases prevented, 7.7 CRC deaths prevented, and 63.1 LYs gained 
per 1,000 beneficiaries, compared with no screening (ie, a mean of 23.0 days per 
beneficiary) (Figure 2A-C). Moreover, recommended screening prevented 37.5 LYs with 
CRC care per 1,000 beneficiaries (Figure 2D). To achieve this effect, 2,131 colonoscopies 
had to be performed, causing 8.3 complications (Figure 2E and F).
Figure 2   Increases in Benefits, Burden, and Harms Associated With More Intensive  
Colonoscopy Screening Than Recommended in Medicare Beneficiaries With  
a Negative Screening Colonoscopy Result at 55 Years
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Figure 2   Continued. Figure 2   Continued.
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Numbers are per 1,000 beneficiaries and undiscounted. 
CRC indicates colorectal cancer; LY, life-year.
a  For each scenario, the distribution of additional LYs with CRC care prevented over the different phases of care 
and stages of CRC is given in Appendix 2.
b Only complications necessitating hospitalization or an emergency department visit were considered. 
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Compared with screening once every 10 years, screening every 5 years resulted in 1.7 
additional CRC cases prevented, 0.6 additional CRC deaths prevented, and 5.8 additional 
LYs gained per 1,000 beneficiaries (ie, a mean of 2.1 additional days of life per beneficiary). 
Moreover, screening every 5 years prevented 10.9 additional LYs with CRC care per 1,000 
beneficiaries. To achieve this relatively small added benefit, 783 additional colonoscopies 
had to be performed, causing 1.3 additional complications. Continuing screening up to 85 
instead of 75 years resulted in even fewer additional CRC cases prevented, CRC deaths 
prevented, and LYs gained: 0.2, 0.3, and 1.2 per 1,000 beneficiaries (ie, a mean of 0.4 
additional days of life per beneficiary), respectively. To achieve this marginal additional 
benefit, 369 additional colonoscopies had to be performed, causing 2.4 additional 
complications. Furthermore, instead of preventing additional LYs with CRC care, screening 
up to 85 instead of 75 years increased the number of LYs with CRC care. Further intensifying 
screening by reducing the screening interval to 3 years or by continuing screening up to 
95 years resulted in even smaller increases in the benefits of screening, also relative to the 
corresponding increases in burden and harms (Figure 2).
Net Health Benefit
In previously screened beneficiaries, recommended screening resulted in 63.1 LYs gained 
per 1,000 beneficiaries, compared with no screening (Table 2). On top of that, screening 
resulted in 13.4 QALYs gained per 1,000 beneficiaries through preventing LYs with CRC 
care. However, to achieve these benefits, colonoscopies had to be performed, resulting in 
a loss of 11.7 QALYs per 1,000 beneficiaries. Furthermore, these colonoscopies caused 
complications, resulting in a loss of another 0.3 QALYs per 1000 beneficiaries. Hence, 
recommended screening resulted in a net health benefit of 63.1 + 13.4 – 11.7 – 0.3 = 64.5 
QALYs gained per 1,000 beneficiaries. 
When a screening interval of 5 instead of 10 years was applied, the gain in quality of life by 
preventing additional LYs with CRC care was exceeded by the loss of quality of life due to 
additional colonoscopies and additional complications. As a result, applying a screening 
interval of 5 instead of 10 years resulted in fewer QALYs than LYs gained: 3.2 vs 5.8 per 1,000 
beneficiaries. When screening was continued up to 85 instead of 75 years, the overall loss 
of quality of life exceeded the associated increase in LYs gained. Hence, continuing 
screening up to 85 instead of 75 years resulted in a loss of QALYs rather than a gain. Both 
applying a screening interval of 3 instead of 5 years and continuing screening up to 95 
instead of 85 years also negatively affected the number of QALYs gained by screening. 
Discounting did not change the direction of the effect on QALYs gained for any of the 
scenarios simulated.
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Efficiency
Screening previously screened beneficiaries every 5 instead of 10 years was the only 
scenario of more intensive screening that resulted in QALYs gained: 0.7 per 1,000 beneficiaries 
(discounted result) (Table 3). To gain these QALYs, 675 additional colonoscopies and an 
additional $528,000 were required; hence, 909 additional colonoscopies and an additional 
$711,000 were required per additional QALY gained (discounted results).
Previously Unscreened Beneficiaries
In previously unscreened beneficiaries, more intensive screening than recommended was 
slightly less unfavorable or inefficient; however, screening every 3 instead of 5 years and 
continuing screening beyond 75 years were still associated with a loss of QALYs rather 
than a gain and screening every 5 instead of 10 years was still inefficient, necessitating 416 
additional colonoscopies and an additional $317,000 per additional QALY gained 
(discounted results) (Appendix 4).
Sensitivity Analyses
When the base-case utility losses for colonoscopies and complications were doubled or 
when a lower risk for CRC or a worse-than-average life expectancy was assumed, screening 
previously screened beneficiaries every 5 instead of 10 years resulted in a loss of QALYs 
rather than a gain (Table 4). None of the other sensitivity analyses changed the direction 
of the effect on QALYs gained for any of the scenarios simulated. Assuming a 25% higher 
risk for CRC resulted in the least unfavorable efficiency ratios: Screening previously 
screened beneficiaries every 5 instead of 10 years required 249 additional colonoscopies 
and an additional $181,000 per additional QALY gained (discounted results) (Table 4). 
Again, results in beneficiaries without prior screening were slightly less unfavorable 
(Appendix 4): In previously unscreened beneficiaries at 25% increased risk for CRC, 
screening every 5 instead of 10 years was associated with 174 additional colonoscopies 
and an additional $121,000 per additional QALY gained.
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Table 4   The Efficiency of More Intensive Colonoscopy Screening than Recommended 
in Medicare Beneficiaries with a Negative Screening Colonoscopy at Age 55: 
Results of Sensitivity Analyses (3% discounted).
Scenario Outcome ANALYSIS ANALYSIS
Ba
se
 ca
se
U
til
ity
 lo
ss
 
co
lo
no
sc
op
ie
s a
nd
 
co
m
pl
ic
at
io
ns
*0
.5
U
til
ity
 lo
ss
 
co
lo
no
sc
op
ie
s a
nd
 
co
m
pl
ic
at
io
ns
*2
U
til
ity
 lo
ss
 LY
s w
ith
 
co
nt
in
ui
ng
 ca
re
 =
 0
U
til
ity
 lo
ss
 LY
s w
ith
 
co
nt
in
ui
ng
 ca
re
 st
ag
e 
I a
nd
 II
 C
RC
 =
 0
.1
2 
an
d 
0.
18
Co
st
s L
Ys
 w
ith
  
CR
C 
ca
re
*2
M
is
s r
at
es
 
co
lo
no
sc
op
y 
- 
pr
ox
im
al
*2
a
M
is
s r
at
es
 
co
lo
no
sc
op
y 
- e
nt
ire
 
co
lo
n 
an
d 
re
ct
um
*2
a
Ad
he
re
nc
e 
to
 
su
rv
ei
lla
nc
e 
= 
0%
CR
Cr
is
k*
1.
25
CR
Cr
is
k*
0.
75
Li
fe
-e
xp
ec
ta
nc
y 
in
di
vi
du
al
s w
ith
 n
o 
co
m
or
bi
di
ty
b
Li
fe
-e
xp
ec
ta
nc
y 
in
di
vi
du
al
s w
ith
 
se
ve
re
 co
m
or
bi
di
ty
b
Applying  
shorter  
screening  
intervals 
5 yearsc ∆Colonoscopies/ 
∆QALYs gained
909 258 unfavorablef 11,787 587 909 536 267 1,488 249 unfavorablef 655 unfavorablef
∆US$/∆QALYs  
gained (*1,000)
711 202 9,224 459 582 413 200 1,167 181 505
3 yearsd ∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs  
gained (*1,000)
Continuing  
screening  
beyond age 75
up to  
age 85c
∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs  
gained (*1,000)
up to  
age 95e
∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs  
gained (*1,000)
QALY = quality-adjusted life-year
a  Assuming twice the base case miss-rates implies a sensitivity of 50% for small adenomas (≤5mm), 70% for 
medium-sized adenomas (6-9mm), and 90% for large adenomas (≥10mm) and CRC. 
b  Individuals are classified as having no comorbidity if none of the following conditions is present: a moderate 
or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS. Individuals 
are classified as having severe comorbidity if diagnosed with constructive obstructive pulmonary disease, 
congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic 
hepatitis, or AIDS.
c  Compared with recommended screening
d Compared with applying shorter screening intervals - 5 years
e Compared with continuing screening beyond age 75 - up to age 85
f The sensitivity analysis changed the direction of the effect on QALYs gained
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and overtreatment of CRC), nor did we explicitly weigh the benefits against the burden 
and harms. This is one of the strengths of the present study because it allows us to draw 
conclusions about the net health benefit of screening. Whereas clinicians and patients 
might be reluctant to apply a relatively long screening interval or to discontinue screening 
after 75 years on the basis of a certain balance between colonoscopies and LYs gained, 
they are more likely to respond to evidence demonstrating that more intensive screening 
than recommended negatively affects health. Furthermore, in our earlier study we did not 
consider costs, which is necessary to evaluate the appropriateness of screening from a 
societal perspective.
Our study has 3 main limitations. First, although CRC screening is recommended from 50 
years onward, we focused our analysis on the Medicare population; ie, we addressed the 
appropriateness of more intensive screening than recommended from 65 years onward. 
We chose to do so because patterns of more intensive screening than recommended 
have mainly been documented in the Medicare population. Nevertheless, an additional 
analysis shows that more intensive screening than recommended is also inefficient when 
started at 50 years (Appendix 5). Second, because we aimed to illustrate the impact of 
more intensive screening than recommended, we assumed 100% adherence to all 
screening scenarios. However, in reality, a beneficiary with negative results on screening 
colonoscopies at 65 and 68 years might be unlikely to receive another screening 
colonoscopy at 71 years. If a lower adherence rate were assumed, the scenarios of more 
intensive screening than recommended would be more similar to recommended 
screening. Third, although we did perform a sensitivity analysis on the sensitivity of 
colonoscopy for adenomas and CRC, we did not perform an analysis assuming low-quality 
colonoscopies. If a proper colonoscopy cannot be performed because of a bad bowel 
preparation, for example, an early repeated screening colonoscopy is of course justified.
Our analysis highlights some critical future research directions. First, it shows that 
continuing screening up to very advanced age can be inefficient or even harmful. This is 
also likely to be true for surveillance in patients who have had adenomas removed, 
particularly in those at relatively low risk for CRC. Investigating the appropriateness of 
surveillance at advanced age is particularly important because a substantial proportion of 
those being screened eventually enter surveillance. Furthermore, our sensitivity analyses 
demonstrate that the effectiveness and cost-effectiveness of screening depend on an 
individual’s life expectancy and, more importantly, risk for CRC, which reinforces the need 
for research on personalizing CRC screening recommendations. Finally, our study 
demonstrates the importance of considering effects on quality of life when screening is 
evaluated. However, data regarding the utility losses associated with CRC screening are 
sparse or even absent. More research is needed in this area.
DISCUSSION
Recent studies show that many Medicare beneficiaries undergo more intensive 
colonoscopy screening than recommended.(7,8) Our study shows that the resulting 
balance among benefits, burden, and harms is often unfavorable. Screening previously 
screened Medicare beneficiaries up to 85 instead of 75 years, for example, resulted in only 
1.2 additional LYs gained per 1,000 beneficiaries, whereas it required 369 additional 
colonoscopies, causing 2.4 additional complications (undiscounted results). As a result, 
this practice was associated with a loss of QALYs rather than a gain (ie, a net harm). The 
only scenario favorable for beneficiaries was screening every 5 instead of 10 years, which 
required 909 additional colonoscopies and an additional $711,000 per additional QALY 
gained (discounted results). This well exceeds the conventional thresholds for the 
willingness to pay per QALY gained of $50,000 and $100,000; and although some 
researchers regard these thresholds as being too low,(49) even these researchers suggest 
a threshold well below $711,000. Results in previously unscreened beneficiaries were 
slightly less unfavorable. However, screening every 3 instead of 5 years and continuing 
screening beyond 75 years were still associated with a loss of QALYs rather than a gain; and 
screening every 5 instead of 10 years still required 416 additional colonoscopies and an 
additional $317,000 per additional QALY gained.
The small increase in LYs gained by applying a shorter screening interval than 
recommended is explained by a combination of 2 factors: (1) the high sensitivity of 
colonoscopy for the detection of adenomas and CRC(36) and (2) the low progression rate 
of adenomas into CRC.(29) As a result of the former, adenomas and CRC are unlikely to be 
prevalent in individuals who just underwent a screening colonoscopy with negative 
results. As a result of the latter, adenomas that remain undetected during the first 
colonoscopy at 65 years or newly developed adenomas after this colonoscopy are unlikely 
to develop into CRC before 75 years, when the next recommended screening colonoscopy 
takes place. Hence, an additional screening colonoscopy at 70 years is unlikely to add 
much benefit. The small increase in LYs gained by continuing screening beyond 75 years 
is explained by the same 2 factors and by the high risk for other-cause mortality at 
advanced age, which reduces both the probability that screening will prevent CRC 
mortality and the number of LYs gained if CRC mortality is prevented. Moreover, the risks 
for colonoscopy-related complications and overdiagnosis and overtreatment of CRC 
increase with age, negatively affecting the net health benefit of screening.(16)
In the analysis underlying the US Preventive Services Task Force recommendation 
statement on CRC screening,(13) we already demonstrated that both applying shorter 
screening intervals than 10 years and continuing screening beyond 75 years result in a 
small increase in LYs gained and a large increase in colonoscopies performed in those 
starting screening at 50 years. However, in that analysis we did not quantify the possible 
harms of screening (ie, nonlethal colonoscopy-related complications and overdiagnosis 
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Conclusions
Screening Medicare beneficiaries more intensively than recommended is not only 
inefficient from a societal perspective; often it is also unfavorable for those being screened. 
This study provides strong evidence and a clear rationale for clinicians and policymakers 
to actively discourage this practice.
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Appendix 1. Complications of Colonoscopy
A study by Warren and colleagues reported risks for complications of colonoscopy by age 
and by polypectomy status, however, not by both factors simultaneously.(16) We 
performed additional statistical analyses on the data used in this study to derive these 
risks. In Warren’s study, Medicare claims data were used to determine the risks for serious 
gastrointestinal events (i.e. perforations, gastrointestinal bleeding or transfusions), other 
gastrointestinal events (i.e. paralytic ileus, nausea and vomiting, dehydration, abdominal 
pain), and cardiovascular events (i.e. myocardial infarction or angina, arrhythmias, 
congestive heart failure, cardiac or respiratory arrest, syncope, hypotension, or shock) in 
groups of Medicare beneficiaries undergoing either a screening colonoscopy without 
polypectomy, or a colonoscopy with polypectomy. These risks were compared to the risks 
observed in equally sized, matched control groups (i.e. groups of Medicare beneficiaries 
who did not undergo a colonoscopy). For both types of colonoscopy we used generalized 
linear modeling to predict the risk for each type of complication based on colonoscopy 
status (yes/ no) and age. By subtracting the predicted age specific risks without 
colonoscopy from the predicted risks with colonoscopy, we determined the age specific 
risks associated with both types of colonoscopy. The risks for complications associated 
with colonoscopies with polypectomy increased exponentially with age (Appendix 1, 
Figure). Screening colonoscopies without polypectomy were not associated with an 
excess risk for complications. In our study, we used the estimated age specific risks 
associated with colonoscopies with polypectomy for all modeled colonoscopies with 
polypectomy. 
Appendix 1, Figure 1  Age-specific Risks for Serious Gastrointestinal Complications (A), 
Other Gastrointestinal Complications (B), and Cardiovascular Complications (C)  
Associated with Colonoscopies with Polypectomy.
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Appendix 1, Figure 1  Continued.
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Appendix 2. The Additional Numbers of LYs With CRC Care Prevented by 
More Intensive Colonoscopy Screening Than Recommended in Medicare 
Beneficiaries With a Negative Screening Colonoscopy at Age 55
Appendix 2, Table 1  The Additional Number of LYs with CRC Care Prevented by 
More Intensive Colonoscopy Screening than Recommended in Medicare Beneficiaries 
with a Negative Screening Colonoscopy at Age 55 (numbers per 1,000 beneficiaries; 
undiscounted).a
Initial care Continuing careb Terminal care - death CRC Total  
(Figure 2D)
Stage I  
CRC
Stage II  
CRC
Stage III  
CRC
Stage IV  
CRC
Stage I 
CRC
Stage II 
CRC
Stage III 
CRC
Stage IV 
CRC
Stage I 
CRC`
Stage II 
CRC
Stage III 
CRC 
Stage IV 
CRC
Recommended screeningc -0.92 4.40 2.85 1.41 -25.64 28.70 17.04 4.07 0.20 1.16 1.39 2.88 37.5
Applying shorter screening intervals 5 yearsd 0.28 0.57 0.32 0.10 1.07 5.19 2.55 0.35 0.04 0.13 0.12 0.18 10.9
3 yearse 0.28 0.17 0.09 0.01 3.00 2.18 0.94 0.06 0.00 0.04 0.03 0.03 6.8
Continuing screening beyond age 75 up to age 85d -0.32 0.07 0.03 0.05 -2.29 -0.17 -0.05 0.09 0.01 0.04 0.04 0.12 -2.4
up to age 95f -0.02 -0.01 -0.00 0.00 -0.06 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.1
LY = life-year; CRC = colorectal cancer
a  Positve values indicate that LYs with CRC care are prevented by screening; negative values indicate that LYs with 
CRC care are induced by screening.
b  As LYs with continuing care for CRC and with terminal care before death from another cause are assigned the 
same utility loss in our analysis, they are summed up in this table. 
c Compared with no screening.
d Compared with recommended screening.
e Compared with applying shorter screening intervals - 5 years.
f Compared with continuing screening beyond age 75 - up to age 85.
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Appendix 3. Detailed Results for 5-Yearly Instead of 10-Yearly 
Colonoscopy Screening in Medicare Beneficiaries With a Negative 
Screening Colonoscopy at Age 55
Appendix 3, Table 1  The Effects of Applying a Screening Interval of 5 instead of  
10 Years for Colonoscopy Screening in Medicaire Beneficiaries with a Negative Screening 
Colonoscopy at Age 55 (results per 1,000 individuals; undiscounted)
5-yearly  
colonoscopy  
screening
10-yearly  
colonoscopy  
screening
Difference
EFFECTS ON HEALTH CARE USE
Colonoscopies
   Screening - polypectomy 456 367 89
   Screening - no polypectomy 1,976 1,326 649
   Surveillance - polypectomy 142 132 10
   Surveillance - no polypectomy 340 307 34
Complications of colonoscopy 9.5 8.3 1.3
LYs with initial CRC care
   Stage I 11.4 11.6 -0.3
   Stage II 6.1 6.7 -0.6
   Stage III 2.7 3.1 -0.3
   Stage IV 0.6 0.7 -0.1
LYs with continuing CRC care
   Stage I 206.6 207.4 -0.8
   Stage II 100.0 104.7 -4.7
   Stage III 45.1 47.4 -2.3
   Stage IV 2.8 3.1 -0.3
LYs with terminal care - CRC
   Stage I 0.9 0.9 -0.0
   Stage II 1.5 1.6 -0.1
   Stage III 1.2 1.3 -0.1
   Stage IV 1.2 1.4 -0.2
LYs with terminal care - other cause
   Stage I 15.8 16.1 -0.3
   Stage II 7.8 8.3 -0.5
   Stage III 3.4 3.6 -0.2
   Stage IV 0.3 0.3 -0.0
Appendix 3, Table 1  Continued.
5-yearly  
colonoscopy  
screening
10-yearly  
colonoscopy  
screening
Difference
EFFECTS ON HEALTH
CRC cases 24.0 25.6 -1.7
CRC deaths 5.7 6.3 -0.6
LYs lost due to CRC 90.4 96.2 -5.8
Utility loss (QALYs lost)
   Screening colonoscopies 13.3 9.3 4.0
   Surveillance colonoscopies 2.6 2.4 0.2
   Complications of colonoscopy 0.4 0.3 0.0
   LYs with CRC care 37.2 38.9 -1.8
   Total 53.5 50.9 2.6
QALYs lost 143.9 147.1 -3.2
EFFECTS ON COSTS (*$1,000)
   Screening colonoscopies 2,252 1,578 674
   Surveillance colonoscopies 457 416 41
   Complications of colonoscopy 58 50 8
   LYs with CRC care 2,922 3,071 -149
   Total 5,689 5,115 573
LY = life-year; CRC = colorectal cancer; QALY = quality-adjusted life-year
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Appendix 4. Results in Previously Unscreened Medicare Beneficiaries
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Appendix 4, Table 3  The Efficiency of More Intensive Colonoscopy Screening than 
Recommended in Medicare Beneficiaries without Prior Screening: Results of Sensitivity 
Analyses (3% discounted).
Scenario Outcome ANALYSIS ANALYSIS
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nd
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a
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- e
nt
ire
 
co
lo
n 
an
d 
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um
*2
a
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he
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e 
to
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rv
ei
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e 
= 
0%
CR
Cr
is
k*
1.
25
CR
Cr
is
k*
0.
75
Li
fe
-e
xp
ec
ta
nc
y 
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vi
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al
s w
ith
 n
o 
co
m
or
bi
di
ty
b
Li
fe
-e
xp
ec
ta
nc
y 
in
di
vi
du
al
s w
ith
 
se
ve
re
 co
m
or
bi
di
ty
b
Applying 
shorter 
screening 
intervals 
5 yearsc ∆Colonoscopies/ 
∆QALYs gained
416 193 unfavorablef 791 327 416 297 174 563 174 unfavorablef 338 13,821
∆US$/∆QALYs gained 
(*1,000)
317 147 604 249 249 223 125 432 121 252 11,272
3 yearsd ∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs gained 
(*1,000)
Continuing 
screening 
beyond age 75
up to 
age 85c
∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs gained 
(*1,000)
up to 
age 95e
∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs gained 
(*1,000)
QALY = quality-adjusted life-year
a  Assuming twice the base case miss-rates implies a sensitivity of 50% for small adenomas (≤5mm), 70% for 
medium-sized adenomas (6-9mm), and 90% for large adenomas (≥10mm) and CRC. 
b  Individuals are classified as having no comorbidity if none of the following conditions is present: an ulcer, a 
history of acute myocardial infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, constructive obstructive pulmonary disease, congestive heart failure, moderate 
or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS. Individuals 
are classified as having severe comorbidity if diagnosed with constructive obstructive pulmonary disease, 
congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic 
hepatitis, or AIDS.
c  Compared with recommended screening
d  Compared with applying shorter screening intervals - 5 years
e  Compared with continuing screening beyond age 75 - up to age 85
f  The sensitivity analysis changed the direction of the effect on QALYs gained
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Appendix 5. Results for More Intensive Colonoscopy Screening Than 
Recommended From Age 50 Onwards
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Appendix 5, Table 3  The Efficiency of More Intensive Colonoscopy Screening than 
Recommended from Age 50 onwards: Results of Sensitivity Analyses (3% discounted).
Scenario Outcome ANALYSIS ANALYSIS
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∆US$/∆QALYs 
gained (*1,000)
415 168 1,445 291 341 298 201 148 334 2,274
3 yearsd ∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs 
gained (*1,000)
Continuing 
screening 
beyond  
age 75
up to  
age 85c
∆Colonoscopies/ 
∆QALYs gained
616 224 unfavorablef 694 769 616 484 333 504 218 unfavorablef 917 847
∆US$/∆QALYs 
gained (*1,000)
529 192 597 661 466 421 291 430 183 798 740
up to  
age 95e
∆Colonoscopies/ 
∆QALYs gained
unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable unfavorable
∆US$/∆QALYs 
gained (*1,000)
QALY = quality-adjusted life-year
a  Assuming twice the base case miss-rates implies a sensitivity of 50% for small adenomas (≤5mm), 70% for 
medium-sized adenomas (6-9mm), and 90% for large adenomas (≥10mm) and CRC. 
b  Individuals are classified as having no comorbidity if none of the following conditions is present: an ulcer, a 
history of acute myocardial infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, constructive obstructive pulmonary disease, congestive heart failure, moderate 
or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS. Individuals 
are classified as having severe comorbidity if diagnosed with constructive obstructive pulmonary disease, 
congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic 
hepatitis, or AIDS.
c Compared with recommended screening
d Compared with applying shorter screening intervals - 5 years
e Compared with continuing screening beyond age 75 - up to age 85
f The sensitivity analysis changed the direction of the effect on QALYs gained
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INTRODUCTION
In its most recent recommendation statement on colorectal cancer (CRC) screening, the 
US Preventive Services Task Force (USPSTF) recommends screening using fecal occult 
blood testing, sigmoidoscopy, or colonoscopy, starting at age 50 years and continuing up 
to age 75 years (1). The USPSTF recommends against routine screening in persons older 
than 75 years with an adequate screening history (1). This latter recommendation is 
warranted by an analysis showing that the benefits of continuing screening from age 50 
to 85 years instead of 75 years do not justify the additional colonoscopies required (2). 
Although the USPSTF did not address the appropriateness of screening in inadequately 
screened elderly persons, this recommendation has led many members of the medical 
community to believe that no one older than 75 years should be screened for CRC (3, 4). 
However, because unscreened elderly persons are at greater risk for CRC than adequately 
screened elderly persons, screening them is likely to be effective and cost-effective up to 
a more advanced age. If so, the lack of more specific recommendations on the age to stop 
screening may result in an unfounded denial of access to screening in elderly persons 
who were never screened for CRC—a group representing 23% of all US persons older than 
75 years (5). 
Many other elderly persons continue to be screened up to their late 80s or early 90s (6). 
However, at these ages, screening is not likely to be cost-effective, even in those without 
previous screening. First, the high risk for death of competing disease at advanced age 
tends to offset the benefits of screening (7, 8). Second, the risks for screening-induced 
harms (colonoscopy-related complications and overdiagnosis and overtreatment of CRC) 
increase with increasing age (9). 
The objective of this study was to determine up to what age CRC screening should be 
considered in elderly persons without previous screening and to determine which 
screening test— colonoscopy, sigmoidoscopy, or fecal immunochemical test (FIT)—is 
indicated at what age. We performed separate analyses for elderly persons with no, 
moderate, and severe comorbid conditions because the effectiveness and cost-effectiveness 
of screening depend heavily on a person’s life expectancy.
METHODS
We used the Microsimulation Screening Analysis–Colon (MISCAN-Colon) model (Erasmus 
University Medical Center, Rotterdam, the Netherlands) to quantify the effectiveness and 
costs of screening. 
MISCAN-Colon 
MISCAN-Colon is a well-established microsimulation model for CRC developed at the 
Department of Public Health of the Erasmus University Medical Center. The model’s 
ABSTRACT
Background: The US Preventive Services Task Force recommends against routine screening 
for colorectal cancer (CRC) in adequately screened persons older than 75 years but does 
not address the appropriateness of screening in elderly persons without previous screening.
Objective: To determine at what ages CRC screening should be considered in unscreened 
elderly persons and to determine which test is indicated at each age.
Design: Microsimulation modeling study.
Data Sources: Observational and experimental studies.
Target Population: Unscreened persons aged 76 to 90 years with no, moderate, and 
severe comorbid conditions.
Time Horizon: Lifetime.
Perspective: Societal.
Intervention: One-time colonoscopy, sigmoidoscopy, or fecal immunochemical test (FIT) 
screening.
Outcome Measures: Quality-adjusted life-years gained, costs, and costs per quality- 
adjusted life-year gained.
Results of Base-Case Analysis: In unscreened elderly persons with no comorbid conditions, 
CRC screening was cost-effective up to age 86 years. Screening with colonoscopy was 
indicated up to age 83 years, sigmoidoscopy was indicated at age 84 years, and FIT was 
indicated at ages 85 and 86 years. In unscreened persons with moderate comorbid 
conditions, screening was cost-effective up to age 83 years (colonoscopy indicated up to 
age 80 years, sigmoidoscopy at age 81 years, and FIT at ages 82 and 83 years). In unscreened 
persons with severe comorbid conditions, screening was cost-effective up to age 80 years 
(colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and FIT at ages 
79 and 80 years).
Results of Sensitivity Analyses: Results were most sensitive to assuming a lower 
willingness to pay per quality-adjusted life-year gained.
Limitation: Only persons at average risk for CRC were considered.
Conclusion: In unscreened elderly persons CRC screening should be considered well 
beyond age 75 years. A colonoscopy is indicated at most ages.
Primary Funding Source: National Cancer Institute.
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Screening Strategies
We simulated 1-time colonoscopy, 1-time sigmoidoscopy, and 1-time FIT screening within 
each cohort. Test characteristics and complication rates for each screening test are given 
in Appendix Table 1. Patients with an adenoma or CRC detected during sigmoidoscopy 
or with a positive FIT result were referred for a diagnostic colonoscopy. Persons with 
adenomas detected and removed during a screening or diagnostic colonoscopy were 
assumed to have colonoscopy surveillance according to the current guidelines (28). We 
assumed that surveillance continued until the diagnosis of CRC or death. Adherence to 
screening and diagnostic and surveillance colonoscopies was assumed to be 100%. 
We restricted ourselves to 1-time colonoscopy and 1-time sigmoidoscopy screening 
because performing more screening colonoscopies or sigmoidoscopies is unlikely to be 
cost-effective at older age. We explored the effect of FIT screening during 2 consecutive 
years in a sensitivity analysis. 
Utility Losses Associated With CRC Screening
We assumed a utility loss (that is, a loss of quality of life) equal to 2 full days of life per 
colonoscopy (0.0055 quality-adjusted life-years [QALYs]), 1 day of life per sigmoidoscopy 
(0.0027 QALYs), and 2 weeks of life per complication (0.0384 QALYs) (Table 1). We also 
assigned a utility loss to each LY with CRC care (29).
The assignment of utility losses to LYs with CRC care works 2 ways: On the one hand, 
screening prevents cancer by the detection and removal of adenomas, thereby reducing 
LYs with CRC care and hence resulting in a gain of quality of life. On the other hand, 
screening results in overdiagnosis and overtreatment of cancer, resulting in LYs with CRC 
care in persons who would never have been diagnosed with CRC without screening and 
hence a loss of quality of life. The net effect on quality of life depends on the balance 
between cancer cases prevented and cancer cases overdiagnosed and can be either 
positive or negative. 
Costs Associated With CRC Screening
The cost-effectiveness analyses were conducted from a societal perspective. The costs of 
colonoscopy, sigmoidoscopy, and FIT were based on 2007 Medicare payment rates and 
copayments (Table 1) (32). The costs of complications were obtained from a cost analysis 
of cases of unexpected hospital use after endoscopy in 2007 (33). We added patient time 
costs to both (30). The costs of LYs with CRC care were obtained from an analysis of SEER–
Medicare linked data and included copayments and patient time costs (31). We adjusted 
all costs to reflect the 2013 level using the US Consumer Price Index (34). 
The assignment of costs to LYs with CRC care also works 2 ways: On the one hand, 
screening prevents cancer, reducing the costs of CRC care. On the other hand, screening 
results in overtreatment of cancer, increasing these costs. The net effect can be either a 
reduction or an increase in costs.
structure, underlying assumptions, and calibration are described in the Model Appendix 
included at the end of this thesis. In brief, MISCAN-Colon simulates the life histories of a 
large population from birth to death. As each simulated person ages, 1 or more adenomas 
may develop. These adenomas can progress from small (≤5 mm) to medium (6 to 9 mm) 
to large (≥10 mm) size. Some adenomas can develop into preclinical cancer, which may 
progress through stages I to IV. During each stage, CRC may be diagnosed because of 
symptoms. Survival after clinical diagnosis is determined by the stage at diagnosis, the 
localization of the cancer, and the person’s age (10). 
Screening will alter some of the simulated life histories: Some cancer cases will be prevented by 
the detection and removal of adenomas; other cancer cases will be detected in an earlier 
stage with a more favorable survival. However, screening can also result in serious 
complications and overdiagnosis and overtreatment of CRC (that is, the detection and 
treatment of cancer that would not have been diagnosed without screening). By comparing 
all life histories with screening with the corresponding life histories without screening, 
MISCAN-Colon quantifies the effectiveness of screening as well as the associated costs. 
MISCAN-Colon was calibrated to the age-, stage-, and localization-specific incidence of 
CRC as seen in the SEER (Surveillance, Epidemiology, and End Results) Program before the 
introduction of screening (that is, between 1975 and 1979) and the age-specific prevalence 
and multiplicity distribution of adenomas seen in autopsy studies (11–21). The preclinical 
duration of CRC and the adenoma dwell-time were calibrated to the rates of interval and 
surveillance-detected cancer seen in randomized, controlled trials evaluating screening 
using guaiac fecal occult blood tests and a 1-time sigmoidoscopy (22–26). 
Model Inputs
Populations Simulated
For each age between 76 and 90 years, we simulated a cohort of 10 million elderly persons 
without previous screening with no, moderate, and severe comorbid conditions (a total of 
45 cohorts). Compared with cohorts of adequately screened elderly persons, the risk for 
CRC in these cohorts was substantially greater: CRC and adenomas were prevalent in 0.3% 
and 14.1%, respectively, of simulated patients aged 80 years with negative screening 
colonoscopies at ages 50, 60, and 70 years and in 2.6% and 44.9%, respectively, of simulated 
patients aged 80 years without previous screening.
We used comorbid condition level–specific life tables to simulate elderly persons with no, 
moderate, and severe comorbid conditions (27). Persons are classified as having moderate 
comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular 
disease, diabetes, paralysis, cerebrovascular disease, or a history of acute myocardial 
infarction; severe comorbid conditions if they have chronic obstructive pulmonary 
disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, 
dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of 
these conditions are present.
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Outcomes
For each cohort, we quantified the effectiveness (that is, the number of CRC cases 
prevented, CRC deaths prevented, LYs gained, and QALYs gained) and costs of 1-time 
colonoscopy, sigmoidoscopy, and FIT screening, applying the conventional 3% annual 
discount rate for both.
Analyses
We first determined the cost-effectiveness of each screening strategy compared with no 
screening for all cohorts. For each comorbid condition level, we determined the upper 
age at which each screening strategy was cost-effective compared with no screening, 
assuming a willingness to pay per QALY gained of $100 000. 
We subsequently performed an analysis to determine the optimal screening strategy for 
each cohort (that is, the most effective, still cost-effective screening strategy). To do so, we 
first excluded all dominated screening strategies (that is, those that were more costly and 
less effective than other strategies or combinations of other strategies). We determined 
the incremental cost-effectiveness ratio for all remaining strategies (“efficient strategies”): 
the additional costs per additional QALY gained compared with the next less effective and 
costly efficient strategy. From the efficient strategies, we selected the optimal strategy, 
again assuming a willingness to pay per QALY gained of $100 000.
Sensitivity Analyses
We repeated our analyses assuming half and twice the base-case utility losses for 
colonoscopy, sigmoidoscopy, and complications; a utility loss of 0.12, 0.18, 0.24, and 0.70 
QALYs for each LY with continuing care for stage I, II, III, and IV CRC, respectively; 25% 
higher and 25% lower costs for colonoscopy, sigmoidoscopy, and FIT; 25% higher and 25% 
lower costs for CRC care; twice the base-case miss rates for adenomas and CRC for both 
sigmoidoscopy and colonoscopy; no surveillance in patients with adenomas; 25% higher 
and 25% lower risk for CRC in all cohorts; and a willingness to pay per QALY gained of 
$50 000. Further, we explored the effect of FIT screening during 2 consecutive years. 
Role of the Funding Source
The study was supported by the National Cancer Institute. The funding source had no role 
in the study’s design, conduct, and reporting.
This study did not include patient-specific information and was exempt from institutional 
review board review.
Table 1   Model Inputs: Utility Losses and Costs Associated with Colorectal Cancer Screening.
UTILITY LOSS (QALYs)*
Per FIT 0
Per sigmoidoscopy
without biopsy 0.003
with biopsy 0.003
Per colonoscopy
without polypectomy/ biopsy 0.005
with polypectomy/ biopsy 0.005
Per complication of colonoscopy 0.038
Per LY with CRC care†‡ Initial care Continuing 
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
COSTS (2013 US$)§
Per FIT 42
Per sigmoidoscopy
without biopsy 299
with biopsy 557
Per colonoscopy
without polypectomy/ biopsy 887
with polypectomy/ biopsy 1,096
Per complication of colonoscopy 6,045
Per LY with CRC care† Initial care Continuing 
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 36,683 3,050 63,809 19,176
Stage II CRC 49,234 2,870 63,555 17,279
Stage III CRC 59,759 4,021 67,041 21,457
Stage IV CRC 77,790 12,178 88,368 49,866
QALY = quality-adjusted life-year; FIT = fecal immunochemical test; LY = life-year; CRC = colorectal cancer
* The loss of quality of life associated with a particular event.
† Care for CRC was divided in three clinically relevant phases: the initial, continuing, and terminal care phase. 
The initial care phase was defined as the first 12 months after diagnosis; the terminal care phase was defined 
as the final 12 months of life; the continuing care phase was defined as all months in between. In the terminal 
care phase, we distinguished between CRC patients dying from CRC and CRC patients dying from another 
cause. For patients surviving less than 24 months, the final 12 months were allocated to the terminal care 
phase and the remaining months were allocated to the initial care phase. 
‡ Utility losses for LYs with initial care were derived from a study by Ness and colleagues(29). For LYs with 
continuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing care for 
stage III and IV CRC, we assumed the corresponding utility losses for LYs with initial care. For LYs with terminal 
care for CRC, we assumed the utility loss for LYs with initial care for stage IV CRC. For LYs with terminal care for 
another cause, we assumed the corresponding utility losses for LYs with continuing care. 
§ Costs include copayments and patient time costs (i.e. the opportunity costs of spending time on screening 
or being treated for a complication or CRC), but do not include travel costs, costs of lost productivity, 
and unrelated health care and non-health care costs in added years of life. We assumed that the value 
of patient time was equal to the median wage rate in 2012: $16.71 per hour(30). We assumed that FITs, 
sigmoidoscopies, colonoscopies, and complications used up 1, 4, 8 and 16 hours of patient time, respectively. 
Patient time costs were already included in the estimates for the costs of LYs with CRC care obtained from a 
study by Yabroff and colleagues(31).
170 | Chapter 5 Colorectal cancer screening in elderly individuals without previous screening | 171
5
76 years, it resulted in overdiagnosis and hence overtreatment of 7.7 CRC cases per 1000 
healthy persons aged 90 years. As a result, colonoscopy screening resulted in a positive 
overall effect on length and quality of life (that is, a net health benefit) in healthy persons 
aged 76 years (67.2 QALYs gained per 1000 persons) but in a net harm in healthy persons 
aged 90 years (1.7 QALYs lost per 1000 persons). 
One-time sigmoidoscopy and, particularly, 1-time FIT screening were generally less 
effective than 1-time colonoscopy screening (Table 2). For example, in healthy persons 
aged 76 years, colonoscopy screening resulted in 67.2 QALYs gained per 1000 persons, 
RESULTS
Effectiveness
The effectiveness of CRC screening in unscreened elderly persons declined with increasing 
age (Table 2). For example, 1-time colonoscopy screening prevented fewer CRC deaths 
(4.5 vs. 11.9 per 1000 persons) and resulted in fewer LYs gained (12.3 vs. 68.5 per 1000 
persons) in healthy persons aged 90 years than in healthy persons aged 76 years. Moreover, 
whereas colonoscopy screening prevented 15.4 CRC cases per 1000 healthy persons aged 
Table 2   Effectiveness of 1-Time Colonoscopy, Sigmoidoscopy, and FIT Screening  
in Elderly Persons Without Previous Screening With No Comorbid Conditions 
(compared with no screening; results per 1,000 individuals; 3% discounted).*
CRC cases 
prevented†
CRC deaths 
prevented
LYs gained‡ Impact on quality of life (QALYs)§ QALYs gained¶
Screening test Diagnostic 
colonoscopies
Surveillance 
colonoscopies
Complications LYs with  
CRC care ǁ
Screening strategy Age (A) (B) (C) (D) (E) (F) (A+B+C+D+E+F)
1-time colonoscopy screening 76** 15.4 11.9 68.5 -5.5 0 -3.2 -0.6 8.1 67.2
80 10.4 10.7 52.9 -5.5 0 -2.8 -0.7 3.0 46.9
85 0.8 7.4 28.3 -5.5 0 -2.0 -0.9 -2.9 17.1
90 -7.7 4.5 12.3 -5.5 0 -1.4 -1.1 -6.1 -1.7
1-time sigmoidoscopy screening 76 12.0 9.4 54.6 -2.7 -1.6 -2.2 -0.4 6.2 53.9
80 8.2 8.7 43.1 -2.7 -1.7 -2.0 -0.5 2.3 38.6
85 0.6 6.0 23.1 -2.7 -1.7 -1.4 -0.6 -2.3 14.3
90 -6.2 3.7 9.9 -2.7 -1.6 -1.0 -0.7 -4.9 -1.0
1-time FIT screening 76 1.7 4.1 25.9 0 -0.4 -0.5 -0.1 -0.6 24.2
80 0.2 4.2 22.5 0 -0.4 -0.4 -0.1 -2.2 19.2
85 -2.8 3.4 13.8 0 -0.5 -0.4 -0.1 -3.8 9.0
90 -6.2 2.3 6.6 0 -0.5 -0.3 -0.2 -4.7 0.9
FIT = fecal immunochemical test; CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
* Persons are classified as having no comorbid conditions if none of the following conditions is present: an ulcer, 
a history of acute myocardial infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, constructive obstructive pulmonary disease, congestive heart failure, moderate or 
severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS.
† Negative values occur when the number of CRC cases prevented by screening is exceeded by the number of 
CRC cases over-diagnosed by screening.
‡ The impact of screening on quantity of life.
§ The impact of the screening test, diagnostic colonoscopies, surveillance colonoscopies, complications, and LYs 
with CRC care on quality of life. Values are derived by multiplying number(s) of events with the corresponding 
utility loss(es) per event stated in Table 1. An example: When applying the once-only colonoscopy screening 
strategy, in each cohort, 1,000 individuals undergo a screening colonoscopy. As the utility loss per screening 
colonoscopy is 0.0055 QALYs, the total utility loss due to screening colonoscopies is 5.5 QALYs in each cohort.
ǁ  Screening results in a gain of quality of life by preventing LYs with CRC care and a loss of quality of life by adding LYs with CRC 
care. The net effect can be a gain of quality of life (positive values) or a loss of quality of life (negative values). As a result of 
the shift from preventing to over-diagnosing CRC with increasing age, the net effect on quality of life becomes less favorable 
with age. Whereas once-only colonoscopy screening in unscreened elderly without comorbidity reduced the total number of 
LYs with CRC care for stage III or IV CRC at age 76 (-14 LYs per 1,000 individuals), it increased this number of LYs at age 90 (+16 
LYs per 1,000 individuals).  
¶ The impact of screening on quantity and quality of life incorporated in one measure, i.e. the net health benefit of screening. 
Discrepancies between the columns might occur due to rounding.
**More detailed results for this cohort are given in Appendix Table 2.
172 | Chapter 5 Colorectal cancer screening in elderly individuals without previous screening | 173
5
whereas sigmoidoscopy and FIT screening resulted in 53.9 and 24.2 QALYs gained per 
1000 persons, respectively. The only exceptions were seen at the most advanced ages, 
at which FIT screening was most effective—a result primarily explained by the 0 utility 
loss associated with this test. In persons with moderate and, particularly, severe 
comorbid conditions, screening was less effective than in persons without comorbid 
conditions (Appendix Table 3).
Costs
Whereas the effectiveness of screening in unscreened elderly persons declined with 
increasing age, the net costs of screening increased substantially (Table 3). While 
colonoscopy screening was associated with a lifetime cost of $725 000 per 1000 healthy 
persons aged 76 years, it was associated with a lifetime cost of $2 130 000 per 1000 healthy 
persons aged 90 years. This increase was again explained by the shift from preventing 
to overtreating CRC with age. 
Besides being the most effective strategy, colonoscopy screening was also the most 
expensive (Table 3). For example, in healthy persons aged 76 years, the costs of 
colonoscopy screening were $725 000 per 1000 persons compared with $439 000 and 
$218 000 for sigmoidoscopy and FIT screening, respectively. In persons with moderate 
and, particularly, severe comorbid conditions, screening was not only less effective but 
also more costly (Appendix Table 4). 
Cost-Effectiveness Compared With No Screening
As the effectiveness of screening declined with increasing age and the costs increased 
substantially, the cost-effectiveness of screening deteriorated rapidly with age (Figure 1). 
In unscreened elderly persons without comorbid conditions, colonoscopy and sigmoidoscopy 
screening were cost-effective up to age 85 years, whereas FIT screening was cost-effective up 
to age 86 years. In elderly persons with moderate comorbid conditions, colonoscopy and 
sigmoidoscopy screening were cost-effective up to age 82 years, whereas FIT screening was 
cost-effective up to age 83 years. In persons with severe comorbid conditions, colonoscopy 
and sigmoidoscopy screening were cost-effective up to age 79 years, whereas FIT screening 
was cost-effective up to age 80 years.
Incremental Cost-Effectiveness
We determined the optimal screening strategy for each cohort on the basis of the 
incremental cost-effectiveness ratios of the efficient screening strategies. In unscreened 
elderly persons with no comorbid conditions, colonoscopy screening was most effective 
and still cost-effective up to age 83 years (Appendix Table 5 and Figure 2), sigmoidoscopy 
screening was the optimal strategy at age 84 years, and FIT screening was the optimal 
strategy at ages 85 and 86 years. In elderly persons with moderate comorbid conditions, 
colonoscopy screening was the optimal strategy up to age 80 years, sigmoidoscopy T
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screening was the optimal strategy at age 81 years, and FIT screening was the optimal 
strategy at ages 82 and 83 years. In persons with severe comorbid conditions, colonoscopy 
screening was the optimal strategy up to age 77 years, followed by sigmoidoscopy 
screening at age 78 years and FIT screening at ages 79 and 80 years.
Sensitivity Analyses
Besides comorbid condition level, the upper age at which screening was cost-effective 
was most sensitive to lowering the willingness-to-pay threshold to $50 000 per QALY 
gained (Appendix Table 6). Based on this threshold, screening unscreened elderly 
persons with no, moderate, and severe comorbid conditions should be considered up 
to age 84, 80, and 77 years, respectively. The upper ages at which screening should be 
considered were robust to all other sensitivity analyses. 
The tests that were indicated at specific ages differed substantially between analyses 
(Appendix Table 6). Besides the threshold for the willingness to pay per QALY gained, the 
level of CRC risk and utility losses associated with colonoscopy, sigmoidoscopy, and 
complications were the most important factors in this respect. 
In persons aged 84 years without comorbid conditions and persons aged 78 years with 
severe comorbid conditions, sigmoidoscopy screening was not cost-effective compared 
with FIT screening during 2 consecutive years (Appendix Table 6). In persons aged 85 
years without comorbid conditions, persons aged 82 years with moderate comorbid 
conditions, and persons aged 79 and 80 years with severe comorbid conditions, FIT screening 
during 2 consecutive years was cost-effective compared with 1-time FIT screening.
Figure 1   Cost-effectiveness of 1-time colonoscopy, sigmoidoscopy, and FIT screening 
compared with no screening in elderly persons without previous screening 
with no, moderate, and severe comorbid conditions.
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SEVERE COMORBIDITY 
Results are presented per 1000 persons and discounted by 3% per year. Persons are classified as having moderate 
comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have 
chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal 
failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of these conditions 
are present. The dashed line indicates a willingness to pay per QALY gained of $100 000. Screening strategies 
costing less than $100 000 per QALY gained are considered cost-effective. Asterisks for missing screening 
strategies indicate that they were associated with a net health loss rather than a benefit (Appendix Table 3 and 
Table 2). FIT = fecal immunochemical test; QALY = quality-adjusted life-year.
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DISCUSSION
Our study shows that in elderly persons without previous screening for CRC, screening 
remains cost-effective well beyond age 75 years, which is the recommended age to 
discontinue screening in adequately screened persons (Table 4). In unscreened elderly 
persons with no comorbid conditions, screening was cost-effective up to age 86 years. 
Screening with colonoscopy was most effective and still cost-effective up to 83 years, 
sigmoidoscopy was indicated at age 84 years, and FIT was indicated at ages 85 and 86 
years. In unscreened elderly persons with moderate comorbid conditions, screening was 
cost-effective up to age 83 years (colonoscopy indicated up to age 80 years, sigmoidoscopy 
at age 81 years, and FIT at ages 82 and 83 years). In persons with severe comorbid 
conditions, screening was cost-effective up to age 80 years (colonoscopy indicated up to 
age 77 years, sigmoidoscopy at age 78 years, and FIT at ages 79 and 80 years). 
In a situation when an elderly person is willing to have only 1 type of screening test, the 
cost-effectiveness of that test compared with no screening becomes relevant. In such a 
person without comorbid conditions, colonoscopy and sigmoidoscopy screening can be 
considered up to age 85 years and FIT screening can be considered up to age 86 years. 
The ages for similar persons with moderate comorbid conditions are 82 years for 
colonoscopy and sigmoidoscopy and 83 years for FIT; for persons with severe comorbid 
conditions, the ages are 79 years for colonoscopy and sigmoidoscopy and 80 years for FIT. 
Although the incidence of CRC increases up to very advanced ages (19), the effectiveness 
of screening declines with increasing age. This decline is primarily explained by the 
increasing risk for other-cause death with age, which reduces both the probability that 
screening will prevent CRC death and the number of LYs gained if death is prevented. 
Moreover, the risks for screening-induced harms (colonoscopy-related complications and, 
more importantly, overdiagnosis and overtreatment of CRC) increase with age (9). At the 
same time, the shift from preventing to overtreating CRC causes the net costs of screening 
to increase with age. Together, these phenomena explain the rapid deterioration of the 
cost-effectiveness of screening with increasing age. 
Results are presented per 1000 persons and discounted by 3% per year. Persons are classified as having moderate 
comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have 
chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal 
failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of these conditions 
are present. In elderly persons without previous screening with no, moderate, or severe comorbid conditions, 
none of the screening strategies are cost-effective from age 87, 84, and 81 years onward, respectively (Figure 1). 
For each age, the efficient screening strategies are connected by an efficiency frontier. A solid line indicates that 
the ICER of a screening strategy is <$100 000 per QALY gained, implying that the strategy is considered cost-
effective. A dashed line indicates that the ICER of a screening strategy exceeds $100 000 per QALY gained, 
implying that the strategy is not considered cost-effective. FIT = fecal immunochemical test; ICER = incremental 
cost-effectiveness ratio; QALY = quality-adjusted life-year.
Figure 2   The incremental cost-effectiveness of the efficient screening strategies  
in elderly persons without previous screening with no, moderate, and severe 
comorbid conditions.
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Although colonoscopy every 10 years, sigmoidoscopy every 5 years, and FIT every year are 
almost equally effective when applied from age 50 to 75 years (1, 2), colonoscopy is more 
effective than sigmoidoscopy and FIT when only 1 screening examination is performed 
because of its greater overall sensitivity for adenomas and CRC. However, because 
colonoscopy is also more expensive than sigmoidoscopy and FIT and because the 
effectiveness of all screening tests is marginal at very advanced ages, screening with 
colonoscopy is not cost-effective compared with sigmoidoscopy and FIT at the most 
advanced ages at which screening should be considered. 
Screening remains cost-effective up to a more advanced age in persons without comorbid 
conditions than in those with comorbid conditions because their more favorable life 
expectancy increases the probability that screening will prevent CRC, thus increasing the 
effectiveness of screening while simultaneously reducing the costs of CRC care. 
To our knowledge, our study is the first to investigate the net health benefit and the 
cost-effectiveness of CRC screening in persons older than 75 years without previous 
screening. An earlier study by Ko and Sonnenberg (7) demonstrated that the effectiveness 
of screening for preventing CRC death declines with increasing age, whereas the 
probability of screening-related complications increases with age. Further, a study by Lin 
and colleagues (8) demonstrated that the number of LYs gained by screening declines 
with age, resulting in an increase in the number of colonoscopies required per LY gained. 
However, neither study considered costs or measured the overdiagnosis and overtreatment 
of cancer, which is the most important adverse effect of screening in elderly persons. As a 
result, these studies cannot easily be used to determine whether unscreened elderly 
persons should be screened. Some other, more recent studies have suggested that 
screening should be continued after age 75 years (3, 4). However, these studies did not 
distinguish between adequately screened elderly persons and elderly persons without 
previous screening. Further, these studies based their conclusions only on CRC incidence 
data. 
The USPSTF selected its recommended screening strategies on the basis of the number of 
colonoscopies required per LY gained (undiscounted) (1, 2), but we based our conclusions 
on the costs per QALY gained (discounted at 3% per year). We did so for 2 reasons. First, 
policymakers should be able to compare the efficiency of a wide range of health 
interventions; the USPSTF outcome measure does not allow for this. Second, we believe 
that effects on both length and quality of life should be considered. However, the 2 
approaches led to screening recommendations associated with similar numbers of 
colonoscopies per LY gained: Screening with colonoscopy as recommended by the 
USPSTF (that is, at ages 50, 60, and 70 years) required 30 to 35 colonoscopies per LY gained 
(2). Also, screening with colonoscopy in unscreened persons aged 83 years with no 
comorbid conditions, for example, required 32 colonoscopies per LY gained. 
Our study has 2 main limitations. First, we did not perform separate analyses by sex and 
race. However, we do not expect that results from such analyses would have differed T
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Appendix, Table 1  Test Characteristics of Colonoscopy, Sigmoidoscopy, and FIT.
Test Characteristic Test
Colonoscopy Sigmoidoscopy FIT
Specificity 90%* 92%* 97.7%
Sensitivity
Small adenomas (≤5mm) 75%† 75%† 0%‡
Medium-sized adenomas 
(6-9mm)
85%† 85%† 5.2%‡
Large adenomas (≥10mm) 95%† 95%† 26%‡
CRCs that would not have 
been clinically detected in 
their current stage
95%† 95%† 41%‡
CRCs that would have been 
clinically detected in their 
current stage
95%† 95%† 77%‡
Reach 95% reaches the 
cecum; the reach of 
the remaining 5% is 
distributed uniformly 
over colon and 
rectum
100% reaches the 
recto-sigmoid 
junction, 88% 
reaches the sigmoid-
descending junction, 
6% reaches the 
splenic flexure§
whole colon and 
rectum
Complication rate
Positive test increases 
exponentially with 
age; from 20 per 1,000 
colonoscopies at age 
76 to 48 per 1,000 
colonoscopies  
at age 90ǁ
0 0
Negative test 0 0 0
Mortality rate
Positive test 0.033 per 1,000¶ 0 0
Negative test 0 0 0
* We assumed that in 10% of all negative colonoscopies and in 8% of all negative sigmoidoscopies a non-
adenomatous lesion was detected, resulting in a polypectomy or a biopsy, respectively.
† The sensitivity of colonoscopy and sigmoidoscopy for the detection of adenomas and CRC within the reach 
of the endoscope was obtained from a systematic review on miss rates observed in tandem colonoscopy 
studies (39). 
‡ The test characteristics of FIT were fitted to the positivity rates and detection rates as observed in the first 
screening round of the Dutch screening trial. We assumed that the probability that a CRC bleeds and thus 
the sensitivity of FIT for CRC depends on the time until clinical diagnosis, in concordance with our findings for 
gFOBT (25).
§ The reach of sigmoidoscopy was obtained from a study by Painter and colleagues (38).
ǁ  Age-specific risks for complications of colonoscopy requiring a hospital admission or emergency department 
visit were obtained from a study by Warren and colleagues (9).
¶  The mortality rate associated with colonoscopies with a polypectomy was derived by multiplying the risk 
for a perforation obtained from a study by Warren and colleagues by the risk of mortality after a perforation 
obtained from a study by Gatto and colleagues (9, 37).
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Appendix, Table 2  The Effects of 1-time Colonoscopy Screening in  
76-Year-Olds Without Prior Screening Without Comorbid Conditions (results per  
1,000 individuals; 3% discounted).*
Screening No screening Screening - No screening†
EFFECTS ON HEALTH CARE USE
Colonoscopies
   Screening - polypectomy 461 0 461
   Screening - no polypectomy 539 0 539
   Surveillance - polypectomy 219 0 219
   Surveillance - no polypectomy 370 0 370
Complications of colonoscopy 16.2 0 16.2
LYs with initial CRC care‡
   Stage I 11.5 6.4 5.1
   Stage II 8.0 12.4 -4.4
   Stage III 5.1 7.3 -2.2
   Stage IV 0.7 2.9 -2.2
LYs with continuing CRC care
   Stage I 92.8 34.9 57.9
   Stage II 60.0 61.6 -1.6
   Stage III 33.9 30.7 3.2§
   Stage IV 1.5 5.2 -3.7
LYs with terminal care - CRC
   Stage I 0.5 0.7 -0.2
   Stage II 1.0 2.6 -1.6
   Stage III 1.5 3.2 -1.8
   Stage IV 1.1 5.8 -4.7
LYs with terminal care - other cause
   Stage I 8.3 5.1 3.2
   Stage II 5.4 9.3 -4.0
   Stage III 2.9 4.6 -1.8
   Stage IV 0.2 1.0 -0.8
EFFECTS ON HEALTH
CRC cases 27.9 43.4 -15.4
CRC deaths 4.5 16.4 -11.9
LYs lost due to CRC (A) 32.5 100.9 -68.5ǁ
Utility losses (QALYs)
   Screening colonoscopies 5.5 0 5.5
   Surveillance colonoscopies 3.2 0 3.2
   Complications of colonoscopy 0.6 0 0.6
   LYs with CRC care 25.7 33.8 -8.1
   Total (B) 35.1 33.8 1.3
QALYs lost (A+B) 67.5 134.7 -67.2¶
Appendix, Table 2  Continued.
Screening No screening Screening - No screening†
EFFECTS ON COSTS (*$1,000)
   Screening colonoscopies 983 0 983
   Surveillance colonoscopies 569 0 569
   Complications of colonoscopy 98 0 98
   LYs with CRC care 2,404 3,329 -925
   Total 4,054 3,329     725**
LY = life-year; CRC = colorectal cancer; QALY = quality-adjusted life-year
*  Individuals are classified as having no comorbidity if none of the following conditions is present: an ulcer, a 
history of acute myocardial infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, 
cerebrovascular disease, constructive obstructive pulmonary disease, congestive heart failure, moderate or 
severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS.
†  Discrepancies between columns might occur due to rounding.
‡  As screening results in the prevention and earlier detection of CRC, it reduces the total numbers of LYs with 
initial care for CRC, terminal care for CRC, and terminal care for other causes in CRC patients; however, as 
screening improves the average survival of CRC patients, it increases the total number of LYs with continuing 
care for CRC. 
§  The increase in LYs with continuing care for stage III CRC is explained by the more favorable average survival 
that we model for screen-detected versus clinically detected cancers as described in the Model Appendix 
included at the end of this thesis.
ǁ number of LYs gained by screening (Table 2).
¶  The number of QALYs gained by screening (Table 2).
**The costs of screening (Table 3).
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Appendix, Table 3  The Effectiveness of 1-Time Colonoscopy, Sigmoidoscopy, and FIT 
Screening in Elderly Persons Without Prior Screening With Moderate and Severe Comorbid 
Conditions (compared with no screening; results per 1,000 individuals; 3% discounted).*
MODERATE COMORBIDITY
CRC cases 
prevented†
CRC deaths 
prevented
LYs gained‡ Impact on quality of life (QALYs)§ QALYs gained¶
Screening test Diagnostic 
colonoscopies
Surveillance 
colonoscopies
Complications LYs with CRC careǁ
Screening strategy Age (A) (B) (C) (D) (E) (F) (A+B+C+D+E+F)
1-time colonoscopy screening 76 8.8 9.0 46.3 -5.5 0 -2.6 -0.6 3.8 41.4
80 4.0 8.1 35.2 -5.5 0 -2.2 -0.7 -0.0 26.8
85 -4.3 5.6 18.9 -5.5 0 -1.6 -0.8 -4.2 6.8
90 -11.0 3.5 8.8 -5.5 0 -1.1 -1.0 -6.1 -4.8
1-time sigmoidoscopy screening 76 6.8 7.2 36.9 -2.7 -1.6 -1.8 -0.4 2.9 33.4
80 3.1 6.6 28.7 -2.7 -1.7 -1.6 -0.4 -0.1 22.2
85 -3.5 4.6 15.4 -2.7 -1.7 -1.1 -0.5 -3.4 5.9
90 -8.8 2.9 7.1 -2.7 -1.6 -0.7 -0.6 -4.9 -3.5
1-time FIT screening 76 -0.1 3.3 17.9 0 -0.4 -0.4 -0.1 -1.5 15.6
80 -1.9 3.4 15.4 0 -0.4 -0.4 -0.1 -2.8 11.7
85 -4.8 2.7 9.4 0 -0.5 -0.3 -0.1 -4.0 4.6
90 -7.7 1.9 4.8 0 -0.5 -0.2 -0.2 -4.4 -0.5
SEVERE COMORBIDITY
CRC cases 
prevented†
CRC deaths 
prevented
LYs gained‡ Impact on quality of life (QALYs)§ QALYs gained¶
Screening test Diagnostic 
colonoscopies
Surveillance 
colonoscopies
Complications LYs with CRC careǁ
Screening strategy Age (A) (B) (C) (D) (E) (F) (A+B+C+D+E+F)
1-time colonoscopy screening 76 2.6 6.7 32.3 -5.5 0 -2.0 -0.5 1.4 25.7
80 -2.2 5.9 23.3 -5.5 0 -1.6 -0.6 -1.7 13.9
85 -9.4 4.0 12.2 -5.5 0 -1.1 -0.8 -4.5 0.4
90 -14.6 2.6 5.8 -5.5 0 -0.7 -1.0 -5.7 -7.1
1-time sigmoidoscopy screening 76 2.0 5.3 25.8 -2.7 -1.6 -1.4 -0.3 1.1 20.8
80 -1.9 4.8 19.0 -2.7 -1.7 -1.2 -0.4 -1.4 11.6
85 -7.6 3.3 10.0 -2.7 -1.7 -0.8 -0.5 -3.6 0.6
90 -11.7 2.1 4.6 -2.7 -1.6 -0.5 -0.6 -4.5 -5.4
1-time FIT screening 76 -2.2 2.5 12.7 0 -0.4 -0.3 -0.1 -1.8 10.1
80 -4.2 2.5 10.4 0 -0.4 -0.3 -0.1 -2.9 6.7
85 -7.1 2.0 6.2 0 -0.5 -0.2 -0.1 -3.7 1.7
90 -9.5 1.4 3.2 0 -0.5 -0.1 -0.2 -4.0 -1.7
FIT = fecal immunochemical test; CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
*  Individuals are classified as having moderate comorbidity if diagnosed with an ulcer, rheumatologic disease, peripheral 
vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of a history of acute myocardial infarction 
and as having severe comorbidity if diagnosed with constructive obstructive pulmonary disease, congestive heart 
failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS.
†  Negative values occur when the number of CRC cases prevented by screening is exceeded by the number of CRC 
cases over-diagnosed by screening.
‡  The impact of screening on quantity of life.
§  The impact of the screening test, diagnostic colonoscopies, surveillance colonoscopies, complications, and LYs with 
CRC care on quality of life. Values are derived by multiplying number(s) of events with the corresponding utility loss(es) 
per event stated in Table 1. An example: When applying the once-only colonoscopy screening strategy, in each cohort, 1,000 
individuals undergo a screening colonoscopy. As the utility loss per screening colonoscopy is 0.0055 QALYs, the total utility 
loss due to screening colonoscopies is 5.5 QALYs in each cohort.
ǁ  Screening results in a gain of quality of life by preventing LYs with CRC care and a loss of quality of life by adding LYs with CRC 
care. The net effect can be a gain of quality of life (positive values) or a loss of quality of life (negative values). As a result of 
the shift from preventing to over-diagnosing CRC with increasing age, the net effect on quality of life becomes less favorable 
with age. 
¶  The impact of screening on quantity and quality of life incorporated in one measure, i.e. the net health benefit of screening. 
Discrepancies between the columns might occur due to rounding.
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Appendix, Table 6  CRC Screening in Elderly Without Prior Screening: Results  
of Sensitivity Analyses.
NO COMORBIDITY
Analysis Up to what age should  
CRC screening be considered?
Which screening strategy is indicated at what age?
Age
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Base Case 86 COL COL COL COL COL COL COL COL SIG FIT FIT
Utility loss colonoscopy, sigmoidoscopy, complication*0.5 86 COL COL COL COL COL COL COL COL COL SIG FIT
Utility loss colonoscopy, sigmoidoscopy, complication*2 86 COL COL COL COL COL COL SIG FIT FIT FIT FIT
Utility loss LYs with continuing care stage I, II CRC = 0.12, 0.18 84 COL COL COL COL COL COL COL SIG SIG
Costs of colonoscopy, sigmoidoscopy, FIT*1.25 86 COL COL COL COL COL COL COL SIG FIT FIT FIT
Costs of colonoscopy, sigmoidoscopy, FIT*0.75 86 COL COL COL COL COL COL COL COL COL SIG FIT
Costs of CRC care*1.25 86 COL COL COL COL COL COL COL COL SIG FIT FIT
Costs of CRC care*0.75 87 COL COL COL COL COL COL COL COL SIG FIT FIT FIT
Miss rates colonoscopy, sigmoidoscopy*2 86 COL COL COL COL COL COL COL COL FIT FIT FIT
No surveillance in adenoma patients 86 COL COL COL COL COL COL COL COL COL SIG FIT
CRC risk*1.25 86 COL COL COL COL COL COL COL COL COL COL FIT
CRC risk*0.75 86 COL COL COL COL COL SIG SIG SIG FIT FIT FIT
2 annual FITs as an additional screening strategy 86 COL COL COL COL COL COL COL COL 2FITs 2FITs FIT
Threshold willingness to pay per QALY gained = $50,000 84 COL COL COL COL COL SIG SIG FIT FIT
MODERATE COMORBIDITY
Analysis Up to what age should  
CRC screening be considered?
Which screening strategy is indicated at what age?
Age
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Base Case 83 COL COL COL COL COL SIG FIT FIT
Utility loss colonoscopy, sigmoidoscopy, complication*0.5 84 COL COL COL COL COL COL SIG FIT FIT
Utility loss colonoscopy, sigmoidoscopy, complication*2 83 COL COL COL SIG FIT FIT FIT FIT
Utility loss LYs with continuing care stage I, II CRC = 0.12, 0.18 81 COL COL COL COL SIG SIG
Costs of colonoscopy, sigmoidoscopy, FIT*1.25 83 COL COL COL COL SIG FIT FIT FIT
Costs of colonoscopy, sigmoidoscopy, FIT*0.75 84 COL COL COL COL COL COL SIG FIT FIT
Costs of CRC care*1.25 83 COL COL COL COL COL SIG FIT FIT
Costs of CRC care*0.75 84 COL COL COL COL COL SIG FIT FIT FIT
Miss rates colonoscopy, sigmoidoscopy*2 83 COL COL COL COL COL SIG FIT FIT
No surveillance in adenoma patients 84 COL COL COL COL COL COL COL FIT FIT
CRC risk*1.25 83 COL COL COL COL COL COL COL FIT
CRC risk*0.75 83 COL COL SIG SIG SIG FIT FIT FIT
2 annual FITs as an additional screening strategy 83 COL COL COL COL COL SIG 2FITs FIT
Threshold willingness to pay per QALY gained = $50,000 80 COL COL SIG SIG FIT
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Appendix, Table 6  Continued.
SEVERE COMORBIDITY
Analysis Up to what age should 
 CRC screening be considered?
Which screening strategy is indicated at what age?
Age
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Base Case 80 COL COL SIG FIT FIT
Utility loss colonoscopy, sigmoidoscopy, complication*0.5 80 COL COL COL SIG SIG
Utility loss colonoscopy, sigmoidoscopy, complication*2 80 SIG FIT FIT FIT FIT
Utility loss LYs with continuing care stage I, II CRC = 0.12, 0.18 78 COL SIG SIG
Costs of colonoscopy, sigmoidoscopy, FIT*1.25 80 SIG SIG FIT FIT FIT
Costs of colonoscopy, sigmoidoscopy, FIT*0.75 80 COL COL COL SIG SIG
Costs of CRC care*1.25 80 COL COL SIG SIG FIT
Costs of CRC care*0.75 81 COL COL SIG FIT FIT FIT
Miss rates colonoscopy, sigmoidoscopy*2 80 COL COL FIT FIT FIT
No surveillance in adenoma patients 81 COL COL COL SIG FIT FIT
CRC risk*1.25 80 COL COL COL COL FIT
CRC risk*0.75 80 SIG SIG FIT FIT FIT
2 annual FITs as an additional screening strategy 80 COL COL 2FITs 2FITs 2FITs
Threshold willingness to pay per QALY gained = $50,000 77 SIG FIT
CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year; COL = one-time colonoscopy screening; 
SIG = one-time sigmoidoscopy screening; FIT = one-time fecal immunochemical test screening; 2FITs = fecal 
immunochemical test screening during two consecutive years
* Individuals are classified as having moderate comorbidity if diagnosed with an ulcer, rheumatologic disease, 
peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease, and in case of a history of acute myocardial 
infarction; as having severe comorbidity if diagnosed with constructive obstructive pulmonary disease, congestive 
heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis or AIDS; 
and as having no comorbidity if none of these conditions is present.
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Saini SD*, van Hees F*, Vijan S. Smarter Screening for Cancer: Possibilities and Challenges of Personalization. 
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An important emerging model for screening and many preventive strategies is personali-
zation. This approach uses individual patient characteristics to project the benefit of 
screening for a given patient and has the potential to improve cancer outcomes while 
reducing the probability of harm and preserving scarce health care resources. Yet all too 
often, the existing health care system fails to personalize screening in even the most 
rudimentary way. A recent study found that 75-year-old patients with severe comorbidities 
were nearly 2 times more likely to be screened for colorectal cancer than 76-year-old 
patients with no comorbidities, even though healthy 76-year-old patients tend to live 
longer and gain greater benefit from screening.(1) In another study, 48% of primary care 
physicians reported that they would recommend breast cancer screening for women 
diagnosed with terminal lung cancer, a group of patients for whom screening cannot 
provide any benefit, may cause harm, and is a waste of resources.(2) Although most 
clinicians would agree that cancer screening should focus on patients most likely to 
benefit, the US health care system is failing to achieve this type of personalized care. 
If most clinicians agree that cancer screening should be personalized, why is such an 
approach not implemented in practice? Numerous studies have demonstrated how the 
benefits of preventive services such as cancer screening change over the life span. Others 
have shown how the benefits vary by factors such as screening history and comorbidity 
status. Yet these data alone are clearly not enough. Indeed, a more systematic approach 
to synthesizing these data for clinical use and developing systems of care that support 
their implementation is needed. In this Viewpoint, we provide an overview of how 
personalized recommendations for cancer screening can be developed and discuss 
challenges to implementation that must be overcome if clinicians are to provide the best 
possible care for their patients. 
The benefit of a given screening test for a given patient is a function of 2 key variables: 
cancer risk and life expectancy. However, unaided clinical judgment is not reliable for 
estimating these variables and integrating them into an appropriate screening 
recommendation for an individual patient. Although clinicians have at their disposal 
multiple prediction tools for both of these variables,(3,4) these tools are rarely used. One 
reason they are not used more frequently is that these tools do not provide clinically 
meaningful information needed for personalization. For instance, if prediction tools 
indicate that an individual has a 4-fold increased risk of developing lung cancer within the 
next 5 years and a life expectancy of 8 years, how should this information be used to arrive 
at a screening decision? For risk models to be useful in practice, a way is needed to 
translate simple risk estimates into clinically meaningful estimates of benefit, which can 
then be used to guide individual clinical decisions. 
Clinical trials, which are often used to study screening tests, are not aimed at individual 
decision making, instead establishing overall causality and average efficacy. Thus, 
alternative methods are needed to personalize estimates of screening benefit. One 
alternative approach involves disease simulation modeling.(5,6) Simulation models have 
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the ability to simultaneously incorporate cancer risk, life expectancy, and screening 
efficacy, and, although less familiar to many clinicians than clinical trials, have been used 
to inform US Preventive Services Task Force (USPSTF) screening recommendations. Even 
though validated simulation models are available for a variety of screen-detectable 
cancers,(5) the capability of these models to provide personalized recommendations for 
screening has not been fully exploited. 
MISCAN-Colon, a widely cited simulation model of colorectal cancer screening, can be 
used to illustrate how the benefit of screening can vary according to characteristics such 
as age, sex, race, screening history, comorbidity status, and exposure to risk factors for 
colorectal cancer (“background risk”)(Figure). For example, all other factors being equal, a 
recently screened, average-risk, 75-year-old white woman with no comorbidities is nearly 
twice as likely to benefit from screening as one who has severe comorbidities (3.7 vs 2.2 
cancer deaths prevented per 1000 individuals screened). Yet health status is not explicitly 
incorporated into current guidelines for colorectal cancer screening. Moreover, patients 
at low risk for colorectal cancer (either because of a prior negative screening colonoscopy 
or a low background risk for colorectal cancer) are substantially less likely to benefit from 
screening, but guidelines do not distinguish between individuals based on these factors. 
These simple examples do not consider interactions between cancer risk and life expectancy, 
but models can quantitatively weigh such complexities. For instance, smoking and obesity 
are risk factors for colorectal cancer, but also are risk factors for early mortality. When these 
factors are weighed together, MISCAN-Colon suggests that an obese smoker should not 
be screened for colorectal cancer more aggressively than a nonobese nonsmoker. 
Even with personalized screening recommendations available, this approach is unlikely to 
be accepted unless the context in which it will be implemented is considered. Patients 
and physicians may be unreceptive to personalized screening. For instance, personalized 
screening approaches would recommend against screening for low-benefit individuals. 
However, many patients are reluctant to stop screening even if the expected benefit is 
low.(8) For some patients, the necessary degree of benefit is likely to be substantially 
greater than physicians presume, such that these patients might elect less aggressive 
approaches than are currently suggested. Moreover, physicians might find personaliza-
tion time consuming and cumbersome or might simply disagree with personalized 
 recommendations, ultimately failing to incorporate them into their practice. In addition, 
systems of care may have existing approaches to screening that directly conflict with 
personalized recommendations. For example, current quality measures for colorectal 
cancer screening encourage screening individuals up to age 75 years.(1) A physician who 
appropriately discourages screening in a 74-year-old with limited life expectancy could be 
penalized under such age-based quality measures. As a result, physicians in such systems 
of care may be less likely to embrace a personalized approach.
Efforts at multiple levels are needed to overcome these challenges. At the patient level, 
personalized information about the benefits and harms of screening needs to be Fi
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incorporated into educational materials. We also need a better understanding of how to 
communicate such information so that it can be used to aid decision making. Similarly, 
physicians need easily accessible, personalized estimates of benefit (ideally embedded 
into electronic health record systems) to inform patient-physician discussions. Because 
many of these discussions will include estimates of life expectancy, they will be difficult. In 
addition, health care systems need to be willing to implement personalized approaches 
to screening and establish clinically sensitive, personalized measures of quality. For 
instance, colorectal cancer screening quality measures, which are currently based primarily 
on age, could be modified to use both age and health status. Better yet, these measures 
could consider whether an active discussion about the benefits and harms of screening 
took place, with an informed decision used as the marker of quality. 
Current decisions about cancer screening are often based primarily on patient age. As a 
result, some patients who are likely to benefit from screening are not being screened, and 
others who are not likely to benefit are being screened unnecessarily. Simulation models, 
integrated with point-of-care decision aids and decision support tools, could help bridge 
the gap between prediction models and clinical decision making. Implementing 
personalized screening recommendations in clinical practice presents many challenges. 
However, these challenges must be met to provide optimal cancer screening for patients.
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INTRODUCTION
Screening for colorectal cancer (CRC) has been shown to be effective and cost effective in 
reducing CRC mortality and is therefore widely recommended.(1-4) The US Preventive 
Services Task Force (USPSTF), for example, calls for routine screening for average risk 
individuals starting at age 50 years and continuing up to age 75 years.(1) Although 
clinicians are generally aware that factors other than age affect the effectiveness and cost 
effectiveness of CRC screening,(5) many make their decisions on screening for elderly 
individuals primarily based on age: individuals aged 75 years or younger are offered 
screening, whereas individuals aged over 75 years are not. This practice is in concordance 
with existing age-based guidelines and performance measures.(6) On the other hand, a 
substantial minority of clinicians still offer CRC screening to elderly individuals with a 
life-expectancy less than 5 years.(5, 7-9) Hence, screening is not always targeted at those 
elderly individuals most likely to benefit. 
The effectiveness and cost effectiveness of screening for a particular elderly individual 
depend on two key variables: CRC risk and life-expectancy. Both of these variables are 
affected by age. With increasing age, the average risk for CRC increases, but simultaneously 
the average life-expectancy declines. This results in a deterioration of the effectiveness 
and cost effectiveness of screening with age. An individual’s risk for CRC, however, is also 
affected by the individual’s sex, race, screening history, and level of exposure to other risk 
factors for CRC, such as a family history of CRC and smoking (i.e., the individual’s 
“background risk for CRC”). Similarly, an individual’s life-expectancy is affected by the 
individual’s sex, race, and comorbidity status. Therefore, ideally all these factors should be 
considered when making decisions about offering CRC screening. 
The objective of this study was to determine the appropriate age to stop colonoscopy 
screening (i.e., the maximum age at which screening is cost effective) given an individual’s 
sex, race, screening history, background risk for CRC, and comorbidity status. We focused 
on colonoscopy screening, because it is the most commonly used screening modality in 
the United States today.(10) Through this work, we hope to facilitate a more personalized 
approach to CRC screening for elderly individuals, which would ultimately result in more 
efficient screening. As the population ages, and clinicians are faced with increasing 
numbers of both healthy and unhealthy elderly individuals, such an approach will become 
increasingly relevant to clinical practice. 
METHODS
To quantify the effectiveness and cost effectiveness of screening we used Microsimulation 
Screening Analysis-Colon (MISCAN-Colon).
ABSTRACT
Background & Aims: Colorectal cancer (CRC) screening decisions for elderly individuals 
are often made based primarily on age—other factors that affect the effectiveness and 
cost effectiveness of screening are often not considered. We investigated the relative 
importance of factors that could be used to identify those elderly individuals most likely 
to benefit from CRC screening and determined the maximum ages at which screening 
remains cost effective based on these factors.
Methods: We used a microsimulation model (Microsimulation Screening Analysis-Colon) 
that was calibrated to the incidence of CRC in the US and the prevalence of adenomas 
reported in autopsy studies to determine the appropriate age to stop colonoscopy screening 
in 19,200 cohorts of individuals defined by sex, race, screening history, background risk 
for CRC, and comorbidity status. We applied a willingness-to-pay threshold of $100,000 
per quality-adjusted life-year (QALY) gained.
Results: A less-intensive screening history, a higher background risk for CRC, and fewer 
comorbidities were associated with cost-effective screening at older ages. Sex and race 
had only a small effect on the appropriate age to stop screening. For some individuals 
likely to be screened in current practice (for example, 74-year-old white women with 
moderate comorbidities, half the average background risk for CRC, and negative findings 
from a screening colonoscopy 10 y prior), screening resulted in a loss of QALYs, rather than 
a gain. For some individuals unlikely to be screened in current practice (for example, 
81-year-old black men with no comorbidities, an average background risk for CRC, and no 
prior screening), screening was highly cost effective. While screening some previously 
screened, low-risk individuals was not even cost effective at age 66 years, screening some 
healthy, high-risk individuals remained cost effective up to age 88 years.
Conclusion: The current approach to CRC screening in elderly individuals, in which 
decisions are often based primarily on age, is inefficient, resulting in underuse of screening 
for some and overuse of screening for others. CRC screening could be more effective and 
cost effective if individual factors for each patient were considered.
Keywords: colon cancer screening; individualized care; MISCAN; tumor 
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VI.  Comorbidity status (no/ moderate/ severe comorbidities (see below)).
This amounted to a total of 19,200 cohorts. Our analysis does not address individuals 
previously diagnosed with an adenoma or CRC.
Background Risk for CRC
To determine plausible sex- and race-specific ranges for the background risk for CRC, we 
used the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (Appendix 1). 
(28, 29) This tool allowed us to determine an individual’s background risk for CRC based on 
the following risk factors: the number of first-degree relatives with CRC, current leisure-time 
vigorous activity, aspirin/ NSAID use, vegetable intake, body mass index, current and past 
smoking (men only), and estrogen status within the last two years (women only). Based on 
these risk factors, the background risk for CRC in white women ranged from 0.5 times up 
to 3.5 times the average background risk in white women. The corresponding ranges in 
white men, black women, and black men were 0.5-4.9, 0.4-3.5, and 0.5-5.3, respectively. 
For each combination of sex and race, we modeled cohorts with the minimum risk, the 
maximum risk, all risks between the minimum risk and average risk using an increment of 
0.1, all risks between the average risk and twice the average risk using an increment of 0.2, 
and all risks between twice the average risk and the maximum risk using an increment of 
0.5. We modeled different risk levels by multiplying the age-specific onset rates of 
adenomas. We did not exclude individuals with a family history of CRC from our analyses.
Comorbidity Status
To simulate individuals with no, moderate, and severe comorbidities, we used US sex-, 
race-, and comorbidity status specific life-tables.(30) Individuals are classified as having 
moderate comorbidities if diagnosed with an ulcer, rheumatologic disease, peripheral 
vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of a history of 
acute myocardial infarction; as having severe comorbidities if diagnosed with chronic 
obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, 
chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no 
comorbidities if none of these conditions is present.
Screening Strategy
Within each cohort, we simulated a screening colonoscopy for all individuals simulated. 
Individuals in whom adenomas were removed were assumed to undergo colonoscopy 
surveillance according to the current guidelines.(31) We assumed that surveillance continued 
until the diagnosis of CRC or death. Adherence to surveillance was assumed to be 100%.
Test Characteristics of Colonoscopy
The sensitivity of colonoscopy for the detection of adenomas and CRC was obtained from 
a systematic review on miss rates observed in tandem colonoscopy studies and was 75% 
MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for CRC developed at the 
Department of Public Health of the Erasmus University Medical Center (Rotterdam, the 
Netherlands). The model’s structure, underlying assumptions, and calibration are described in 
the Model Appendix at the end of this thesis. In brief, MISCAN-Colon simulates the life 
histories of a large population of persons from birth to death. As each simulated person 
ages, one or more adenomas may develop. These adenomas can progress from small 
(≤5mm in diameter), to medium (6-9mm), to large size (≥10mm). Some adenomas can 
develop into preclinical cancer, which may progress through stages I to IV. However, 
during each stage, CRC may also be diagnosed because of symptoms. Survival after 
clinical diagnosis is determined by the stage at diagnosis, the localization of the cancer, 
and the person’s age. 
Screening will alter some of the simulated life histories. Some cancers will be prevented by 
the detection and removal of adenomas; other cancers will be detected in an earlier stage 
with a more favorable survival. However, screening can also result in serious complications 
and overdiagnosis and overtreatment of CRC. By comparing all life histories with screening 
with the corresponding life histories without screening, MISCAN-Colon quantifies the 
effectiveness of screening as well as the associated costs. 
For our current study, we calibrated four distinct versions of MISCAN-Colon: a version for 
white men, white women, black men, and black women (Model Appendix). To do so, 
we used sex- and race-specific data on the age-, stage-, and localization-specific incidence 
of CRC as observed in the US before the introduction of mass endoscopic screening 
(i.e. between 1990 and 1994) and data on the age-specific prevalence and multiplicity 
distribution of adenomas as observed in autopsy studies.(11-21) Moreover, we used US 
sex- and race-specific CRC survival data.(22) We assumed that the average preclinical 
duration of CRC and adenoma dwell-time were independent of sex and race. These 
durations were calibrated to the rates of interval and surveillance-detected cancers 
observed in randomized controlled trials evaluating screening using guaiac fecal occult 
blood tests and a once-only sigmoidoscopy.(23-27)
Model Inputs
Populations Simulated
We simulated a cohort of 10 million individuals for each combination of:
I.  Age (66/ 67/ (…)/ 90 years);
II.  Sex (men/ women);
III.  Race (black/ white);
IV.  Screening history (negative finding from a screening colonoscopy 10 years prior/ 15 
years prior/ 20 years prior/ no prior screening);
V.  Background risk for CRC (white men: 17 levels, white women: 14 levels, black men: 18 
levels, black women: 15 levels (see below)); and
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for small adenomas (≤5mm in diameter), 85% for medium-sized adenomas (6-9mm), and 
95% for large adenomas (≥10mm) and CRC.(32) We assumed that 95% of all colonoscopies 
reached the cecum; for the remaining 5% the reach of the procedure was assumed to be 
distributed uniformly over colon and rectum. Age-specific risks for nonlethal complications 
of colonoscopy were derived from a study by Warren and colleagues.(33, 34) We assumed 
that one of every 30,000 colonoscopies involving a polypectomy resulted in death.(34, 35) 
Utility Losses Associated with Colonoscopy Screening 
We assumed a utility loss (i.e., a loss of quality of life) equivalent to two full days of life per 
colonoscopy (0.0055 quality-adjusted life-years [QALYs]) and two weeks of life per 
complication (0.0384 QALYs). Utility losses for life-years (LYs) with CRC care were derived 
from a study by Ness and colleagues (Table 1).(36)
Costs Associated with Colonoscopy Screening
The cost effectiveness analyses were conducted from a societal perspective. The costs of 
colonoscopies were based on 2007 Medicare payment rates and copayments (Table 1).(37) 
The costs of complications were obtained from a cost analysis of cases of unexpected 
hospital use after endoscopy in 2007.(38) We added patient time costs to both.(39) The 
costs of LYs with CRC care were obtained from an analysis of Surveillance, Epidemiology, 
and End Results-Medicare linked data and included patient deductibles, copayments, and 
patient time costs.(40) We adjusted all costs to reflect the 2013 level using the US Consumer 
Price Index.(41)
Outcomes
For each cohort, we quantified the effectiveness of screening (i.e., the number of CRC 
cases prevented, CRC deaths prevented, LYs gained, and QALYs gained by screening) as 
well as the associated costs, applying the conventional 3% annual discount rate to both.
(42) We expressed the cost effectiveness of screening in terms of the costs per QALY 
gained.
Analyses
For all demographic groups, we first quantified the effect of age on the effectiveness and 
cost effectiveness of screening. To demonstrate the (relative) importance of also 
considering factors other than age, we subsequently quantified the effect of screening 
history, background risk for CRC, and comorbidity status on the effectiveness and cost 
effectiveness of screening. Finally, we determined the appropriate age to stop screening 
given an individual’s sex and race, screening history, background risk for CRC, and 
comorbidity status, applying the currently recommended willingness-to-pay threshold of 
$100,000 per QALY gained.(43)
Table 1   Model Inputs: Utility Losses and Costs Associated with Colonoscopy Screening.
UTILITY LOSS (QALYs)1
Per colonoscopy
without polypectomy/ biopsy 0.005
with polypectomy/ biopsy 0.005
Per complication of colonoscopy 0.038
Per LY with CRC care2, 3 Initial care Continuing  
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
COSTS (2013 US$)4
Per colonoscopy
without polypectomy/ biopsy 887
with polypectomy/ biopsy 1,096
Per complication of colonoscopy 6,045
Per life-year with CRC care2 Initial care Continuing  
care
Terminal care 
Death CRC
Terminal care 
Death other cause
Stage I CRC 36,683 3,050 63,809 19,176
Stage II CRC 49,234 2,870 63,555 17,279
Stage III CRC 59,759 4,021 67,041 21,457
Stage IV CRC 77,790 12,178 88,368 49,866
QALY = quality-adjusted life-year; LY = life-year; CRC = colorectal cancer
1  The loss of quality of life associated with a particular event.
2  Care for CRC was divided in three clinically relevant phases: the initial, continuing, and terminal care phase. The 
initial care phase was defined as the first 12 months after diagnosis; the terminal care phase was defined as the 
final 12 months of life; the continuing care phase was defined as all months in between. In the terminal care 
phase, we distinguished between CRC patients dying from CRC and CRC patients dying from another cause. 
For patients surviving less than 24 months, the final 12 months were allocated to the terminal care phase and 
the remaining months were allocated to the initial care phase. 
3  Utility losses for LYs with initial care were derived from a study by Ness and colleagues.(36) For LYs with 
continuing care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing care for 
stage III and IV CRC, we assumed the corresponding utility losses for LYs with initial care. For LYs with terminal 
care for CRC, we assumed the utility loss for LYs with initial care for stage IV CRC. For LYs with terminal care for 
another cause, we assumed the corresponding utility losses for LYs with continuing care. 
4  Costs include copayments and patient time costs (i.e. the opportunity costs of spending time on screening 
or being treated for a complication or CRC), but do not include travel costs, costs of lost productivity, and 
unrelated health care and non-health care costs in added years of life. We assumed that the value of patient 
time was equal to the median wage rate in 2012: $16.71 per hour.(39) We assumed that colonoscopies and 
complications used up 8 and 16 hours of patient time, respectively. Patient time costs were already included in 
the estimates for the costs of LYs with CRC care obtained from a study by Yabroff and colleagues.(40)
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Sensitivity Analyses
We repeated our analyses assuming 1) 50% higher and 50% lower utility losses for 
colonoscopies and complications; 2) 25% higher and 25% lower costs for colonoscopies; 
3) 25% higher and 25% lower costs for CRC care; and 4) a cost effectiveness threshold of 
$50,000 per QALY gained. Moreover, we performed a multivariate probabilistic sensitivity 
analysis on the above-mentioned utility losses and costs for one representative case 
(details on this analysis are given in Appendix 5).
RESULTS
The Effect of Age on the Effectiveness and Cost Effectiveness of Screening 
The effectiveness of colonoscopy screening declined with increasing age. While screening 
healthy, average risk, white women with a negative screening colonoscopy 10 years prior 
resulted in 27.8 QALYs gained per 1,000 women aged 66 years, it resulted in a loss of QALYs, 
rather than a gain in women aged 85 years and older (Figure 1A). On the other hand, the 
costs of screening increased with age: from $602,000 per 1,000 women aged 66 years to 
$1,061,000 per 1,000 women aged 90 years (Figure 1B). As a result, the cost effectiveness 
of screening deteriorated with age. While screening was associated with a cost of $22,000 
per QALY gained for women aged 66 years, it was associated with a cost of nearly $4M per 
QALY gained for women aged 84 years (Figure 1C). Sex and race had relatively little effect 
on the effectiveness and cost effectiveness of screening (Figure 1).
The Effect of Factors Other than Age on the Effectiveness and  
Cost Effectiveness of Screening
Screening history and comorbidity status had a large effect on the effectiveness of 
colonoscopy screening. While screening healthy, average risk, 75-year-old, white women 
with a negative screening colonoscopy 10 years prior (our “reference cohort” for this 
comparison) resulted in 13.4 QALYs gained per 1,000 women, screening women with 
identical characteristics, but without prior screening, resulted in 55.2 QALYs gained per 
1,000 women (factor difference = 55.2 QALYs gained/ 13.4 QALYs gained = 4.1) (Figure 2A). 
Similarly, screening women with severe, rather than no comorbidities resulted in 4.3 QALYs 
gained per 1,000 women (factor difference = 3.1). These relative differences in effectiveness 
were comparable to the difference in effectiveness between screening 70-year-old and 
80-year-old women. Nevertheless, the most important factor influencing the effectiveness 
of screening was the individual’s background risk for CRC. While screening women with 
the lowest possible background risk resulted in 0.8 QALYs gained per 1,000 women, 
screening women with the highest possible background risk resulted in 106.5 QALYs 
gained per 1,000 women (factor difference = 137.7). The relative effect of all factors on the 
cost effectiveness of screening was slightly larger than the corresponding effect on the 
Figure 1   The Effect of Age on the Effectiveness (A), Costs (B), and Cost Effectiveness (C) 
of Colonoscopy Screening: Results for Average Risk Individuals with a Negative 
Screening Colonoscopy 10 Years Prior and No Comorbidities (QALYs gained 
and costs per 1,000 individuals; 3% discounted).
QALY = quality-adjusted life-year
1  Detailed results on the effectiveness and costs of screening can be found in Appendix 2.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of 
screening). A negative value indicates that screening is associated with a net harm, rather than a net health 
benefit.
3  The costs of screening and surveillance colonoscopies, complications of colonoscopy, and overtreatment of 
CRC minus the savings associated with preventing CRC treatment.
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effectiveness of screening (Figure 2B). The relative importance of considering factors 
other than age did not differ substantially by sex and race (Figure 2).
The Appropriate Ages to Stop Screening
As expected, screening was cost effective up to a more advanced age for individuals 
without prior screening compared with individuals with prior screening; for individuals 
without comorbidities compared with individuals with comorbidities; and for individuals 
with a high background risk for CRC compared with individuals with a low background risk 
for CRC (Table 2). 
Table 3 shows the appropriate ages to stop screening for all individuals. Although 
screening some previously screened, low risk individuals was not even cost effective at 
age 66 years, screening some healthy, high risk individuals was cost effective up to age 88 
years. Results were comparable across the demographic groups. 
Sensitivity Analyses
Results were robust to varying the utility losses associated with colonoscopies and 
complications and to varying the costs of colonoscopies and CRC care (Appendix 4 
[univariate deterministic sensitivity analyses] and Appendix 5 [multivariate probabilistic 
sensitivity analysis]). Applying a willingness-to-pay threshold of $50,000 instead of 
$100,000 per QALY gained reduced the maximum age at which screening was cost 
effective by an average of 3 years.
Figure 2   The Relative Effect of Age, Screening History, Comorbidity Status, and 
 Background Risk for CRC on the Effectiveness (A) and Cost Effectiveness (B) of 
Colonoscopy Screening (QALYs gained per 1,000 individuals; 3% discounted).
CRC = colorectal cancer; QALY = quality-adjusted life-year; NSC = negative screening colonoscopy; SCR = screening; 
RR CRC = background risk for CRC; CM = comorbidities; FH = family history; CS = cost saving; NE = negative effect
1  The dashed lines indicate results for healthy, average risk, 75-year-old individuals with a negative screening 
colonoscopy 10 years prior.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of 
screening). A negative value indicates that screening is associated with a net harm, rather than a net health 
benefit.
3  See also Figure 1.
4  Individuals are classified as having moderate comorbidities if diagnosed with an ulcer, rheumatologic disease, 
peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of a history of acute 
myocardial infarction; as having severe comorbidities if diagnosed with chronic obstructive pulmonary disease, 
congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic 
hepatitis, or AIDS; and as having no comorbidities if none of these conditions is present. ‘Moderate comorbidities’ 
corresponds with ‘low/medium comorbidity’ and ‘severe comorbidities’ corresponds with ‘high comorbidity’ as 
used in the study by Cho and colleagues.(30)
5  The range of the background risk for CRC is based on the National Cancer Institute’s Colorectal Cancer Risk 
Assessment Tool.(28) This tool incorporates the following risk factors: the number of first-degree relatives with 
CRC, current leisure-time vigorous activity, aspirin/ NSAID use, vegetable intake, body mass index, current and 
past smoking (men only), and estrogen status within the last two years (women only). In white women, the 
minimum background risk for CRC is 0.5, the maximum background risk in the absence of a family history of CRC 
is 2.0, and the maximum background risk in the presence of a family history of CRC is 3.5. In white men, black 
women, and black men, the corresponding risks are 0.5, 2.0, and 4.9; 0.4, 1.8, and 3.5; and 0.5, 2.5, and 5.3, 
respectively. 
6 Cannot be calculated.
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Table 2   The Costs per QALY Gained (*$1,000) of Colonoscopy Screening for White Females  
by Screening History, Comorbidity Status, Background Risk for CRC, and Age  
(3% discounted).1  
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
NO COMORBIDITY2 NO COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54
66 124 73 51 37 28 22 14 9 5 3 1 CS CS CS 66 16 11 9 6 5 3 1 CS CS CS CS CS CS CS
68 152 86 59 42 31 24 16 10 6 4 2 CS CS CS 68 17 12 9 7 5 4 2 0 CS CS CS CS CS CS
70 202 108 70 50 38 29 19 12 8 5 3 CS CS CS 70 19 14 10 8 6 5 2 1 CS CS CS CS CS CS
72 324 153 93 67 48 38 24 17 12 8 5 1 CS CS 72 24 17 13 10 8 7 4 2 1 CS CS CS CS CS
74 >500 232 130 88 64 49 32 22 16 12 8 3 CS CS 74 29 21 17 13 11 9 6 4 2 1 0 CS CS CS
76 >500 417 193 123 86 66 43 30 22 17 13 6 2 CS 76 36 27 22 18 15 12 9 7 5 4 2 0 CS CS
78 NE >500 343 186 126 94 59 41 31 24 19 10 6 3 78 49 36 30 24 21 18 14 11 9 7 6 3 1 CS
80 NE NE >500 323 201 141 86 59 45 36 28 17 11 7 80 67 51 41 35 30 26 21 17 15 13 11 8 5 3
82 NE NE NE >500 >500 325 168 107 80 64 51 34 24 18 82 115 85 69 58 50 45 37 31 27 24 21 17 14 11
84 NE NE NE NE NE >500 468 237 164 125 98 65 48 36 84 235 161 126 105 90 79 65 56 49 45 40 33 28 25
86 NE NE NE NE NE NE NE >500 >500 349 245 142 99 79 86 >500 441 299 229 189 163 129 110 98 87 79 66 57 51
88 NE NE NE NE NE NE NE NE NE NE NE >500 322 234 88 NE NE NE >500 >500 >500 405 312 263 222 199 160 134 120
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 453
MODERATE COMORBIDITY2 MODERATE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54
66 180 100 68 50 38 30 19 13 9 6 4 0 CS CS 66 22 17 13 10 8 7 4 2 1 CS CS CS CS CS
68 238 123 82 58 44 34 23 16 11 8 5 1 CS CS 68 25 18 14 11 9 8 5 3 2 1 CS CS CS CS
70 367 168 103 73 55 42 28 20 14 10 7 3 CS CS 70 29 21 17 14 11 9 7 5 3 2 1 CS CS CS
72 >500 260 144 100 71 55 37 26 19 14 11 5 2 CS 72 35 26 21 17 14 12 9 7 5 4 2 0 CS CS
74 NE >500 244 154 105 79 52 37 28 22 17 10 5 2 74 47 36 29 24 20 18 14 11 9 7 6 3 1 CS
76 NE NE >500 277 172 127 79 55 42 34 27 17 11 7 76 67 51 41 35 30 26 21 17 15 13 11 8 5 3
78 NE NE >500 >500 300 200 116 79 61 48 39 25 18 13 78 93 70 57 47 41 36 30 25 22 19 17 13 10 8
80 NE NE NE >500 >500 378 191 120 92 73 58 38 28 22 80 139 103 82 69 60 53 44 38 33 30 27 22 18 15
82 NE NE NE NE NE >500 >500 259 180 138 107 70 53 42 82 289 193 149 122 104 92 76 66 57 52 47 39 34 30
84 NE NE NE NE NE NE NE >500 >500 383 259 150 106 81 84 >500 >500 373 284 225 192 151 128 111 101 91 76 66 58
86 NE NE NE NE NE NE NE NE NE NE >500 389 232 177 86 NE NE >500 >500 >500 >500 343 268 227 197 176 142 122 108
88 NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 88 NE NE NE NE NE NE NE >500 >500 >500 >500 >500 391 328
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE
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Table 2   Continued.  
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
SEVERE COMORBIDITY2 SEVERE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54
66 335 160 104 74 56 45 30 21 16 12 9 4 1 CS 66 34 26 21 17 14 12 9 7 5 3 2 CS CS CS
68 >500 210 129 89 66 52 35 25 18 14 11 5 2 CS 68 38 29 23 19 16 14 10 8 6 4 3 1 CS CS
70 >500 373 187 125 92 70 47 34 25 20 15 9 5 2 70 47 36 29 24 21 18 14 11 9 7 6 3 1 CS
72 NE >500 348 208 139 104 67 49 36 29 23 14 9 6 72 65 48 39 33 29 25 20 17 14 12 10 7 4 3
74 NE NE >500 407 229 160 98 69 53 42 34 22 15 11 74 88 66 54 46 39 35 28 24 20 18 16 11 9 7
76 NE NE NE >500 427 272 148 100 75 60 49 32 23 18 76 124 91 73 61 53 47 38 33 28 25 23 18 14 12
78 NE NE NE NE >500 >500 298 177 128 99 79 53 39 31 78 216 149 118 96 83 73 61 52 45 41 37 31 26 22
80 NE NE NE NE NE NE >500 334 220 164 127 81 60 48 80 425 256 190 154 131 113 93 80 70 63 58 48 41 36
82 NE NE NE NE NE NE NE >500 >500 461 311 170 122 96 82 NE >500 >500 388 296 244 190 157 133 120 109 91 78 70
84 NE NE NE NE NE NE NE NE NE NE >500 472 267 196 84 NE NE NE >500 >500 >500 491 363 295 253 223 177 149 131
86 NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 86 NE NE NE NE NE NE NE NE >500 >500 >500 >500 437 364
88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE 88 NE NE NE NE NE NE NE NE NE NE NE NE NE >500
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE
QALY = quality-adjusted life-year; CRC = colorectal cancer; CS = cost saving; NE = negative effect
1  The black lines indicate a willingness-to-pay threshold of $100,000 per QALY gained. Green cells indicate that screening is 
cost-effective given this threshold. Red cells indicate that screening is not cost-effective given this threshold. Similar tables 
for white males, black females, and black males are given in Appendix 3.
2  Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3  Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4  Background risk for CRC only possible in case of a family history of CRC.
222 | Chapter 7 Personalizing colonoscopy screening for elderly individuals | 223
7
Table 3   The Appropriate Ages to Stop Colonoscopy Screening: Results by Sex, Race,  
Screening History, Comorbidity Status, and Background Risk for CRC.1  
WHITE FEMALES WHITE FEMALES
SCREENING HISTORY SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 67 <665 0.5 73 70 67 0.5 81 78 74
0.6 69 66 <665 0.6 73 70 67 0.6 76 73 70 0.6 82 79 76
0.7 72 69 <665 0.7 76 72 70 0.7 78 75 72 0.7 83 80 77
0.8 74 71 68 0.8 78 74 71 0.8 80 76 73 0.8 83 81 78
0.9 76 73 70 0.9 79 76 73 0.9 80 78 74 0.9 84 81 78
1.0 78 75 71 1.0 80 77 74 1.0 81 79 76 1.0 84 82 79
1.2 80 77 74 1.2 81 79 76 1.2 82 80 77 1.2 85 82 80
1.4 81 79 75 1.4 83 80 77 1.4 83 81 78 1.4 85 83 80
1.6 82 80 77 1.6 83 81 78 1.6 84 82 79 1.6 86 83 81
1.8 83 81 78 1.8 84 82 79 1.8 85 82 80 1.8 86 83 81
2.0 84 81 78 2.0 85 82 80 2.0 85 83 80 2.0 86 84 81
2.54 85 82 80 2.54 85 83 81 2.54 86 84 81 2.54 87 84 82
3.04 86 83 81 3.04 86 84 82 3.04 86 84 82 3.04 87 85 82
3.54 86 84 82 3.54 87 85 82 3.54 87 85 82 3.54 87 85 83
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Table 3   Continued.  
WHITE MALES WHITE MALES
SCREENING HISTORY SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 68 <665 0.5 73 71 67 0.5 81 79 74
0.6 69 66 <665 0.6 73 70 67 0.6 76 73 69 0.6 82 80 76
0.7 71 69 <665 0.7 75 73 69 0.7 78 75 71 0.7 83 80 77
0.8 74 71 67 0.8 78 74 70 0.8 80 77 72 0.8 83 81 77
0.9 76 73 69 0.9 79 76 72 0.9 80 77 73 0.9 83 81 78
1.0 78 74 70 1.0 80 77 73 1.0 81 78 75 1.0 84 81 78
1.2 80 77 73 1.2 81 79 75 1.2 82 80 76 1.2 84 82 79
1.4 81 79 75 1.4 82 80 76 1.4 83 80 77 1.4 85 82 79
1.6 82 80 76 1.6 83 81 77 1.6 83 81 78 1.6 85 83 80
1.8 83 80 77 1.8 83 81 78 1.8 84 82 79 1.8 85 83 80
2.0 83 81 78 2.0 84 82 79 2.0 84 82 79 2.0 85 83 80
2.54 84 82 80 2.54 85 83 80 2.54 85 83 80 2.54 86 83 81
3.04 85 83 80 3.04 85 83 81 3.04 86 83 81 3.04 86 84 81
3.54 85 83 81 3.54 86 84 81 3.54 86 84 81 3.54 86 84 81
4.04 86 84 81 4.04 86 84 81 4.04 86 84 81 4.04 86 84 82
4.54 86 84 82 4.54 86 84 82 4.54 87 84 82 4.54 87 84 82
4.94 86 84 82 4.94 87 84 82 4.94 87 84 82 4.94 87 84 82
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Table 3   Continued.  
BLACK FEMALES BLACK FEMALES
SCREENING HISTORY SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 68 <665 <665 0.4 80 78 73
0.5 <665 <665 <665 0.5 69 67 <665 0.5 72 70 <665 0.5 81 79 75
0.6 68 <665 <665 0.6 73 70 <665 0.6 75 73 69 0.6 82 80 77
0.7 72 70 <665 0.7 75 73 68 0.7 77 75 71 0.7 83 81 77
0.8 74 72 67 0.8 77 75 70 0.8 79 77 72 0.8 84 81 78
0.9 76 74 69 0.9 78 76 72 0.9 80 78 74 0.9 84 82 79
1.0 77 75 71 1.0 79 78 73 1.0 81 79 75 1.0 85 82 80
1.2 79 77 73 1.2 81 79 76 1.2 82 80 77 1.2 85 83 80
1.4 80 79 75 1.4 82 80 77 1.4 83 81 78 1.4 85 83 81
1.6 81 80 77 1.6 83 81 78 1.6 84 82 79 1.6 86 84 81
1.8 82 80 77 1.8 83 81 79 1.8 84 82 80 1.8 86 84 82
2.04 83 81 78 2.04 84 82 80 2.04 85 83 80 2.04 86 84 82
2.54 84 82 80 2.54 85 83 81 2.54 86 84 82 2.54 87 85 82
3.04 85 83 81 3.04 86 84 82 3.04 86 84 82 3.04 87 86 83
3.54 86 84 82 3.54 87 85 83 3.54 87 86 83 3.54 88 86 83
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woman with moderate comorbidities (e.g. diabetes), half the average background risk for 
CRC, and a negative screening colonoscopy 10 years prior, on the other hand, might 
currently be offered screening, while our study shows that screening these individuals is 
harmful. While screening some previously screened, low risk individuals is not even cost 
effective at age 66 years, screening healthy, high risk individuals can remain cost effective 
up to age 88 years. To facilitate the use of our results in clinical practice, we developed a 
web tool that can be used to quantify the cost effectiveness of colonoscopy screening for 
individual elderly patients. This tool can be accessed at: http://www.frankly.yetes.nl/. 
DISCUSSION
In current practice, decisions on CRC screening for elderly individuals are often based 
primarily on age.(6) Our study shows that this approach is inefficient, resulting in underuse 
of screening for some and overuse of screening for others. An 81-year-old black man with 
no comorbidities, an average background risk for CRC, and no prior screening, for example, 
might currently be denied screening, while our study shows that screening these 
individuals is highly cost effective (costs per QALY gained: $50,000). A 74-year-old white 
Table 3   Continued.  
BLACK MALES BLACK MALES
SCREENING HISTORY SCREENING HISTORY
Negative screening colonoscopy
10 years prior
Negative screening colonoscopy
15 years prior
Negative screening colonoscopy
20 years prior
No prior screening
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 68 <665 <665 0.5 71 69 <665 0.5 80 78 72
0.6 66 <665 <665 0.6 71 69 <665 0.6 74 71 67 0.6 81 79 73
0.7 70 68 <665 0.7 74 71 67 0.7 76 73 68 0.7 82 80 75
0.8 72 70 <665 0.8 76 72 67 0.8 77 74 70 0.8 82 80 75
0.9 74 71 67 0.9 77 74 70 0.9 79 76 71 0.9 83 81 76
1.0 76 73 68 1.0 78 76 70 1.0 80 78 72 1.0 84 81 76
1.2 78 75 70 1.2 80 78 72 1.2 81 79 73 1.2 84 81 76
1.4 79 78 72 1.4 81 79 73 1.4 82 80 75 1.4 84 81 77
1.6 80 78 73 1.6 82 80 75 1.6 82 81 76 1.6 85 82 79
1.8 81 79 75 1.8 82 81 76 1.8 83 81 76 1.8 85 82 79
2.0 82 80 75 2.0 83 81 76 2.0 84 81 77 2.0 86 82 80
2.5 83 81 77 2.5 84 82 79 2.5 85 82 79 2.5 86 83 80
3.04 84 82 79 3.04 85 82 80 3.04 86 83 80 3.04 87 83 80
3.54 85 82 80 3.54 86 83 80 3.54 86 83 80 3.54 87 84 80
4.04 86 83 80 4.04 86 84 80 4.04 87 84 80 4.04 87 84 80
4.54 87 83 80 4.54 87 84 81 4.54 87 84 81 4.54 88 84 81
5.04 87 84 81 5.04 87 84 82 5.04 87 84 82 5.04 88 84 82
5.34 87 84 81 5.34 88 84 82 5.34 88 84 82 5.34 88 84 82
CRC = colorectal cancer; RR CRC = background risk for CRC
1  Given a willingness-to-pay threshold of $100,000 per QALY gained.
2  Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3  Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4  Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged  
65 years or younger. 
230 | Chapter 7 Personalizing colonoscopy screening for elderly individuals | 231
7
Although our study shows that the appropriate age to stop screening varies widely 
among individuals, our results are in line with the USPSTF recommendation to discontinue 
routine screening for CRC in adequately screened individuals aged over 75 years.(1) Based 
on our analyses, the appropriate age to stop screening for average risk, white women with 
a negative screening colonoscopy 10 years prior is 78 years for those with no comorbidities, 
75 years for those with moderate comorbidities, and 71 years for those with severe 
comorbidities. Results for the other demographic groups were comparable. Our results 
are also in agreement with the results of an earlier study on the cost effectiveness of 
screening in elderly individuals without prior screening.(44) In that study, in which we did 
not consider previously screened individuals, nor stratify results by sex and race or 
background risk for CRC, we found colonoscopy screening to be cost effective up to age 
85, 82, and 79 years for average risk individuals with no, moderate, and severe comorbidities, 
respectively. For white women, the corresponding ages found in our current study were 
84, 82, and 79 years. Finally, our results are in line with the results of an earlier study on FIT 
screening in elderly individuals with an adequate screening history.(45) In that study, in 
which we did not consider previously unscreened individuals, nor stratify results by sex 
and race or background risk for CRC, we found FIT screening to have a favorable balance 
between benefits and harms up to age 76, 74, and 71 years for average risk individuals with 
no, moderate, and severe comorbidities, respectively. For white women, the corresponding 
ages to stop colonoscopy screening found in our current study were 78, 75, and 71 years. 
The idea of personalizing screening decisions for elderly patients is not new. Walter and 
Covinsky described a theoretical framework for personalization in elderly individuals in 
2001.(46) This framework, which focused primarily on the effect of life-expectancy on the 
effectiveness of screening, was followed by many studies that examined the univariate 
relationships between sex and race, screening history, comorbidity status, and cancer risk 
on the one hand, and the effectiveness and cost effectiveness of CRC screening on the 
other.(47-49) However, none of these studies considered all relevant factors simultaneously, 
using a multivariate approach. This complicates the use of the results of these studies in 
clinical practice. For example, how should one approach an individual with a high risk for 
CRC, but a poor life-expectancy, or vice versa? We believe that our study is more applicable to 
the complex situations commonly encountered in clinical practice. Additionally, our work may 
prove useful to policy makers aiming at improving the efficiency of cancer prevention. 
Our study has several important limitations. First, in our analyses we did not consider 
individuals with a negative screening colonoscopy less than 10 years prior. Because some 
screening guidelines recommend a screening interval of 5 years for individuals with a 
family history of CRC, we provided results for high-risk individuals with a negative 
screening colonoscopy 5 years prior in an Appendix (Appendix 6). Second, we only 
considered screening by colonoscopy. Since the costs of a screening sigmoidoscopy and, 
particularly, a fecal occult blood test are considerably lower than those of a colonoscopy, 
these screening modalities might remain cost effective up to a more advanced age. 
However, in an earlier study, age differences between tests were found to be small.(44) 
Third, we did not consider individuals with multiple prior negative screening colonoscopies. 
However, since the interval since the last negative screening colonoscopy is likely to be 
the most important screening-related predictor of CRC risk, having had multiple prior 
negative screening colonoscopies is unlikely to substantially lower the appropriate age to 
stop screening. Finally, the National Cancer Institute’s CRC Risk Assessment Tool only 
provides risk estimates for average risk adenoma patients. Since recommendations for 
surveillance in adenoma patients should be tailored according to the characteristics of 
adenomas removed during colonoscopy, we could not use our current approach to 
provide guidance for elderly individuals with adenomas removed during a prior 
colonoscopy. Given that the majority of colonoscopies in elderly patients are performed 
for post-polypectomy surveillance,(50) this is an important area for future research. 
Although we believe that effectiveness and cost effectiveness should be important 
criteria when making decisions about offering medical interventions, we recognize that 
decisions on CRC screening should also be based on patient preferences. This requires 
reliable, personalized information on the benefits, burden, and harms of screening. Hence, 
additional studies focusing on those outcomes most meaningful to patients are required. 
Another important future research direction is the development of new prediction 
models for both CRC risk and life-expectancy. Research in this area should not only focus 
on developing more sophisticated and accurate models, but also on developing simpler 
models that are less time consuming to use than the currently available models. Along 
these lines, it is important to realize that implementing personalized screening in clinical 
practice will be challenging: many patients are reluctant to discontinue screening even if 
the expected benefit is low,(51) physicians might find personalization cumbersome, and 
system-level incentives, which currently encourage “one size fits all” age-based screening, 
need to be aligned with benefit. 
In conclusion: The current approach to CRC screening in elderly individuals, in which the 
decision to offer screening is often based primarily on age, is inefficient, resulting in 
underuse of screening for some and overuse of screening for others. A more personalized 
approach to screening has great potential to increase the efficiency of screening. As the 
population ages, this will become increasingly important. 
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Appendix 1. Background Risk for CRC
To determine plausible sex- and race-specific ranges for the background risk for CRC 
(i.e. the relative level of exposure to risk factors for CRC other than sex, race, and screening 
history, which are already incorporated in MISCAN-Colon), we used the National Cancer 
Institute’s Colorectal Cancer Risk Assessment Tool.(28,29) Using this tool, we determined 
the absolute risk of developing CRC between ages 50 and 85 (not corrected for other 
cause mortality) for previously unscreened white women, white men, black women, and 
black men for all combinations of the following risk factors:
-  the number of first-degree relatives with a history of CRC (0/ 1/ ≥2);
-  current leisure-time vigorous activity (0/ >0 and ≤2/ >2 and ≤4/ >4 hours per week);
-  use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) (nonuser/ 
regular user);
-  vegetable intake (<5/ ≥5 servings per day);
-  body mass index (≤24.9/ 25.0 to ≤30/ >30 kg/m2);
-  years of smoking (in current and former smokers) (0/ >0 and <15/ ≥15 and <35/ ≥35 
years; men only);
-  usual number of cigarettes smoked per day (in current and former smokers) (never 
smoker/ >0 and <11/ ≥11 and ≤20/ >20 cigarettes per day; men only); and
-  estrogen status within the last two years (negative (postmenopausal and not on 
hormone replacement therapy/ positive (premenopausal or on hormone-replacement 
therapy); women only).
For white women this risk ranged from 2.7% (for women with the following characteristics: 
0 first-degree relatives with a history of CRC, >4 hours of leisure-time vigorous activity per 
week, a regular user of aspirin or NSAIDs, ≥5 servings of vegetables per day, a body mass 
index ≤24.9 kg/m2, and a positive estrogen status during the last two years) to 21.3% (for 
women with the following characteristics: ≥2 first-degree relatives with a history of CRC, 
0 hours of leisure-time vigorous activity per week, a nonuser of aspirin or NSAIDs, 
<5 servings of vegetables per day, a body mass index >30 kg/m2, and a negative estrogen 
status during the last two years). For white men, black women, and black men, the risk 
ranged from 4.4% to 43.5%, from 3.0% to 23.3%, and from 4.3% to 47.1%. 
To incorporate these risk levels in MISCAN-Colon, we transformed these absolute risks into 
relative risks. To do this, we first used the sex- and race-specific versions of MISCAN-Colon 
(which are calibrated on CRC incidence data observed in SEER between 1990 and 1994) 
to determine average risks of developing CRC between ages 50 and 85 (uncorrected 
for other cause mortality). The resulting average risks for white women, white men, black 
women, and black men were 6.0%, 8.8%, 6.7%, and 9.0%, respectively. We then calculated 
the ranges of the relative background risk for CRC in white women, white men, black 
women, and black men 0.5 - 3.5, 0.5 - 4.9, 0.4 - 3.5, and 0.5 - 5.3, respectively. 
For each combination of sex and race, we modeled cohorts with the minimum risk, the 
maximum risk, all risks between the minimum risk and average risk using an increment 
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of 0.1, all risks between the average risk and twice the average risk using an increment of 
0.2, and all risks between twice the average risk and the maximum risk using an increment 
of 0.5. Hence, for white women we modeled cohorts with a background risk for CRC of 
0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, and 3.5 (14 levels); for black women 
we modeled cohorts with a background risk of 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 
2.0, 2.5, 3.0, and 3.5 (15 levels); for white men we modeled cohorts with a background risk 
of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 4.9 (17 levels); and for 
black men we modeled cohorts with a background risk of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 
1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.3 (18 levels).
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Appendix 2: The Impact of Age on the Effectiveness, Costs, and Cost-
Effectiveness of Colonoscopy Screening – Detailed Results
Appendix 2, Table 1  The Impact of Age on the Effectiveness, Costs,  
and Cost-Effectiveness of Colonoscopy Screening: Results for Healthy, Average Risk,  
White Women with a Negative Screening Colonoscopy 10 Years Prior (effectiveness  
and costs per 1,000 females; 3% discounted).
EFFECTIVENESS COSTS (*$1,000)* COST-EFFECTIVENESS
Age CRC cases  
prevented1
CRC deaths 
prevented
LYs 
gained
QALYs 
gained2
Screening 
colonoscopies
Surveillance 
colonoscopies
Complications  CRC care3 Total Costs/ QALY gained  
(*$1,000)
66 7.4 3.5 28.0 27.8 932 224 25 -578 602 22
67 7.3 3.5 27.0 26.7 932 218 26 -565 610 23
68 7.1 3.4 26.1 25.4 932 211 27 -549 621 24
69 6.9 3.4 25.0 24.0 932 204 27 -526 638 27
70 6.8 3.3 23.8 22.5 932 197 29 -506 652 29
71 6.5 3.2 21.7 20.0 932 191 30 -479 674 34
72 6.2 3.1 20.4 18.4 932 185 31 -452 696 38
73 6.0 2.9 19.0 16.7 932 178 32 -425 718 43
74 5.7 2.8 17.7 15.1 932 172 33 -399 739 49
75 5.4 2.7 16.4 13.4 933 164 35 -370 761 57
76 5.1 2.6 15.1 11.8 933 159 36 -346 783 66
77 4.9 2.5 13.9 10.3 933 154 38 -320 806 78
78 4.6 2.4 12.7 8.8 934 148 40 -294 829 94
79 4.2 2.2 11.6 7.5 934 143 42 -267 852 114
80 4.0 2.1 10.6 6.2 935 136 44 -241 874 141
81 3.4 1.9 9.2 4.4 934 127 46 -200 907 205
82 2.9 1.7 7.9 2.9 934 117 47 -160 937 325
83 2.4 1.6 6.8 1.5 933 108 49 -125 965 652
84 2.0 1.4 5.8 0.2 933 100 51 -95 989 3,973
85 1.5 1.3 5.0 -0.8 933 87 52 -66 1,006 negative effect
86 1.0 1.1 4.0 -2.0 931 77 53 -35 1,026 negative effect
87 0.6 0.9 3.1 -3.0 930 67 54 -9 1,041 negative effect
88 0.3 0.7 2.4 -3.9 928 58 54 13 1,053 negative effect
89 -0.0 0.6 1.8 -4.5 926 50 55 28 1,059 negative effect
90 -0.2 0.5 1.3 -5.1 925 43 56 37 1,061 negative effect
CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
1  A negative value indicates that the number of CRC cases prevented by screening is exceeded by the number 
of CRC cases over-diagnosed by screening.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of screening). 
A negative value indicates that screening is associated with a net harm, rather than a net health benefit.
3  Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with CRC care. The net effect can 
be a reduction in costs (negative values) or an increase in costs (positive values).
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Appendix 2. Table 2  The Impact of Age on the Effectiveness. Costs.  
and Cost-Effectiveness of Colonoscopy Screening: Results for Healthy. Average Risk.  
White Men with a Negative creening Colonoscopy 10 Years Prior (effectiveness  
and costs per 1.000 females; 3% discounted).
EFFECTIVENESS COSTS (*$1.000)* COST-EFFECTIVENESS
Age CRC cases  
prevented1
CRC deaths 
prevented
LYs 
gained
QALYs 
gained2
Screening 
colonoscopies
Surveillance 
colonoscopies
Complications  CRC care3 Total Costs/ QALY gained  
(*$1.000)
66 8.3 4.3 31.4 31.6 938 255 28 -631 590 19
67 8.0 4.1 29.6 29.4 937 244 29 -600 610 21
68 7.6 4.0 28.1 27.4 937 233 30 -569 631 23
69 7.3 3.9 26.3 25.3 937 223 31 -535 655 26
70 6.9 3.8 24.7 23.4 937 212 31 -503 677 29
71 6.7 3.5 22.3 20.5 937 205 33 -474 700 34
72 6.4 3.4 20.7 18.5 937 197 34 -447 720 39
73 6.0 3.3 19.1 16.6 936 189 35 -414 746 45
74 5.7 3.1 17.6 14.7 936 182 36 -382 773 53
75 5.3 2.9 16.0 12.8 936 172 38 -348 798 63
76 5.1 2.9 15.1 11.6 937 169 40 -329 817 70
77 4.8 2.8 14.0 10.2 938 164 42 -307 837 82
78 4.6 2.7 13.1 9.1 940 159 44 -289 854 94
79 4.3 2.6 12.2 8.0 940 154 46 -262 878 110
80 3.9 2.5 11.3 6.7 941 147 49 -231 906 135
81 3.1 2.2 9.4 4.4 940 132 50 -167 954 217
82 2.4 2.0 8.1 2.8 939 118 50 -119 988 358
83 1.8 1.7 6.8 1.2 937 106 52 -76 1,019 870
84 1.1 1.5 5.6 -0.3 936 95 53 -36 1,048 negative effect
85 0.7 1.3 4.5 -1.6 934 81 54 -3 1,066 negative effect
86 0.2 1.0 3.4 -2.9 932 68 53 21 1,073 negative effect
87 -0.1 0.8 2.5 -3.9 929 56 53 38 1,076 negative effect
88 -0.3 0.6 1.8 -4.6 927 46 52 48 1,073 negative effect
89 -0.4 0.4 1.2 -5.1 924 38 52 47 1,061 negative effect
90 -0.4 0.3 0.8 -5.4 922 30 51 45 1,048 negative effect
CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
1  A negative value indicates that the number of CRC cases prevented by screening is exceeded by the number 
of CRC cases over-diagnosed by screening.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of screening). 
A negative value indicates that screening is associated with a net harm. rather than a net health benefit.
3  Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with CRC care. The net effect can 
be a reduction in costs (negative values) or an increase in costs (positive values).
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Appendix 2, Table 3  The Impact of Age on the Effectiveness, Costs,  
and Cost-Effectiveness of Colonoscopy Screening: Results for Healthy, Average Risk, 
Black Women with a Negative Screening Colonoscopy 10 Years Prior (effectiveness  
and costs per 1,000 females; 3% discounted).
EFFECTIVENESS COSTS (*$1,000)* COST-EFFECTIVENESS
Age CRC cases prevented1 CRC deaths 
prevented
LYs 
gained
QALYs 
gained2
Screening 
colonoscopies
Surveillance 
colonoscopies
Complications  CRC care3 Total Costs/ QALY gained  
(*$1,000)
66 6.4 4.0 31.7 30.6 933 218 23 -486 688 23
67 6.3 3.9 30.5 29.1 933 210 24 -470 696 24
68 6.1 3.8 29.0 27.4 933 203 25 -449 711 26
69 5.8 3.7 27.5 25.5 933 195 26 -425 728 28
70 5.6 3.6 26.1 23.9 932 188 26 -404 743 31
71 5.4 3.4 23.5 21.1 932 181 27 -382 759 36
72 5.2 3.3 22.5 19.8 932 175 29 -365 771 39
73 4.9 3.1 20.6 17.5 932 167 30 -334 794 45
74 4.6 3.0 19.3 16.0 932 161 31 -314 810 51
75 4.3 2.9 17.6 14.0 932 151 32 -284 830 59
76 3.9 2.7 15.9 11.9 931 143 33 -250 857 72
77 3.4 2.5 14.1 9.7 931 134 34 -216 884 91
78 3.1 2.3 12.6 8.0 930 127 35 -188 904 113
79 2.7 2.1 11.2 6.3 930 119 37 -159 927 148
80 2.4 1.9 9.9 4.7 930 111 38 -134 945 200
81 2.1 1.7 8.4 3.1 929 103 39 -109 963 315
82 1.8 1.6 7.4 1.8 929 95 41 -86 979 544
83 1.4 1.4 6.1 0.3 928 87 42 -62 996 2,916
84 1.1 1.2 5.1 -0.8 928 81 44 -43 1,009 negative effect
85 0.9 1.1 4.4 -1.5 927 70 45 -30 1,012 negative effect
86 0.6 1.0 3.6 -2.4 927 64 47 -9 1,028 negative effect
87 0.3 0.9 3.0 -3.2 926 58 49 7 1,040 negative effect
88 0.2 0.7 2.5 -3.8 925 54 50 17 1,047 negative effect
89 -0.0 0.6 2.0 -4.3 924 50 52 29 1,055 negative effect
90 -0.2 0.5 1.5 -4.8 924 45 54 38 1,060 negative effect
CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
1  A negative value indicates that the number of CRC cases prevented by screening is exceeded by the number 
of CRC cases over-diagnosed by screening.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of screening). 
A negative value indicates that screening is associated with a net harm, rather than a net health benefit.
3  Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with CRC care. The net effect can 
be a reduction in costs (negative values) or an increase in costs (positive values).
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Appendix 2, Table 4  The Impact of Age on the Effectiveness, Costs,  
and Cost-Effectiveness of Colonoscopy Screening: Results for Healthy, Average Risk, 
Black Men with a Negative Screening Colonoscopy 10 Years Prior (effectiveness  
and costs per 1,000 females; 3% discounted).
EFFECTIVENESS COSTS (*$1,000)* COST-EFFECTIVENESS
Age CRC cases  
prevented1
CRC deaths 
prevented
LYs 
gained
QALYs 
gained2
Screening 
colonoscopies
Surveillance 
colonoscopies
Complications  CRC care3 Total Costs/ QALY gained 
(*$1,000)
66 6.3 4.2 29.8 28.1 938 222 25 -451 733 26
67 6.1 4.1 28.6 26.7 937 214 26 -433 744 28
68 6.0 4.1 27.7 25.6 937 208 27 -421 751 29
69 5.7 3.9 26.1 23.6 937 199 28 -393 771 33
70 5.4 3.8 24.6 21.8 937 190 29 -369 787 36
71 5.1 3.6 22.1 19.0 937 182 30 -338 811 43
72 4.7 3.4 20.3 16.8 936 172 31 -304 835 50
73 4.3 3.2 18.4 14.7 936 163 32 -274 858 58
74 4.1 3.0 17.2 13.3 936 158 33 -259 868 65
75 3.7 2.9 15.6 11.4 936 147 34 -227 890 78
76 3.3 2.6 14.0 9.4 935 138 35 -192 916 97
77 3.0 2.5 12.8 8.0 934 130 36 -168 933 117
78 2.6 2.3 11.2 6.1 934 121 37 -136 956 156
79 2.2 2.1 10.0 4.6 933 113 39 -113 972 210
80 1.8 1.9 8.8 3.2 932 105 40 -87 989 307
81 1.4 1.6 7.1 1.3 931 94 41 -56 1,010 754
82 1.1 1.5 6.2 0.3 930 86 42 -37 1,020 3,557
83 0.7 1.2 4.9 -1.1 929 76 43 -13 1,034 negative effect
84 0.6 1.1 4.2 -1.9 928 71 44 -4 1,038 negative effect
85 0.3 0.9 3.3 -2.8 927 60 45 12 1,042 negative effect
86 0.2 0.8 2.9 -3.3 926 56 47 19 1,048 negative effect
87 0.0 0.8 2.5 -3.8 926 52 48 27 1,054 negative effect
88 -0.0 0.7 2.2 -4.2 925 49 51 29 1,055 negative effect
89 -0.2 0.6 1.6 -4.7 925 44 53 40 1,061 negative effect
90 -0.3 0.5 1.3 -5.0 924 39 55 43 1,062 negative effect
CRC = colorectal cancer; LY = life-year; QALY = quality-adjusted life-year
1  A negative value indicates that the number of CRC cases prevented by screening is exceeded by the number 
of CRC cases over-diagnosed by screening.
2  The effect of screening on quantity and quality of life incorporated in one measure (i.e. the net health benefit of screening). 
A negative value indicates that screening is associated with a net harm, rather than a net health benefit.
3  Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with CRC care. The net effect can 
be a reduction in costs (negative values) or an increase in costs (positive values).
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Appendix 3: The Costs per QALY Gained of Colonoscopy Screening  
by Screening History, Comorbidity Status, Background Risk for CRC,  
and Age – Results for White Men, Black Women, and Black Men
Appendix 3, Table 1  The Costs per QALY Gained (*$1,000) of Colonoscopy  
Screening for White Men by Screening History, Comorbidity Status, Background Risk  
for CRC, and Age (3% discounted).1  
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
NO COMORBIDITY2 NO COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94
66 116 68 47 33 24 19 11 7 3 1 CS CS CS CS CS CS CS 66 11 8 5 3 2 1 CS CS CS CS CS CS CS CS CS CS CS
68 152 86 57 40 30 23 14 9 5 3 1 CS CS CS CS CS CS 68 13 9 6 4 3 2 0 CS CS CS CS CS CS CS CS CS CS
70 214 113 71 51 38 29 18 12 8 5 3 CS CS CS CS CS CS 70 15 11 8 6 4 3 1 CS CS CS CS CS CS CS CS CS CS
72 388 169 101 70 51 39 25 17 11 8 5 0 CS CS CS CS CS 72 19 14 11 8 6 5 3 1 CS CS CS CS CS CS CS CS CS
74 >500 265 141 95 69 53 33 23 16 11 8 3 CS CS CS CS CS 74 24 18 14 11 9 8 5 3 2 1 CS CS CS CS CS CS CS
76 NE 493 211 131 93 70 45 30 22 16 12 6 2 CS CS CS CS 76 32 24 19 15 13 11 8 6 4 3 2 0 CS CS CS CS CS
78 NE >500 342 187 129 94 57 40 30 23 18 10 5 2 CS CS CS 78 41 32 26 21 18 16 12 10 8 7 5 3 1 CS CS CS CS
80 NE NE >500 295 196 135 80 56 41 33 26 16 10 7 4 1 1 80 59 46 38 32 28 25 20 17 14 13 11 8 6 5 3 2 2
82 NE NE NE >500 >500 358 177 114 82 66 53 36 26 21 16 12 12 82 110 84 69 58 52 46 39 34 30 27 25 21 18 16 14 12 11
84 NE NE NE NE NE NE >500 305 196 145 113 78 57 45 37 32 32 84 246 174 136 114 100 90 75 66 59 55 50 43 38 34 31 29 28
86 NE NE NE NE NE NE NE NE >500 >500 413 219 141 111 88 78 67 86 >500 >500 402 302 243 211 172 147 129 119 108 93 82 74 68 64 61
88 NE NE NE NE NE NE NE NE NE NE NE NE >500 406 245 207 161 88 NE NE NE >500 >500 >500 >500 469 386 321 285 232 197 173 157 145 139
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 90 NE NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 >500 493 449
MODERATE COMORBIDITY2 MODERATE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94
66 163 91 62 44 32 25 16 11 7 4 2 CS CS CS CS CS CS 66 16 12 9 7 5 4 2 0 CS CS CS CS CS CS CS CS CS
68 227 118 76 54 40 31 20 14 9 6 4 CS CS CS CS CS CS 68 18 13 10 8 6 5 3 1 0 CS CS CS CS CS CS CS CS
70 405 176 105 73 54 42 28 19 13 10 7 2 CS CS CS CS CS 70 23 17 14 11 9 7 5 3 2 1 CS CS CS CS CS CS CS
72 >500 325 167 110 79 60 39 27 20 15 11 5 2 CS CS CS CS 72 31 24 19 16 13 11 8 6 5 3 2 0 CS CS CS CS CS
74 NE >500 270 164 113 85 53 38 28 21 17 10 5 2 1 CS CS 74 40 31 25 21 18 16 12 10 8 6 5 3 1 CS CS CS CS
76 NE NE >500 282 177 128 78 54 41 32 25 16 10 7 4 2 1 76 56 43 35 30 26 23 19 16 13 12 10 7 5 4 2 1 1
78 NE NE >500 >500 305 196 109 75 57 44 36 24 17 12 9 6 5 78 78 61 50 42 37 34 28 24 21 19 17 13 11 9 7 6 6
80 NE NE NE >500 >500 354 169 113 83 65 52 36 26 20 16 12 11 80 120 92 75 63 56 50 42 37 33 30 27 23 19 17 15 14 13
82 NE NE NE NE NE NE >500 354 218 163 126 84 65 53 43 38 35 82 331 227 175 143 125 111 93 80 73 66 62 53 47 43 39 36 34
84 NE NE NE NE NE NE NE NE >500 491 313 191 135 102 85 75 76 84 >500 >500 443 336 275 235 187 159 141 128 118 101 90 81 74 70 67
86 NE NE NE NE NE NE NE NE NE NE NE >500 399 261 203 162 151 86 NE NE NE >500 >500 >500 >500 428 346 306 269 218 188 166 150 141 133
88 NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500 472 88 NE NE NE NE NE NE NE NE >500 >500 >500 >500 >500 497 421 371 346
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
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Appendix 3, Table 1  Continued.  
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
SEVERE COMORBIDITY2 SEVERE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.54 3.04 3.54 4.04 4.54 4.94
66 433 184 116 80 59 47 31 22 16 12 9 4 1 CS CS CS CS 66 31 24 19 16 13 11 8 6 5 3 2 0 CS CS CS CS CS
68 >500 282 162 105 77 61 40 29 22 16 13 7 4 1 CS CS CS 68 37 28 23 19 16 14 11 8 7 5 4 2 0 CS CS CS CS
70 NE >500 256 157 111 85 55 39 30 23 19 11 7 4 2 1 CS 70 46 36 30 25 22 19 15 12 10 9 7 5 3 2 1 CS CS
72 NE NE >500 276 178 127 80 56 42 33 27 17 12 8 5 4 2 72 62 48 40 34 30 26 21 18 15 13 12 9 7 5 4 3 2
74 NE NE >500 >500 333 219 121 83 62 48 40 26 19 14 11 8 7 74 88 67 55 47 42 37 31 26 23 20 18 15 12 10 8 7 7
76 NE NE NE NE >500 448 202 128 94 73 58 40 29 23 19 15 13 76 134 98 80 68 60 54 45 39 35 31 28 23 20 17 15 14 13
78 NE NE NE NE NE >500 377 218 151 111 88 61 46 37 31 25 22 78 223 158 125 106 93 83 69 60 54 49 45 38 33 29 27 25 24
80 NE NE NE NE NE NE >500 >500 282 199 149 100 75 61 51 44 41 80 >500 319 232 188 162 141 115 100 90 81 75 64 57 52 47 44 42
82 NE NE NE NE NE NE NE NE >500 >500 447 219 169 135 107 92 87 82 NE >500 >500 >500 427 347 264 214 188 166 154 129 114 103 95 89 85
84 NE NE NE NE NE NE NE NE NE NE NE >500 >500 333 262 208 214 84 NE NE NE NE NE >500 >500 >500 >500 489 425 318 272 234 208 195 184
86 NE NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500 86 NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 >500 >500
88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
QALY = quality-adjusted life-year; CRC = colorectal cancer; CS = cost saving; NE = negative effect
1  The black line indicates a willingness-to-pay threshold of $100,000 per QALY gained. Green cells indicate that screening is cost-effective 
given this threshold. Red cells indicate that screening is not cost-effective given this threshold.
2  Detailed information on comorbidity status is given in Figure 2, footnote 4.
3  Detailed information on background risk for CRC is given in Figure 2, footnote 5.
4  Background risk for CRC only possible in case of a family history of CRC.
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Appendix 3, Table 2  The Costs per QALY Gained (*$1,000) of Colonoscopy  
Screening for Black Women by Screening History, Comorbidity Status, Background Risk 
for CRC, and Age (3% discounted).1    
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
NO COMORBIDITY2 NO COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54 Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54
66 308 125 75 51 37 28 23 15 10 7 4 3 CS CS CS 66 19 14 10 8 6 5 4 2 1 0 CS CS CS CS CS
68 444 151 89 60 43 32 26 17 11 8 6 4 1 CS CS 68 21 15 11 9 7 5 4 3 2 1 CS CS CS CS CS
70 >500 196 111 72 52 39 31 20 14 10 7 5 2 CS CS 70 24 17 13 10 8 7 6 4 3 2 1 0 CS CS CS
72 >500 313 154 96 66 50 39 26 18 13 10 7 3 1 CS 72 29 21 16 13 10 9 7 5 4 3 2 1 CS CS CS
74 NE >500 230 132 88 66 51 34 24 18 14 11 6 3 1 74 36 26 20 16 13 11 10 8 6 5 4 3 1 CS CS
76 NE >500 426 209 130 95 72 47 34 25 20 16 10 6 3 76 47 33 26 22 18 16 14 11 9 8 6 5 3 2 1
78 NE NE >500 454 229 154 113 71 50 38 30 25 16 11 8 78 63 45 35 30 25 22 20 16 14 12 10 9 7 5 4
80 NE NE NE >500 >500 300 200 112 77 57 46 38 25 18 14 80 90 63 50 42 36 32 29 24 21 18 16 15 12 10 8
82 NE NE NE NE NE >500 >500 227 142 103 80 62 42 31 24 82 154 102 79 66 56 50 45 38 34 30 27 25 21 18 16
84 NE NE NE NE NE NE NE >500 380 226 164 122 79 59 45 84 379 203 146 118 100 88 78 66 59 53 49 45 39 34 30
86 NE NE NE NE NE NE NE NE NE >500 455 274 153 110 82 86 >500 >500 336 240 191 165 142 118 103 92 84 78 67 60 54
88 NE NE NE NE NE NE NE NE NE NE NE >500 432 258 175 88 NE NE >500 >500 >500 420 333 252 212 183 163 148 125 111 99
90 NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 90 NE NE NE NE NE NE NE >500 >500 >500 >500 >500 399 323 275
MODERATE COMORBIDITY2 MODERATE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54 Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54
66 >500 178 102 67 49 37 30 20 14 10 7 5 2 CS CS 66 26 18 14 11 9 8 7 5 3 2 1 1 CS CS CS
68 >500 210 116 77 54 41 33 22 16 11 8 6 3 0 CS 68 27 20 15 12 10 8 7 5 4 3 2 1 CS CS CS
70 >500 309 156 98 69 52 41 27 19 15 11 9 4 2 0 70 33 23 18 15 12 10 9 7 5 4 3 2 1 CS CS
72 NE >500 245 142 93 70 54 36 26 20 15 12 7 4 2 72 41 29 23 19 16 14 12 9 8 6 5 4 2 1 CS
74 NE >500 419 204 128 94 71 47 34 26 21 17 10 6 4 74 50 36 28 24 20 17 16 13 10 9 7 6 4 3 2
76 NE NE >500 481 239 164 119 75 54 40 33 27 18 13 9 76 74 53 42 35 30 26 24 20 17 15 13 12 9 7 6
78 NE NE NE >500 430 255 174 102 72 54 43 36 24 17 13 78 91 64 50 42 36 32 29 24 21 19 17 15 12 10 8
80 NE NE NE NE NE >500 484 208 133 94 75 62 42 31 25 80 159 106 82 68 59 52 47 40 35 32 29 27 22 19 17
82 NE NE NE NE NE NE NE >500 360 223 160 120 80 58 47 82 418 223 159 128 106 95 84 72 63 57 52 48 41 36 33
84 NE NE NE NE NE NE NE NE >500 >500 371 238 143 100 75 84 >500 >500 312 236 188 163 141 117 102 92 84 78 66 58 53
86 NE NE NE NE NE NE NE NE NE NE >500 >500 309 199 136 86 NE NE >500 >500 417 339 274 214 181 159 143 132 111 98 89
88 NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 428 88 NE NE NE NE NE >500 >500 >500 >500 462 380 329 263 225 197
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE >500 90 NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 >500 423
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Appendix 3, Table 2  Continued.
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
SEVERE COMORBIDITY2 SEVERE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54 Age 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.04 2.54 3.04 3.54
66 NE 474 204 122 87 64 52 35 26 19 15 12 7 4 2 66 45 33 26 21 18 16 14 11 9 7 6 5 3 1 0
68 NE >500 290 165 109 80 64 43 32 24 19 16 10 6 4 68 53 38 30 25 21 18 17 13 11 9 8 7 5 3 2
70 NE >500 497 234 147 103 82 53 39 30 24 20 13 9 6 70 64 46 36 30 26 22 20 17 14 12 11 9 7 5 4
72 NE NE >500 443 217 149 111 73 51 40 32 27 18 13 10 72 83 57 45 38 32 29 26 21 18 16 14 13 10 8 6
74 NE NE NE >500 482 281 188 114 78 60 49 41 28 21 16 74 123 84 65 55 47 42 37 32 27 24 22 20 16 14 12
76 NE NE NE NE >500 469 278 151 101 76 62 51 35 27 21 76 150 101 78 65 56 49 44 37 33 29 27 24 20 18 15
78 NE NE NE NE NE NE >500 373 205 143 110 91 60 46 37 78 302 180 131 108 91 80 72 60 53 48 44 40 34 30 27
80 NE NE NE NE NE NE NE >500 384 224 168 131 84 62 51 80 >500 268 186 147 121 107 96 79 70 63 57 54 46 41 37
82 NE NE NE NE NE NE NE NE >500 >500 432 270 158 108 86 82 NE >500 415 296 228 193 168 139 119 106 96 89 76 67 61
84 NE NE NE NE NE NE NE NE NE NE NE >500 449 252 171 84 NE NE NE >500 >500 >500 429 315 255 218 194 176 146 127 114
86 NE NE NE NE NE NE NE NE NE NE NE NE NE >500 465 86 NE NE NE NE NE NE NE >500 >500 >500 >500 461 343 282 245
88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 88 NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
QALY = quality-adjusted life-year; CRC = colorectal cancer; CS = cost saving; NE = negative effect
1  The black line indicates a willingness-to-pay threshold of $100,000 per QALY gained. Green cells indicate that screening is 
cost-effective given this threshold. Red cells indicate that screening is not cost-effective given this threshold.
2  Detailed information on comorbidity status is given in Figure 2, footnote 4.
3  Detailed information on background risk for CRC is given in Figure 2, footnote 5.
4  Background risk for CRC only possible in case of a family history of CRC.
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Appendix 3, Table 3  The Costs per QALY Gained (*$1,000) of Colonoscopy  
Screening for Black Men by Screening History, Comorbidity Status, Background Risk  
for CRC, and Age (3% discounted).1      
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
NO COMORBIDITY2 NO COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34
66 155 90 60 44 34 26 17 12 8 6 4 1 CS CS CS CS CS CS 66 15 11 9 7 6 5 3 2 1 0 CS CS CS CS CS CS CS CS
68 191 108 68 50 38 29 20 14 9 7 4 1 CS CS CS CS CS CS 68 16 12 10 8 6 5 3 2 1 0 CS CS CS CS CS CS CS CS
70 276 136 85 60 46 36 24 17 12 9 6 3 0 CS CS CS CS CS 70 19 15 12 9 8 7 5 4 3 2 1 CS CS CS CS CS CS CS
72 >500 216 123 85 65 50 33 23 17 13 10 5 3 1 CS CS CS CS 72 25 19 16 13 11 10 7 6 5 4 3 1 CS CS CS CS CS CS
74 >500 357 180 117 86 65 42 30 23 18 14 8 5 3 1 CS CS CS 74 30 24 20 17 15 13 10 9 7 6 5 3 2 1 0 CS CS CS
76 NE >500 340 190 131 97 61 44 33 26 21 14 10 7 4 3 2 2 76 41 33 27 23 21 18 15 13 11 10 9 7 5 4 3 3 2 2
78 NE NE >500 385 229 156 91 64 49 40 32 22 15 12 9 7 6 6 78 55 44 37 32 28 26 22 19 17 15 14 11 9 8 7 6 5 5
80 NE NE NE >500 >500 307 154 102 77 60 50 34 25 19 16 13 12 12 80 79 63 52 45 40 37 32 28 25 23 22 18 16 14 13 12 11 10
82 NE NE NE NE NE >500 387 217 147 112 89 60 42 34 29 26 21 22 82 135 102 84 72 65 59 51 45 42 38 36 31 27 25 23 21 20 20
84 NE NE NE NE NE NE NE >500 404 248 175 107 78 61 49 45 40 38 84 257 185 145 123 108 98 83 74 68 63 59 51 46 42 39 36 35 34
86 NE NE NE NE NE NE NE NE NE >500 467 223 145 107 87 77 69 62 86 >500 426 296 239 197 175 145 128 115 106 99 86 76 70 65 61 58 57
88 NE NE NE NE NE NE NE NE NE NE NE >500 301 205 141 130 125 102 88 NE >500 >500 >500 451 373 283 240 209 189 171 146 128 116 106 100 95 91
90 NE NE NE NE NE NE NE NE NE NE NE NE NE >500 484 463 383 308 90 NE NE NE NE NE NE NE >500 >500 >500 >500 >500 416 347 309 278 258 245
MODERATE COMORBIDITY2 MODERATE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34
66 224 121 78 57 43 34 23 16 12 9 6 3 1 CS CS CS CS CS 66 20 16 13 10 9 7 5 4 3 2 1 CS CS CS CS CS CS CS
68 339 163 98 71 53 42 28 20 15 11 9 4 2 0 CS CS CS CS 68 24 19 15 13 11 9 7 6 4 3 3 1 CS CS CS CS CS CS
70 >500 224 126 88 67 52 35 25 19 15 11 7 4 2 0 CS CS CS 70 28 22 18 15 13 12 9 8 6 5 4 3 1 0 CS CS CS CS
72 NE >500 239 151 110 83 54 39 30 24 19 13 8 6 4 3 1 1 72 41 33 27 23 21 19 15 13 11 10 9 7 5 4 3 2 2 1
74 NE >500 372 208 145 105 67 48 37 29 24 16 11 8 6 4 3 3 74 48 39 32 28 25 22 19 16 14 13 11 9 7 6 5 4 3 3
76 NE NE >500 436 258 174 103 72 55 44 36 25 19 15 12 9 8 7 76 67 54 45 39 35 31 27 24 21 19 18 15 13 11 10 9 8 8
78 NE NE NE >500 446 259 139 93 71 57 46 32 24 19 15 13 12 11 78 80 64 54 46 41 38 33 29 26 24 22 19 16 14 13 12 11 11
80 NE NE NE NE NE >500 356 201 140 106 87 59 44 36 29 27 25 23 80 145 112 92 79 71 64 56 49 45 42 39 34 30 27 25 24 23 22
82 NE NE NE NE NE NE NE >500 >500 304 223 135 93 75 66 58 51 53 82 447 282 212 174 151 135 115 101 92 85 79 69 62 57 53 50 48 46
84 NE NE NE NE NE NE NE NE NE >500 >500 309 185 143 111 104 96 86 84 >500 >500 500 371 298 253 206 176 158 144 133 115 101 93 87 82 78 76
86 NE NE NE NE NE NE NE NE NE NE NE >500 311 206 161 142 128 111 86 NE >500 >500 >500 >500 433 319 265 228 208 191 160 140 128 118 110 105 102
88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 88 NE NE NE NE NE NE NE NE NE NE >500 >500 >500 >500 >500 >500 493 456
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
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Appendix 3, Table 3  Continued.     
NEGATIVE SCREENING COLONOSCOPY 10 YEARS PRIOR NO PRIOR SCREENING
SEVERE COMORBIDITY2 SEVERE COMORBIDITY2
Background risk for CRC3 Background risk for CRC3
Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34 Age 0.5 0.6 0.7 0.8 0.9 1.0 1.2 1.4 1.6 1.8 2.0 2.5 3.04 3.54 4.04 4.54 5.04 5.34
66 >500 364 186 125 93 71 48 35 28 22 18 11 8 5 3 2 1 0 66 42 34 28 24 21 19 16 13 11 10 8 6 4 3 2 2 1 1
68 NE >500 306 190 133 100 66 48 37 29 24 16 12 9 7 5 4 3 68 55 44 37 32 28 25 21 18 16 14 12 10 8 6 5 5 4 4
70 NE >500 419 238 162 120 77 55 43 34 28 19 14 11 9 7 6 5 70 61 48 40 35 31 28 24 21 18 16 15 12 10 8 7 6 6 5
72 NE NE >500 >500 359 231 133 92 71 55 45 32 24 19 17 14 12 11 72 97 75 62 54 48 44 37 33 30 27 24 21 18 16 14 13 12 12
74 NE NE NE NE >500 >500 269 171 122 93 75 52 41 35 29 26 22 22 74 168 126 101 87 77 69 60 53 48 43 40 35 31 28 26 24 23 22
76 NE NE NE NE NE >500 >500 257 175 132 103 70 54 47 39 33 31 30 76 230 166 132 112 99 88 76 67 60 55 52 45 40 37 34 32 30 30
78 NE NE NE NE NE NE NE >500 403 266 187 114 89 76 61 54 52 50 78 >500 317 232 189 163 142 120 105 95 87 81 70 63 58 54 51 49 47
80 NE NE NE NE NE NE NE >500 >500 398 277 158 117 93 76 70 65 62 80 >500 451 306 241 205 180 149 128 116 106 99 85 77 70 66 62 60 58
82 NE NE NE NE NE NE NE NE NE >500 >500 363 223 174 139 120 107 106 82 NE >500 >500 >500 462 376 289 239 210 189 172 145 129 118 109 103 98 96
84 NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 463 524 380 307 84 NE NE NE NE NE NE NE >500 >500 >500 >500 >500 444 381 340 308 285 275
86 NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 438 378 295 86 NE NE NE NE NE NE NE >500 >500 >500 >500 >500 410 354 316 283 272 259
88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 88 NE NE NE NE NE NE NE NE NE NE NE NE NE NE >500 >500 >500 >500
90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE 90 NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE NE
QALY = quality-adjusted life-year; CRC = colorectal cancer; CS = cost saving; NE = negative effect
1  The black line indicates a willingness-to-pay threshold of $100,000 per QALY gained. Green cells indicate that screening is 
cost-effective given this threshold. Red cells indicate that screening is not cost-effective given this threshold. 
2 Detailed information on comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
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Appendix 4: The Appropriate Ages to Stop Screening  
– Results of Univariate Deterministic Sensitivity Analyses
Appendix 4, Table 1  The Appropriate Ages to Stop Colonoscopy Screening Assuming 
50% Lower Utility Losses for Colonoscopies and Complications.1  
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 68 <665 <665 0.5 72 70 67 0.5 75 72 70 0.5 82 80 76
0.6 72 69 <665 0.6 76 73 70 0.6 78 75 72 0.6 83 81 77
0.7 75 72 69 0.7 78 75 71 0.7 80 77 73 0.7 84 81 78
0.8 77 74 70 0.8 80 76 73 0.8 81 78 75 0.8 84 82 79
0.9 79 75 72 0.9 81 78 74 0.9 82 79 76 0.9 85 82 80
1.0 80 77 73 1.0 81 79 76 1.0 82 80 77 1.0 85 82 80
1.2 81 79 76 1.2 83 80 77 1.2 84 81 78 1.2 86 83 80
1.4 82 80 77 1.4 84 81 79 1.4 85 82 80 1.4 86 84 81
1.6 83 81 78 1.6 84 82 80 1.6 85 83 80 1.6 86 84 81
1.8 84 82 79 1.8 85 82 80 1.8 85 83 81 1.8 86 84 82
2.0 85 82 80 2.0 85 83 81 2.0 86 84 81 2.0 87 84 82
2.54 86 83 81 2.54 86 84 82 2.54 86 84 82 2.54 87 85 83
3.04 86 84 82 3.04 87 85 82 3.04 87 85 83 3.04 87 85 83
3.54 87 85 83 3.54 87 85 83 3.54 87 86 83 3.54 88 86 83
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Appendix 4, Table 1  Continued.  
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 68 <665 <665 0.5 72 70 66 0.5 75 73 69 0.5 82 80 76
0.6 71 69 <665 0.6 75 73 69 0.6 78 75 71 0.6 83 80 77
0.7 74 71 67 0.7 78 75 71 0.7 80 77 73 0.7 83 81 78
0.8 77 73 69 0.8 80 76 72 0.8 81 78 74 0.8 84 81 79
0.9 79 75 71 0.9 80 78 73 0.9 81 79 75 0.9 84 82 79
1.0 80 77 72 1.0 81 79 75 1.0 82 80 76 1.0 84 82 79
1.2 81 79 75 1.2 82 80 77 1.2 83 81 77 1.2 85 83 80
1.4 82 80 76 1.4 83 81 78 1.4 84 81 79 1.4 85 83 80
1.6 83 81 77 1.6 84 81 79 1.6 84 82 79 1.6 85 83 80
1.8 83 81 79 1.8 84 82 79 1.8 85 82 80 1.8 86 83 81
2.0 84 82 79 2.0 85 83 80 2.0 85 83 80 2.0 86 84 81
2.54 85 83 80 2.54 85 83 81 2.54 86 83 81 2.54 86 84 81
3.04 85 83 81 3.04 86 84 81 3.04 86 84 81 3.04 86 84 82
3.54 86 84 81 3.54 86 84 82 3.54 86 84 82 3.54 87 84 82
4.04 86 84 82 4.04 87 84 82 4.04 87 84 82 4.04 87 84 82
4.54 87 84 82 4.54 87 85 82 4.54 87 85 82 4.54 87 84 82
4.94 87 84 82 4.94 87 85 82 4.94 87 85 82 4.94 87 85 82
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Appendix 4, Table 1  Continued.  
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 67 <665 <665 0.4 71 69 <665 0.4 81 79 75
0.5 68 <665 <665 0.5 72 70 <665 0.5 75 73 68 0.5 82 80 77
0.6 72 69 <665 0.6 75 73 68 0.6 77 75 71 0.6 83 81 78
0.7 74 72 67 0.7 77 75 71 0.7 79 77 73 0.7 84 82 79
0.8 76 74 70 0.8 79 77 73 0.8 80 78 75 0.8 85 82 80
0.9 77 75 72 0.9 80 78 74 0.9 81 79 76 0.9 85 83 80
1.0 79 77 73 1.0 81 79 76 1.0 82 80 77 1.0 85 83 80
1.2 80 79 75 1.2 82 80 77 1.2 83 81 78 1.2 86 84 81
1.4 82 80 77 1.4 83 81 78 1.4 84 82 80 1.4 86 84 82
1.6 82 81 78 1.6 84 82 80 1.6 85 83 80 1.6 86 84 82
1.8 83 81 79 1.8 85 83 80 1.8 85 83 81 1.8 87 85 82
2.04 84 82 80 2.04 85 83 81 2.04 86 84 81 2.04 87 85 83
2.54 85 83 81 2.54 86 84 82 2.54 87 85 82 2.54 87 86 83
3.04 86 84 82 3.04 87 85 83 3.04 87 86 83 3.04 88 86 83
3.54 87 85 83 3.54 87 86 83 3.54 88 86 83 3.54 88 87 84
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Appendix 4, Table 1  Continued.  
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 69 <665 0.5 73 71 67 0.5 82 79 73
0.6 70 67 <665 0.6 74 71 <665 0.6 76 73 68 0.6 82 80 75
0.7 73 70 <665 0.7 76 73 68 0.7 78 75 70 0.7 83 81 76
0.8 75 72 67 0.8 77 74 70 0.8 79 77 71 0.8 84 81 76
0.9 76 74 69 0.9 79 76 71 0.9 80 78 72 0.9 84 81 76
1.0 77 75 70 1.0 80 78 72 1.0 81 79 73 1.0 84 81 77
1.2 79 78 72 1.2 81 79 73 1.2 82 80 75 1.2 85 82 78
1.4 80 78 73 1.4 82 80 75 1.4 83 81 76 1.4 85 82 79
1.6 81 80 75 1.6 82 81 76 1.6 84 81 76 1.6 86 83 80
1.8 82 80 76 1.8 84 81 76 1.8 84 81 77 1.8 86 83 80
2.0 83 81 76 2.0 84 81 78 2.0 85 82 79 2.0 86 83 80
2.5 84 81 79 2.5 85 82 80 2.5 86 83 80 2.5 87 84 80
3.04 85 83 80 3.04 86 83 80 3.04 86 83 80 3.04 87 84 80
3.54 86 83 80 3.54 87 84 80 3.54 87 84 80 3.54 87 84 81
4.04 87 84 81 4.04 87 84 81 4.04 88 84 82 4.04 88 84 82
4.54 87 84 81 4.54 87 84 82 4.54 88 84 82 4.54 88 84 82
5.04 87 84 82 5.04 88 84 82 5.04 88 84 82 5.04 88 84 82
5.34 88 84 82 5.34 88 84 82 5.34 88 84 82 5.34 88 84 82
CRC = colorectal cancer; RR CRC = background risk for CRC
1  Given a willingness-to-pay threshold of $100,000 per QALY gained.
2  Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3  Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4  Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years 
or younger.
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Appendix 4, Table 2  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming 50% Higher Utility Losses for Colonoscopies and Complications.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 67 <665 <665 0.5 71 68 <665 0.5 80 76 72
0.6 <665 <665 <665 0.6 71 68 <665 0.6 74 71 68 0.6 81 78 74
0.7 70 66 <665 0.7 74 71 67 0.7 76 73 70 0.7 82 79 76
0.8 72 69 <665 0.8 76 73 70 0.8 78 75 71 0.8 82 80 76
0.9 74 71 68 0.9 77 74 71 0.9 79 76 73 0.9 83 80 77
1.0 76 73 70 1.0 79 75 72 1.0 80 77 74 1.0 83 81 78
1.2 79 75 72 1.2 80 78 74 1.2 81 79 76 1.2 84 82 79
1.4 80 77 74 1.4 82 79 76 1.4 82 80 77 1.4 85 82 79
1.6 81 78 75 1.6 82 80 77 1.6 83 81 78 1.6 85 82 80
1.8 82 79 76 1.8 83 81 78 1.8 84 81 79 1.8 85 83 80
2.0 83 80 77 2.0 84 81 79 2.0 84 82 79 2.0 86 83 80
2.54 84 82 79 2.54 85 82 80 2.54 85 83 80 2.54 86 84 81
3.04 85 82 80 3.04 86 83 81 3.04 86 84 81 3.04 86 84 82
3.54 85 83 81 3.54 86 84 81 3.54 86 84 82 3.54 87 85 82
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Appendix 4, Table 2  Continued. 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 67 <665 <665 0.5 71 69 <665 0.5 80 77 73
0.6 66 <665 <665 0.6 71 68 <665 0.6 74 71 68 0.6 81 78 74
0.7 69 67 <665 0.7 73 71 67 0.7 76 73 70 0.7 82 80 75
0.8 72 69 <665 0.8 75 73 69 0.8 78 75 71 0.8 82 80 76
0.9 74 71 67 0.9 77 74 70 0.9 79 76 72 0.9 83 80 77
1.0 76 73 69 1.0 79 75 71 1.0 80 77 73 1.0 83 81 77
1.2 79 75 71 1.2 80 78 73 1.2 81 79 75 1.2 84 81 78
1.4 80 77 73 1.4 81 79 75 1.4 82 80 76 1.4 84 82 79
1.6 81 79 74 1.6 82 80 76 1.6 83 80 77 1.6 84 82 79
1.8 82 80 76 1.8 83 80 77 1.8 83 81 78 1.8 85 82 80
2.0 82 80 77 2.0 83 81 78 2.0 84 81 79 2.0 85 83 80
2.54 83 81 79 2.54 84 82 79 2.54 84 82 80 2.54 85 83 80
3.04 84 82 80 3.04 85 83 80 3.04 85 83 80 3.04 86 83 81
3.54 85 83 80 3.54 85 83 81 3.54 85 83 81 3.54 86 84 81
4.04 85 83 81 4.04 86 84 81 4.04 86 84 81 4.04 86 84 81
4.54 86 84 81 4.54 86 84 81 4.54 86 84 81 4.54 86 84 82
4.94 86 84 81 4.94 86 84 82 4.94 86 84 82 4.94 87 84 82
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Appendix 4, Table 2  Continued. 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 79 76 71
0.5 <665 <665 <665 0.5 66 <665 <665 0.5 70 68 <665 0.5 80 78 73
0.6 <665 <665 <665 0.6 70 68 <665 0.6 73 71 66 0.6 81 79 75
0.7 69 67 <665 0.7 73 71 66 0.7 76 74 69 0.7 82 80 76
0.8 72 70 <665 0.8 75 73 69 0.8 77 75 71 0.8 83 80 77
0.9 74 72 67 0.9 77 74 70 0.9 79 76 72 0.9 83 81 77
1.0 76 74 69 1.0 78 76 72 1.0 80 78 73 1.0 84 81 78
1.2 78 75 72 1.2 80 78 73 1.2 81 79 76 1.2 84 82 80
1.4 79 78 73 1.4 81 79 76 1.4 82 80 77 1.4 85 83 80
1.6 80 79 75 1.6 82 80 77 1.6 83 81 78 1.6 85 83 80
1.8 81 79 76 1.8 83 81 78 1.8 83 81 79 1.8 85 83 81
2.04 82 80 77 2.04 83 81 78 2.04 84 82 80 2.04 86 84 81
2.54 83 81 79 2.54 85 83 80 2.54 85 83 81 2.54 86 84 82
3.04 85 83 80 3.04 85 84 81 3.04 86 84 82 3.04 87 85 82
3.54 85 84 81 3.54 86 84 82 3.54 86 84 82 3.54 87 85 83
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Appendix 4, Table 2  Continued. 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 69 67 <665 0.5 79 77 70
0.6 <665 <665 <665 0.6 69 67 <665 0.6 72 70 <665 0.6 80 78 72
0.7 68 <665 <665 0.7 72 70 <665 0.7 74 71 67 0.7 81 79 73
0.8 70 68 <665 0.8 74 71 67 0.8 76 73 68 0.8 82 80 73
0.9 72 70 <665 0.9 75 72 67 0.9 77 74 70 0.9 82 80 75
1.0 74 71 67 1.0 77 74 69 1.0 79 76 70 1.0 82 80 75
1.2 77 74 69 1.2 79 77 71 1.2 80 78 72 1.2 83 81 76
1.4 78 76 70 1.4 80 78 72 1.4 81 79 73 1.4 84 81 76
1.6 79 78 72 1.6 81 79 73 1.6 82 80 75 1.6 84 81 77
1.8 80 78 73 1.8 82 80 75 1.8 82 80 76 1.8 84 82 77
2.0 81 79 75 2.0 82 80 76 2.0 83 81 76 2.0 85 82 79
2.5 82 80 76 2.5 84 81 77 2.5 84 81 77 2.5 86 83 80
3.04 84 81 77 3.04 84 82 78 3.04 85 82 79 3.04 86 83 80
3.54 84 82 78 3.54 85 82 80 3.54 86 83 80 3.54 86 83 80
4.04 85 82 80 4.04 86 83 80 4.04 86 83 80 4.04 87 84 80
4.54 86 83 80 4.54 86 83 80 4.54 87 84 80 4.54 87 84 80
5.04 86 83 80 5.04 87 84 80 5.04 87 84 81 5.04 87 84 81
5.34 87 84 80 5.34 87 84 80 5.34 87 84 81 5.34 88 84 81
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years  
or younger.
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Appendix 4, Table 3  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming 25% Higher Colonoscopy Costs.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 67 <665 <665 0.5 71 68 <665 0.5 80 77 73
0.6 66 <665 <665 0.6 71 68 <665 0.6 74 71 68 0.6 81 78 74
0.7 70 66 <665 0.7 74 71 68 0.7 76 73 70 0.7 82 79 76
0.8 72 70 66 0.8 76 73 70 0.8 78 75 72 0.8 83 80 77
0.9 75 72 68 0.9 78 74 71 0.9 80 76 73 0.9 83 81 77
1.0 76 73 70 1.0 79 76 73 1.0 80 77 74 1.0 84 81 78
1.2 79 75 72 1.2 81 78 74 1.2 82 79 76 1.2 84 82 79
1.4 80 77 74 1.4 82 79 76 1.4 83 80 77 1.4 85 82 80
1.6 81 79 76 1.6 83 80 77 1.6 83 81 78 1.6 85 82 80
1.8 82 80 76 1.8 83 81 78 1.8 84 82 79 1.8 85 83 80
2.0 83 80 77 2.0 84 82 79 2.0 85 82 80 2.0 86 83 81
2.54 84 82 79 2.54 85 82 80 2.54 85 83 80 2.54 86 84 81
3.04 85 82 80 3.04 86 83 81 3.04 86 84 81 3.04 87 84 82
3.54 86 83 81 3.54 86 84 82 3.54 86 84 82 3.54 87 85 82
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Appendix 4, Table 3  Continued. 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 68 66 <665 0.5 71 69 <665 0.5 80 78 73
0.6 66 <665 <665 0.6 71 69 <665 0.6 74 71 68 0.6 81 79 75
0.7 70 67 <665 0.7 74 71 67 0.7 76 73 70 0.7 82 80 76
0.8 72 70 <665 0.8 76 73 69 0.8 78 75 71 0.8 83 80 77
0.9 74 71 67 0.9 78 74 70 0.9 80 77 72 0.9 83 80 77
1.0 76 73 69 1.0 79 76 72 1.0 80 77 73 1.0 83 81 77
1.2 79 75 71 1.2 80 78 74 1.2 81 79 75 1.2 84 81 78
1.4 80 78 73 1.4 82 79 75 1.4 82 80 76 1.4 84 82 79
1.6 81 79 75 1.6 82 80 76 1.6 83 81 77 1.6 85 82 79
1.8 82 80 76 1.8 83 81 77 1.8 83 81 78 1.8 85 82 80
2.0 83 80 77 2.0 83 81 78 2.0 84 81 79 2.0 85 83 80
2.54 84 81 79 2.54 84 82 79 2.54 85 82 80 2.54 85 83 80
3.04 84 82 80 3.04 85 83 80 3.04 85 83 80 3.04 86 83 81
3.54 85 83 80 3.54 85 83 81 3.54 86 83 81 3.54 86 84 81
4.04 85 84 81 4.04 86 84 81 4.04 86 84 81 4.04 86 84 81
4.54 86 84 81 4.54 86 84 81 4.54 86 84 81 4.54 86 84 82
4.94 86 84 82 4.94 86 84 82 4.94 86 84 82 4.94 87 84 82
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Appendix 4, Table 3  Continued. 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 66 <665 <665 0.4 79 76 71
0.5 <665 <665 <665 0.5 67 <665 <665 0.5 70 69 <665 0.5 80 78 73
0.6 66 <665 <665 0.6 71 69 <665 0.6 74 71 67 0.6 82 79 76
0.7 70 67 <665 0.7 74 71 66 0.7 76 74 69 0.7 82 80 77
0.8 72 70 <665 0.8 76 74 69 0.8 78 75 71 0.8 83 81 77
0.9 74 72 67 0.9 77 75 71 0.9 79 77 73 0.9 83 81 78
1.0 76 74 69 1.0 78 76 72 1.0 80 78 73 1.0 84 81 79
1.2 78 76 72 1.2 80 78 75 1.2 81 79 76 1.2 85 82 80
1.4 80 78 73 1.4 81 79 76 1.4 82 80 77 1.4 85 83 80
1.6 81 79 76 1.6 82 80 77 1.6 83 81 78 1.6 85 83 80
1.8 81 80 77 1.8 83 81 78 1.8 84 82 79 1.8 86 84 81
2.04 82 80 77 2.04 83 81 79 2.04 84 82 80 2.04 86 84 81
2.54 83 82 79 2.54 85 83 80 2.54 85 83 81 2.54 86 84 82
3.04 85 83 80 3.04 85 84 81 3.04 86 84 82 3.04 87 85 82
3.54 86 84 81 3.54 86 84 82 3.54 87 85 82 3.54 87 86 83
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Appendix 4, Table 3  Continued. 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 70 67 <665 0.5 80 78 70
0.6 <665 <665 <665 0.6 70 67 <665 0.6 72 70 <665 0.6 80 78 72
0.7 69 <665 <665 0.7 72 70 <665 0.7 75 71 67 0.7 81 79 73
0.8 71 69 <665 0.8 74 71 67 0.8 76 74 69 0.8 82 80 73
0.9 72 70 <665 0.9 76 73 67 0.9 78 75 70 0.9 82 80 75
1.0 74 71 67 1.0 77 74 70 1.0 79 76 71 1.0 83 81 75
1.2 77 74 70 1.2 79 77 71 1.2 80 78 72 1.2 84 81 76
1.4 78 76 71 1.4 80 78 72 1.4 81 79 73 1.4 84 81 76
1.6 80 78 72 1.6 81 79 73 1.6 82 80 75 1.6 84 81 77
1.8 80 78 73 1.8 82 80 75 1.8 82 81 76 1.8 85 82 78
2.0 81 79 75 2.0 82 81 76 2.0 83 81 76 2.0 85 82 79
2.5 82 81 76 2.5 84 81 77 2.5 84 81 78 2.5 86 83 80
3.04 84 81 77 3.04 84 82 79 3.04 85 82 79 3.04 86 83 80
3.54 84 82 79 3.54 85 82 80 3.54 86 83 80 3.54 87 83 80
4.04 85 83 80 4.04 86 83 80 4.04 86 83 80 4.04 87 84 80
4.54 86 83 80 4.54 86 83 80 4.54 87 84 80 4.54 87 84 80
5.04 87 83 80 5.04 87 84 80 5.04 87 84 81 5.04 87 84 81
5.34 87 84 80 5.34 87 84 80 5.34 87 84 81 5.34 88 84 81
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years  
or younger.
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Appendix 4, Table 4  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming 25% Lower Colonoscopy Costs.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 67 <665 <665 0.5 72 69 66 0.5 75 72 69 0.5 82 79 76
0.6 71 68 <665 0.6 75 72 69 0.6 78 74 71 0.6 83 80 77
0.7 74 71 68 0.7 77 74 71 0.7 79 76 73 0.7 84 81 78
0.8 76 73 70 0.8 79 76 73 0.8 81 78 74 0.8 84 82 79
0.9 78 75 72 0.9 80 77 74 0.9 81 79 76 0.9 85 82 79
1.0 80 76 73 1.0 81 79 76 1.0 82 80 77 1.0 85 82 80
1.2 81 78 75 1.2 82 80 77 1.2 83 81 78 1.2 85 83 80
1.4 82 80 77 1.4 84 81 78 1.4 84 82 79 1.4 86 83 81
1.6 83 81 78 1.6 84 82 79 1.6 85 82 80 1.6 86 84 81
1.8 84 82 79 1.8 85 82 80 1.8 85 83 80 1.8 86 84 82
2.0 84 82 80 2.0 85 83 80 2.0 86 83 81 2.0 87 84 82
2.54 85 83 81 2.54 86 84 81 2.54 86 84 82 2.54 87 85 82
3.04 86 84 82 3.04 87 85 82 3.04 87 85 83 3.04 87 85 83
3.54 87 85 82 3.54 87 85 83 3.54 87 85 83 3.54 87 86 83
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Appendix 4, Table 4  Continued. 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 67 <665 <665 0.5 72 69 <665 0.5 75 72 69 0.5 82 80 75
0.6 71 68 <665 0.6 74 72 68 0.6 77 74 71 0.6 83 80 77
0.7 74 71 67 0.7 77 74 70 0.7 79 77 72 0.7 83 81 78
0.8 76 73 69 0.8 79 76 72 0.8 80 78 74 0.8 84 81 78
0.9 78 75 71 0.9 80 77 73 0.9 81 79 75 0.9 84 81 79
1.0 80 76 72 1.0 81 78 74 1.0 82 80 76 1.0 84 82 79
1.2 81 79 74 1.2 82 80 76 1.2 83 80 77 1.2 85 82 80
1.4 82 80 76 1.4 83 81 77 1.4 84 81 78 1.4 85 83 80
1.6 83 81 77 1.6 84 81 79 1.6 84 82 79 1.6 85 83 80
1.8 83 81 78 1.8 84 82 79 1.8 84 82 80 1.8 85 83 81
2.0 84 82 79 2.0 85 82 80 2.0 85 83 80 2.0 86 83 81
2.54 85 83 80 2.54 85 83 81 2.54 85 83 81 2.54 86 84 81
3.04 85 83 81 3.04 86 84 81 3.04 86 84 81 3.04 86 84 81
3.54 86 84 81 3.54 86 84 81 3.54 86 84 82 3.54 87 84 82
4.04 86 84 82 4.04 86 84 82 4.04 87 84 82 4.04 87 84 82
4.54 86 84 82 4.54 87 84 82 4.54 87 84 82 4.54 87 84 82
4.94 87 84 82 4.94 87 84 82 4.94 87 84 82 4.94 87 85 82
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Appendix 4, Table 4  Continued. 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 66 <665 <665 0.4 70 68 <665 0.4 81 79 75
0.5 67 <665 <665 0.5 72 69 <665 0.5 74 72 68 0.5 82 80 77
0.6 71 69 <665 0.6 75 73 68 0.6 77 74 70 0.6 83 81 77
0.7 74 71 66 0.7 77 74 70 0.7 79 77 72 0.7 84 81 79
0.8 76 74 69 0.8 78 76 72 0.8 80 78 74 0.8 84 82 80
0.9 77 75 71 0.9 80 78 73 0.9 81 79 76 0.9 85 83 80
1.0 78 76 72 1.0 80 79 75 1.0 82 80 77 1.0 85 83 80
1.2 80 78 75 1.2 82 80 77 1.2 83 81 78 1.2 86 84 81
1.4 81 80 77 1.4 83 81 78 1.4 84 82 79 1.4 86 84 82
1.6 82 80 77 1.6 84 82 79 1.6 85 83 80 1.6 86 84 82
1.8 83 81 79 1.8 84 82 80 1.8 85 83 81 1.8 87 84 82
2.04 84 82 80 2.04 85 83 80 2.04 85 84 81 2.04 87 85 82
2.54 85 83 81 2.54 86 84 82 2.54 86 84 82 2.54 87 86 83
3.04 86 84 82 3.04 87 85 83 3.04 87 85 83 3.04 88 86 83
3.54 87 85 83 3.54 87 86 83 3.54 87 86 83 3.54 88 86 83
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Appendix 4, Table 4  Continued. 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 67 <665 0.5 73 71 <665 0.5 81 79 73
0.6 70 67 <665 0.6 73 71 <665 0.6 75 72 67 0.6 82 80 75
0.7 72 70 <665 0.7 75 72 67 0.7 77 74 70 0.7 83 81 75
0.8 74 71 67 0.8 77 74 70 0.8 79 77 71 0.8 83 81 76
0.9 76 73 68 0.9 78 76 70 0.9 80 78 72 0.9 84 81 76
1.0 77 74 70 1.0 79 78 72 1.0 80 78 73 1.0 84 81 77
1.2 79 77 72 1.2 81 79 73 1.2 82 80 75 1.2 85 82 77
1.4 80 78 73 1.4 82 80 75 1.4 82 81 76 1.4 85 82 79
1.6 81 79 75 1.6 82 81 76 1.6 83 81 76 1.6 86 82 80
1.8 82 80 75 1.8 83 81 76 1.8 84 81 77 1.8 86 83 80
2.0 82 81 76 2.0 84 81 77 2.0 84 82 79 2.0 86 83 80
2.5 84 81 78 2.5 85 82 80 2.5 85 83 80 2.5 87 83 80
3.04 85 82 80 3.04 86 83 80 3.04 86 83 80 3.04 87 84 80
3.54 86 83 80 3.54 86 84 80 3.54 87 84 80 3.54 87 84 81
4.04 87 84 80 4.04 87 84 81 4.04 87 84 81 4.04 88 84 82
4.54 87 84 81 4.54 87 84 82 4.54 87 84 82 4.54 88 84 82
5.04 87 84 82 5.04 87 84 82 5.04 88 84 82 5.04 88 84 82
5.34 88 84 82 5.34 88 84 82 5.34 88 84 82 5.34 88 84 82
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years or 
younger.
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Appendix 4, Table 5  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming 25% Higher CRC Care Costs.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 67 <665 0.5 73 71 68 0.5 81 78 74
0.6 69 66 <665 0.6 73 71 68 0.6 76 73 70 0.6 82 80 76
0.7 72 70 66 0.7 76 73 70 0.7 78 75 72 0.7 83 80 77
0.8 75 72 69 0.8 78 75 71 0.8 80 77 73 0.8 83 81 78
0.9 77 74 70 0.9 80 76 73 0.9 81 78 74 0.9 84 81 78
1.0 78 75 72 1.0 80 77 74 1.0 81 79 76 1.0 84 82 79
1.2 80 77 74 1.2 82 79 76 1.2 83 80 77 1.2 85 82 80
1.4 82 79 76 1.4 83 80 77 1.4 84 81 78 1.4 85 83 80
1.6 82 80 77 1.6 84 81 78 1.6 84 82 79 1.6 85 83 80
1.8 83 81 78 1.8 84 82 79 1.8 85 82 80 1.8 86 83 81
2.0 84 81 79 2.0 85 82 80 2.0 85 83 80 2.0 86 84 81
2.54 85 82 80 2.54 85 83 81 2.54 86 84 81 2.54 86 84 82
3.04 86 83 81 3.04 86 84 81 3.04 86 84 82 3.04 87 85 82
3.54 86 84 82 3.54 86 84 82 3.54 87 85 82 3.54 87 85 82
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Appendix 4, Table 5  Continued. 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 70 68 <665 0.5 73 71 67 0.5 81 79 74
0.6 69 67 <665 0.6 73 71 67 0.6 76 73 70 0.6 82 80 76
0.7 72 70 <665 0.7 76 73 69 0.7 78 75 71 0.7 83 80 77
0.8 74 71 68 0.8 78 75 71 0.8 80 77 73 0.8 83 80 77
0.9 76 73 69 0.9 79 76 72 0.9 80 78 74 0.9 83 81 78
1.0 78 75 71 1.0 80 77 73 1.0 81 79 75 1.0 84 81 78
1.2 80 77 73 1.2 81 79 75 1.2 82 80 76 1.2 84 82 79
1.4 81 79 75 1.4 82 80 77 1.4 83 80 77 1.4 84 82 79
1.6 82 80 76 1.6 83 81 77 1.6 83 81 78 1.6 85 82 80
1.8 83 80 77 1.8 83 81 78 1.8 84 81 79 1.8 85 83 80
2.0 83 81 78 2.0 84 82 79 2.0 84 82 79 2.0 85 83 80
2.54 84 82 80 2.54 85 83 80 2.54 85 83 80 2.54 85 83 81
3.04 85 83 80 3.04 85 83 81 3.04 85 83 81 3.04 86 83 81
3.54 85 83 81 3.54 86 84 81 3.54 86 84 81 3.54 86 84 81
4.04 86 84 81 4.04 86 84 81 4.04 86 84 81 4.04 86 84 81
4.54 86 84 82 4.54 86 84 82 4.54 86 84 81 4.54 86 84 81
4.94 86 84 82 4.94 86 84 82 4.94 86 84 82 4.94 86 84 82
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Appendix 4, Table 5  Continued. 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 68 67 <665 0.4 80 78 73
0.5 <665 <665 <665 0.5 70 68 <665 0.5 73 70 66 0.5 81 79 75
0.6 69 67 <665 0.6 73 71 <665 0.6 76 73 69 0.6 82 80 77
0.7 72 70 <665 0.7 75 73 69 0.7 77 75 71 0.7 83 81 77
0.8 75 73 67 0.8 77 75 71 0.8 79 77 73 0.8 83 81 78
0.9 76 74 70 0.9 78 76 72 0.9 80 78 74 0.9 84 82 79
1.0 77 75 71 1.0 80 78 73 1.0 81 79 76 1.0 84 82 80
1.2 79 78 73 1.2 81 79 76 1.2 82 80 77 1.2 85 83 80
1.4 80 79 76 1.4 82 80 77 1.4 83 81 78 1.4 85 83 80
1.6 82 80 77 1.6 83 81 78 1.6 84 82 79 1.6 86 84 81
1.8 82 80 77 1.8 84 81 79 1.8 84 82 80 1.8 86 84 81
2.04 83 81 78 2.04 84 82 80 2.04 85 83 80 2.04 86 84 82
2.54 84 83 80 2.54 85 83 81 2.54 86 84 81 2.54 87 84 82
3.04 85 83 81 3.04 86 84 82 3.04 86 84 82 3.04 87 85 83
3.54 86 84 82 3.54 87 85 82 3.54 87 85 83 3.54 87 86 83
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Appendix 4, Table 5  Continued. 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 68 <665 <665 0.5 71 69 <665 0.5 80 78 72
0.6 67 <665 <665 0.6 71 69 <665 0.6 74 71 67 0.6 81 79 73
0.7 71 69 <665 0.7 74 71 67 0.7 76 74 68 0.7 82 80 73
0.8 73 71 <665 0.8 76 73 68 0.8 78 75 70 0.8 82 80 75
0.9 75 71 67 0.9 77 74 70 0.9 79 77 71 0.9 83 81 75
1.0 76 74 68 1.0 78 76 70 1.0 80 78 72 1.0 83 81 76
1.2 78 76 70 1.2 80 78 72 1.2 81 79 73 1.2 84 81 76
1.4 80 78 72 1.4 81 79 73 1.4 82 80 75 1.4 84 81 77
1.6 80 78 73 1.6 82 80 75 1.6 82 81 76 1.6 84 82 77
1.8 81 79 75 1.8 82 81 76 1.8 83 81 76 1.8 85 82 78
2.0 82 80 75 2.0 83 81 76 2.0 84 81 77 2.0 85 82 79
2.5 83 81 77 2.5 84 81 78 2.5 84 82 79 2.5 86 83 80
3.04 84 82 79 3.04 85 82 79 3.04 85 83 80 3.04 86 83 80
3.54 85 82 80 3.54 86 83 80 3.54 86 83 80 3.54 86 83 80
4.04 86 83 80 4.04 86 83 80 4.04 86 83 80 4.04 87 84 80
4.54 86 83 80 4.54 86 83 80 4.54 87 84 80 4.54 87 84 80
5.04 87 83 80 5.04 87 84 80 5.04 87 84 81 5.04 87 84 80
5.34 87 84 80 5.34 87 84 80 5.34 87 84 81 5.34 87 84 80
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years  
or younger.
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Appendix 4, Table 6  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming 25% Lower CRC Care Costs.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 69 66 <665 0.5 72 70 67 0.5 81 78 74
0.6 68 <665 <665 0.6 73 70 67 0.6 75 72 70 0.6 82 79 76
0.7 71 69 <665 0.7 75 72 69 0.7 77 74 71 0.7 83 80 77
0.8 74 71 68 0.8 77 74 71 0.8 79 76 73 0.8 83 81 78
0.9 76 73 70 0.9 79 75 72 0.9 80 77 74 0.9 84 81 78
1.0 77 74 71 1.0 80 77 74 1.0 81 78 75 1.0 84 82 79
1.2 80 77 73 1.2 81 79 76 1.2 82 80 77 1.2 85 82 80
1.4 81 78 75 1.4 82 80 77 1.4 83 81 78 1.4 85 83 80
1.6 82 80 76 1.6 83 81 78 1.6 84 82 79 1.6 86 83 81
1.8 83 80 77 1.8 84 82 79 1.8 85 82 80 1.8 86 84 81
2.0 83 81 78 2.0 85 82 80 2.0 85 83 80 2.0 86 84 81
2.54 85 82 80 2.54 85 83 81 2.54 86 84 81 2.54 87 85 82
3.04 85 83 81 3.04 86 84 82 3.04 87 84 82 3.04 87 85 83
3.54 86 84 82 3.54 87 85 82 3.54 87 85 83 3.54 87 86 83
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Appendix 4, Table 6  Continued 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 69 67 <665 0.5 73 70 67 0.5 81 78 74
0.6 68 66 <665 0.6 72 70 66 0.6 75 73 69 0.6 82 80 76
0.7 71 69 <665 0.7 75 72 68 0.7 78 75 71 0.7 83 80 77
0.8 73 71 67 0.8 77 74 70 0.8 79 76 72 0.8 83 81 77
0.9 75 73 69 0.9 79 75 71 0.9 80 77 73 0.9 84 81 78
1.0 77 74 70 1.0 80 77 73 1.0 81 78 74 1.0 84 81 79
1.2 80 77 72 1.2 81 79 75 1.2 82 80 76 1.2 84 82 79
1.4 81 78 74 1.4 82 80 76 1.4 83 80 77 1.4 85 83 80
1.6 82 80 76 1.6 83 81 77 1.6 83 81 78 1.6 85 83 80
1.8 83 80 77 1.8 83 81 78 1.8 84 82 79 1.8 85 83 80
2.0 83 81 78 2.0 84 82 79 2.0 84 82 80 2.0 86 83 81
2.54 84 82 79 2.54 85 83 80 2.54 85 83 80 2.54 86 84 81
3.04 85 83 80 3.04 85 83 81 3.04 86 84 81 3.04 86 84 81
3.54 85 84 81 3.54 86 84 81 3.54 86 84 81 3.54 87 84 82
4.04 86 84 82 4.04 86 84 82 4.04 86 84 82 4.04 87 84 82
4.54 86 84 82 4.54 87 84 82 4.54 87 84 82 4.54 87 85 82
4.94 87 84 82 4.94 87 84 82 4.94 87 85 82 4.94 87 85 82
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Appendix 4, Table 6  Continued 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 68 <665 <665 0.4 80 78 72
0.5 <665 <665 <665 0.5 69 67 <665 0.5 72 70 <665 0.5 81 79 75
0.6 68 <665 <665 0.6 72 70 <665 0.6 75 73 68 0.6 82 80 77
0.7 71 69 <665 0.7 75 73 68 0.7 77 75 70 0.7 83 81 77
0.8 74 72 66 0.8 77 74 70 0.8 79 77 72 0.8 84 81 78
0.9 75 74 69 0.9 78 76 72 0.9 80 78 73 0.9 84 82 79
1.0 77 75 70 1.0 79 78 73 1.0 81 79 75 1.0 85 83 80
1.2 79 77 73 1.2 81 79 76 1.2 82 80 77 1.2 85 83 80
1.4 80 78 75 1.4 82 80 77 1.4 83 81 78 1.4 86 84 81
1.6 81 80 77 1.6 83 81 78 1.6 84 82 79 1.6 86 84 82
1.8 82 80 77 1.8 83 81 79 1.8 84 82 80 1.8 86 84 82
2.04 83 81 78 2.04 84 82 80 2.04 85 83 80 2.04 87 84 82
2.54 84 82 80 2.54 85 83 81 2.54 86 84 82 2.54 87 85 83
3.04 85 83 81 3.04 86 84 82 3.04 87 85 82 3.04 88 86 83
3.54 86 84 82 3.54 87 85 83 3.54 87 86 83 3.54 88 86 84
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Appendix 4, Table 6  Continued 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 68 <665 <665 0.5 71 69 <665 0.5 80 78 72
0.6 66 <665 <665 0.6 71 69 <665 0.6 74 71 67 0.6 82 79 73
0.7 70 67 <665 0.7 74 71 <665 0.7 76 73 68 0.7 82 80 75
0.8 72 70 <665 0.8 75 72 67 0.8 77 74 70 0.8 83 81 75
0.9 74 71 67 0.9 77 74 70 0.9 79 76 71 0.9 83 81 76
1.0 75 72 67 1.0 78 75 70 1.0 80 78 72 1.0 84 81 76
1.2 78 75 70 1.2 80 78 72 1.2 81 79 73 1.2 84 81 77
1.4 79 78 72 1.4 81 79 73 1.4 82 80 75 1.4 85 82 78
1.6 80 78 73 1.6 82 80 75 1.6 82 81 76 1.6 85 82 79
1.8 81 79 75 1.8 82 81 76 1.8 84 81 76 1.8 86 83 80
2.0 82 80 75 2.0 83 81 76 2.0 84 81 77 2.0 86 83 80
2.5 83 81 77 2.5 84 82 79 2.5 85 82 80 2.5 87 83 80
3.04 84 82 79 3.04 85 83 80 3.04 86 83 80 3.04 87 84 80
3.54 85 83 80 3.54 86 83 80 3.54 86 84 80 3.54 88 84 81
4.04 86 83 80 4.04 87 84 80 4.04 87 84 81 4.04 88 84 82
4.54 87 84 81 4.54 87 84 82 4.54 87 84 82 4.54 88 84 82
5.04 87 84 82 5.04 87 84 82 5.04 88 84 82 5.04 88 86 82
5.34 88 84 82 5.34 88 84 82 5.34 88 84 82 5.34 88 86 82
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals 
aged 65 years or younger.
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Appendix 4, Table 7  The Appropriate Ages to Stop Colonoscopy Screening  
Assuming a Cost-Effectiveness Threshold of $50,000.1 
WHITE FEMALES
SCREENING HISTORY
WHITE FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 68 <665 <665 0.5 78 74 70
0.6 <665 <665 <665 0.6 68 <665 <665 0.6 71 69 <665 0.6 79 75 72
0.7 <665 <665 <665 0.7 71 68 <665 0.7 74 71 68 0.7 80 77 73
0.8 70 66 <665 0.8 73 70 67 0.8 76 73 69 0.8 81 78 74
0.9 72 69 <665 0.9 75 72 69 0.9 77 74 71 0.9 81 78 75
1.0 74 71 67 1.0 77 74 70 1.0 79 75 72 1.0 82 79 76
1.2 77 73 70 1.2 79 75 72 1.2 80 77 74 1.2 83 80 77
1.4 79 75 72 1.4 80 77 74 1.4 81 78 75 1.4 83 81 77
1.6 80 77 73 1.6 81 78 75 1.6 82 79 76 1.6 84 81 78
1.8 81 78 74 1.8 82 79 76 1.8 83 80 77 1.8 84 81 78
2.0 81 79 76 2.0 82 80 77 2.0 83 81 78 2.0 84 82 79
2.54 83 80 77 2.54 84 81 78 2.54 84 82 79 2.54 85 82 80
3.04 84 81 79 3.04 84 82 80 3.04 85 82 80 3.04 85 82 80
3.54 84 82 80 3.54 85 82 80 3.54 85 83 80 3.54 85 83 80
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Appendix 4, Table 7  Continued. 
WHITE MALES
SCREENING HISTORY
WHITE MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 69 67 <665 0.5 79 75 70
0.6 <665 <665 <665 0.6 68 66 <665 0.6 72 69 <665 0.6 80 77 72
0.7 66 <665 <665 0.7 71 68 <665 0.7 74 71 67 0.7 80 78 73
0.8 69 67 <665 0.8 73 71 66 0.8 76 73 69 0.8 81 78 74
0.9 71 69 <665 0.9 75 72 68 0.9 77 74 70 0.9 81 79 75
1.0 73 71 66 1.0 77 73 69 1.0 79 75 71 1.0 82 79 75
1.2 76 73 69 1.2 79 75 71 1.2 80 77 73 1.2 82 80 76
1.4 79 75 71 1.4 80 77 73 1.4 81 78 74 1.4 83 80 77
1.6 80 77 72 1.6 81 78 74 1.6 81 79 75 1.6 83 80 77
1.8 81 78 74 1.8 82 79 75 1.8 82 80 76 1.8 83 81 78
2.0 81 79 75 2.0 82 80 76 2.0 82 80 77 2.0 83 81 78
2.54 82 80 77 2.54 83 81 77 2.54 83 81 78 2.54 84 81 79
3.04 83 81 78 3.04 84 81 79 3.04 84 81 79 3.04 84 82 79
3.54 84 81 79 3.54 84 82 79 3.54 84 82 79 3.54 85 82 79
4.04 84 82 79 4.04 84 82 80 4.04 85 82 80 4.04 85 82 80
4.54 85 82 80 4.54 85 83 80 4.54 85 83 80 4.54 85 83 80
4.94 85 82 80 4.94 85 83 80 4.94 85 83 80 4.94 85 83 80
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Appendix 4, Table 7  Continued. 
BLACK FEMALES
SCREENING HISTORY
BLACK FEMALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 <665 <665 <665 0.4 76 73 67
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 67 <665 <665 0.5 78 75 70
0.6 <665 <665 <665 0.6 67 <665 <665 0.6 71 69 <665 0.6 80 77 72
0.7 <665 <665 <665 0.7 70 68 <665 0.7 73 71 66 0.7 80 78 73
0.8 69 67 <665 0.8 73 70 <665 0.8 75 73 68 0.8 81 79 75
0.9 72 69 <665 0.9 75 73 67 0.9 77 74 70 0.9 82 79 76
1.0 73 71 <665 1.0 76 74 69 1.0 78 75 71 1.0 82 80 76
1.2 76 74 69 1.2 78 76 72 1.2 80 78 73 1.2 82 80 77
1.4 77 75 71 1.4 79 78 73 1.4 80 79 75 1.4 83 81 77
1.6 79 77 73 1.6 80 79 75 1.6 81 79 76 1.6 83 81 78
1.8 80 78 74 1.8 81 79 76 1.8 82 80 77 1.8 84 81 79
2.04 81 79 75 2.04 82 80 77 2.04 82 80 77 2.04 84 82 79
2.54 82 80 77 2.54 83 81 78 2.54 83 81 79 2.54 85 82 80
3.04 83 81 78 3.04 84 82 79 3.04 84 82 80 3.04 85 83 80
3.54 84 82 79 3.54 85 83 80 3.54 85 83 80 3.54 85 83 81
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Appendix 4, Table 7  Continued. 
BLACK MALES
SCREENING HISTORY
BLACK MALES
SCREENING HISTORY
Negative screening colonoscopy 
10 years prior
Negative screening colonoscopy 
15 years prior
Negative screening colonoscopy 
20 years prior
No prior screening
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
0.5 <665 <665 <665 0.5 <665 <665 <665 0.5 66 <665 <665 0.5 77 74 67
0.6 <665 <665 <665 0.6 <665 <665 <665 0.6 70 67 <665 0.6 78 75 70
0.7 <665 <665 <665 0.7 69 66 <665 0.7 72 69 <665 0.7 79 77 70
0.8 68 <665 <665 0.8 71 69 <665 0.8 74 71 <665 0.8 80 78 71
0.9 70 67 <665 0.9 73 71 <665 0.9 75 72 67 0.9 80 78 72
1.0 72 69 <665 1.0 75 71 67 1.0 76 74 68 1.0 81 78 72
1.2 74 71 67 1.2 77 74 69 1.2 78 75 70 1.2 81 79 73
1.4 76 74 68 1.4 78 76 70 1.4 79 78 71 1.4 82 80 73
1.6 78 75 70 1.6 79 77 71 1.6 80 78 72 1.6 82 80 75
1.8 79 76 71 1.8 80 78 72 1.8 81 78 73 1.8 82 80 75
2.0 80 78 72 2.0 80 78 73 2.0 81 79 73 2.0 82 81 75
2.5 81 79 73 2.5 82 80 75 2.5 82 80 75 2.5 83 81 76
3.04 82 80 75 3.04 82 81 76 3.04 83 81 76 3.04 84 81 76
3.54 82 81 76 3.54 83 81 76 3.54 84 81 76 3.54 84 81 76
4.04 84 81 76 4.04 84 81 77 4.04 84 81 77 4.04 84 81 77
4.54 84 81 77 4.54 84 81 77 4.54 84 81 77 4.54 84 82 77
5.04 84 81 77 5.04 84 82 78 5.04 84 82 78 5.04 85 82 78
5.34 84 81 77 5.34 85 82 79 5.34 85 82 79 5.34 85 82 78
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
5  In these cohorts screening was not cost-effective at age 66 years. We did not perform analyses for individuals aged 65 years or 
younger.
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for the different phases/ stages of CRC care, but no correlation across these groups of 
parameters. From these distributions we drew 1,000 random parameter sets, and for each 
set we determined the costs and QALYs gained associated with colonoscopy screening at 
age 78 years (i.e. the appropriate age to stop colonoscopy screening according to our base 
case analysis); at younger ages: 75, 76, and 77 years; and at older ages 79, 80, and 81 years.
Appendix 5, Figure 1 shows that the number of QALYs gained by screening decreases 
with age and that the costs of screening increase with age. The proportion of parameter 
sets for which screening is cost-effective given a willingness-to-pay threshold of $100,000 
per QALY gained (i.e., the proportion of symbols above the dashed line) decreases with 
age. Appendix 5, Figure 2 shows that the probability that screening is cost-effective at 
age 78 years (i.e. the appropriate age to stop screening according to our base case analysis) 
is 62%. The probabilities that screening is cost-effective at ages 75, 76, and 77 years are 
99%, 94%, and 85%, respectively. The probabilities that screening is cost-effective at ages 
79, 80, and 81 years are 34%, 10%, and 1%, respectively. Hence, the probability that our 
estimates of the appropriate ages to stop screening are more than one year off, is small.  
Appendix 5: The Appropriate Ages to Stop Screening  
– Results of a Multivariate Probabilistic Sensitivity Analysis
To assess the overall impact of uncertainty in model inputs on the appropriate age to stop 
colonoscopy screening, we performed a multivariate probabilistic sensitivity analysis for 
one representative case: healthy, average risk, white women with a negative screening 
colonoscopy 10 years prior. The inputs that were varied were identical to those varied in 
the univariate deterministic sensitivity analyses: the utility losses for colonoscopies and 
complications, the costs for colonoscopies, and the costs for CRC care. For the utility losses 
for colonoscopies and complications, we assumed a lognormal distribution with a mean 
corresponding to the base case utility loss and a standard deviation corresponding to 25% 
of the base case utility loss. For the costs of colonoscopies and CRC care, we assumed a 
lognormal distribution with a mean corresponding to the base case costs and a standard 
deviation corresponding to 12.5% of the base case costs. We assumed perfect correlation 
between the disutilities associated with colonoscopies and complications, between the 
costs of colonoscopies with and without a polypectomy/ biopsy, and between the costs 
Appendix 5, Figure 1  The Costs and QALYs Gained of Colonoscopy Screening  
for Healthy, Average Risk, White Women, with a Negative Screening Colonoscopy  
10 Years Prior: Results of a Multivariate Probabilistic Sensitivity Analysis.1
Appendix 5, Figure 2  The Probability that Screening Healthy, Average Risk,  
White Women, with a Negative Screening Colonoscopy 10 Years Prior is Cost-Effective  
as a Function of the Willingness-To-Pay per QALY Gained: Results of a Multivariate 
Probabilistic Sensitivity Analysis.1
1The dashed line indicates a willingness-to-pay threshold of $100,000 per QALY gained. 1The dashed line indicates a willingness-to-pay threshold of $100,000 per QALY gained.
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Appendix 6: The Appropriate Ages to Stop Screening – Results for  
High Risk Individuals with a Negative Screening Colonoscopy 5 Years Prior
Appendix 6, Table 1  The Appropriate Ages to Stop Colonoscopy Screening:  
Results for High Risk Individuals with a Negative Screening Colonoscopy 5 Years Prior.1  
WHITE FEMALES WHITE MALES BLACK FEMALES BLACK MALES
COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2 COMORBIDITY STATUS2
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
RR CRC3 No 
comorbidity 
Moderate 
comorbidity
Severe 
comorbidity
2.0 81 79 76 2.0 81 80 75 2.04 81 79 76 2.0 80 78 73
2.54 83 81 78 2.54 82 81 78 2.54 83 80 77 2.5 82 80 75
3.04 84 82 80 3.04 83 82 79 3.04 84 82 80 3.04 83 81 76
3.54 85 83 80 3.54 84 82 80 3.54 85 83 81 3.54 84 81 77
4.04 85 83 81 4.04 85 82 80
4.54 86 84 81 4.54 86 83 80
4.94 86 84 81 5.04 87 83 80
5.34 87 84 81
CRC = colorectal cancer; RR CRC = background risk for CRC
1 Given a willingness-to-pay threshold of $100,000 per QALY gained.
2 Detailed information on the assessment of comorbidity status is given in Figure 2, footnote 4.
3 Detailed information on the assessment of background risk for CRC is given in Figure 2, footnote 5.
4 Background risk for CRC only possible in case of a family history of CRC.
Submitted:
van Hees F*, Saini SD*, van Ballegooijen M, de Koning HJ, Zauber AG, Vijan S, Lansdorp-Vogelaar I. 
The Potential Effects of Personalizing the Age to Stop Colonoscopy Screening on Population Health 
and Medicare Spending. 
*Drs. van Hees and Dr. Saini contributed equally as co-primary authors.
The Potential Effects of 
Personalizing the Age to Stop 
Colonoscopy Screening on Population 
Health and Medicare Spending
8
Potential effects of personalizing the age to stop colonoscopy screening | 321
8
INTRODUCTION
Recent studies have demonstrated that colorectal cancer (CRC) screening in elderly 
individuals could be more cost-effective if individual patient characteristics, such as sex, 
race, screening history, and comorbidity status, were considered.[1 2] The objective of our 
current study was to quantify the potential clinical and economic effects of personalized 
versus uniform age-based colonoscopy screening in the 2013 US Medicare population, 
thereby illustrating the impact that personalizing cancer screening could have on health 
and health care budgets.   
METHODS
In a prior study, we used the micro-simulation model MISCAN-Colon to determine the 
costs and effects of colonoscopy screening in cohorts of individuals characterized by their 
age (66-90 years), sex (male/ female), race (black/ white), screening history (a negative 
screening colonoscopy 10 years prior/ 15 years prior/ 20 years prior/ no prior screening), 
and comorbidity status (no/ moderate/ severe comorbidity).[2] In this study, we used 
these data to determine the appropriate age to stop colonoscopy screening according to 
sex, race, screening history, and comorbidity status using four distinct thresholds for the 
willingness-to-pay per quality-adjusted life-year (QALY) gained ($25,000, $50,000, $75,000, 
and $100,000). By applying these thresholds, we constructed four scenarios of personalized 
screening varying in screening intensity (Table).
We then modeled the 2013 US Medicare population (39.6M individuals). Data on the 
number of individuals by age, sex, and race were obtained from the US Census Bureau.[3] 
Data on the age-specific, sex-specific, and race-specific proportions of individuals 
up-to-date with screening, not up-to-date but previously screened, and never screened 
were obtained from the 2013 National Health Interview Survey.[4] Finally, data on the 
age-specific, sex-specific, and race-specific proportions of individuals with no, moderate, 
and severe comorbidity were obtained from a publication by Cho and colleagues.[5] In 
our analysis, we assumed that individuals who were not black or white (e.g. Hispanic or 
Asian) had an identical risk for CRC, screening history distribution, and comorbidity status 
distribution as whites. Moreover, we assumed that being up-to-date with CRC screening 
tests other than colonoscopy (e.g. fecal immunochemical testing) conferred identical 
protection from CRC as being up-to-date with colonoscopy screening. In addition, we 
assumed that those not up-to-date but previously screened were protected as if they had 
had a negative screening colonoscopy 15 years prior. Finally, we assumed no correlations 
between screening history and comorbidity status, screening history and CRC risk, and 
comorbidity status and CRC risk. Since we aimed to quantify the potential impact of 
personalized colonoscopy screening, we assumed that everyone would be willing to have 
colonoscopy screening in the future, also those without prior screening.
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Table   The appropriate ages to stop colonoscopy screening in one scenario of age-based  
screening and four scenarios of personalized screening, years.
SCREENING HISTORY SCREENING HISTORY
Negative screening colonoscopy               
10 years prior
Negative screening colonoscopy               
15 years prior
Negative screening colonoscopy               
20 years prior
No prior screening
COMORBIDITY STATUS COMORBIDITY STATUS COMORBIDITY STATUS COMORBIDITY STATUS
No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
No 
comorbidity
Moderate 
comorbidity
Severe 
comorbidity
AGE BASED SCREENING AGE BASED SCREENING
All demographic groups 75 75 75 75 75 75 All demographic groups 75 75 75 75 75 75
PERSONALIZED SCREENINGa PERSONALIZED SCREENINGa
Scenario a  
(WTP = $25,000/QALY 
gained)
Scenario a  
(WTP = $25,000/QALY 
gained)
White females 68 ≤66 ≤66 72 69 ≤66 White females 74 71 68 79 75 71
White males 68 ≤66 ≤66 72 69 ≤66 White males 74 71 67 80 76 71
Black females 67 ≤66 ≤66 71 69 ≤66 Black females 74 71 ≤66 79 76 71
Black males ≤66 ≤66 ≤66 70 67 ≤66 Black males 72 69 ≤66 77 74 67
Scenario b  
(WTP = $50,000/QALY 
gained)
Scenario b  
(WTP = $50,000/QALY 
gained)
White females 74 71 67 77 74 70 White females 79 75 72 82 79 76
White males 73 71 66 77 73 69 White males 79 75 71 82 79 75
Black females 73 71 ≤66 76 74 69 Black females 78 75 71 82 80 76
Black males 72 69 ≤66 75 71 67 Black males 76 74 68 81 78 72
Scenario c  
(WTP = $75,000/QALY 
gained)
Scenario c  
(WTP = $75,000/QALY 
gained)
White females 76 73 70 79 76 72 White females 80 77 74 83 81 78
White males 76 73 69 79 75 72 White males 80 77 73 83 80 77
Black females 76 74 69 78 76 72 Black females 80 78 73 83 81 78
Black males 74 71 67 77 74 69 Black males 78 76 70 82 80 75
Scenario d  
(WTP = $100,000/QALY 
gained)
Scenario d  
(WTP = $100,000/QALY 
gained)
White females 78 75 71 80 77 74 White females 81 79 76 84 82 79
White males 78 74 70 80 77 73 White males 81 78 75 84 81 78
Black females 77 75 71 79 78 73 Black females 81 79 75 85 82 80
Black males 76 73 68 78 76 70 Black males 80 78 72 84 81 76
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To determine the impact of personalized screening, we compared the undiscounted 
lifetime Medicare costs and CRC deaths prevented under the four scenarios of personalized 
screening to the costs and CRC deaths prevented by uniform colonoscopy screening up 
to age 75 years.   
RESULTS
Across the full projected lifespan of the 2013 Medicare population, uniform colonoscopy 
screening up to age 75 years would prevent 177,000 CRC deaths at a cost of $1,787M 
(Figure). Personalized screening would be more efficient: while the least intensive 
personalized screening scenario (scenario a) would still be less effective (and substantially 
less costly!) than uniform screening, personalized screening scenario b would be both 
more effective and less costly. At the uniform screening cost level ($1,787M), personalized 
screening would prevent approximately 21,200 additional CRC deaths (+11%). Alternatively, 
the same number of CRC deaths (177,000) could be prevented at substantially lower costs 
($1,500M lower costs or -84%). The benefits of personalized screening were most sensitive 
to the proportion of never screened individuals willing to have future colonoscopy 
screening (data not shown). 
DISCUSSION
The potential impact of personalizing decisions on colonoscopy screening in the Medicare 
population is large: compared with uniform age-based screening either tens of thousands 
of additional CRC deaths can be prevented or billions of dollars can be saved. Dedicated 
efforts to personalize cancer screening decisions are needed. Particular emphasis should 
be put on screening those without prior screening.
Figure   The lifetime number of CRC deaths prevented and the lifetime costs from a 
Medicare perspective associated with four scenarios of personalized screening 
versus age-based screening up to age 75 years.*
CRC = colorectal cancer; QALY = quality-adjusted life-year.
Scenario a = personalized screening, WTP = $25,000/ QALY gained; scenario b = personalized screening, 
WTP = $50,000/ QALY gained; scenario c = personalized screening, WTP = $75,000/ QALY gained, scenario 
d = personalized screening, WTP = $100,000/ QALY gained. 
*Undiscounted results.
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In this chapter, we will first answer the research questions formulated in Chapter 1. 
Subsequently, we will explain how trials can be used to inform models, how models can 
also be used to inform trials and, hence, why modelers and trialists should cooperate. After 
that, we will discuss some important areas for future research. Finally, we will briefly 
summarize the conclusions that can be derived from our work and postulate our recom-
mendations. 
ANSWERS TO THE RESEARCH QUESTIONS
How can models be used to inform policy decisions regarding screening programs?
Models can be used to extrapolate evidence from RCTs and answer questions that 
might arise during the whole cycle of a screening program: during the decision phase 
the optimal screening strategy can be determined; during the planning phase the 
resource requirements, costs, and effects of the program can be estimated; during the 
implementation phase observed data can be compared to model estimates to see 
whether the program functions as expected; and during the established program 
phase modeling can be used to further optimize the program based on emerging 
data.  
Although RCTs are the gold standard for determining the effectiveness of screening, they 
also have their limitations. First, RCTs are expensive and time consuming. As a result, the 
number of RCTs that have evaluated CRC screening is limited. Second, RCTs usually have a 
limited follow-up time. Hence, they cannot be used to determine lifetime health effects 
and costs, which is necessary to determine the cost-effectiveness of screening. Third, the 
effectiveness of screening in a certain country might differ from that observed in an RCT, 
for example because attendance rates to screening are substantially lower or higher. 
Finally, country-level resource demands for a certain screening program cannot easily be 
inferred from an RCT. To summarize: RCTs alone do not answer the question of which 
screening strategy is optimal for a certain country.
We demonstrated that decision models provide a useful tool to extrapolate evidence 
from RCTs during the whole cycle of a screening program, using the role MISCAN-Colon 
played in the Dutch CRC screening program as an example.[1] In the decision phase of the 
Dutch screening program, modeling analyses informed the decision to choose FIT 
screening over gFOBT screening, to choose a higher age to start screening than 
recommended by the Council of Europe and to choose a lower cut-off for referral to 
colonoscopy than recommended by the test’s manufacturer. A modeling analysis also 
informed the decision to temporarily elevate the cut-off for referral to colonoscopy when 
a shortage of colonoscopy capacity was imminent during the first year of the program. If 
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modeling would not have been used at these instances, other choices could have been 
made, and the balance between the benefits and harms of the screening program could 
have turned out less favorable than it will now.
What is the appropriate interval for a first surveillance colonoscopy in adenoma 
patients given the characteristics of the adenomas that were removed and the sex 
and age of the patient?
The appropriate surveillance interval depends heavily on a patient’s adenoma risk 
score (i.e., risk according to all relevant characteristics of adenomas removed during 
colonoscopy) and to a lesser extent on sex and age. While some patients with risk 
score 0 should receive a surveillance colonoscopy after 10 years, some patients with 
risk scores 4 and 5 should receive a surveillance colonoscopy after only 2 years. 
Surveillance should no longer be recommended in patients with risk score 0 aged 70 
years or older, patients with risk score 1 and males with risk score 2 aged 75 years or 
older, and higher-risk patients aged 80 years or older.
Several important predictors of advanced adenoma recurrence in newly diagnosed 
adenoma patients have been identified.[2 3] These predictors include characteristics of 
adenomas removed during colonoscopy: the presence of multiple, large (≥10mm), villous, 
and proximal adenomas, as well as patient characteristics: male sex and older age. The 
identification of these predictors allows for extensive risk stratification of adenoma 
patients followed by careful tailoring of surveillance recommendations. However, most 
surveillance guidelines do not consider all relevant predictors and are thus restricted in 
providing tailored recommendations.
In prior work, we analyzed data from a cohort of Dutch adenoma patients to develop a 
score chart that can be used to risk-stratify adenoma patients according to all relevant 
characteristics of adenomas removed during colonoscopy.[4] This chart results in an 
“adenoma risk score” for each patient (range: 0-5). In the study described in this thesis, we 
modeled a cohort of adenoma patients for each combination of adenoma risk score (0-5), 
sex (men/ women), and age (40/ 45/ (…)/ 80 years).[5] Within each cohort, we simulated 
colonoscopy surveillance every 1 up to 10 years as well as referral to the Dutch national 
CRC screening program from the first subsequent screen eligible age onwards and after a 
minimum of 10 years. For each cohort, we selected the optimal surveillance strategy using 
a cost-effectiveness threshold equal to the incremental cost-effectiveness ratio of the 
Dutch National CRC Screening program. The appropriate interval for a first surveillance 
colonoscopy was the surveillance interval corresponding with the strategy selected. This 
analysis showed that the appropriate interval for colonoscopy surveillance depends 
heavily on a patient’s adenoma risk score and to a lesser extent on sex and age. While 
some patients with risk score 0 should receive a surveillance colonoscopy after 10 years, 
some patients with risk scores 4 and 5 should receive a surveillance colonoscopy after only 
2 years. The analysis also showed that existing surveillance guidelines do not consistently 
target colonoscopies at those patients most likely to benefit. According to the 2002 Dutch 
guidelines, which were based on adenoma multiplicity only, for example, a 60 year-old 
female with 3 small, non-villous, distal adenomas was recommended colonoscopy 
surveillance after 3 years, while a 60 year-old female with 2 large, villous, proximal 
adenomas was recommended colonoscopy surveillance after 6 years. [6] However, 
according to our analysis, the former patient (who has an adenoma risk score of 1) should 
be recommended colonoscopy surveillance after 7 years, while the latter patient (who has 
an adenoma risk score of 4) should be recommended colonoscopy surveillance after 3 
years: almost the exact opposite. Results were robust to variations in the overall level of 
health care costs in a country. However, applying higher cost-effectiveness thresholds 
resulted in substantially more intensive surveillance recommendations, particularly in 
those with a low adenoma risk score. The Dutch guidelines for surveillance in adenoma 
patients were revisited based on the results of our study in May 2013.[7]
Is more intensive colonoscopy screening than recommended favorable for Medicare 
beneficiaries and, if so, is it efficient from a societal perspective?
Screening average-risk Medicare beneficiaries more intensively than recommended is 
often associated with a net harm and is always inefficient from a societal perspective.
In current practice, many US Medicare beneficiaries (i.e., US individuals aged 65 years and 
older) receive more intensive colonoscopy screening than recommended: 20% of 
beneficiaries with a negative screening colonoscopy result receive a repeated screening 
colonoscopy within 5 year’s time instead of after the recommended 10 years.[8 9] 
Moreover, 25% of beneficiaries with a negative screening colonoscopy result at age 75 
years or older receive yet another screening colonoscopy at an even more advanced age. 
Although the reasons for these practices might vary, sometimes they are likely to result 
from the beneficiary’s or clinician’s perception that screening should occur more 
frequently than recommended.
We modeled a cohort of 65 year-old, average-risk Medicare beneficiaries with a negative 
screening colonoscopy at age 55 years and compared colonoscopy screening as 
recommended by guidelines (i.e., at ages 65 and 75 years) with scenarios of more intensive 
screening in which either a shorter screening interval was applied or in which screening 
was continued after age 75 years.[10] This comparison showed that more intensive 
screening than recommended generally results in only small increases in the benefits of 
screening (i.e., CRC cases prevented, CRC deaths prevented, and LYs gained) compared 
with the increases in the burden and harms associated with screening (i.e., colonoscopies 
performed and complications experienced). As a result, most scenarios of more intensive 
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screening than recommended were associated with a net harm (i.e., QALYs lost), rather 
than a net health benefit (i.e., QALYs gained). The only scenario that resulted in a net health 
benefit (i.e., colonoscopy screening every 5 instead of 10 years) was very inefficient from a 
societal perspective, requiring 909 additional colonoscopies and an additional $711,000 
per additional QALY gained. Results in beneficiaries without prior screening were only 
slightly less unfavorable. Results in individuals at high risk for CRC, however, were substantially 
more favorable; indicating that more intensive colonoscopy screening than recommended 
might be justified in those at high risk.
Should CRC screening be considered in elderly individuals without previous screening? 
If so, up to what age and which screening test should be used at what age?
Screening elderly individuals without previous screening should be considered well 
beyond age 75 years. Screening remains cost-effective up to age 86 years in individuals 
with no comorbidity, up to age 83 years in individuals with moderate comorbidity, 
and up to age 80 years in individuals with severe comorbidity. At most ages, 
a screening colonoscopy is indicated.  
In its most recent recommendation statement on CRC screening, the US Preventive 
Services Task Force (USPSTF) recommends against routine screening in individuals aged 
older than 75 years with an adequate screening history.[11] Although the USPSTF did not 
address screening in inadequately screened individuals, this recommendation has led 
many members of the medical community to believe that no one aged older than 75 
years should be screened for CRC. However, since unscreened elderly individuals (a group 
representing 23% of all US elderly individuals) are at substantially higher risk for CRC than 
those who are adequately screened, screening them is likely to be cost-effective up to a 
more advanced age.
We modeled a cohort of elderly individuals without previous screening for each combination 
of age (76-90 years) and comorbidity status (no/ moderate/ severe comorbidity).[12] 
In these cohorts, we modeled one-time colonoscopy, one-time sigmoidoscopy, and 
one-time FIT screening. This showed that screening previously unscreened individuals 
remains cost- effective well beyond age 75 years. The maximum age at which screening 
was cost- effective was 86 years for individuals with no comorbidity, 83 years for individuals 
with moderate comorbidity, and 80 years for individuals with severe comorbidity. 
In unscreened individuals with no comorbidity, a screening colonoscopy was most 
effective and still cost-effective up to age 83 years, a screening sigmoidoscopy was 
indicated at age 84 years, and FIT screening was indicated at ages 85 and 86 years. In those 
with moderate comorbidity, a screening colonoscopy was indicated up to age 80 years, 
a screening sigmoidoscopy was indicated at age 81 years, and FIT screening was indicated 
at ages 82 and 83 years. Finally, in those with severe comorbidity, a screening colonoscopy 
was indicated up to age 77 years, a screening sigmoidoscopy was indicated at age 78 years, 
and FIT screening was indicated at ages 79 and 80 years. Results were most sensitive to the 
cost-effectiveness threshold applied. Applying a threshold of $50,000 instead of $100,000 
per QALY gained resulted in upper ages for screening that were 2 to 3 years lower than 
those stated above.
Why should decisions on cancer screening be personalized and how can personalized 
screening recommendations be derived?
Screening history, comorbidity status, and background risk for CRC are important 
determinants of the effectiveness of CRC screening. Disease simulation models can 
be used to integrate estimates of cancer risk, life expectancy, and screening efficacy 
into clinically meaningful estimates of the benefits of screening.
An important emerging model for screening is personalization. In this approach, individual 
patient characteristics are used to project the benefits, burden, harms, and sometimes 
also the costs of screening. This information is subsequently used to guide clinical deci-
sion-making. Personalization has the potential to improve cancer outcomes while 
reducing the harms of screening and preserving scarce health care resources. Yet, all to 
often, the US health care system fails to personalize screening in even the most rudimentary 
way. For example, a recent study found that 75 year-old individuals with severe comorbidity 
were nearly twice as likely to be screened for CRC than 76 year-old individuals with no 
comorbidity, even though healthy 76 year-olds tend to live longer and, hence, gain greater 
benefit from screening.[13] In another study, 48% of primary care physicians reported that 
they would recommend breast cancer screening for women diagnosed with terminal 
lung cancer:[14] a group of patients for whom screening cannot provide any benefit, may 
cause harm, and is a waste of resources.
We modeled one-time colonoscopy screening in a cohort of 75 year-old, white women 
with a negative screening colonoscopy 10 years prior, no comorbidity, and an average 
background risk for CRC.[15] Subsequently, we varied all patient characteristics (i.e., age, 
sex, race, screening history, comorbidity status, and background risk for CRC) in a 
one-by-one fashion. This showed that screening history, comorbidity status, and 
background risk for CRC are equally or more important determinants of the effectiveness 
of screening than age. The effects of sex and race were less pronounced. The analysis also 
demonstrated how disease simulation models can be used integrate estimates of cancer 
risk, life expectancy, and screening efficacy into clinically meaningful estimates of the 
effectiveness of screening and, hence, to derive personalized screening recommendations. 
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What is the appropriate age to stop colonoscopy screening given an individual’s 
sex, race, screening history, background risk for CRC, and comorbidity status?
The appropriate age to stop colonoscopy screening depends heavily on an individual’s 
screening history, background risk for CRC, and comorbidity status. While screening 
some previously screened, low-risk individuals was not even cost-effective at age 
66 years, screening some, healthy, high-risk individuals remained cost-effective 
 up to age 88 years.
In concordance with existing age-based guidelines and performance measures for CRC 
screening, many US clinicians make their decisions on CRC screening for elderly individuals 
primarily on the basis of age.[13] Other factors that influence the effectiveness of screening, 
such as sex, race, screening history, background risk for CRC, and comorbidity status are 
often ignored. As a result, CRC screening might not always be targeted at those individuals 
most likely to benefit.
We modeled a cohort of individuals for each combination of age (66-90 years), sex (men/ 
women), race (black/ white), screening history (a negative screening colonoscopy 10 years 
prior/ 15 years prior/ 20 years prior/ no prior screening), background risk for CRC (white 
men: 17 levels, white women: 14 levels, black men: 18 levels, black women: 15 levels), and 
comorbidity status (no/ moderate/ severe comorbidity) (a total of 19,200 cohorts).[16] 
Within these cohorts we modeled one-time colonoscopy screening. This showed that 
screening remains cost-effective up to a substantially older age in individuals without 
prior screening compared with individuals with prior screening, in individuals with a high 
background risk for CRC compared with individuals with a low background risk for CRC, 
and in individuals without comorbidity compared with individuals with comorbidity. In 
contrast, the effects of sex and race on the appropriate age to stop screening were small. 
Our analysis also demonstrated that the current age-based approach to screening results 
in overuse of screening in some and underuse of screening in others. For example, we 
found screening 81 year-old black men with no comorbidity, an average background risk 
for CRC, and no previous screening (a group unlikely to be screened in current practice) to 
be highly cost-effective (ICER: $50,000/ QALY gained). In contrast, we found screening 74 
year-old white women with moderate comorbidity, half the average background risk for 
CRC, and a negative screening colonoscopy 10 years prior (a group likely to be screened in 
current practice) to be harmful. While screening some previously screened, low-risk 
individuals was not even cost-effective at age 66 years, screening some, healthy, high-risk 
individuals remained cost-effective up to age 88 years. Results were most sensitive to 
the cost-effectiveness threshold that was applied: applying a threshold of $50,000 instead 
of $100,000 per QALY gained reduced the maximum age at which screening was 
cost-effective by an average of 3 years.
What would be the effect of personalizing colonoscopy screening in the Medicare 
population on population health and Medicare spending?
The potential effect of personalizing colonoscopy screening in the Medicare population 
is large: compared with uniform age-based screening either tens of thousands of 
additional CRC deaths can be prevented or billions of dollars can be saved.
In current practice, decisions on CRC screening are often based solely on age: individuals 
aged 75 years or younger are offered screening, whereas individuals aged older than 
75 years are not.[13] Studies have shown that screening could be more cost-effective if 
individual patient characteristics, such as sex, race, screening history, and comorbidity 
status, were considered.[16] However, the order of magnitude of the benefit that could be 
achieved by personalizing screening decisions is unclear.
We used data on the cost-effectiveness of colonoscopy screening by age, sex, race, 
screening history, and comorbidity status (see the previous paragraph) to construct four 
scenarios of personalized screening with increasing screening intensity.[17] To do so, we 
determined the appropriate ages to stop colonoscopy screening according to sex, race, 
screening history, and comorbidity status using four distinct cost-effectiveness thresholds: 
$25,000, $50,000, $75,000, and $100,000 per QALY gained. We then modeled the 2013 US 
Medicare population by age, sex, race, screening history, and comorbidity status and 
compared the undiscounted life-time Medicare costs and CRC deaths prevented under 
the four scenarios of personalized colonoscopy screening with the costs and CRC deaths 
prevented by uniform age-based colonoscopy screening up to age 75 years. This showed 
that personalized colonoscopy screening is substantially more efficient than uniform 
age-based screening. In the current Medicare population, personalizing colonoscopy 
screening could potentially prevent 21,200 additional CRC deaths (+11%) or save $1,500M 
(-84%). This is assuming that everyone in whom screening is cost-effective would be 
willing to have future colonoscopy screening, also those without prior screening.
THE SYNERGY BETWEEN TRIALS AND MODELS
How trials are used to inform models
The process of building a disease model can be subdivided into three steps. The first step 
is to identify all disease stages that should be modeled. The second step is to inform the 
transitions between disease stages using all relevant data that is available. The third step is 
to consult experts in order to make assumptions for those characteristics of the disease 
process that are unknown and sometimes even unobservable. 
After a disease model has been build, it should be properly maintained. This implies that 
every time new data becomes available, the assumptions made in the model should be 
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tested against that data. If the outcomes of the model correspond with the data, the 
model is “validated” against the data. If the outcomes of the model do not correspond 
with the data, at least one assumption made in the model must be wrong. In this case, the 
assumption most likely to be wrong should be identified and the model parameters 
corresponding to this assumption should be changed. Usually new parameter values are 
determined by “calibrating” the model against the new data. During this process different 
sets of parameter values are explored and the parameter set for which the model 
outcomes show the best fit with the observed data is selected. We will illustrate the 
process of validating and calibrating a model using an example. 
In 2010, the long-term outcomes of the U.K. Flexible Sigmoidoscopy Screening (UKFSS) 
trial were published.[18] Within this RCT, one-time sigmoidoscopy screening in average-risk 
individuals was compared with no screening. Among the outcomes reported in the paper 
was the cumulative incidence of distal CRC. We figured that this incidence could give us 
important information about the time it takes a progressive adenoma to develop into 
CRC (i.e., the adenoma dwell-time).
During sigmoidoscopy screening, most adenomas and preclinical cancers prevalent in 
the distal colon are detected and removed or treated. As a result, during follow-up, the 
incidence of distal CRC in the intervention group of a sigmoidoscopy screening trial is 
lower than that in the control group. Exactly how low the distal CRC incidence in the 
intervention group is, depends on the adenoma dwell-time. The longer the adenoma 
dwell-time, the lower the incidence of distal CRC. However, the incidence of distal CRC in 
the intervention group also depends on other factors, such as the attendance to screening 
and diagnostic and surveillance colonoscopies, the sensitivity of sigmoidoscopy and 
colonoscopy for the detection of adenomas and CRC, the reach of sigmoidoscopy and 
colonoscopy, the age-distribution of the population screened, etcetera. By exactly 
mimicking the UKFSS trial in MISCAN-Colon and comparing the simulated incidence of 
distal CRC with that observed in the trial, we could determine whether the mean adenoma 
dwell-time in our model of 7.6 years, which was based on expert opinion, was either 
correct, too short, or too long. 
After simulating the UKFSS, we observed that the distal CRC incidence simulated by the 
model was substantially higher than that seen in the trial, indicating that the adenoma 
dwell-time in MISCAN-Colon was too short. Therefore, we decided to calibrate the 
adenoma dwell-time in our model to the distal CRC incidence observed in the trial. This 
resulted in an estimate for the mean adenoma dwell-time of 12.5 years (+4.9 years [+64%] 
compared with the old mean adenoma dwell-time). When we simulated the UKFSS trial 
using the new adenoma dwell-time, the simulated distal CRC incidence nicely matched 
that observed in the trial (Model Appendix, Figure 4). In all papers described in this 
thesis, the MISCAN-Colon model with the newly calibrated, longer adenoma dwell-time 
was used.
How models can also be used to inform trials
The adenoma dwell-time is an important determinant of the effectiveness of CRC 
screening, particularly of screening using colonoscopy, which is the screening modality 
relying most on the detection and removal of adenomas versus the early detection of 
CRC. The adenoma dwell-time is also an important determinant of the optimal distribution 
of screening examinations over an individual’s lifespan, again particularly for colonoscopy 
screening. Based on the results of an analysis performed with 2 micro-simulation models, 
one of which was the MISCAN-Colon model with the old, short adenoma dwell-time, the 
USPSTF has been recommending 10-yearly colonoscopy screening starting at age 50 
years and continuing up to age 75 years (i.e., screening at ages 50, 60, and 70 years) since 
2008.[11 19] However, a longer adenoma dwell-time implies that more cancers that 
develop later in life are already present in the form of an adenoma at a relatively young 
age. Hence, a screening colonoscopy at a relative young age is likely to prevent more 
future cancers than we expected based on our old model and a younger age to start 
screening than 50 years could be indicated.
A recent analysis (again performed for the USPSTF) using the new MISCAN-Colon model, 
confirms this hypothesis: in most of the colonoscopy screening strategies found to be 
efficient, the first screening examination takes place at age 45 years instead of age 50 
years.[20] However, this finding was insufficient for the USPSTF to recommend an earlier 
age to start colonoscopy screening. The task force states that: “there continues to be 
insufficient empiric data to support lowering the recommended age to begin colorectal 
cancer screening from 50 to 45”.[21] Hence, studies should be conducted to evaluate the 
effectiveness of starting colonoscopy screening at age 45 years instead of age 50 years. 
 
Why modelers and trialists should cooperate
The example described above shows that modelers need trials to inform their models and 
that trialists can benefit from modeling work to inform their trials. Hence, modelers and 
trialists should cooperate. At the Department of Public Health of the Erasmus University 
Medical Center we try to lead by example in that respect. First, we have got a long-lasting, 
intensive collaboration with the Department of Gastroenterology and Hepatology of the 
Erasmus University Medical Center. Second, whenever the results of modeling work for 
external clinical parties prompts a trial to be conducted, we will work together with those 
external parties to try and obtain funding for such a trial. Finally, we obtained funding 
from the Dutch National Institute for Public Health and the Environment to monitor and 
evaluate the Dutch national CRC screening program. This allows us to test the assumptions 
made in MISCAN-Colon using data from the program. The other way around, the Dutch 
National Institute for Public Health and the Environment can ask us to perform modeling 
analyses whenever important decisions about the screening program have to be made, 
as they did when a shortage of colonoscopy capacity was imminent in 2014 (see Chapter 2). 
We feel that it is important for trialists, modelers, as well as funders of health care research to 
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know that cooperation between trialists and modelers offers many advantages. Without 
the use of trial data, it is impossible to make a good model. Without the use of models, 
on the other hand, trial data cannot be extrapolated and trials will not have their maximum 
effect on health.
FUTURE RESEARCH DIRECTIONS
Cancer screening in general, and CRC screening in particular, is a rapidly developing field. 
Many countries are in the process of implementing CRC screening programs and 
personalized medicine is a topic of growing interest. Some topics we expect to be working 
on in the near future are mentioned below.
Identify optimal screening programs given local conditions in different countries
Remarkable differences are observed when comparing the CRC screening programs that 
are implemented across the world.[22] For example, in Europe alone, the Netherlands 
invites individuals for FIT screening, whereas regions of Belgium, regions of Italy, and 
Poland offer gFOBT, sigmoidoscopy, and colonoscopy screening, respectively. Another 
source of discrepancy is the target population invited for screening. For example, in some 
countries, such as Finland and Sweden, screening is confined to individuals aged between 
60 and 69 years, whereas in other countries, such as Denmark and Estonia, a clearly larger 
range of at risk individuals is covered by screening (i.e., everyone age between 50 and 74 
years). Finally, even in countries offering the same screening test, different screening 
intervals are applied: while most countries that offer gFOBT screening invite individuals 
every 2 years, Latvia offers yearly gFOBT screening.
Given the different background risk for CRC, the different life expectancy, the different 
costs of screening tests and CRC care, and the different amounts of resources available in 
different countries, implementing the same screening program in all countries is neither 
optimal nor feasible. In many of the examples above, however, there is no plausible reason 
for the differences in CRC screening programs that are observed. Models such as 
MISCAN-Colon could be used to determine optimal CRC screening programs given the 
local conditions in different countries. Similar research might be conducted for other 
forms of cancer screening.
Determine the appropriate interval for subsequent surveillance colonoscopies in 
adenoma patients and personalize the age to stop surveillance
In Chapter 3 of this thesis, we determined the appropriate interval for a first surveillance 
colonoscopy in adenoma patients given their adenoma risk score, sex, and age.[5] 
Although this is often considered to be the most important clinical decision to be made 
in adenoma patients, most patients will have to undergo multiple surveillance 
colonoscopies over the course of their lives. To determine the appropriate intervals for 
subsequent surveillance colonoscopies, a study is required that quantifies the risk for 
advanced adenoma recurrence based on findings during index colonoscopy and at least 
one surveillance colonoscopy. To obtain sufficient power to perform such a study, data 
from several existing cohorts of adenoma patients have to be pooled.[2 3] If such a study 
shows that only adenoma findings at index colonoscopy are important, the new 
surveillance interval can be read from Table 4 in Chapter 3 using the adenoma risk score 
at index colonoscopy and the sex and actual age of the patient. If the study shows that 
only adenoma findings during the last surveillance colonoscopy are important, the new 
surveillance interval can be read from the table using the adenoma risk score corresponding 
with the most recent surveillance colonoscopy and the sex and actual age of the patient. 
If findings during both colonoscopies are important, the new surveillance interval will lie 
somewhere in between these surveillance intervals. In this case, a new modeling study 
could be performed to determine the appropriate interval for a surveillance colonoscopy 
given the adenoma risk scores on two or more previous colonoscopies.
Another way to improve surveillance recommendations would be to personalize the age 
to stop surveillance according to a patient’s comorbidity status. The ages resulting from 
the analysis described in Chapter 3 of this thesis might be slightly too low for adenoma 
patients with no or mild comorbidity and slightly too high for patients with moderate or 
severe comorbidity. 
Further personalize CRC screening recommendations  
In Chapter 7 of this thesis, we described a study in which we personalized the age to stop 
colonoscopy screening in US elderly individuals according to their sex, race, screening 
history, comorbidity status, and background risk for CRC.[16] This study could be extended 
in several directions. First, for each group of patients, one could determine the costs and 
effects of other screening modalities than colonoscopy and determine which screening 
test is optimal given an individual’s characteristics (as we did for previously unscreened 
elderly individuals in Chapter 5 of this thesis).[12] Second, screening recommendations 
could also be personalized based on an individual’s preferences (for one screening test 
over another, for example). Finally, analyses could be performed that not only aim to 
personalize the age to stop screening, but also the age to start screening and the screening 
interval.
In the United States an opportunistic approach to screening is used. That is, the system 
relies on the patient and the health care provider to remember that screening should take 
place. Hence, patients and providers generally meet before screening is offered. This 
would be the obvious moment for personalization. The Netherlands, on the other hand, 
has an organized CRC screening program. That is, all individuals with a certain age in a 
certain year are automatically offered screening. This organized approach offers several 
advantages compared with an opportunistic approach to screening: participation is 
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generally higher and everyone has an equal chance to participate in screening, which 
many regard as being equitable. However, because screening is offered automatically, 
implementing personalized screening might be harder. Nonetheless, the National Institute 
for Public Health and the Environment might consider offering elderly individuals the 
opportunity to fill out an online questionnaire that helps them to determine whether 
screening is still worthwhile in their situation. Another possibility for personalization in the 
Dutch national screening program that could be explored, is to relate the interval for a 
next FIT to the hemoglobin concentration measured during FIT screening. 
Continue to improve MISCAN-Colon
As described above and in the Model Appendix, MISCAN-Colon has been validated and, 
if needed, calibrated to the results of several large trials on the effectiveness of CRC 
screening and surveillance in adenoma patients. For example, data from the Nottingham, 
Minnesota, and Funen trials on the effectiveness of gFOBT screening have been used to 
estimate the average preclinical duration of CRC. Similarly, data from the UKFSS trial on the 
effectiveness of 1-time sigmoidoscopy screening have been used to estimate the average 
adenoma dwell-time. It is of the utmost importance to keep testing the assumptions 
made in MISCAN-Colon against the new evidence that becomes available. 
 In the near future, we expect to be able to test our assumptions regarding the risks for 
two consecutive false positive or false negative FIT screening results. Currently, we assume 
that individuals with a false positive or false negative test result are not at increased risk for 
another false positive or false negative test result. However, based on data from multiple 
rounds of the Dutch FIT screening trials, it appears that those with a false positive test 
result are at increased risk of having another false positive test result (probably because 
they suffer from another condition which causes bleeding, such as hemorrhoids) and that 
those with a false negative test result are at increased risk of having another false negative 
test result (probably because they have a type of adenoma that is less likely to bleed). 
We also expect to be able to test our assumptions regarding the adenoma dwell-time in 
the proximal colon. Currently, we assume that this dwell-time is equal to the adenoma 
dwell-time in the distal colon. However, this assumption should be tested against the 
outcomes of the colonoscopy screening studies that are underway. If the adenoma 
dwell-time in the proximal colon differs from the adenoma dwell-time in the distal colon, 
we would need to model distal and proximal adenomas using different transition 
probabilities and durations in states. We should grasp this opportunity to also simulate the 
distribution of adenomas over the colorectum correctly. Currently, we use the simple 
assumption that this distribution of adenomas over the colorectum is equal to the 
distribution of CRC. 
Furthermore, in the near future, we expect to be able to add a separate pathway for sessile 
serrated lesions to our model. This pathway is estimated to account for one-third of all CRC 
cases (two-third is accounted for by the adenoma-carcinoma pathway). Sessile serrated 
lesions are often flat or depressed, making them more difficult to detect with endoscopy. 
If they also differ from adenomas in other respects, such as the survival associated with 
the cancers that they cause, this might affect the cost-effectiveness of CRC screening in 
general and the specific CRC screening programs that should be recommended in certain 
settings. We also expect to be able to add the adenoma characteristics dysplasia and 
villous aspect to our model.  
 Finally, we should continue to update the input parameters used in MISCAN-Colon. 
Priority should be given to the costs of CRC care for both the US and the Netherlands, the 
CRC survival probabilities for the Netherlands, and all utility losses, since the data that are 
currently used are dated and some utility losses are still based on expert opinion. 
CONCLUSIONS AND RECOMMENDATIONS
Based on the results of the studies described in this thesis, we derived the following 
conclusions:
- Decision models provide a useful tool to extrapolate evidence from RCTs and inform 
decisions about CRC screening programs. (Chapter 2)
- The appropriate interval for a first surveillance colonoscopy in adenoma patients 
depends heavily on a patient’s adenoma risk score (i.e., risk according to all relevant 
characteristics of adenomas removed during colonoscopy) and to a lesser extent on sex 
and race. While some patients with risk score 0 should receive a surveillance colonoscopy 
after 10 years, some patients with risk scores 4 and 5 should receive a surveillance 
colonoscopy after only 2 years. Personalizing surveillance using the adenoma risk score 
targets colonoscopies at those patients most likely to benefit. (Chapter 3)
- Screening can have negative effects on quality-of-life. As a result, more intensive 
screening is not always better. More intensive colonoscopy screening than recommended 
in average-risk US Medicare beneficiaries, for example, is often harmful and always 
inefficient. (Chapter 4) 
- An individual’s screening history is an important determinant of the effectiveness and 
cost-effectiveness of CRC screening. In contrast with adequately screened individuals, 
screening previously unscreened individuals remains cost-effective well beyond age 75 
years: up to age 86 years in those with no comorbidity, 83 years in those with moderate 
comorbidity, and 80 years in those with severe comorbidity. A screening colonoscopy is 
indicated at most ages. (Chapter 5)
- Disease simulation models can be used to integrate estimates of cancer risk, life 
expectancy, and screening efficacy into clinically meaningful estimates of the 
effectiveness of screening and, hence, to derive personalized screening recommenda-
tions. (Chapter 6)
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- Besides screening history, an individual’s comorbidity status and background risk for 
CRC are also important determinants of the effectiveness and cost-effectiveness of CRC 
screening. While colonoscopy screening is not even cost-effective at age 66 years in 
some, low-risk individuals, it remains cost-effective up to age 88 years in some previously 
unscreened, healthy, high-risk individuals. (Chapter 7) 
- The potential effects of personalizing screening are large. On the Medicare population- 
level, personalizing colonoscopy screening could potentially prevent tens of thousands 
of additional CRC deaths or save billions of dollars. (Chapter 8)
Based on these conclusions, we formulated the following recommendations:
- Decision models should be used more frequently to inform decisions about screening.
- When making decisions about surveillance in newly diagnosed adenoma patients all 
relevant characteristics of adenomas removed during colonoscopy should be considered. 
This can be achieved by using the adenoma risk score.
- When evaluating screening, effects on quality of life must be considered. Not considering 
effects on quality of life can lead to wrong decisions.  
- More intensive screening than recommended can be harmful. The current practice of 
more intensive colonoscopy screening than recommended in Medicare beneficiaries 
should be actively discouraged.
- When making decisions about stopping CRC screening, an individual’s screening history, 
comorbidity status, and background risk for CRC should be considered. CRC screening 
guidelines should provide guidance on the appropriate age to stop screening according 
to these factors.
- Efforts should be made to overcome barriers to the implementation of personalized 
CRC screening in clinical practice, also in the Netherlands.
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MISCAN-COLON
General Model Structure
In all chapters of this thesis, the MISCAN-Colon model was used. MISCAN-Colon is a 
stochastic microsimulation model for colorectal cancer (CRC) programmed in Delphi 
(Borland Software Corporation, Scotts Valley, California, United States). It can be used to 
explain and predict trends in CRC incidence and mortality and to quantify the effects and 
costs of primary prevention of CRC, screening for CRC, and surveillance after polypectomy. 
The term ‘microsimulation’ implies that individuals are moved through the model one at 
a time, rather than as proportions of a cohort. This allows future state transitions to depend 
on past transitions, giving the model a ‘memory’. Furthermore, unlike most traditional 
Markov models, MISCAN-Colon does not use yearly transition probabilities. Instead it 
generates durations in states, thereby increasing model flexibility and computational 
performance. The term ‘stochastic’ implies that the model simulates sequences of events 
by drawing from distributions of probabilities/ durations, rather than using fixed values. 
Hence, the results of the model are subject to random variation.
MISCAN-Colon consists of 3 modules: a demography module, a natural history module, 
and a screening and surveillance module.
The Demography Module
Using birth- and life-tables representative for the population under consideration, 
MISCAN-Colon draws a date of birth and a date of non-CRC death for each individual 
simulated (see Table 1 for an overview of the data used in the different chapters). In 
MISCAN-Colon the maximum age an individual can achieve is exactly 100 years.
The Natural History Module
Transitions
As each simulated person ages, one or more adenomas may develop (Figure 1). These 
adenomas can be progressive or non-progressive. Both progressive and non-progressive 
adenomas can grow in size from small (≤5mm), to medium (6-9mm), to large (≥10mm). 
However, only progressive adenomas can develop into preclinical cancer. A preclinical 
cancer may progress through stages I to IV. However, during each stage CRC may be 
diagnosed because of symptoms. Survival after clinical diagnosis is determined by the 
stage of the cancer at diagnosis, the localization of the cancer, and the patient’s age and 
is based on CRC survival data observed in the population under consideration (Table 1). 
For individuals with synchronous CRCs at time of diagnosis, the survival of the most 
advanced cancer is used. The date of death for individuals with CRC is set to the earliest 
simulated death (either due to CRC or due to another cause (see: ‘The demography 
module’). 
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Transition Probabilities and Durations in States
An individual’s risk of developing adenomas depends on the individual’s age and a 
personal risk index. As a result of the latter most individuals develop no adenomas, whilst 
some develop many. We assumed that the distribution of adenomas over the colorectum 
equaled the distribution of cancers as observed in the population under consideration 
before the introduction of screening (Table 1). The age-specific onset of adenomas and 
the dispersion of the personal risk index were calibrated to data on the age-specific 
prevalence and multiplicity distribution of adenomas as observed in autopsy/ colonoscopy 
studies (see Table 1 for an overview of the data used in the different chapters and Figure 2 
for calibration results). The age-specific probability of adenoma-progressivity and the 
age- and localization-specific transition probabilities between preclinical cancer stages 
and between preclinical and clinical cancer stages were simultaneously calibrated to the 
age-, stage-, and localization-specific incidence of CRC as observed in the population 
under consideration, again before the introduction of screening (Table 1 and Figure 3). 
The average durations of the preclinical cancer stages were calibrated to the rates of 
screen-detected and interval cancers observed in randomized controlled trials evaluating 
screening using gFOBT[1-4]. The average total preclinical duration of the preclinical cancer 
stages was found to be 4.7 years. The average duration from the emergence of an 
adenoma (state 2) until progression into preclinical cancer (state 7) (i.e. the adenoma 
dwell-time) was calibrated to the interval cancer rates observed in a randomized controlled 
trial evaluating once-only sigmoidoscopy screening and was found to be 12.5 years 
Figure 1   The general model structure of MISCAN-Colon.
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(Figure 4, see also Chapter 9).[5] We assumed an equal overall dwell-time for adenomas 
developing into CRC from a medium size (30% of all CRCs) and from a large size (70% of all 
CRCs). The durations of the preclinical cancer stages as well as the adenoma dwell-time 
were assumed to be equal in all populations modeled in this thesis. 
All durations in the adenoma and preclinical cancer phase are drawn from exponential 
distributions. Durations within the adenoma phase and within the preclinical cancer 
phase are assumed to be perfectly correlated (i.e. if a small adenoma grows into a 
medium-sized adenoma rapidly, it will also grow into a large adenoma or develop into 
CRC rapidly); however, durations in the adenoma phase are assumed to be uncorrelated 
with durations in the preclinical cancer phase (i.e. a rapidly growing adenoma does not 
necessarily develop into a rapidly progressing cancer).  The proportion of medium sized, 
non-progressive adenomas growing large and the average duration in the medium size, 
non-progressive adenoma state (state 5) were calibrated to size-specific adenoma 
detection rates observed in a Dutch randomized controlled trial on colonoscopy screening 
(data not shown).[6]
We validated MISCAN-Colon against the long-term mortality outcomes of the National 
Polyp Study: a study assessing the effectiveness of colonoscopic polypectomy. The model 
showed good concordance with the mortality rates observed (Figure 5).[7]  
Figure 2   Calibration results: adenoma prevalence observed in selected autopsy studies 
versus simulated by MISCAN-Colon in Chapter 3 (A), Chapters 4 and 5 (B), 
and Chapters 6 and 7 (C) of this thesis.*
*Stage- and localization-specific model outcomes also showed good concordance with observed data.
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The Screening and Surveillance Module
Screening and surveillance will alter some of the simulated life histories: Some cancers will 
be prevented by the detection and removal of adenomas; other cancers will be detected 
in an earlier stage with a more favorable survival. Because the stage-specific survival of 
screen-detected CRC as observed in randomized controlled trials on guaiac fecal occult 
blood testing was substantially more favorable than that of clinically detected CRC, even 
after correcting for lead-time bias,[4] we assigned those screen-detected and surveillance- 
detected cancers that would have been clinically detected in the same stage a survival 
corresponding to a one stage less progressive cancer. Hence, a cancer detected in stage II, 
that would also have been clinically diagnosed in stage II, is assigned the survival of a 
clinically diagnosed stage I cancer. The only exceptions are stage IV cancers. These cancers 
are always assigned the survival of a clinically diagnosed stage IV cancer. 
Besides modeling positive health effects of screening and surveillance, we also model 
colonoscopy-related complications and over-diagnosis and over-treatment of CRC 
(i.e. the detection and treatment of cancers that would not have been diagnosed without 
screening/ surveillance).[8]
Figure 3   Calibration results: CRC incidence observed in the populations under 
 consideration versus simulated by MISCAN-Colon in Chapter 3 (A),  
Chapters 4 and 5 (B), and Chapters 6 and 7 (C) of this thesis.*
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Integrating Modules
Within MISCAN-Colon the results of the demography module, the natural history module, 
and the screening and surveillance module are integrated. In the demography module 
dates of birth and a dates of non-CRC death are generated. In the natural history module 
adenomas and CRCs are added to some of the generated life histories. In the screening 
and surveillance module screening and surveillance are superimposed to the life histories 
with adenomas and CRC. By comparing the life histories without screening and surveillance 
with the life histories with screening and surveillance, MISCAN-Colon quantifies the effects 
and costs of screening.  
In Patient A in Figure 6, the natural history module generates an adenoma. This adenoma 
progresses into cancer, is diagnosed in stage II, and results in CRC death before non-CRC 
death would have occurred. In the screening module a screening examination is simulated, 
indicated by the vertical arrow. During this examination the adenoma is detected, and as 
a result both CRC and CRC death are prevented. Hence, in Patient A, screening prolongs 
life by the amount indicated by the horizontal arrow. Patient B in Figure 6 also develops 
an adenoma. This adenoma has the potential to progress into preclinical cancer. However, 
patient B would never have been diagnosed with CRC in a scenario without screening, 
because he would have died from another cause before the cancer would have been 
diagnosed (see life history 2). During the screening examination simulated in the screening 
module, again indicated by the vertical arrow, CRC is screen-detected in stage I. Hence, in 
patient B, screening results in over-diagnosis of CRC: it detects a cancer that would never 
have been diagnosed in a scenario without screening. Hence, screening does not prolong 
life, but it does result in additional LYs with CRC care (over-treatment) as indicated by the 
horizontal arrow.
Figure 4   Distal CRC Incidence Observed in the Intervention Group of the UK Flexible 
Sigmoidoscopy Trial Versus Simulated by MISCAN-Colon (per year of follow-up 
(A), cumulative (B)).
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Figure 5   Cumulative CRC Mortality Observed in the National Polyp Study Versus 
 Simulated by MISCAN-Colon.
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Figure 6   Integrating Modules: Two example Patients.
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In most developed countries, colorectal cancer (CRC) is an important public health 
problem. In the Netherlands alone, 13,370 individuals were diagnosed with CRC in 2013. In 
the same year, 4,940 individuals died of the disease. This makes CRC the second most 
common cancer and the second most common cause of cancer-related death in the 
Netherlands today. The lifetime risk of developing CRC in the Netherlands is 4.4%. The 
lifetime risk of dying of the disease is 1.8%. In the US, the relative burden of CRC is 
comparable to that in the Netherlands.
One way to reduce CRC mortality is CRC screening. During screening individuals without 
signs or symptoms are offered a test aimed at detecting unrecognized disease in an early 
stage. CRC is particularly well suited for screening because it has a long pre-clinical 
screen-detectable phase. During this phase, screening can prevent CRC by detecting and 
removing its precursor lesion (i.e., the adenoma) or it might detect CRC in an earlier stage, 
resulting in an improved prognosis. However, screening can also result in serious 
complications and overdiagnosis and overtreatment of cancer (i.e., the detection and 
treatment of cancers that would never have been diagnosed without screening). Multiple 
tests are available for screening. First, there are stool tests: the guaiac fecal occult blood 
test (gFOBT) aimed at detecting any blood in stool, the fecal immunochemical test (FIT) 
aimed at detecting human blood only, and the fecal DNA test aimed at detecting human 
blood as well as mutated DNA from neoplastic cells. Second, there are endoscopic tests: 
sigmoidoscopy, during which the distal end of the colorectum is inspected, and 
colonoscopy, during which the entire colorectum is visualized. Finally, there is an imaging 
test: CT colonography, during which images of the colorectum are inspected for 
anomalies. All screening tests differ from one another in important respects. They differ in 
their acceptability to the population being screened, their ability to detect adenomas and 
CRC, the burden that they cause, the risks they are associated with, and their costs. All tests 
other than colonoscopy require referral to colonoscopy if positive. 
A second way to reduce CRC mortality is surveillance in adenoma patients. Adenoma 
patients are individuals in whom adenomas were detected and removed, either as a result 
of screening or during a colonoscopy indicated because of symptoms. Because adenoma 
patients are at increased risk for CRC compared with the general population, they are 
recommended to undergo more intensive testing using colonoscopy: the test most 
sensitive for detecting adenomas and CRC. 
The Netherlands started rolling out a national CRC screening program in January 2014. Within 
this program, ultimately, all individuals aged 55 up to 75 years will be invited for biennial FIT 
screening. In the US, CRC screening was already introduced in the late 1980s. In contrast with 
the Netherlands, screening in the US is not nationally organized. Instead, most screening is 
carried out ‘opportunistically’: that is, the system relies on the patient and health care provider 
to remember that screening should take place. Another important difference is that in 
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the US, individuals are free to choose between the different screening tests available.
In this thesis, we used a microsimulation model to inform both clinical and policy decisions 
regarding CRC screening and surveillance in adenoma patients. In Chapter 2, we showed 
how models were used to inform decisions about the Dutch national CRC screening 
program. In Chapter 3, we described an analysis that formed the basis of the new Dutch 
guidelines for surveillance in adenoma patients. In Chapter 4, we quantified the effects of 
observed patterns of more intensive colonoscopy screening than recommended in US 
Medicare beneficiaries on the effectiveness and cost-effectiveness of screening. In 
Chapter 5, we studied the cost-effectiveness of CRC screening in US elderly without 
previous screening. In Chapter 6, we showed why the age to stop colonoscopy screening 
should be different for individuals with different characteristics. In Chapter 7, we 
constructed personalized recommendations for colonoscopy screening in US elderly 
individuals. Finally, in Chapter 8 we quantified the effects that personalizing CRC in elderly 
individuals could have on US population health and health care expenditures.  
How models can be used to inform decisions regarding  
screening programs
RCTs are the gold standard for determining the effectiveness of screening, but they 
also have their limitations. First, RCTs are expensive and time consuming. As a result, 
the number of RCTs that have evaluated CRC screening is limited. Second, RCTs usually 
have a limited follow-up time. Hence, they cannot be used to determine lifetime health 
effects and costs, which is necessary to determine the cost-effectiveness of screening. 
Third, the effectiveness of screening in a certain country might differ from that observed 
in an RCT, for example because attendance rates to screening are substantially lower or 
higher. Finally, country-level resource demands for a certain screening program cannot 
easily be inferred from an RCT. To summarize: RCTs alone do not answer the question of 
which screening strategy is optimal for a certain country.
In Chapter 2 of this thesis, we demonstrated that decision models provide a useful tool to 
extrapolate evidence from RCTs during the whole cycle of a screening program, using the 
role MISCAN-Colon played in the Dutch CRC screening program as an example.[1] In the 
decision phase of the Dutch screening program, modeling analyses were used to inform 
the decisions to 1) choose FIT screening over gFOBT screening, 2) choose a higher age to 
start screening than recommended by the Council of Europe, and 3) choose a lower 
cut-off for referral to colonoscopy than recommended by the test’s manufacturer. A 
modeling analysis also informed the decision to temporarily elevate the cut-off for referral 
to colonoscopy when a shortage of colonoscopy capacity was imminent during the first 
year of the program. If modeling would not have been used at these instances, other 
choices could have been made, and the balance between the benefits and harms of the 
screening program could have turned out less favorable than it will now.
Personalizing surveillance in Dutch adenoma patients
Several important predictors of advanced adenoma recurrence in newly diagnosed 
adenoma patients have been identified. These predictors include characteristics of 
adenomas removed during colonoscopy: the presence of multiple, large (≥10mm), villous, 
and proximal adenomas, as well as patient characteristics: male sex and older age. The 
identification of these predictors allows for extensive risk stratification of adenoma 
patients followed by careful tailoring of surveillance recommendations. However, existing 
surveillance guidelines do not consider all relevant predictors and are thus restricted in 
providing tailored recommendations. In prior work, we analyzed data from a cohort of 
Dutch adenoma patients to develop a score chart that can be used to risk-stratify adenoma 
patients according to all relevant characteristics of adenomas removed during colonoscopy. 
This chart results in a so-called ‘adenoma risk score’ for each adenoma patient (range: 0-5).
In Chapter 3 of this thesis, we determined the appropriate interval for colonoscopy 
surveillance in newly diagnosed adenoma patients given their adenoma risk score, sex, 
and age. This analysis showed that the appropriate interval for colonoscopy surveillance 
depends heavily on a patient’s adenoma risk score and to a lesser extent on sex and age. 
While some patients with risk score 0 could receive a surveillance colonoscopy after 10 
years, some patients with risk scores 4 and 5 should receive a surveillance colonoscopy 
after only 2 years. The analysis also showed that existing surveillance guidelines do not 
consistently target colonoscopies at those patients most likely to benefit. According to the 
2002 Dutch guidelines, which are based on adenoma multiplicity only, for example, a 60 
year-old female with 3 small, non-villous, distal adenomas was recommended colonoscopy 
surveillance after 3 years, while a 60 year-old female with 2 large, villous, proximal 
adenomas was recommended colonoscopy surveillance after 6 years. However, according 
to our analysis, the former patient (who has an adenoma risk score of 1) should be 
recommended colonoscopy surveillance after 7 years, while the latter patient (who has an 
adenoma risk score of 4 [corresponding to an almost 4-fold higher risk for CRC]) should be 
recommended colonoscopy surveillance after 3 years: almost the exact opposite. The 
Dutch guidelines for surveillance in adenoma patients were revisited based on the results 
of our study in May 2013.
More intensive colonoscopy screening than recommended in  
the Medicare population
All US guidelines for CRC screening recommend a screening interval of 10 years for 
colonoscopy screening in average-risk individuals. Moreover, the US Preventive Services 
Task Force and the American College of Physicians recommend against routine screening 
in adults older that 75 years with an adequate screening history. Still, many US Medicare 
beneficiaries (i.e., US individuals aged 65 years and older) undergo more intensive 
colonoscopy screening than recommended: 20% of beneficiaries with a negative 
screening colonoscopy result receive a repeated screening colonoscopy within 5 year’s 
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time instead of after the recommended 10 years. Moreover, 25% of beneficiaries with a 
negative screening colonoscopy result at age 75 years or older receive yet another 
screening colonoscopy at an even more advanced age. 
In Chapter 4 of this thesis, we showed that more intensive colonoscopy screening than 
recommended in average-risk Medicare beneficiaries results in only small increases in the 
benefits of screening (i.e., CRC cases prevented, CRC deaths prevented, and LYs gained) 
compared with the increases in the burden and harms associated with screening (i.e., 
colonoscopies performed and complications experienced). As a result, more intensive 
screening than recommended is often associated with a net harm (i.e., QALYs lost), rather 
than a net health benefit. The only scenario that resulted in a net health benefit (i.e., 
colonoscopy screening every 5 instead of 10 years) was very inefficient from a societal 
perspective, requiring 909 additional colonoscopies and an additional $711,000 per 
additional QALY gained.
CRC screening in US elderly individuals without previous screening
In its most recent recommendation statement on colorectal cancer (CRC) screening, the 
US Preventive Services Task Force (USPSTF) recommends against routine screening in 
persons older than 75 years with an adequate screening history. This recommendation 
has led many members of the medical community to believe that no one older than 75 
years should be screened for CRC. However, because unscreened elderly persons are at 
greater risk for CRC than adequately screened elderly persons, screening them is likely to 
be effective and cost-effective up to a more advanced age. If so, the lack of more specific 
recommendations on the age to stop screening may result in an unfounded denial of 
access to screening in elderly persons who were never screened for CRC—a group 
representing 23% of all US persons older than 75 years. 
In Chapter 5, we demonstrated the importance of considering an individual’s screening 
history when making decisions about screening. We showed that CRC screening remains 
cost-effective well beyond age 75 years in elderly individuals without previous screening. 
The maximum age at which screening was cost-effective was 86 years for individuals with 
no comorbidity, 83 years for individuals with moderate comorbidity, and 80 years for 
individuals with severe comorbidity. In unscreened individuals with no comorbidity, a 
screening colonoscopy was most effective and still cost-effective up to age 83 years, a 
screening sigmoidoscopy was indicated at age 84 years, and FIT screening was indicated 
at ages 85 and 86 years. In those with moderate comorbidity, a screening colonoscopy 
was indicated up to age 80 years, a screening sigmoidoscopy was indicated at age 81 
years, and FIT screening was indicated at ages 82 and 83 years. Finally, in those with severe 
comorbidity, a screening colonoscopy was indicated up to age 77 years, a screening 
sigmoidoscopy was indicated at age 78 years, and FIT screening was indicated at ages 79 
and 80 years.
Personalizing colonoscopy screening for US elderly individuals
The effectiveness of CRC screening does not only depend on the screening strategy that 
is used. It also depends on the characteristics of the individuals being screened. Screening 
is more effective in individuals at high risk for CRC, than in individuals at low risk for CRC. 
Moreover, screening is more effective in individuals with a favorable life expectancy, than 
in individuals with an unfavorable life expectancy. Although clinicians are generally aware 
that factors other than age affect the effectiveness and, thus, the cost-effectiveness of 
screening, many still make their decisions on screening for elderly individuals primarily on 
the basis of age: individuals aged 75 years or younger are offered screening, whereas 
individuals aged older than 75 years are not.
In Chapter 6 of this thesis, we explained why recommendations for screening should be 
personalized and how models can be used to derive personalized screening recommen-
dations. Next, in Chapter 7, we constructed personalized recommendations for colonoscopy 
screening in US elderly. To do so, we determined the cost-effectiveness of colonoscopy 
screening for 19,200 cohorts of individuals characterized by age, sex, race, screening 
history, background risk for CRC (i.e., level of exposure to risk factors for CRC), and comorbidity 
status. This analysis showed that while screening some previously screened, low-risk 
individuals is not even cost-effective at age 66 years, screening some, healthy, high-risk 
individuals remains cost-effective up to age 88 years. It also showed that the current 
uniform, age-based approach to screening is inefficient: resulting in harmful screening in 
some, and the denial of cost-effective screening in others. Finally, in Chapter 8, we estimated 
the effects that personalizing CRC screening in elderly individuals could have on US 
population health and health care expenditures. To do so, we modeled the 2013 Medicare 
population (39.6M individuals) and compared the lifetime health effects and costs of uniform 
age-based screening up to age 75 years with four scenarios of personalized screening 
with increasing screening intensity. This analysis showed that personalized screening is 
more efficient than uniform age-based screening up to age 75 years. At the uniform 
age-based screening cost-level personalized screening could potentially prevent 21,200 
additional CRC deaths (+11%). Alternatively, personalized screening could result in the 
same number of CRC deaths prevented at $1,500M lower costs (-84%). 
Based on the results of the studies described in this thesis, we derived the following 
conclusions:
- Decision models provide a useful tool to extrapolate evidence from RCTs and inform 
decisions about screening. (Chapter 2)
- The appropriate interval for a first surveillance colonoscopy in adenoma patients 
depends heavily on a patient’s adenoma risk score (i.e., risk for CRC according to all 
relevant characteristics of adenomas removed during colonoscopy). Personalizing 
surveillance using the adenoma risk score targets colonoscopies at those patients 
most likely to benefit. (Chapter 3)
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- Screening also has negative effects on health. As a result, more intensive screening is 
not always better. More intensive colonoscopy screening than recommended in 
average-risk US Medicare beneficiaries, for example, is often harmful and always 
inefficient. (Chapter 4)
- An individual’s screening history is an important determinant of the effectiveness and 
cost-effectiveness of CRC screening. In contrast with adequately screened individuals, 
screening previously unscreened individuals remains cost-effective well beyond age 
75 years. (Chapter 5)
- Disease simulation models can be used to integrate estimates of cancer risk, life expectancy, 
and screening efficacy into clinically meaningful estimates of the effectiveness of 
screening and, hence, to derive personalized screening recommendations. (Chapter 6)
- Besides screening history, comorbidity status and background risk for CRC are also 
important determinants of the effectiveness and cost-effectiveness of CRC screening. 
(Chapter 7) 
- The potential effects of personalizing screening decisions in elderly individuals are 
large. On the Medicare population-level, personalizing colonoscopy screening could 
prevent tens of thousands of additional CRC deaths or save billions of dollars. (Chapter 8)
Based on these conclusions, we formulated the following recommendations:
- Decision models should be used more frequently to inform decisions about screening.
- When making decisions about surveillance in newly diagnosed adenoma patients all 
relevant characteristics of adenomas removed during colonoscopy should be considered. 
This can be achieved by using the adenoma risk score.
- When evaluating screening, effects on quality of life must be considered. Not considering 
effects on quality of life can lead to wrong decisions.  
- More intensive screening than recommended can be harmful. The current practice of 
more intensive colonoscopy screening than recommended in Medicare beneficiaries 
should be actively discouraged.
- When making decisions about stopping CRC screening, an individual’s screening history, 
comorbidity status, and background risk for CRC should be considered. 
- Efforts should be made to overcome barriers to the implementation of personalized 
CRC screening and surveillance in adenoma patients in clinical practice.
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In de meeste ontwikkelde landen is dikkedarmkanker (DDK) een belangrijk gezondheids-
probleem. In 2013 werden alleen al in Nederland 13,370 mensen gediagnosticeerd met 
DDK. In hetzelfde jaar overleden 4,940 mensen aan de ziekte. Hiermee is DDK op dit 
moment de op één na meest voorkomende kanker en de op één na meest voorkomende 
oorzaak van sterfte aan kanker in Nederland. Het risico om gedurende het leven met DDK 
gediagnosticeerd te worden is 4.4%. Het risico om aan de ziekte te overlijden is 1.8%. In de 
Verenigde Staten (VS) is de relatieve ziektelast ten gevolge van DDK vergelijkbaar met die 
in Nederland.
Eén van de manieren waarop DDK-sterfte verminderd kan worden is DDK-screening. 
Screening wil zeggen dat mensen zonder symptomen een test aangeboden krijgen 
waarmee ziekte in een vroeg stadium gedetecteerd kan worden. DDK is bij uitstek geschikt 
voor screening omdat het een lange periode kent waarin de ziekte nog geen symptomen 
veroorzaakt, maar al wel te detecteren is. Gedurende deze periode kan screening DDK 
voorkómen door het detecteren en verwijderen van het voorstadium ervan (het adenoom) 
of de prognose van DDK verbeteren door de ziekte in een vroeger stadium te detecteren. 
Screening kan echter ook ernstige complicaties en overdiagnose en overbehandeling van 
kanker veroorzaken (het kan ervoor zorgen dat kankers gediagnosticeerd en behandeld 
worden die zonder screening nooit gediagnosticeerd zouden zijn). Er zijn verschillende tests 
beschikbaar voor DDK-screening. Ten eerste zijn er de ontlastingstests: de guajak ‘fecal occult 
blood tests’ (gFOBTs) gericht op het detecteren van elke vorm van bloed, de immunologische 
‘fecal occult blood tests’ (iFOBTs) gericht op het detecteren van menselijk bloed en de fecaal 
DNA tests gericht op het detecteren van menselijk bloed en gemuteerd DNA. Ten tweede 
zijn er endoscopische tests: sigmoïdoscopie, waarbij de distale (linker) zijde van de dikke 
darm wordt geïnspecteerd, en colonoscopie, waarbij de gehele dikke darm wordt 
gevisualiseerd. Ten slotte is er een test waarbij gebruik wordt gemaakt van een beeld - 
vormende techniek: de CT-colografie, waarbij beelden van de dikke darm worden beoordeeld 
op afwijkingen. Alle screeningtests verschillen op belangrijke punten van elkaar. Ze verschillen 
in de mate waarin ze geaccepteerd worden door de populatie die screening moet 
ondergaan, in hun vermogen om adenomen en dikke darm te detecteren, in de belasting 
die het ondergaan van de test met zich meebrengt, in hun risico’s op complicaties en in hun 
kosten. Alle tests, behalve colonoscopie, vereisen dat een colonoscopie wordt verricht 
wanneer de uitslag van de test afwijkend is.
Een tweede manier waarop DDK-sterfte verminderd kan worden, is surveillance in adenoom -
patiënten. Adenoompatiënten zijn mensen bij wie naar aanleiding van deelname aan 
screening (of een colonoscopie naar aanleiding van symptomen) adenomen zijn 
gedetecteerd en verwijderd. Omdat adenoompatiënten een verhoogd risico op DDK hebben 
ten opzichte van de algemene populatie, wordt hen meer intensieve follow-up aanbevolen 
in de vorm van periodiek onderzoek door middel van colonoscopie: de test met de 
hoogste gevoeligheid voor het detecteren van adenomen en DDK.
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In Nederland werd in 2014 begonnen met het uitrollen van een nationaal bevolking-
sonderzoek DDK. Binnen dit bevolkingsonderzoek, zal uiteindelijk iedereen tussen de 55 
en 75 jaar uitgenodigd worden voor tweejaarlijkse iFOBT screening. In de VS werd 
DDK-screening al geïntroduceerd in de jaren ’80. In tegenstelling tot Nederland, is er in de 
VS geen sprake van een nationaal georganiseerd screeningsprogramma. In plaats daarvan 
vindt ‘opportunistische screening’ plaats. Dat wil zeggen dat de patiënt of de zorgverlener 
eraan moet denken dat screening plaats moet vinden. Een ander belangrijk verschil met 
Nederland is dat mensen in de VS vrij zijn om te kiezen welke screeningtest ze willen 
ondergaan.  
In dit proefschrift gebruikten we een micro-simulatie model om beslissingen over 
DDK-screening en surveillance in adenoompatiënten te informeren. In Hoofdstuk 2 
lieten we zien hoe modellen zijn gebruikt om beslissingen over het Nederlandse 
bevolkings onderzoek DDK te informeren. In Hoofdstuk 3 beschreven we de analyse die 
ten grondslag ligt aan de nieuwe Nederlandse richtlijnen voor surveillance in adenoom-
patiënten. In Hoofdstuk 4 bepaalden we de gevolgen van meer intensieve colonoscopie-
screening dan aanbevolen in Amerikaanse 65-plussers. In Hoofdstuk 5 bepaalden we de 
kosteneffectiviteit van DDK-screening in Amerikaanse ouderen die nooit eerder op DDK 
gescreend waren. In Hoofdstuk 6 lieten we zien waarom de stopleeftijd voor colono-
scopiescreening afhankelijk zou moeten zijn van eigenschappen van de patiënt in kwestie. 
In Hoofdstuk 7 genereerden we gepersonaliseerde aanbevelingen voor colono scopie-
screening in Amerikaanse ouderen. Ten slotte kwantificeerden we in Hoofdstuk 8 de 
voordelen die gepersonaliseerde colonoscopiescreening in ouderen zou kunnen hebben 
voor de Amerikaanse maatschappij.
Hoe modellen gebruikt kunnen worden om beslissingen over 
screeningsprogramma’s te informeren 
Gerandomiseerde gecontroleerde trials (zogenaamde ‘randomized controlled trials’ 
[RCTs]) worden beschouwd als de gouden standaard voor het bepalen van de effectiviteit 
van screening, maar ze kennen ook hun beperkingen. Ten eerste zijn RCTs erg duur en 
tijdrovend. Hierdoor is het aantal RCTs waarin de effectiviteit van DDK-screening is 
geëvalueerd zeer beperkt. Ten tweede is de follow-up tijd die gehanteerd wordt binnen 
RCTs doorgaans niet lang genoeg om het volledige effect en de volledige kosten van 
screening te bepalen. Ten derde kan de effectiviteit van screening in een specifieke 
setting sterk afwijken van de effectiviteit geobserveerd in een RCT, bijvoorbeeld doordat 
de opkomst bij screening sterk afwijkt. Ten slotte is het moeilijk om de benodigde 
zorgcapaciteit voor een specifiek screeningsprogramma te bepalen aan de hand van de 
resultaten van een RCT. Al met al is het onmogelijk om enkel aan de hand van RCTs te 
bepalen welke screeningsstrategie optimaal is in een specifieke setting. 
In Hoofdstuk 2 van dit proefschrift, demonstreerden we dat modellen een belangrijke rol 
kunnen spelen bij het beantwoorden van vragen over screeningsprogramma’s. Dit deden 
we aan de hand van de modelanalyses die ten grondslag liggen aan de huidige 
vormgeving van het Nederlandse bevolkingsonderzoek DDK. In de beslissingsfase van 
het bevolkingsonderzoek, werd op basis van modelanalyses gekozen voor 1) iFOBT 
screening in plaats van gFOBT screening, 2) een hogere startleeftijd dan aanbevolen door 
de Raad van Europa en 3) een lagere afkapwaarde voor doorverwijzing naar colonoscopie 
dan aanbevolen door de producent van de iFOBT. Toen tijdens de implementatiefase van 
het bevolkingsonderzoek een groot tekort aan colonoscopiecapaciteit dreigde werd op 
basis van een modelanalyse besloten om de afkapwaarde voor doorverwijzing naar 
colonoscopie tijdelijk te verhogen. Als deze modelanalyses niet verricht zouden zijn, 
zouden andere, minder gunstige keuzes gemaakt kunnen zijn.
Het personaliseren van surveillance voor Nederlandse adenoompatiënten
Patiënten bij wie ooit een adenoom verwijderd is, lopen een verhoogd risico op het 
ontwikkelen van nieuwe adenomen. Recent zijn verschillende factoren geïdentificeerd 
aan de hand waarvan het risico op een nieuw adenoom bij deze patiënten bepaald kan 
worden. Voorbeelden van deze factoren zijn karakteristieken van eerder verwijderde 
adenomen, zoals de aanwezigheid van meerdere adenomen, grote adenomen (≥10mm), 
zogenaamde villeuze adenomen (dit is een weefselkenmerk) en proximaal (rechts) 
gelokaliseerde adenomen, maar ook patiëntkarakteristieken, zoals geslacht en leeftijd. 
Het feit dat al deze voorspellende factoren bekend zijn, betekent dat het mogelijk is om 
adenoompatienten in een groot aantal risicogroepen te verdelen. Vervolgens kunnen de 
surveillance-aanbevelingen zorgvuldig op het risico van de patiënt worden afgestemd. 
De meeste surveillancerichtlijnen houden echter maar rekening met één of enkele 
factoren en stemmen hun aanbevelingen dus maar beperkt af op het risico van de patiënt. 
In een eerdere studie, hebben we een score ontwikkeld aan de hand waarvan adenoom-
patienten - op basis van alle relevante karakteristieken van adenomen verwijderd tijdens 
een eerste colonoscopie - in risicogroepen verdeeld kunnen worden: de ‘adenoom risico 
score’ (ARS). De ARS die kan worden behaald loopt van 0 (laag risico) tot 5 (hoog risico).
In Hoofdstuk 3 van dit proefschrift, hebben we voor elke combinatie van ARS, geslacht 
en leeftijd het juiste interval voor een eerste surveillance colonoscopie bepaald. Deze 
analyse toonde aan dat het juiste surveillance interval sterk afhankelijk is van de ARS van 
een patiënt en minder van geslacht en leeftijd. Waar sommige patiënten met ARS 0 pas na 
10 jaar een colonoscopie hoeven te ondergaan, moeten sommige patiënten met risico 
score 4 of 5 al na 2 jaar een colonoscopie ondergaan. De analyse liet ook zien dat bestaande 
surveillancerichtlijnen er niet altijd in slagen colonoscopiën te richten op patiënten met 
het hoogste risico. Zo zou een vrouw van 60 jaar met 3 kleine, niet villeuze, distale 
adenomen op basis van de oude Nederlandse richtlijnen voor surveillance (die alleen 
gebaseerd zijn op het aantal adenomen dat is verwijderd) na 3 jaar een colonoscopie 
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moeten ondergaan, terwijl een even oude vrouw met 2 grote, villeuze proximale 
adenomen na 6 jaar een colonoscopie zou moeten ondergaan. Volgens onze analyse, zou 
de eerste vrouw (met een ARS van 1) echter na 7 jaar een colonoscopie moeten ondergaan, 
terwijl de tweede vrouw (met een ARS van 4 [corresponderend met een bijna 4 maal zo 
hoog risico]) na 3 jaar een colonoscopie zou moeten ondergaan: bijna exact het 
tegenovergestelde. De Nederlandse richtlijnen voor surveillance in adenoompatienten 
zijn in mei 2013 herzien op basis van de resultaten van deze analyse.
Intensievere colonoscopiescreening dan aanbevolen in Amerikaanse 
65-plussers
Alle Amerikaanse richtlijnen voor DDK-screening bevelen een screeninginterval van 10 jaar 
aan voor screening door middel van colonoscopie. De ‘US Preventive Service Task Force’ 
en het ‘American College of Physicians’ bevelen daarnaast aan om mensen ouder dan 
75 jaar, met een adequate screeningsgeschiedenis, niet langer te screenen. Ondanks deze 
aanbevelingen worden veel Amerikaanse 65-plussers vaker gescreend dan aanbevolen: 
20% van alle 65-plussers met een negatieve screeningscolonoscopie, ondergaan binnen 
5 jaar (in plaats van ná 10 jaar) een nieuwe screeningscolonoscopie en 25% van alle 
mensen met een negatieve screeningscolonoscopie na leeftijd 75 jaar ondergaan op 
latere leeftijd nog een screeningscolonoscopie.
In Hoofdstuk 4 van dit proefschrift lieten we zien dat intensievere colonoscopiescreening 
dan aanbevolen in Amerikaanse 65-plussers slechts tot een kleine toename van de 
positieve gezondheidseffecten van screening leidt, vergeleken met de toename in de 
belasting en het aantal complicaties ten gevolge van screening. Wanneer de positieve 
gezondheidseffecten worden afgewogen tegen de negatieve gezondheidseffecten, blijkt 
dat intensievere screening dan aanbevolen vaak gepaard gaat met een netto verlies aan 
gezondheid in plaats van een netto winst. Het enige scenario dat leidt tot een netto winst 
aan gezondheid (5-jaarlijkse in plaats van 10-jaarlijkse colonoscopiescreening) was niet 
kosteneffectief: elk gewonnen levensjaar ging ten koste van 909 colonoscopiën en 
$711.000.
DDK-screening in niet eerder gescreende Amerikaanse ouderen
Sinds 2008 raadt de ‘US Preventive Services Task Force’ screening naar DDK af voor mensen 
ouder dan 75 jaar met een adequate screeningsgeschiedenis. Deze aanbeveling heeft 
ertoe geleid dat veel Amerikaanse artsen denken dat niemand ouder dan 75 jaar 
gescreend hoeft te worden. Omdat ouderen die nooit eerder gescreend zijn een hoger 
risico op DDK hebben dan ouderen met een adequate screeningsgeschiedenis, is het 
echter waarschijnlijk dat screening in deze groep langer effectief en kosteneffectief blijft. 
Mocht dit het geval zijn, dan kan het gebrek aan meer specifieke aanbevelingen voor de 
juiste stopleeftijd voor screening ertoe leiden dat niet eerder gescreende ouderen 
toegang tot screening wordt ontzegd zonder duidelijke reden. 
In Hoofdstuk 5 van dit proefschrift, toonden we aan hoe belangrijk het is om de 
screenings geschiedenis van een persoon in acht te nemen bij het maken van de 
beslissingen omtrent het stoppen van screening naar DDK. We lieten zien dat DDK- 
screening in niet eerder gescreende ouderen kosteneffectief blijft tot ver boven een 
leeftijd van 75 jaar. In niet eerder gescreende ouderen zonder comorbiditeit bleek 
screening kosteneffectief te blijven tot en met leeftijd 86 jaar, in ouderen met matig- 
ernstige en ernstige comorbiditeit bleek screening kosteneffectief te blijven tot en met 
respectievelijk 83 en 80 jaar. In niet eerder gescreende ouderen zonder comorbiditeit was 
colonoscopiescreening het meest effectief en nog steeds kosteneffectief tot en met 
leeftijd 83 jaar, terwijl op leeftijd 84 jaar sigmoïdoscopie- en op leeftijden 85 en 86 jaar 
iFOBT-screening aanbevolen zou moeten worden. In ouderen met matig-ernstige 
comorbiditeit zou tot en met leeftijd 80 jaar colonoscopiescreening aanbevolen moeten 
worden, terwijl op leeftijd 81 jaar sigmoïdoscopie- en op leeftijden 82 en 83 jaar iFOBT- 
screening aanbevolen zou moeten worden. In ouderen met ernstige comorbiditeit zou 
tot en met leeftijd 77 jaar colonoscopiescreening aanbevolen moeten worden, terwijl op 
leeftijd 78 jaar sigmoïdoscopie- en op leeftijden 79 en 80 jaar iFOBT-screening aanbevolen 
zou moeten worden.
Het personaliseren van colonoscopiescreening voor  
Amerikaanse ouderen       
De effectiviteit van screening naar DDK hangt niet alleen af van de screeningstrategie die 
wordt gekozen, maar ook van de karakteristieken van de personen die gescreend worden. 
Screening is effectiever in personen met een hoog risico op DDK, dan in personen met 
een laag risico op DDK en in personen met een gunstige levensverwachting, dan in 
personen met een ongunstige levensverwachting. Hoewel artsen zich er doorgaans van 
bewust zijn dat andere factoren dan leeftijd de effectiviteit en kosteneffectiviteit van 
screening beïnvloeden, baseren veel van hen de beslissing om een persoon te screenen 
primair op zijn of haar leeftijd: personen van 75 jaar of jonger worden doorgaans 
gescreend, personen ouder dan 75 jaar doorgaans niet.
In Hoofdstuk 6 van dit proefschrift, legden we uit waarom aanbevelingen voor screening 
in ouderen gepersonaliseerd moeten worden en hoe modellen gebruikt kunnen worden 
om tot gepersonaliseerde screeningsaanbevelingen te komen. In Hoofdstuk 7 ontwikkelden 
we gepersonaliseerde aanbevelingen voor colonoscopiescreening in Amerikaanse 
ouderen. Om tot deze aanbevelingen te komen, bepaalden we de kosteneffectiviteit van 
colonoscopiescreening naar leeftijd, geslacht, etniciteit, screeningsgeschiedenis, achter-
grondrisico op DDK (dat wil zeggen: het niveau van blootstelling aan risicofactoren voor 
DDK) en comorbiditeitsstatus. Uit deze analyse bleek dat colonoscopiescreening in 
sommige eerder gescreende personen met een laag achtergrondrisico niet meer 
kosteneffectief is op leeftijd 66 jaar, terwijl screening in andere, niet eerder gescreende, 
gezonde personen met een hoog achtergrondrisico kosteneffectief blijft tot en met 
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leeftijd 88 jaar. In Hoofdstuk 8 kwantificeerden we de impact die het personaliseren van 
colonoscopiescreening onder ouderen zou kunnen hebben op het niveau van de 
Amerikaanse populatie. Hiertoe modelleerden we de Amerikaanse populatie 65-plussers 
in 2013 (39,6 miljoen mensen) en vergeleken we de gezondheidseffecten en kosten van 
uniforme, op leeftijd gebaseerde, screening tot en met leeftijd 75 jaar met 4 scenario’s 
van gepersonaliseerde screening met een toenemende intensiteit van screening. Deze 
analyse toonde aan dat gepersonaliseerde screening efficienter is dan uniforme, op 
leeftijd gebaseerde, screening. Wanneer uitgegaan wordt van de kosten van uniforme, 
op leeftijd gebaseerde screening, kan gepersonaliseerde screening 21.200 extra 
sterfgevallen aan DDK voorkomen (+11%). Andersom kan het aantal DDK sterfgevallen 
dat voorkomen wordt door middel van uniforme, op leeftijd gebaseerde, screening 
behaald worden tegen substantieel lagere kosten (-$1.500M [-84%]).
Op basis van de resultaten van de studies beschreven in dit proefschrift, trekken we de 
volgende conclusies:
-  Modellen kunnen gebruikt worden om de resultaten van gerandomiseerde gecontroleerde 
trials te extrapoleren en een belangrijke rol spelen bij het informeren van beslissingen 
over screening. (Hoofdstuk 2)
-  Het juiste interval voor een eerste surveillance colonoscopie bij adenoompatiënten 
hangt in belangrijke mate af van de ‘adenoom risico score’ van een patiënt (het risico op 
DDK gegeven alle relevante karakteristieken van adenomen verwijderd tijdens een 
eerder colonoscopie). Waar sommige patiënten met risico score 0 pas na 10 jaar een 
colonoscopie hoeven te ondergaan, moeten sommige patiënten met risico score 4 of 5 
al na 2 jaar een colonoscopie ondergaan. Het personaliseren van surveillance op basis 
van de ‘adenoom risico score’ zorgt voor een efficiënter gebruik van surveillance 
colonoscopiën. (Hoofdstuk 3)
-  Screening heeft behalve positieve effecten ook negatieve effecten op de gezondheid. 
Meer screening is hierdoor niet altijd beter. Intensievere colonoscopiescreening dan 
aanbevolen in Amerikaanse 65-plussers met een gemiddeld risico op DDK, bijvoorbeeld, 
heeft vaak een negatief netto effect op de gezondheid en is nooit kosteneffectief. 
(Hoofdstuk 4)
-  De effectiviteit en kosteneffectiviteit van screening hangen in belangrijke mate af van 
de screeningsgeschiedenis van een persoon. In tegenstelling tot screening van 
personen met een adequate screeningsgeschiedenis, blijft screening van niet eerder 
gescreende personen kosteneffectief tot ver boven leeftijd 75 jaar. (Hoofdstuk 5)
-  Modellen kunnen gebruikt worden om schattingen van het risico op kanker, de levens-
verwachting en de werkzaamheid van screening te integreren en te vertalen in 
schattingen van de effectiviteit en kosteneffectiviteit van screening in een bepaald 
individu. Op die manier kunnen aanbevelingen voor screening gepersonaliseerd 
worden. (Hoofdstuk 6)
- De effectiviteit en kosteneffectiviteit van screening hangen niet alleen sterk af van de 
screeningsgeschiedenis van een persoon, maar ook van zijn comorbiditeitsstatus en 
achtergrondrisico op DDK. (Hoofdstuk 7)
-  De potentiële effecten van het personaliseren van screening voor ouderen zijn groot. 
Op het niveau van de Amerikaanse populatie kan het personaliseren van screening 
leiden tot tienduizenden extra voorkomen sterfgevallen aan DDK of een besparing van 
ongeveer $1.500M. (Hoofdstuk 8)  
Op basis van deze conclusies komen we tot de volgende aanbevelingen:
-  Modellen zouden vaker gebruikt moeten worden om beslissingen over screening te 
informeren.
-  Bij het aanbevelen van intervallen voor colonoscopie surveillance moeten alle relevante 
karakteristieken van eerder verwijderde adenomen in acht genomen worden. Dit kan 
gerealiseerd worden door het gebruik van de ‘adenoom risico score’.
-  Bij het evalueren van screening moeten effecten op de kwaliteit van leven meegenomen 
worden. Het negeren van deze effecten kan leiden tot verkeerde beslissingen.
-  Intensievere screening dan aanbevolen kan negatieve gevolgen hebben voor de 
gezondheid. De huidige praktijk van intensievere colonoscopiescreening dan aanbevolen 
in Amerikaanse 65-plussers moet ontmoedigd worden.
-  Beslissingen over het stoppen van DDK-screening moeten niet alleen gemaakt worden 
op basis van de leeftijd van een persoon. De screeningsgeschiedenis, het achtergrond-
risico op DDK en de comorbiditeitsstatus van de persoon moeten ook meegewogen 
worden.
-  Barrières voor het implementeren van gepersonaliseerde DDK-screening en surveillance 
in adenoompatiënten moeten weggenomen worden.
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